

September 2020

Volume 27 Number 2

Editors:

Kaye Wilson & Doris Chong
email: enquiry@pharmac.govt.nz
Telephone +64 4 460 4990
Facsimile +64 4 460 4995
Level 9, 40 Mercer Street
PO Box 10 254 Wellington

Freephone Information Line

0800 66 00 50 (9am – 5pm weekdays)

Circulation

Published each April, August and December.
Changes to the contents are published in monthly updates.

Accessible in an electronic format at no cost from the PHARMAC website
www.pharmac.govt.nz/schedule.

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month by subscribing at
www.pharmac.govt.nz/subscriptions.

Production

Typeset automatically from XML and T_EX.
XML version of the Schedule available from
schedule.pharmac.govt.nz/pub/schedule

Programmers

Anrik Drenth & John Geering

email: texschedule@pharmac.govt.nz

©Pharmaceutical Management Agency



ISSN 1179-3686 pdf
ISSN 1172-9376 print

This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit: creativecommons.org/licenses/by/4.0/.

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Section A	General Rules	5
-----------	---------------	---

Section B	Alimentary Tract & Metabolism	6
	Blood & Blood Forming Organs	37
	Cardiovascular System	47
	Dermatologicals	61
	Genito Urinary System	71
	Hormone Preparations – Systemic	77
	Infections – Agents For Systemic Use	88
	Musculoskeletal System	110
	Nervous System	119
	Oncology Agents & Immunosuppressants	158
	Respiratory System & Allergies	233
	Sensory Organs	241
	Various	246

Section C	Extemporaneous Compounds (ECPs)	248
-----------	---------------------------------	-----

Section D	Special Foods	251
-----------	---------------	-----

Section I	National Immunisation Schedule	272
-----------	--------------------------------	-----

Index	284
-------	-----

Introducing PHARMAC

The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

PHARMAC's role:

“Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided.”

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at <https://www.pharmac.govt.nz/about>.

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in DHB Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in DHB Hospitals for which national prices have been negotiated by PHARMAC.

The Schedule does not show the final cost to Government of subsidising each Community Pharmaceutical or to DHB Hospitals in purchasing each Pharmaceutical, since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for Pharmaceuticals used in DHB Hospitals, on any logistics arrangements put in place.

This book contains sections A to D and Section I of the Pharmaceutical Schedule and lists the Pharmaceuticals funded for use in the community, including vaccines, as well as haemophilia and cancer treatments given in DHB hospitals. Section H lists the Pharmaceuticals that can be used in DHB hospitals and is a separate publication.

The Pharmaceuticals in this book are listed by therapeutic group, which is based on the WHO Anatomical Therapeutic Chemical (ATC) system. The listings are displayed alphabetically under each heading.

The index lists both chemical entities and product brand names.

Explaining pharmaceutical entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the subsidy, the supplier's price and the access conditions that may apply.

Example

ANATOMICAL HEADING			
THERAPEUTIC HEADING			
CHEMICAL			
Presentation, form and strength			
10.00	100	Brand A	Brand B
Presentation - Available on a PSO	15.00	50	Brand C
Presentation - Retail pharmacy-specialist	18.00	250 ml OP	Brand D
a) Prescriptions must be written by a paediatrician or paediatric cardiologist; or b) on the recommendation of a paediatrician or a paediatric cardiologist			
CHEMICAL			
Presentation, form and strength			
26.53	100	Brand E	
(35.27)			
Sole Supply			
Fully Subsidised			
Three months supply may be dispensed at one time if endorsed 'certified exemption' by the prescriber or pharmacist.			

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

Practitioner's Supply Order

Conditions of and restrictions on prescribing (including Special Authority where it applies)

Three months or six months, as applicable, dispensed all-at-once

Brand or manufacturer's name

Sole subsidised supply product

Fully subsidised product

Original Pack - Subsidy is rounded up to a multiple of whole packs

Quantity the Subsidy applies to

Subsidy paid on a product before mark-ups and GST

Manufacturer's Price if different from Subsidy

Glossary

Units of Measure

gram	g	microgram.....	mcg	millimole.....	mmol
kilogram.....	kg	milligram	mg	unit.....	u
international unit.....	iu	millilitre.....	ml		

Abbreviations

Ampoule	Amp	Gelatinous	Gel	Solution.....	Soln
Capsule	Cap	Granules	Gran	Suppository.....	Supp
Cream.....	Crm	Infusion	Inf	Tablet.....	Tab
Device.....	Dev	Injection	Inj	Tincture.....	Tinc
Dispersible.....	Disp	Liquid.....	Liq	Trans Dermal Delivery	
Effervescent.....	Eff	Long Acting.....	LA	System.....	TDDS
Emulsion.....	Emul	Ointment.....	Oint		
Enteric Coated.....	EC	Sachet	Sach		

Read the [General Rules](https://www.pharmac.govt.nz/section-a) : <https://www.pharmac.govt.nz/section-a>.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Antacids and Antiflatulents				
Antacids and Reflux Barrier Agents				
ALGINIC ACID				
Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet.....	5.31	30	✓	Gaviscon Infant
SODIUM ALGINATE				
* Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour.....	1.80 (8.60)	60		Gaviscon Double Strength
* Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml.....	1.50 (4.95)	500 ml		Acidex
Phosphate Binding Agents				
ALUMINIUM HYDROXIDE				
* Tab 600 mg	12.56	100	✓	Alu-Tab
CALCIUM CARBONATE				
Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) – Subsidy by endorsement	39.00	500 ml	✓	Roxane
Only when prescribed for patients unable to swallow calcium carbonate tablets or where calcium carbonate tablets are inappropriate and the prescription is endorsed accordingly.				
Antidiarrhoeals				
Agents Which Reduce Motility				
LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a PSO				
* Tab 2 mg	10.75	400	✓	Nodia
* Cap 2 mg	6.25	400	✓	Diamide Relief
Rectal and Colonic Anti-inflammatories				
BUDESONIDE				
Cap 3 mg – Special Authority see SA1886 below – Retail pharmacy.....	166.50	90	✓	Entocort CIR
» SA1886 Special Authority for Subsidy				
Initial application — (Crohn's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:				
Both:				
1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and				
2 Any of the following:				
2.1 Diabetes; or				
2.2 Cushingoid habitus; or				
2.3 Osteoporosis where there is significant risk of fracture; or				
continued...				
<div> <div>✓ fully subsidised</div> <div>Sole Subsidised Supply</div> </div> <div> <div>S29</div> <div>Unapproved medicine supplied under Section 29</div> </div>				

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
- 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
- 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
- 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogenic bone marrow transplantation*.

Note: Indication marked with * is an unapproved indication.

Initial application — (non-cirrhotic autoimmune hepatitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has autoimmune hepatitis*; and
- 2 Patient does not have cirrhosis; and
- 3 Any of the following:
 - 3.1 Diabetes; or
 - 3.2 Cushingoid habitus; or
 - 3.3 Osteoporosis where there is significant risk of fracture; or
 - 3.4 Severe acne following treatment with conventional corticosteroid therapy; or
 - 3.5 History of severe psychiatric problems associated with corticosteroid treatment; or
 - 3.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
 - 3.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated); or
 - 3.8 Adolescents with poor linear growth (where conventional corticosteroid use may limit further growth) .

Note: Indication marked with * is an unapproved indication.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (non-cirrhotic autoimmune hepatitis) from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC-Free (14 applications).....	26.55	21.1 g OP	✓ Colifoam
--	-------	-----------	------------

HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE

Topical aerosol foam, 1% with pramoxine hydrochloride 1%.....	26.55	10 g OP	✓ Proctofoam S29
---	-------	---------	------------------

MESALAZINE

Tab 400 mg	49.50	100	✓ Asacol
Tab EC 500 mg	49.50	100	✓ Asamax
Tab long-acting 500 mg.....	56.10	100	✓ Pentasa
Tab 800 mg	85.50	90	✓ Asacol
Modified release granules, 1 g	141.72	120 OP	✓ Pentasa
Enema 1 g per 100 ml	41.30	7	✓ Pentasa
Suppos 500 mg	22.80	20	✓ Asacol
Suppos 1 g	54.60	30	✓ Pentasa

OLSALAZINE

Tab 500 mg	93.37	100	✓ Dipentum
Cap 250 mg	53.00	100	✓ Dipentum

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SODIUM CROMOGLICATE				
Cap 100 mg.....	92.91	100	✓	Nalcrom
SULFASALAZINE				
* Tab 500 mg	14.00	100	✓	Salazopyrin
Tab EC 500 mg	15.53	100	✓	Salazopyrin EN

Local preparations for Anal and Rectal Disorders

Antihaemorrhoidal Preparations

FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE				
Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchocaine hydrochloride 5 mg per g.....	6.35	30 g OP	✓	Ultraproct
Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg	2.66	12	✓	Ultraproct
HYDROCORTISONE WITH CINCHOCAINE				
Oint 5 mg with cinchocaine hydrochloride 5 mg per g.....	15.00	30 g OP	✓	Proctosedyl
Suppos 5 mg with cinchocaine hydrochloride 5 mg per g	9.90	12	✓	Proctosedyl

Management of Anal Fissures

GLYCERYL TRINITRATE – Special Authority see SA1329 below – Retail pharmacy				
* Oint 0.2%.....	22.00	30 g OP	✓	Rectogesic

➔ [SA1329](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has a chronic anal fissure that has persisted for longer than three weeks.

Antispasmodics and Other Agents Altering Gut Motility

GLYCOPYRRONIUM BROMIDE				
Inj 200 mcg per ml, 1 ml ampoule – Up to 10 inj available on a PSO	17.14	10	✓	Max Health
	34.32	5	✓	Robinul
HYOSCINE BUTYLBROMIDE				
* Tab 10 mg	6.35	100	✓	Buscopan
Buscopan to be Sole Supply on 1 October 2020				
* Inj 20 mg, 1 ml – Up to 5 inj available on a PSO	6.35	5	✓	Buscopan
MEBEVERINE HYDROCHLORIDE				
* Tab 135 mg	9.20	90	✓	Colofac

Antulcerants

Antisecretory and Cytoprotective

MISOPROSTOL				
Subsidised on a PSO only if from a Family Planning New Zealand Clinic or an abortion service provider with a DHB contract and the PSO is endorsed with the name of the institution for which the PSO is required.				
* Tab 200 mcg – Up to 120 tab available on a PSO	41.50	120	✓	Cytotec

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

Helicobacter Pylori Eradication

CLARITHROMYCIN

Tab 500 mg – Subsidy by endorsement.....	10.40	14	✓ Apo-Clarithromycin
a) Maximum of 14 tab per prescription			
b) Subsidised only if prescribed for helicobacter pylori eradication and prescription is endorsed accordingly.			
Note: the prescription is considered endorsed if clarithromycin is prescribed in conjunction with a proton pump inhibitor and either amoxicillin or metronidazole.			

H2 Antagonists

FAMOTIDINE – Only on a prescription

* Tab 20 mg	4.91	100	✓ Famotidine Hovid ^{\$29}
* Tab 40 mg	8.48	100	✓ Famotidine Hovid ^{\$29}

RANITIDINE – Subsidy by endorsement

- a) Only on a prescription
b) Subsidy by endorsement – Subsidised for patients who were taking ranitidine prior to 1 November 2019 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of ranitidine.

* Tab 150 mg	12.91	500	✓ Ranitidine Relief
* Tab 300 mg	18.21	500	✓ Ranitidine Relief
* Oral liq 150 mg per 10 ml	5.14	300 ml	✓ Peptisoothe
* Inj 25 mg per ml, 2 ml	13.40	5	✓ Zantac

(Ranitidine Relief Tab 150 mg to be delisted 1 October 2020)

(Ranitidine Relief Tab 300 mg to be delisted 1 October 2020)

(Zantac Inj 25 mg per ml, 2 ml to be delisted 1 June 2021)

Proton Pump Inhibitors

LANSOPRAZOLE

* Cap 15 mg	4.58	100	✓ Lanzol Relief
* Cap 30 mg	5.41	100	✓ Lanzol Relief

OMEPRAZOLE

For omeprazole suspension refer Standard Formulae, [page 248](#)

* Cap 10 mg	1.98	90	✓ Omeprazole actavis 10
* Cap 20 mg	1.96	90	✓ Omeprazole actavis 20
* Cap 40 mg	3.12	90	✓ Omeprazole actavis 40
* Powder – Only in combination.....	42.50	5 g	✓ Midwest
Only in extemporaneously compounded omeprazole suspension.			
* Inj 40 mg ampoule with diluent.....	33.98	5	✓ Dr Reddy's Omeprazole
			✓ Ocicure ^{\$29}

PANTOPRAZOLE

* Tab EC 20 mg	2.02	100	✓ Panzop Relief
* Tab EC 40 mg	2.85	100	✓ Panzop Relief

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Site Protective Agents

COLLOIDAL BISMUTH SUBCITRATE

Tab 120 mg 14.51 50 ✓ **Gastrodenol** S29

SUCRALFATE

Tab 1 g 35.50 120
(48.28) Carafate

Bile and Liver Therapy

RIFAXIMIN – Special Authority see [SA1461 below](#) – Retail pharmacy

Tab 550 mg 625.00 56 ✓ **Xifaxan**

► [SA1461](#) Special Authority for Subsidy

Initial application only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid for 6 months where the patient has hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

Renewal only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Diabetes

Hyperglycaemic Agents

DIAZOXIDE – Special Authority see [SA1320 below](#) – Retail pharmacy

Cap 25 mg 110.00 100 ✓ **Proglidem** S29
Cap 100 mg 280.00 100 ✓ **Proglidem** S29
Oral liq 50 mg per ml 620.00 30 ml OP ✓ **Proglycem** S29

► [SA1320](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months where used for the treatment of confirmed hypoglycaemia caused by hyperinsulinism.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

GLUCAGON HYDROCHLORIDE

Inj 1 mg syringe kit – Up to 5 kit available on a PSO 32.00 1 ✓ **Glucagen Hypokit**

Insulin - Short-acting Preparations

INSULIN NEUTRAL

▲ Inj human 100 u per ml 25.26 10 ml OP ✓ **Actrapid**
✓ **Humulin R**
▲ Inj human 100 u per ml, 3 ml 42.66 5 ✓ **Actrapid Penfill**
✓ **Humulin R**

Insulin - Intermediate-acting Preparations

INSULIN ASPART WITH INSULIN ASPART PROTAMINE

▲ Inj 100 iu per ml, 3 ml prefilled pen 52.15 5 ✓ **NovoMix 30 FlexPen**

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN ISOPHANE				
▲ Inj human 100 u per ml	17.68	10 ml OP	✓	Humulin NPH
			✓	Protaphane
▲ Inj human 100 u per ml, 3 ml	29.86	5	✓	Humulin NPH
			✓	Protaphane Penfill
INSULIN ISOPHANE WITH INSULIN NEUTRAL				
▲ Inj human with neutral insulin 100 u per ml	25.26	10 ml OP	✓	Humulin 30/70
			✓	Mixtard 30
▲ Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	✓	Humulin 30/70
			✓	PenMix 30
			✓	PenMix 40
			✓	PenMix 50
INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE				
▲ Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml	42.66	5	✓	Humalog Mix 25
▲ Inj lispro 50% with insulin lispro protamine 50% 100 u per ml, 3 ml	42.66	5	✓	Humalog Mix 50

Insulin - Long-acting Preparations

INSULIN GLARGINE				
▲ Inj 100 u per ml, 10 ml	63.00	1	✓	Lantus
▲ Inj 100 u per ml, 3 ml	94.50	5	✓	Lantus
▲ Inj 100 u per ml, 3 ml disposable pen	94.50	5	✓	Lantus SoloStar

Insulin - Rapid Acting Preparations

INSULIN ASPART				
▲ Inj 100 u per ml, 10 ml	30.03	1	✓	NovoRapid
▲ Inj 100 u per ml, 3 ml	51.19	5	✓	NovoRapid Penfill
▲ Inj 100 u per ml, 3 ml syringe	51.19	5	✓	NovoRapid FlexPen
INSULIN GLULISINE				
▲ Inj 100 u per ml, 10 ml	27.03	1	✓	Apidra
▲ Inj 100 u per ml, 3 ml	46.07	5	✓	Apidra
▲ Inj 100 u per ml, 3 ml disposable pen	46.07	5	✓	Apidra SoloStar
INSULIN LISPRO				
▲ Inj 100 u per ml, 10 ml	34.92	10 ml OP	✓	Humalog
▲ Inj 100 u per ml, 3 ml	59.52	5	✓	Humalog

Alpha Glucosidase Inhibitors

ACARBOSE				
* Tab 50 mg	3.50	90	✓	Glucobay
	10.47		✓	Accarb
* Tab 100 mg	6.40	90	✓	Glucobay
	20.23		✓	Accarb

Oral Hypoglycaemic Agents

GLIBENCLAMIDE				
* Tab 5 mg	6.00	100	✓	Daonil

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
GLICLAZIDE				
* Tab 80 mg	15.18	500	✓	Glizide
Glizide to be Sole Supply on 1 November 2020				
GLIPIZIDE				
* Tab 5 mg	3.27	100	✓	Minidiab
METFORMIN HYDROCHLORIDE				
* Tab immediate-release 500 mg	8.63	1,000	✓	Apotex
* Tab immediate-release 850 mg	7.04	500	✓	Apotex
PIOGLITAZONE				
* Tab 15 mg	3.47	90	✓	Vexazone
* Tab 30 mg	5.06	90	✓	Vexazone
* Tab 45 mg	7.10	90	✓	Vexazone
VILDAGLIPTIN				
Tab 50 mg	40.00	60	✓	Galvus
VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE				
Tab 50 mg with 1,000 mg metformin hydrochloride	40.00	60	✓	Galvumet
Tab 50 mg with 850 mg metformin hydrochloride	40.00	60	✓	Galvumet

Diabetes Management

Ketone Testing

BLOOD KETONE DIAGNOSTIC TEST STRIP – Subsidy by endorsement

- Not on a BSO
- Maximum of 20 strip per prescription
- Up to 10 strip available on a PSO
- Patient has any of the following:
 - type 1 diabetes; or
 - permanent neonatal diabetes; or
 - undergone a pancreatectomy; or
 - cystic fibrosis-related diabetes; or
 - metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist.

The prescription must be endorsed accordingly.

Test strips 15.50 10 strip OP ✓ **KetoSens**

Dual Blood Glucose and Blood Ketone Testing

DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER – Subsidy by endorsement

- Maximum of 1 pack per prescription
- Up to 1 pack available on a PSO
- A dual blood glucose and blood ketone diagnostic test meter is subsidised for a patient who has:
 - type 1 diabetes; or
 - permanent neonatal diabetes; or
 - undergone a pancreatectomy; or
 - cystic fibrosis-related diabetes; or
 - metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist.

The prescription must be endorsed accordingly. Only 1 meter per patient will be subsidised (no repeat prescriptions). For the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for a funded CareSens meter.

Meter with 50 lancets, a lancing device and 10 blood glucose
diagnostic test strips 20.00 1 OP ✓ **CareSens Dual**

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Blood Glucose Testing

BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by endorsement

- Maximum of 1 pack per prescription
- Up to 1 pack available on a PSO
- A diagnostic blood glucose test meter is subsidised for a patient who:
 - is receiving insulin or sulphonylurea therapy; or
 - is pregnant with diabetes; or
 - is on home TPN at risk of hypoglycaemia or hyperglycaemia; or
 - has a genetic or an acquired disorder of glucose homeostasis, excluding type 1 or type 2 diabetes and metabolic syndrome.

The prescription must be endorsed accordingly. Only one CareSens meter per patient will be subsidised (no repeat prescriptions). Patients already using the CareSens N POP meter and CareSens N meter are not eligible for a new meter, unless they have:

- type 1 diabetes; or
- permanent neonatal diabetes; or
- undergone a pancreatectomy; or
- cystic fibrosis-related diabetes.

For the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for a funded CareSens meter.

Meter with 50 lancets, a lancing device and 10 diagnostic test

strips.....	10.00	1 OP	✓ CareSens N
	20.00		✓ CareSens N POP
			✓ CareSens N Premier

Note: Only 1 meter available per PSO

BLOOD GLUCOSE DIAGNOSTIC TEST STRIP – Up to 50 test available on a PSO

The number of test strips available on a prescription is restricted to 50 unless:

- Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or
- Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
- Prescribed for a pregnant woman with diabetes and endorsed accordingly; or
- Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or
- Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.

Test strips.....	10.56	50 test OP	✓ CareSens N
			✓ CareSens PRO

BLOOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED)

The number of test strips available on a prescription is restricted to 50 unless:

- Prescribed for a patient on insulin or a sulphonylurea and endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin or sulphonylurea; or
- Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
- Prescribed for a pregnant woman with diabetes and endorsed accordingly; or
- Prescribed for a patient on home TPN at risk of hypoglycaemia or hyperglycaemia and endorsed accordingly; or
- Prescribed for a patient with a genetic or an acquired disorder of glucose homeostasis excluding type 1 or type 2 diabetes and metabolic syndrome and endorsed accordingly.

Blood glucose test strips.....	26.20	50 test OP	✓ SensoCard
--------------------------------	-------	------------	--------------------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Insulin Syringes and Needles				
Subsidy is available for disposable insulin syringes, needles, and pen needles if prescribed on the same form as the one used for the supply of insulin or when prescribed for an insulin patient and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of insulin.				
INSULIN PEN NEEDLES – Maximum of 200 dev per prescription				
* 29 g x 12.7 mm	10.50	100	✓	B-D Micro-Fine
* 31 g x 5 mm	11.75	100	✓	B-D Micro-Fine
* 31 g x 6 mm	9.50	100	✓	Berpu
* 31 g x 8 mm	10.50	100	✓	B-D Micro-Fine
* 32 g x 4 mm	10.50	100	✓	B-D Micro-Fine
INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 200 dev per prescription				
* Syringe 0.3 ml with 29 g x 12.7 mm needle	13.00	100	✓	B-D Ultra Fine
	1.30	10		
	(1.99)			B-D Ultra Fine
* Syringe 0.3 ml with 31 g x 8 mm needle	13.00	100	✓	B-D Ultra Fine II
	1.30	10		
	(1.99)			B-D Ultra Fine II
* Syringe 0.5 ml with 29 g x 12.7 mm needle	13.00	100	✓	B-D Ultra Fine
	1.30	10		
	(1.99)			B-D Ultra Fine
* Syringe 0.5 ml with 31 g x 8 mm needle	13.00	100	✓	B-D Ultra Fine II
	1.30	10		
	(1.99)			B-D Ultra Fine II
* Syringe 1 ml with 29 g x 12.7 mm needle	13.00	100	✓	B-D Ultra Fine
	1.30	10		
	(1.99)			B-D Ultra Fine
* Syringe 1 ml with 31 g x 8 mm needle	13.00	100	✓	B-D Ultra Fine II
	1.30	10		
	(1.99)			B-D Ultra Fine II

Insulin Pumps

INSULIN PUMP – Special Authority see [SA1603 below](#) – Retail pharmacy

a) Maximum of 1 dev per prescription

b) Only on a prescription

c) Maximum of 1 insulin pump per patient each four year period.

Min basal rate 0.025 U/h 8,800.00

Min basal rate 0.1 U/h 4,500.00

1

✓ MiniMed 640G

1

✓ Tandem Basal IQ

✓ Tandem t:slim X2

(Tandem t:slim X2 Min basal rate 0.1 U/h to be delisted 1 December 2020)

➔ [SA1603](#) Special Authority for Subsidy

Initial application — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1 Patient has permanent neonatal diabetes; and

2 A MDI regimen trial is inappropriate; and

3 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 4 Patient/Parent/Guardian has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 5 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 6 Either:
 - 6.1 Applicant is a relevant specialist; or
 - 6.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction; and
- 2 Patient remains fully compliant and transition to MDI is considered inappropriate by the treating physician; and
- 3 It has been at least 4 years since the last insulin pump received by the patient or, in the case of patients qualifying under previous pump therapy for the initial application; the pump is due for replacement; and
- 4 Either:
 - 4.1 Applicant is a relevant specialist; or
 - 4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has had four severe unexplained hypoglycaemic episodes over a six month period (severe as defined as requiring the assistance of another person); and
- 6 Has an average HbA1c between the following range: equal to or greater than 53 mmol/mol and equal to or less than 90 mmol/mol; and
- 7 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 8 Either:
 - 8.1 Applicant is a relevant specialist; or
 - 8.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of at least a 50% reduction from baseline in hypoglycaemic events; and
- 2 HbA1c has not increased by more than 5 mmol/mol from baseline; and
- 3 Either:
 - 3.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 3.2 The pump is due for replacement; and
- 4 Either:
 - 4.1 Applicant is a relevant specialist; or
 - 4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has unpredictable and significant variability in blood glucose including significant hypoglycaemia affecting the ability to reduce HbA1c; and
- 6 In the opinion of the treating clinician, HbA1c could be reduced by at least 10 mmol/mol using insulin pump treatment; and
- 7 Has typical HbA1c results between the following range: equal to or greater than 65 mmol/mol and equal to or less than 90 mmol/mol; and
- 8 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 9 Either:
 - 9.1 Applicant is a relevant specialist; or
 - 9.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of achieving and maintaining a reduction in HbA1c from baseline of 10 mmol/mol; and
- 2 The number of severe unexplained recurrent hypoglycaemic episodes has not increased from baseline; and
- 3 Either:
 - 3.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 3.2 The pump is due for replacement; and
- 4 Either:
 - 4.1 Applicant is a relevant specialist; or
 - 4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Was already on pump treatment prior to 1 September 2012 and had been evaluated by the multidisciplinary team for their suitability for insulin pump therapy at the time of initiating that pump treatment and continues to benefit from pump treatment; and
- 3 The patient has adhered to an intensive MDI regimen using analogue insulins for at least six months prior to initiating pump therapy; and
- 4 The patient is continuing to derive benefit from pump therapy; and
- 5 The patient had achieved and is maintaining a HbA1c of equal to or less than 80 mmol/mol on pump therapy; and
- 6 The patient has had no increase in severe unexplained hypoglycaemic episodes from baseline; and
- 7 The patient's HbA1c has not deteriorated more than 5 mmol/mol from baseline; and
- 8 Either:
 - 8.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 8.2 The pump is due for replacement; and
- 9 Either:
 - 9.1 Applicant is a relevant specialist; or
 - 9.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

All of the following:

- 1 The patient is continuing to derive benefit according to the treatment plan and has maintained a HbA1c of equal to or less than 80 mmol/mol; and
- 2 The patient's HbA1c has not deteriorated more than 5 mmol/mol from the time of commencing pump treatment; and
- 3 The patient has not had an increase in severe unexplained hypoglycaemic episodes from baseline; and
- 4 Either:
 - 4.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 4.2 The pump is due for replacement; and
- 5 Either:
 - 5.1 Applicant is a relevant specialist; or
 - 5.2 Applicant is a nurse practitioner working within their vocational scope.

Insulin Pump Consumables

►SA1906 Special Authority for Subsidy

Initial application — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has permanent neonatal diabetes; and
- 2 A MDI regimen trial is inappropriate; and
- 3 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 4 Patient/Parent/Guardian has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 5 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 6 Either:
 - 6.1 Applicant is a relevant specialist; or
 - 6.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (permanent neonatal diabetes) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction; and
- 2 Patient remains fully compliant and transition to MDI is considered inappropriate by the treating physician.

Initial application — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has had four severe unexplained hypoglycaemic episodes over a six month period (severe as defined as requiring the assistance of another person); and
- 6 Has an average HbA1c between the following range: equal to or greater than 53 mmol/mol and equal to or less than 90 mmol/mol; and
- 7 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 8 Either:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 8.1 Applicant is a relevant specialist; or
- 8.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (severe unexplained hypoglycaemia) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of at least a 50% reduction from baseline in hypoglycaemic events; and
- 2 HbA1c has not increased by more than 5 mmol/mol from baseline, according to the most recent result.

Initial application — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has unpredictable and significant variability in blood glucose including significant hypoglycaemia affecting the ability to reduce HbA1c; and
- 6 In the opinion of the treating clinician, HbA1c could be reduced by at least 10 mmol/mol using insulin pump treatment; and
- 7 Has typical HbA1c results between the following range: equal to or greater than 65 mmol/mol and equal to or less than 90 mmol/mol; and
- 8 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 9 Either:
 - 9.1 Applicant is a relevant specialist; or
 - 9.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (HbA1c) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of achieving and maintaining a reduction in HbA1c from baseline of 10 mmol/mol, according to the most recent result; and
- 2 The number of severe unexplained recurrent hypoglycaemic episodes has not increased from baseline.

Initial application — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Was already on pump treatment prior to 1 September 2012 and had been evaluated by the multidisciplinary team for their suitability for insulin pump therapy at the time of initiating that pump treatment and continues to benefit from pump treatment; and
- 3 The patient has adhered to an intensive MDI regimen using analogue insulins for at least six months prior to initiating pump therapy; and
- 4 The patient is continuing to derive benefit from pump therapy; and
- 5 The patient had achieved and is maintaining a HbA1c of equal to or less than 80 mmol/mol on pump therapy; and
- 6 The patient has had no increase in severe unexplained hypoglycaemic episodes from baseline; and
- 7 The patient's HbA1c has not deteriorated more than 5 mmol/mol from baseline; and
- 8 Either:
 - 8.1 Applicant is a relevant specialist; or
 - 8.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (Previous use before 1 September 2012) from any relevant practitioner. Approvals valid for 2 years for

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

applications meeting the following criteria:

All of the following:

- 1 The patient is continuing to derive benefit according to the treatment plan and has maintained a HbA1c of equal to or less than 80 mmol/mol according to a recent laboratory result; and
- 2 The patient's HbA1c has not deteriorated more than 5 mmol/mol from initial application, according to the most recent result; and
- 3 The patient has not had an increase in severe unexplained hypoglycaemic episodes from baseline.

INSULIN PUMP CARTRIDGE – Special Authority see [SA1906 on page 17](#) – Retail pharmacy

- a) Maximum of 3 sets per prescription
- b) Only on a prescription
- c) Maximum of 13 packs of cartridge sets will be funded per year.

Cartridge 300 U, t:lock x 10.....50.00 1 OP ✓ Tandem Cartridge

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (STEEL CANNULA) – Special Authority see SA1906 on page 17 – Retail pharmacy				
a) Maximum of 3 sets per prescription				
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
10 mm steel needle; 60 cm tubing x 10	130.00	1 OP	✓	MiniMed Sure-T MMT-884A
10 mm steel needle; 80 cm tubing x 10	130.00	1 OP	✓	MiniMed Sure-T MMT-886A
6 mm steel needle; 60 cm tubing x 10	130.00	1 OP	✓	MiniMed Sure-T MMT-864A
6 mm steel needle; 80 cm tubing x 10	130.00	1 OP	✓	MiniMed Sure-T MMT-866A
8 mm steel needle; 60 cm tubing x 10	130.00	1 OP	✓	MiniMed Sure-T MMT-874A
8 mm steel needle; 80 cm tubing x 10	130.00	1 OP	✓	MiniMed Sure-T MMT-876A
10 mm steel needle; 29 G; manual insertion; 60 cm tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Sure-T MMT-884
10 mm steel needle; 29 G; manual insertion; 80 cm tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Sure-T MMT-886
6 mm steel needle; 29 G; manual insertion; 60 cm tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Sure-T MMT-864
6 mm steel needle; 29 G; manual insertion; 60 cm tubing x 10 with 10 needles; luer lock	130.00	1 OP	✓	Sure-T MMT-863
6 mm steel needle; 29 G; manual insertion; 80 cm tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Sure-T MMT-866
8 mm steel needle; 29 G; manual insertion; 60 cm tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Sure-T MMT-874
8 mm steel needle; 29 G; manual insertion; 60 cm tubing x 10 with 10 needles; luer lock	130.00	1 OP	✓	Sure-T MMT-873
8 mm steel needle; 29 G; manual insertion; 80 cm tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Sure-T MMT-876

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (STEEL CANNULA, STRAIGHT INSERTION) – Special Authority see SA1906 on page 17 –			
Retail pharmacy			
a) Maximum of 3 sets per prescription			
b) Only on a prescription			
c) Maximum of 13 infusion sets will be funded per year.			
6 mm steel cannula; straight insertion; 60 cm line × 10 with 10 needles	130.00	1 OP	✓ TruSteel
6 mm steel cannula; straight insertion; 81 cm line × 10 with 10 needles	130.00	1 OP	✓ TruSteel
8 mm steel cannula; straight insertion; 60 cm line × 10 with 10 needles	130.00	1 OP	✓ TruSteel
8 mm steel cannula; straight insertion; 81 cm line × 10 with 10 needles	130.00	1 OP	✓ TruSteel

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA) – Special Authority see SA1906 on page 17 – Retail pharmacy				
a) Maximum of 3 set per prescription				
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
13 mm teflon needle, 110 cm tubing × 10	130.00	1 OP	✓	MiniMed Silhouette MMT-382A
13 mm teflon needle, 45 cm tubing × 10	130.00	1 OP	✓	MiniMed Silhouette MMT-368A
13 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	✓	MiniMed Silhouette MMT-381A
13 mm teflon needle, 80 cm tubing × 10	130.00	1 OP	✓	MiniMed Silhouette MMT-383A
17 mm teflon needle, 110 cm tubing × 10	130.00	1 OP	✓	MiniMed Silhouette MMT-377A
17 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	✓	MiniMed Silhouette MMT-378A
17 mm teflon needle, 80 cm tubing × 10	130.00	1 OP	✓	MiniMed Silhouette MMT-384A
6 mm teflon needle, 110 cm tubing × 10	130.00	1 OP	✓	MiniMed Quick-Set MMT-398A
6 mm teflon needle, 45 cm blue tubing × 10	130.00	1 OP	✓	MiniMed Mio MMT-941A
6 mm teflon needle, 45 cm pink tubing × 10.....	130.00	1 OP	✓	MiniMed Mio MMT-921A
6 mm teflon needle, 60 cm blue tubing × 10	130.00	1 OP	✓	MiniMed Mio MMT-943A
6 mm teflon needle, 60 cm pink tubing × 10.....	130.00	1 OP	✓	MiniMed Mio MMT-923A
6 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	✓	MiniMed Quick-Set MMT-399A
6 mm teflon needle, 80 cm blue tubing.....	130.00	1 OP	✓	MiniMed Mio MMT-945A
6 mm teflon needle, 80 cm clear tubing × 10	130.00	1 OP	✓	MiniMed Mio MMT-965A
6 mm teflon needle, 80 cm pink tubing × 10.....	130.00	1 OP	✓	MiniMed Mio MMT-925A
6 mm teflon needle, 80 cm tubing × 10	130.00	1 OP	✓	MiniMed Quick-Set MMT-387A
9 mm teflon needle, 110 cm tubing × 10	130.00	1 OP	✓	MiniMed Quick-Set MMT-396A
9 mm teflon needle, 60 cm tubing × 10	130.00	1 OP	✓	MiniMed Quick-Set MMT-397A
9 mm teflon needle, 80 cm clear tubing × 10	130.00	1 OP	✓	MiniMed Mio MMT-975A
9 mm teflon needle, 80 cm tubing × 10	130.00	1 OP	✓	MiniMed Quick-Set MMT-386A

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE INSERTION WITH INSERTION DEVICE) – Special Authority see SA1906 on page 17 – Retail pharmacy			
a) Maximum of 3 sets per prescription			
b) Only on a prescription			
c) Maximum of 13 infusion sets will be funded per year.			
13 mm teflon cannula; angle insertion; insertion device; 110 cm line x 10 with 10 needles	140.00	1 OP	✓ AutoSoft 30
13 mm teflon cannula; angle insertion; insertion device; 60 cm line x 10 with 10 needles	140.00	1 OP	✓ AutoSoft 30
INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE INSERTION) – Special Authority see SA1906 on page 17 – Retail pharmacy			
a) Maximum of 3 sets per prescription			
b) Only on a prescription			
c) Maximum of 13 infusion sets will be funded per year.			
13 mm teflon cannula; angle insertion; 120 cm line x 10 with 10 needles	130.00	1 OP	✓ Paradigm Silhouette MMT-382
13 mm teflon cannula; angle insertion; 45 cm line x 10 with 10 needles	130.00	1 OP	✓ Paradigm Silhouette MMT-368
13 mm teflon cannula; angle insertion; 60 cm line x 10 with 10 needles	130.00	1 OP	✓ Paradigm Silhouette MMT-381
13 mm teflon cannula; angle insertion; 80 cm line x 10 with 10 needles	130.00	1 OP	✓ Paradigm Silhouette MMT-383
17 mm teflon cannula; angle insertion; 110 cm line x 10 with 10 needles	130.00	1 OP	✓ Paradigm Silhouette MMT-377
17 mm teflon cannula; angle insertion; 60 cm line x 10 with 10 needles	130.00	1 OP	✓ Paradigm Silhouette MMT-378
17 mm teflon cannula; angle insertion; 60 cm line x 10 with 10 needles; luer lock	130.00	1 OP	✓ Silhouette MMT-373
17 mm teflon cannula; angle insertion; 80 cm line x 10 with 10 needles	130.00	1 OP	✓ Paradigm Silhouette MMT-384

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGHT INSERTION WITH INSERTION DEVICE) – Special Authority see SA1906 on page 17 – Retail pharmacy				
a) Maximum of 3 sets per prescription				
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
6 mm teflon cannula; straight insertion; insertion device; 45 cm blue tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Mio MMT-941
6 mm teflon cannula; straight insertion; insertion device; 45 cm pink tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Mio MMT-921
6 mm teflon cannula; straight insertion; insertion device; 60 cm blue tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Mio MMT-943
6 mm teflon cannula; straight insertion; insertion device; 60 cm pink tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Mio MMT-923
6 mm teflon cannula; straight insertion; insertion device; 80 cm blue tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Mio MMT-945
6 mm teflon cannula; straight insertion; insertion device; 80 cm clear tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Mio MMT-965
6 mm teflon cannula; straight insertion; insertion device; 80 cm pink tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Mio MMT-925
9 mm teflon cannula; straight insertion; insertion device; 80 cm clear tubing x 10 with 10 needles.....	130.00	1 OP	✓	Paradigm Mio MMT-975
6 mm teflon cannula; straight insertion; insertion device; 110 cm line x 10 with 10 needles.....	140.00	1 OP	✓	AutoSoft 90
6 mm teflon cannula; straight insertion; insertion device; 60 cm line x 10 with 10 needles.....	140.00	1 OP	✓	AutoSoft 90
9 mm teflon cannula; straight insertion; insertion device; 110 cm line x 10 with 10 needles.....	140.00	1 OP	✓	AutoSoft 90
9 mm teflon cannula; straight insertion; insertion device; 60 cm line x 10 with 10 needles.....	140.00	1 OP	✓	AutoSoft 90

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGHT INSERTION) – Special Authority see SA1906 on page 17 – Retail pharmacy			
a) Maximum of 3 sets per prescription			
b) Only on a prescription			
c) Maximum of 13 infusion sets will be funded per year.			
6 mm teflon cannula; straight insertion; 110 cm tubing × 10 with 10 needles 130.00	1 OP	✓	Paradigm Quick-Set MMT-398
6 mm teflon cannula; straight insertion; 60 cm tubing × 10 with 10 needles 130.00	1 OP	✓	Paradigm Quick-Set MMT-399
6 mm teflon cannula; straight insertion; 60 cm tubing × 10 with 10 needles; luer lock 130.00	1 OP	✓	Quick-Set MMT-393
6 mm teflon cannula; straight insertion; 80 cm tubing × 10 with 10 needles 130.00	1 OP	✓	Paradigm Quick-Set MMT-387
9 mm teflon cannula; straight insertion; 106 cm tubing × 10 with 10 needles 130.00	1 OP	✓	Paradigm Quick-Set MMT-396
9 mm teflon cannula; straight insertion; 60 cm tubing × 10 with 10 needles 130.00	1 OP	✓	Paradigm Quick-Set MMT-397
9 mm teflon cannula; straight insertion; 60 cm tubing × 10 with 10 needles; luer lock 130.00	1 OP	✓	Quick-Set MMT-392
9 mm teflon cannula; straight insertion; 80 cm tubing × 10 with 10 needles 130.00	1 OP	✓	Paradigm Quick-Set MMT-386

INSULIN PUMP RESERVOIR – Special Authority see [SA1906 on page 17](#) – Retail pharmacy

a) Maximum of 3 sets per prescription			
b) Only on a prescription			
c) Maximum of 13 packs of reservoir sets will be funded per year.			
10 × luer lock conversion cartridges 1.8 ml for Paradigm pumps 50.00	1 OP	✓	ADR Cartridge 1.8
Cartridge for 5 and 7 series pump; 1.8 ml × 10 50.00	1 OP	✓	Paradigm 1.8 Reservoir
Cartridge for 7 series pump; 3.0 ml × 10 50.00	1 OP	✓	Paradigm 3.0 Reservoir

Digestives Including Enzymes

PANCREATIC ENZYME

Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) 34.93	100	✓	Creon 10000
Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase, 1,250 U protease)) 94.40	100	✓	Panzytrat
Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U) 94.38	100	✓	Creon 25000
Modified release granules pancreatin 60.12 mg (amylase 3,600 Ph Eur U, lipase 5,000 Ph Eur U, protease 200 Ph Eur U) 34.93	20 g OP	✓	Creon Micro

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
URSODEOXYCHOLIC ACID – Special Authority see SA1739 below – Retail pharmacy				
Cap 250 mg.....	32.95	100	✓	Ursosan
Ursosan to be Sole Supply on 1 October 2020				

► [SA1739](#) Special Authority for Subsidy

Initial application — (Alagille syndrome or progressive familial intrahepatic cholestasis) from any relevant practitioner.

Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Initial application — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initial application — (Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis).

Initial application — (Pregnancy) from any relevant practitioner. Approvals valid for 6 months where the patient diagnosed with cholestasis of pregnancy.

Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogeneic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Initial application — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition (TPN); and
- 2 Liver function has not improved with modifying the TPN composition.

Renewal — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 6 months where the patient continues to benefit from treatment.

Renewal — (Pregnancy/Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months where the paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels.

Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 100 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure -- doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Laxatives

Bulk-forming Agents

ISPAGHULA (PSYLLIUM) HUSK – Only on a prescription

* Powder for oral soln.....	12.20	500 g OP	✓ Konsyl-D
Konsyl-D to be Sole Supply on 1 November 2020			

MUCILAGINOUS LAXATIVES WITH STIMULANTS

* Dry.....	6.02	500 g OP	
	(17.32)		
	2.41	200 g OP	Normacol Plus
	(8.72)		Normacol Plus

Faecal Softeners

DOCUSATE SODIUM – Only on a prescription

* Tab 50 mg	2.31	100	✓ Coloxyl
Coloxyl to be Sole Supply on 1 October 2020			
* Tab 120 mg	3.13	100	✓ Coloxyl
Coloxyl to be Sole Supply on 1 October 2020			

DOCUSATE SODIUM WITH SENNOSIDES

* Tab 50 mg with sennosides 8 mg.....	3.10	200	✓ Laxsol
---------------------------------------	------	-----	-----------------

POLOXAMER – Only on a prescription

Not funded for use in the ear.

* Oral drops 10%.....	3.98	30 ml OP	✓ Coloxyl
Coloxyl to be Sole Supply on 1 November 2020			

Opioid Receptor Antagonists - Peripheral

METHYLNALTREXONE BROMIDE – Special Authority see [SA1691 below](#) – Retail pharmacy

Inj 12 mg per 0.6 ml vial	36.00	1	✓ Relistor
	246.00	7	✓ Relistor

►SA1691 Special Authority for Subsidy

Initial application — (Opioid induced constipation) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient is receiving palliative care; and
- 2 Either:
 - 2.1 Oral and rectal treatments for opioid induced constipation are ineffective; or
 - 2.2 Oral and rectal treatments for opioid induced constipation are unable to be tolerated.

Osmotic Laxatives

GLYCEROL

* Suppos 3.6 g – Only on a prescription	9.25	20	✓ PSM
---	------	----	--------------

LACTULOSE – Only on a prescription

* Oral liq 10 g per 15 ml	3.33	500 ml	✓ Laevolac
---------------------------------	------	--------	-------------------

MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE

Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg	6.70	30	✓ Molaxole
Molaxole to be Sole Supply on 1 October 2020			

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SODIUM ACID PHOSPHATE – Only on a prescription				
Enema 16% with sodium phosphate 8%.....	2.50	1	✓	Fleet Phosphate Enema
SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription				
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml.....	29.98	50	✓	Micolette

Stimulant Laxatives

BISACODYL – Only on a prescription				
* Tab 5 mg	5.99	200	✓	Lax-Tab
* Suppos 10 mg	3.74	10	✓	Lax-Suppositories
SENNA – Only on a prescription				
* Tab, standardised.....	2.17 (8.21) 0.43 (2.06)	100 20		Senokot Senokot

Metabolic Disorder Agents

ALGLUCOSIDASE ALFA – Special Authority see SA1920 below – Retail pharmacy				
Inj 50 mg vial	1,142.60	1	✓	Myozyme

➔SA1920 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:
All of the following:

- 1 The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and
- 2 Any of the following:
 - 2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
 - 2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
 - 2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
 - 2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
- 3 Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
- 4 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT; or might be reasonably expected to compromise a response to ERT; and
- 5 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
- 3 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 4 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

- 5 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 6 There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
- 7 There is no evidence of new or progressive cardiomyopathy.

BETAINE – Special Authority see [SA1921 below](#) – Retail pharmacy

Powder for oral soln.....575.00 180 g OP ✓ **Cystadane**

►►**SA1921** **Special Authority for Subsidy**

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:
All of the following:

- 1 The patient has a confirmed diagnosis of homocystinuria; and
- 2 Any of the following:
 - 2.1 A cystathionine beta-synthase (CBS) deficiency; or
 - 2.2 A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency; or
 - 2.3 A disorder of intracellular cobalamin metabolism; and
- 3 An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation.

Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

GALSULFASE – Special Authority see [SA1922 below](#) – Retail pharmacy

Inj 1 mg per ml, 5 ml vial.....2,234.00 1 ✓ **Naglazyme**

►►**SA1922** **Special Authority for Subsidy**

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria:
Both:

- 1 The patient has been diagnosed with mucopolysaccharidosis VI; and
- 2 Either:
 - 2.1 Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency by either enzyme activity assay in leukocytes or skin fibroblasts; or
 - 2.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 3 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
- 4 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

IDURSULFASE – Special Authority see [SA1623 below](#) – Retail pharmacy

Inj 2 mg per ml, 3 ml vial.....4,608.30 1 ✓ **Elasprase**

►►**SA1623** **Special Authority for Subsidy**

Initial application only from a metabolic physician. Approvals valid for 24 weeks for applications meeting the following criteria:
All of the following:

- 1 The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II); and
- 2 Either:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.1 Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
- 2.2 Detection of a disease causing mutation in the iduronate 2-sulfatase gene; and
- 3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant; and
- 4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
- 5 Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week.

LARONIDASE – Special Authority see [SA1695 below](#) – Retail pharmacy

Inj 100 U per ml, 5 ml vial	1,335.16	1	✓ Aldurazyme
-----------------------------------	----------	---	--------------

➤ **SA1695** Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 24 weeks for applications meeting the following criteria:

All of the following:

- 1 The patient has been diagnosed with Hurler Syndrome (mucopolysaccharidosis I-H); and
- 2 Either:
 - 2.1 Diagnosis confirmed by demonstration of alpha-L-iduronidase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
 - 2.2 Detection of two disease causing mutations in the alpha-L-iduronidase gene and patient has a sibling who is known to have Hurler syndrome; and
- 3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with laronidase would be bridging treatment to transplant; and
- 4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
- 5 Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 post-HSCT) at doses no greater than 100 units/kg every week.

SAPROPTERIN DIHYDROCHLORIDE – Special Authority see [SA1923 below](#) – Retail pharmacy

Tab soluble 100 mg	1,452.70	30 OP	✓ Kuvan
--------------------------	----------	-------	---------

➤ **SA1923** Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant; and
- 2 Treatment with sapropterin is required to support management of PKU during pregnancy; and
- 3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
- 4 Sapropterin to be used alone or in combination with PKU dietary management; and
- 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy; or
 - 1.2 On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and
- 2 Any of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.1 Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or
- 2.2 Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or
- 2.3 Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and
- 3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
- 4 Sapropterin to be used alone or in combination with PKU dietary management; and
- 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

SODIUM BENZOATE – Special Authority see [SA1599 below](#) – Retail pharmacySoln 100 mg per ml CBS 100 ml ✓ **Amzoate** S29**►SA1599 Special Authority for Subsidy****Initial application** only from a metabolic physician. Approvals valid for 12 months where the patient has a diagnosis of a urea cycle disorder.**Renewal** only from a metabolic physician. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.SODIUM PHENYLBUTYRATE – Special Authority see [SA1924 below](#) – Retail pharmacyGrans 483 mg per g 1,920.00 174 g OP ✓ **Pheburane****►SA1924 Special Authority for Subsidy****Initial application** only from a metabolic physician. Approvals valid for 12 months where the patient has a diagnosis of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.**Renewal** from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.**Gaucher's Disease**TALIGLUCERASE ALFA – Special Authority see [SA1880 below](#) – Retail pharmacyInj 200 unit vial 1,072.00 1 ✓ **Elelyso****►SA1880 Special Authority for Subsidy**

Special Authority approved by the Gaucher Treatment Panel

Notes: Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms or:

The Co-ordinator, Gaucher Treatment Panel Phone: 04 460 4990

PHARMAC PO Box 10 254

Facsimile: 04 916 7571

Wellington

Email: gaucherpanel@pharmac.govt.nz

Completed application forms must be sent to the coordinator for the Gaucher Treatment Panel and will be considered by the Gaucher Treatment Panel at the next practicable opportunity.

Notification of the Gaucher Treatment Panel's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Access Criteria**Initial application** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1) The patient has a diagnosis of symptomatic type 1 or type 3* Gaucher disease confirmed by the demonstration of specific deficiency of glucocerebrosidase in leukocytes or cultured skin fibroblasts, and genotypic analysis; and
- 2) Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by taliglucerase alfa or might be reasonably expected to compromise a response to therapy with taliglucerase alfa; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 3) Taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units), unless otherwise agreed by PHARMAC; and
- 4) Supporting clinical information including test reports, MRI whole body STIR, haematological data, and other relevant investigations, are submitted to the Gaucher Panel for assessment; and
- 5) Any of the following:
 - 6) 1) Patient has haematological complications such as haemoglobin less than 95 g/l, symptomatic anaemia, thrombocytopenia; at least two episodes of severely symptomatic splenic infarcts confirmed with imagery; or massive symptomatic splenomegaly; or
 - 2) Patient has skeletal complications such as acute bone crisis requiring hospitalisation or major pain management strategies; radiological MRI Evidence of incipient destruction of any major joint (e.g. hips or shoulder); spontaneous fractures or vertebral collapse; chronic bone pain not controlled by other pharmaceuticals; or
 - 3) Patient has significant liver dysfunction or hepatomegaly attributable to Gaucher disease; or
 - 4) Patient has reduced vital capacity from clinically significant or progressive pulmonary disease due to Gaucher disease; or
 - 5) Patient is a child and has experienced growth failure with significant decrease in percentile linear growth over a 6-12 month period.

*Unapproved indication

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1) Patient has demonstrated a symptomatic improvement or no deterioration in the main symptom for which therapy was initiated; and
- 2) Patient has demonstrated a clinically objective improvement or no deterioration in haemoglobin levels, platelet counts and liver and spleen size; and
- 3) Radiological (MRI) signs of bone activity performed at two years since initiation of treatment, and three yearly thereafter, demonstrate no deterioration shown by the MRI, compared with MRI taken immediately prior to commencement of therapy or adjusted dose; and
- 4) Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 5) Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 6) Patient is compliant with regular treatment and taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units), unless otherwise agreed by PHARMAC; and
- 7) Supporting clinical information including test reports, MRI whole body STIR, haematological data, and other relevant investigations are submitted to the Gaucher Panel for assessment as required.

Mouth and Throat

Agents Used in Mouth Ulceration

BENZYLAMINE HYDROCHLORIDE

Soln 0.15% – Higher subsidy of \$20.31 per 500 ml with

Endorsement	9.00	500 ml	
	(20.31)		Diffiam

Additional subsidy by endorsement for a patient who has oral mucositis as a result of treatment for cancer, and the prescription is endorsed accordingly.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CARMELLOSE SODIUM WITH GELATIN AND PECTIN				
Paste	17.20	56 g OP	✓	Stomahesive
	4.55	15 g OP		
	(7.90)			Orabase
	1.52	5 g OP		
	(3.60)			Orabase
Powder	8.48	28 g OP		Stomahesive
	(10.95)			
CHLORHEXIDINE GLUCONATE				
Mouthwash 0.2%	2.57	200 ml OP	✓	healthE
<i>(healthE Mouthwash 0.2% to be delisted 1 November 2020)</i>				
CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE				
* Adhesive gel 8.7% with cetalkonium chloride 0.01%	2.06	15 g OP		
	(6.00)			Bonjela
TRIAMCINOLONE ACETONIDE				
Paste 0.1%	5.33	5 g OP	✓	Kenalog in Orabase
Kenalog in Orabase to be Sole Supply on 1 November 2020				

Oropharyngeal Anti-infectives

AMPHOTERICIN B				
Lozenges 10 mg	5.86	20	✓	Fungilin
MICONAZOLE				
Oral gel 20 mg per g	4.74	40 g OP	✓	Decozol
NYSTATIN				
Oral liq 100,000 u per ml	1.76	24 ml OP	✓	Nilstat
Nilstat to be Sole Supply on 1 October 2020				

Other Oral Agents

For folinic mouthwash, pilocarpine oral liquid or saliva substitute formulae refer Standard Formulae, [page 248](#)

THYMOL GLYCERIN				
* Compound, BPC	9.15	500 ml	✓	PSM

Vitamins

Vitamin B

HYDROXOCOBALAMIN				
* Inj 1 mg per ml, 1 ml ampoule – Up to 6 inj available on a PSO	1.89	3	✓	Neo-B12
PYRIDOXINE HYDROCHLORIDE				
a) No more than 100 mg per dose				
b) Only on a prescription				
* Tab 25 mg – No patient co-payment payable	2.70	90	✓	Vitamin B6 25
Vitamin B6 25 to be Sole Supply on 1 October 2020				
* Tab 50 mg	13.63	500	✓	Apo-Pyridoxine
THIAMINE HYDROCHLORIDE – Only on a prescription				
* Tab 50 mg	4.89	100	✓	Max Health
VITAMIN B COMPLEX				
* Tab, strong, BPC	7.15	500	✓	Bplex

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Vitamin C

ASCORBIC ACID

a) No more than 100 mg per dose				
b) Only on a prescription				
* Tab 100 mg	9.90	500	✓	Cvite

Vitamin D

ALFACALCIDOL

* Cap 0.25 mcg	26.32	100	✓	One-Alpha
* Cap 1 mcg	87.98	100	✓	One-Alpha
* Oral drops 2 mcg per ml	60.68	20 ml OP	✓	One-Alpha

CALCITRIOL

* Cap 0.25 mcg	7.95	100	✓	Calcitriol-AFT
* Cap 0.5 mcg	13.75	100	✓	Calcitriol-AFT

COLECALCIFEROL

* Cap 1.25 mg (50,000 iu) – Maximum of 12 cap per prescription	2.50	12	✓	Vit.D3
* Oral liq 188 mcg per ml (7,500 iu per ml)	9.00	4.8 ml OP	✓	Puria

Multivitamin Preparations

MULTIVITAMIN RENAL – Special Authority see [SA1546 below](#) – Retail pharmacy

* Cap	6.49	30	✓	Clinicians Renal Vit
-------------	------	----	---	----------------------

► [SA1546](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or
- 2 The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73 m² body surface area (BSA).

MULTIVITAMINS – Special Authority see [SA1036 below](#) – Retail pharmacy

* Powder	72.00	200 g OP	✓	Paediatric Seravit
----------------	-------	----------	---	--------------------

► [SA1036](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has inborn errors of metabolism.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where patient has had a previous approval for multivitamins.

VITAMINS

* Tab (BPC cap strength)	11.45	1,000	✓	Mvite
* Cap (fat soluble vitamins A, D, E, K) – Special Authority see SA1720 below – Retail pharmacy	23.40	60	✓	Vitabdeck

► [SA1720](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Patient has cystic fibrosis with pancreatic insufficiency; or
- 2 Patient is an infant or child with liver disease or short gut syndrome; or
- 3 Patient has severe malabsorption syndrome.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Minerals				
Calcium				
CALCIUM CARBONATE				
* Tab eff 1.75 g (1 g elemental)	28.40	20	✓	Calcium Sandoz ^{\$29}
* Tab 1.25 g (500 mg elemental)	7.52	250	✓	Arrow-Calcium
CALCIUM GLUCONATE				
* Inj 10%, 10 ml ampoule	32.00	10	✓	Max Health - Hameln ^{\$29}
	64.00	20	✓	Max Health ^{\$29}

Fluoride				
SODIUM FLUORIDE				
* Tab 1.1 mg (0.5 mg elemental)	5.75	100	✓	PSM
Iodine				
POTASSIUM IODATE				
Tab 253 mcg (150 mcg elemental iodine)	4.58	90	✓	NeuroTabs
NeuroTabs to be Sole Supply on 1 October 2020				

Iron				
FERRIC CARBOXYMALTOSE – Special Authority see SA1840 below – Retail pharmacy				
Inj 50 mg per ml, 10 ml	150.00	1	✓	Ferinject

► **SA1840** Special Authority for Subsidy

Initial application — (serum ferritin less than or equal to 20 mcg/L) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has been diagnosed with iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L; and
- 2 Any of the following:
 - 2.1 Patient has been compliant with oral iron treatment and treatment has proven ineffective; or
 - 2.2 Treatment with oral iron has resulted in dose-limiting intolerance; or
 - 2.3 Rapid correction of anaemia is required.

Renewal — (serum ferritin less than or equal to 20 mcg/L) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient continues to have iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L; and
- 2 A re-trial with oral iron is clinically inappropriate.

Initial application — (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or medical practitioner on the recommendation of a internal medicine physician, obstetrician, gynaecologist or anaesthetist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has been diagnosed with iron-deficiency anaemia; and
- 2 Any of the following:

continued...

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.1 Patient has been compliant with oral iron treatment and treatment has proven ineffective; or
- 2.2 Treatment with oral iron has resulted in dose-limiting intolerance; or
- 2.3 Patient has symptomatic heart failure, chronic kidney disease stage 3 or more or active inflammatory bowel disease and a trial of oral iron is unlikely to be effective; or
- 2.4 Rapid correction of anaemia is required.

Renewal — (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or medical practitioner on the recommendation of a internal medicine physician, obstetrician, gynaecologist or anaesthetist.

Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient continues to have iron-deficiency anaemia; and
- 2 A re-trial with oral iron is clinically inappropriate.

FERROUS FUMARATE

* Tab 200 mg (65 mg elemental)3.09 100 ✓ **Ferro-tab**

FERROUS FUMARATE WITH FOLIC ACID

* Tab 310 mg (100 mg elemental) with folic acid 350 mcg4.68 60 ✓ **Ferro-F-Tabs**

FERROUS SULFATE

* Oral liq 30 mg (6 mg elemental) per 1 ml12.08 500 ml ✓ **Ferodan**

FERROUS SULPHATE

* Tab long-acting 325 mg (105 mg elemental)2.06 30 ✓ **Ferrograd**

IRON POLYMALTOSE

* Inj 50 mg per ml, 2 ml ampoule34.50 5 ✓ **Ferrosig**

Magnesium

For magnesium hydroxide mixture refer Standard Formulae, [page 248](#)

MAGNESIUM HYDROXIDE

Suspension 8%72.20 500 ml ✓ **T&R** \$29

MAGNESIUM SULPHATE

* Inj 2 mmol per ml, 5 ml ampoule10.21 10 ✓ **DBL**
✓ **DBL** \$29 \$29

Zinc

ZINC SULPHATE

* Cap 137.4 mg (50 mg elemental)11.00 100 ✓ **Zincaps**

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Antianaemics

Hypoplastic and Haemolytic

►SA1775 Special Authority for Subsidy

Initial application — (chronic renal failure) from any specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin is less than or equal to 100g/L; and
- 3 Any of the following:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
 - 3.2 Both:
 - 3.2.1 Patient has diabetes mellitus; and
 - 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; or
 - 3.3 Patient is on haemodialysis or peritoneal dialysis.

Note: Epoetin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

Initial application — (myelodysplasia) from any specialist. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS)*; and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an unapproved indication

Renewal — (chronic renal failure) from any specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Epoetin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

Renewal — (myelodysplasia) from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an unapproved indication

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

BLOOD AND BLOOD FORMING ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
EPOETIN ALFA – Special Authority see SA1775 on the previous page – Retail pharmacy				
Wastage claimable				
Inj 1,000 iu in 0.5 ml, syringe.....	250.00	6	✓	Binocrit
Inj 2,000 iu in 1 ml, syringe.....	100.00	6	✓	Binocrit
Inj 3,000 iu in 0.3 ml, syringe.....	150.00	6	✓	Binocrit
Inj 4,000 iu in 0.4 ml, syringe.....	96.50	6	✓	Binocrit
Inj 5,000 iu in 0.5 ml, syringe.....	125.00	6	✓	Binocrit
Inj 6,000 iu in 0.6 ml, syringe.....	145.00	6	✓	Binocrit
Inj 8,000 iu in 0.8 ml, syringe.....	175.00	6	✓	Binocrit
Inj 10,000 iu in 1 ml, syringe.....	197.50	6	✓	Binocrit
Inj 40,000 iu in 1 ml, syringe.....	250.00	1	✓	Binocrit

Megaloblastic

FOLIC ACID				
* Tab 0.8 mg	21.84	1,000	✓	Apo-Folic Acid
* Tab 5 mg	12.12	500	✓	Apo-Folic Acid
Oral liq 50 mcg per ml	26.00	25 ml OP	✓	Biomed

Antifibrinolytics, Haemostatics and Local Sclerosants

EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpharm]

For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management group.

Inj 250 iu vial.....	612.50	1	✓	Alprolix
Inj 500 iu vial.....	1,225.00	1	✓	Alprolix
Inj 1,000 iu vial.....	2,450.00	1	✓	Alprolix
Inj 2,000 iu vial.....	4,900.00	1	✓	Alprolix
Inj 3,000 iu vial.....	7,350.00	1	✓	Alprolix

ELTROMBOPAG – Special Authority see [SA1743 below](#) – Retail pharmacy

Wastage claimable				
Tab 25 mg	1,550.00	28	✓	Revolade
Tab 50 mg	3,100.00	28	✓	Revolade

► [SA1743](#) Special Authority for Subsidy

Initial application — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
 - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
 - 3.2 Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding; or
 - 3.3 Patient has a platelet count of less than or equal to 10,000 platelets per microlitre.

Initial application — (idiopathic thrombocytopenic purpura - preparation for splenectomy) only from a haematologist.

Approvals valid for 6 weeks where the patient requires eltrombopag treatment as preparation for splenectomy.

Initial application — (idiopathic thrombocytopenic purpura contraindicated to splenectomy) only from a haematologist.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Either:
 - 3.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 3.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Initial application — (severe aplastic anaemia) only from a haematologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
- 2 Either:
 - 2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Renewal — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 12 months where the patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre.

Renewal — (idiopathic thrombocytopenic purpura contraindicated to splenectomy) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient's significant contraindication to splenectomy remains; and
- 2 The patient has obtained a response from treatment during the initial approval period; and
- 3 Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
- 4 Further treatment with eltrombopag is required to maintain response.

Renewal — (severe aplastic anaemia) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
- 2 Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – [Xpharm]

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for > 14 days predicted use. Access to funded treatment for > 14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria.

Inj 1 mg syringe	1,178.30	1	✓ NovoSeven RT
Inj 2 mg syringe	2,356.60	1	✓ NovoSeven RT
Inj 5 mg syringe	5,891.50	1	✓ NovoSeven RT
Inj 8 mg syringe	9,426.40	1	✓ NovoSeven RT

FACTOR EIGHT INHIBITOR BYPASSING FRACTION – [Xpharm]

For patients with haemophilia. Preferred Brand of bypassing agent for > 14 days predicted use. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Inj 500 U	1,315.00	1	✓ FEIBA NF
Inj 1,000 U	2,630.00	1	✓ FEIBA NF
Inj 2,500 U	6,575.00	1	✓ FEIBA NF

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

BLOOD AND BLOOD FORMING ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – [Xpharm]				
For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.				
Inj 250 iu prefilled syringe.....	287.50	1	✓	Xyntha
Inj 500 iu prefilled syringe.....	575.00	1	✓	Xyntha
Inj 1,000 iu prefilled syringe.....	1,150.00	1	✓	Xyntha
Inj 2,000 iu prefilled syringe.....	2,300.00	1	✓	Xyntha
Inj 3,000 iu prefilled syringe.....	3,450.00	1	✓	Xyntha
NONACOG GAMMA, [RECOMBINANT FACTOR IX] – [Xpharm]				
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.				
Inj 500 iu vial.....	435.00	1	✓	RIXUBIS
Inj 1,000 iu vial.....	870.00	1	✓	RIXUBIS
Inj 2,000 iu vial.....	1,740.00	1	✓	RIXUBIS
Inj 3,000 iu vial.....	2,610.00	1	✓	RIXUBIS
OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – [Xpharm]				
For patients with haemophilia. Preferred Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.				
Inj 250 iu vial.....	210.00	1	✓	Advate
Inj 500 iu vial.....	420.00	1	✓	Advate
Inj 1,000 iu vial.....	840.00	1	✓	Advate
Inj 1,500 iu vial.....	1,260.00	1	✓	Advate
Inj 2,000 iu vial.....	1,680.00	1	✓	Advate
Inj 3,000 iu vial.....	2,520.00	1	✓	Advate
OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) – [Xpharm]				
For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.				
Inj 250 iu vial.....	237.50	1	✓	Kogenate FS
Inj 500 iu vial.....	475.00	1	✓	Kogenate FS
Inj 1,000 iu vial.....	950.00	1	✓	Kogenate FS
Inj 2,000 iu vial.....	1,900.00	1	✓	Kogenate FS
Inj 3,000 iu vial.....	2,850.00	1	✓	Kogenate FS
RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] – [Xpharm]				
For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management group.				
Inj 250 iu vial.....	300.00	1	✓	Adynovate
Inj 500 iu vial.....	600.00	1	✓	Adynovate
Inj 1,000 iu vial.....	1,200.00	1	✓	Adynovate
Inj 2,000 iu vial.....	2,400.00	1	✓	Adynovate
SODIUM TETRADECYL SULPHATE				
* Inj 3% 2 ml.....	28.50 (73.00)	5		Fibro-vein
TRANEXAMIC ACID				
Tab 500 mg.....	9.45	60	✓	Mercury Pharma

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Vitamin K				
PHYTOMENADIONE				
Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO.....	8.00	5	✓	Konakion MM
Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO.....	9.21	5	✓	Konakion MM

Antithrombotic Agents

Antiplatelet Agents

ASPIRIN				
* Tab 100 mg	10.80	990	✓	Ethics Aspirin EC
CLOPIDOGREL				
* Tab 75 mg	4.60	84	✓	Clopidogrel Multichem
DIPYRIDAMOLE				
* Tab long-acting 150 mg.....	10.90	60	✓	Pytazen SR
PRASUGREL – Special Authority see SA1954 below – Retail pharmacy				
Tab 5 mg	108.00	28	✓	Effient
Tab 10 mg	120.00	28	✓	Effient
<i>(Effient Tab 5 mg to be delisted 1 February 2021)</i>				
<i>(Effient Tab 10 mg to be delisted 1 February 2021)</i>				
➤ SA1954 Special Authority for Subsidy				
Renewal — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty or had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.				
Renewal — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.				
Note: * Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.				
TICAGRELOR – Special Authority see SA1955 below – Retail pharmacy				
* Tab 90 mg	90.00	56	✓	Brilinta
➤ SA1955 Special Authority for Subsidy				
Initial application — (acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:				
Both:				
1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and				
2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.				
Initial application — (thrombosis prevention neurological stenting) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:				
Both:				
1 Either:				
1.1 Patient has had a neurological stenting procedure* in the last 60 days; or				
1.2 Patient is about to have a neurological stenting procedure performed*; and				
2 Either:				
2.1 Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet				

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- function assay and requires antiplatelet treatment with ticagrelor; or
- 2.2 Either:
- 2.2.1 Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event; or
- 2.2.2 Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent.

Initial application — (Percutaneous coronary intervention with stent deployment) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone percutaneous coronary intervention; and
- 2 Patient has had a stent deployed in the previous 4 weeks; and
- 3 Patient is clopidogrel-allergic**.

Initial application — (Stent thrombosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Renewal — (subsequent acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Renewal — (thrombosis prevention neurological stenting) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient is continuing to benefit from treatment; and
- 2 Treatment continues to be clinically appropriate.

Renewal — (Percutaneous coronary intervention with stent deployment) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undergone percutaneous coronary intervention; and
- 2 Patient has had a stent deployed in the previous 4 weeks; and
- 3 Patient is clopidogrel-allergic**.

Notes: indications marked with * are unapproved indications.

Note: ** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

Heparin and Antagonist Preparations

ENOXAPARIN SODIUM – Special Authority see [SA1646 on the next page](#) – Retail pharmacy

Inj 20 mg in 0.2 ml syringe.....	27.93	10	✓ Clexane
Inj 40 mg in 0.4 ml syringe.....	37.27	10	✓ Clexane
Inj 60 mg in 0.6 ml syringe.....	56.18	10	✓ Clexane
Inj 80 mg in 0.8 ml syringe.....	74.90	10	✓ Clexane
Inj 100 mg in 1 ml syringe.....	93.80	10	✓ Clexane
Inj 120 mg in 0.8 ml syringe.....	116.55	10	✓ Clexane
			✓ Clexane Forte
Inj 150 mg in 1 ml syringe.....	133.20	10	✓ Clexane
			✓ Clexane Forte

(Clexane Inj 120 mg in 0.8 ml syringe to be delisted 1 January 2021)

(Clexane Inj 150 mg in 1 ml syringe to be delisted 1 January 2021)

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA1646 Special Authority for Subsidy

Initial application — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy; or
- 3 For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner.

Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy; or
- 3 For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

Inj 1,000 iu per ml, 5 ml ampoule	58.57	50	✓ Pfizer
Inj 5,000 iu per ml, 1 ml	28.40	5	✓ Pfizer
	32.66		✓ Hospira
Inj 5,000 iu per ml, 5 ml ampoule	203.68	50	✓ Pfizer
Inj 25,000 iu per ml, 0.2 ml	19.00	5	✓ Hospira
	42.40		✓ Heparin DBL ^{\$29}
			✓ Heparin
			Ratiopharm ^{\$29}
	122.00	10	✓ Wockhardt ^{\$29}
	190.00	50	✓ Pfizer ^{\$29}

(Heparin Ratiopharm ^{\$29} Inj 25,000 iu per ml, 0.2 ml to be delisted 1 January 2021)

(Wockhardt ^{\$29} Inj 25,000 iu per ml, 0.2 ml to be delisted 1 January 2021)

(Pfizer ^{\$29} Inj 25,000 iu per ml, 0.2 ml to be delisted 1 November 2020)

HEPARINISED SALINE

Inj 10 iu per ml, 5 ml	65.48	50	✓ Pfizer
------------------------------	-------	----	----------

Oral Anticoagulants

DABIGATRAN

Cap 75 mg – No more than 2 cap per day	76.36	60	✓ Pradaxa
Cap 110 mg	76.36	60	✓ Pradaxa
Cap 150 mg	76.36	60	✓ Pradaxa

BLOOD AND BLOOD FORMING ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
RIVAROXABAN				
Tab 10 mg – No more than 1 tab per day.....	83.10	30	✓	Xarelto
Tab 15 mg – Up to 14 tab available on a PSO	77.56	28	✓	Xarelto
Tab 20 mg	77.56	28	✓	Xarelto
WARFARIN SODIUM				
Note: Marevan and Coumadin are not interchangeable.				
* Tab 1 mg	3.46	50	✓	Coumadin
	6.46	100	✓	Marevan
* Tab 2 mg	4.31	50	✓	Coumadin
* Tab 3 mg	10.03	100	✓	Marevan
* Tab 5 mg	5.93	50	✓	Coumadin
	11.48	100	✓	Marevan

Blood Colony-stimulating Factors

FILGRASTIM – Special Authority see [SA1259 below](#) – Retail pharmacy

Inj 300 mcg per 0.5 ml prefilled syringe.....	96.22	10	✓	Nivestim
Inj 480 mcg per 0.5 ml prefilled syringe.....	161.50	10	✓	Nivestim

►SA1259 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 20%); or
- 2 Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation; or
- 3 Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation; or
- 4 Treatment of severe chronic neutropenia ($ANC < 0.5 \times 10^9/L$); or
- 5 Treatment of drug-induced prolonged neutropenia ($ANC < 0.5 \times 10^9/L$).

Note: *Febrile neutropenia risk greater than or equal to 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

PEGFILGRASTIM – Special Authority see [SA1912 below](#) – Retail pharmacy

Inj 6 mg per 0.6 ml syringe	1,080.00	1	✓	Neulastim
-----------------------------------	----------	---	---	------------------

►SA1912 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where used for prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 5%*).

Note: *Febrile neutropenia risk greater than or equal to 5% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

Fluids and Electrolytes

Intravenous Administration

GLUCOSE [DEXTROSE]

* Inj 50%, 10 ml ampoule – Up to 5 inj available on a PSO	30.65	5	✓	Biomed
Biomed to be Sole Supply on 1 November 2020				
* Inj 50%, 90 ml bottle – Up to 5 inj available on a PSO	15.00	1	✓	Biomed
Biomed to be Sole Supply on 1 November 2020				

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
POTASSIUM CHLORIDE				
* Inj 75 mg per ml, 10 ml	55.00	50	✓	AstraZeneca Potassium Chloride Aguettant S29
SODIUM BICARBONATE				
Inj 8.4%, 50 ml	19.95	1	✓	Biomed
a) Up to 5 inj available on a PSO				
b) Not in combination				
Inj 8.4%, 100 ml	20.50	1	✓	Biomed
a) Up to 5 inj available on a PSO				
b) Not in combination				
SODIUM CHLORIDE				
Not funded for use as a nasal drop. Not funded for nebuliser use except when used in conjunction with an antibiotic intended for nebuliser use.				
Inj 0.9%, bag – Up to 2000 ml available on a PSO	1.23	500 ml	✓	Baxter
	1.26	1,000 ml	✓	Baxter
Only if prescribed on a prescription for renal dialysis, maternity or post-natal care in the home of the patient, or on a PSO for emergency use. (500 ml and 1,000 ml packs)				
Inj 23.4% (4 mmol/ml), 20 ml ampoule	33.00	5	✓	Biomed
For Sodium chloride oral liquid formulation refer Standard Formulae, page 248				
Inj 0.9%, 5 ml ampoule – Up to 5 inj available on a PSO	2.80	20	✓	Fresenius Kabi
Inj 0.9%, 10 ml ampoule – Up to 5 inj available on a PSO	5.40	50	✓	Fresenius Kabi
Inj 0.9%, 20 ml ampoule	5.00	20	✓	Fresenius Kabi
TOTAL PARENTERAL NUTRITION (TPN)				
Infusion	CBS	1 OP	✓	TPN
WATER				
1) On a prescription or Practitioner's Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or				
2) On a bulk supply order; or				
3) When used in the extemporaneous compounding of eye drops; or				
4) When used for the dilution of sodium chloride soln 7% for cystic fibrosis patients only.				
Inj 5 ml ampoule – Up to 5 inj available on a PSO	7.00	50	✓	InterPharma
Inj 10 ml ampoule – Up to 5 inj available on a PSO	6.63	50	✓	Pfizer
Inj 20 ml ampoule – Up to 5 inj available on a PSO	5.00	20	✓	Fresenius Kabi
	7.50	30	✓	Multichem InterPharma
Oral Administration				
CALCIUM POLYSTYRENE SULPHONATE				
Powder	169.85	300 g OP	✓	Calcium Resonium
COMPOUND ELECTROLYTES				
Powder for oral soln – Up to 5 sach available on a PSO	9.77	50	✓	Electral
COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]				
Soln with electrolytes (2 x 500 ml)	6.55	1,000 ml OP	✓	Pedialyte - Bubblegum
PHOSPHORUS				
Tab eff 500 mg (16 mmol)	82.50	100	✓	Phosphate Phebra

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

BLOOD AND BLOOD FORMING ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
POTASSIUM CHLORIDE				
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq).....	5.26 (11.85)	60		Chlorvescent
* Tab long-acting 600 mg (8 mmol).....	8.90	200	✓	<u>Span-K</u>
SODIUM BICARBONATE				
Cap 840 mg.....	8.52	100	✓	Sodibic
			✓	Sodibic
SODIUM POLYSTYRENE SULPHONATE				
Powder	84.65	454 g OP	✓	<u>Resonium-A</u>

Subsidy
(Manufacturer's Price)
\$

Fully
Subsidised
Per ✓

Brand or
Generic
Manufacturer

Alpha-Adrenoceptor Blockers

Alpha Adrenoceptor Blockers

DOXAZOSIN

Tab 2 mg	8.95	500	✓ Apo-Doxazosin
Tab 4 mg	10.80	500	✓ Apo-Doxazosin

PHENOXYBENZAMINE HYDROCHLORIDE

* Cap 10 mg	65.00	30	✓ BNM ^{\$29}
	216.67	100	✓ Dibenzyline ^{\$29}

PRAZOSIN

* Tab 1 mg	5.53	100	✓ Apo-Prazosin
* Tab 2 mg	7.00	100	✓ Apo-Prazosin
* Tab 5 mg	11.70	100	✓ Apo-Prazosin

TERAZOSIN

* Tab 1 mg	0.59	28	✓ Actavis
Tab 2 mg	7.50	500	✓ Apo-Terazosin
Tab 5 mg	10.90	500	✓ Apo-Terazosin

(Actavis Tab 1 mg to be delisted 1 October 2020)

Agents Affecting the Renin-Angiotensin System

ACE Inhibitors

CAPTOPRIL

* Oral liq 5 mg per ml	94.99	95 ml OP	✓ Capoten
------------------------------	-------	----------	-----------

Oral liquid restricted to children under 12 years of age.

CILAZAPRIL

* Tab 0.5 mg	2.09	90	✓ <u>Zapril</u>
* Tab 2.5 mg	4.80	90	✓ <u>Zapril</u>
* Tab 5 mg	8.35	90	✓ <u>Zapril</u>

ENALAPRIL MALEATE

* Tab 5 mg	1.82	100	✓ <u>Acetec</u>
* Tab 10 mg	2.02	100	✓ <u>Acetec</u>
* Tab 20 mg	2.42	100	✓ <u>Acetec</u>

LISINOPRIL

* Tab 5 mg	2.07	90	✓ <u>Ethics Lisinopril</u>
* Tab 10 mg	2.36	90	✓ <u>Ethics Lisinopril</u>
* Tab 20 mg	3.17	90	✓ <u>Ethics Lisinopril</u>

PERINDOPRIL

* Tab 2 mg	3.75	30	✓ Apo-Perindopril
* Tab 4 mg	4.80	30	✓ Apo-Perindopril

QUINAPRIL

* Tab 5 mg	6.01	90	✓ <u>Arrow-Quinapril 5</u>
* Tab 10 mg	3.16	90	✓ <u>Arrow-Quinapril 10</u>
* Tab 20 mg	4.89	90	✓ <u>Arrow-Quinapril 20</u>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

ACE Inhibitors with Diuretics

CILAZAPRIL WITH HYDROCHLOROTHIAZIDE – Subsidy by endorsement

Subsidy by endorsement – Subsidised for patients who were taking cilazapril with hydrochlorothiazide prior to 1 March 2020 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of cilazapril with hydrochlorothiazide.

* Tab 5 mg with hydrochlorothiazide 12.5 mg.....	10.18	100	✓	Apo-Cilazapril/ Hydrochlorothiazide
--	-------	-----	---	--

(Apo-Cilazapril/ Hydrochlorothiazide Tab 5 mg with hydrochlorothiazide 12.5 mg to be delisted 1 December 2020)

QUINAPRIL WITH HYDROCHLOROTHIAZIDE

Tab 10 mg with hydrochlorothiazide 12.5 mg.....	3.57	28	✓	Accuretic
	3.83	30	✓	Accuretic 10
* Tab 20 mg with hydrochlorothiazide 12.5 mg.....	4.92	30	✓	Accuretic 20

Angiotensin II Antagonists

CANDESARTAN CILEXETIL

* Tab 4 mg	1.90	90	✓	Candestar
* Tab 8 mg	2.28	90	✓	Candestar
* Tab 16 mg	3.67	90	✓	Candestar
* Tab 32 mg	6.39	90	✓	Candestar

LOSARTAN POTASSIUM

* Tab 12.5 mg	1.39	84	✓	Losartan Actavis
* Tab 25 mg	1.63	84	✓	Losartan Actavis
* Tab 50 mg	2.00	84	✓	Losartan Actavis
* Tab 100 mg	2.31	84	✓	Losartan Actavis

Angiotensin II Antagonists with Diuretics

LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE

* Tab 50 mg with hydrochlorothiazide 12.5 mg.....	1.88	30	✓	Arrow-Losartan & Hydrochlorothiazide
---	------	----	---	---

Angiotensin II Antagonists with Neprilysin Inhibitors

SACUBITRIL WITH VALSARTAN – Special Authority see [SA1905 below](#) – Retail pharmacy

Note: Due to the angiotensin II receptor blocking activity of sacubitril with valsartan it should not be co-administered with an ACE inhibitor or another ARB.

Tab 24.3 mg with valsartan 25.7 mg	190.00	56	✓	Entresto 24/26
Tab 48.6 mg with valsartan 51.4 mg	190.00	56	✓	Entresto 49/51
Tab 97.2 mg with valsartan 102.8 mg	190.00	56	✓	Entresto 97/103

► **SA1905** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
All of the following:

- 1 Patient has heart failure; and
- 2 Any of the following:
 - 2.1 Patient is in NYHA/WHO functional class II; or

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

2.2 Patient is in NYHA/WHO functional class III; or

2.3 Patient is in NYHA/WHO functional class IV; and

3 Either:

3.1 Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; or

3.2 An ECHO is not reasonably practical, and in the opinion of the treating practitioner the patient would benefit from treatment; and

4 Patient is receiving concomitant optimal standard chronic heart failure treatments.

Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Antiarrhythmics

For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaesthetics, Local, [page 119](#)

AMIODARONE HYDROCHLORIDE

▲ Tab 100 mg	3.80	30	✓ Aratac
▲ Tab 200 mg	5.25	30	✓ Aratac
Inj 50 mg per ml, 3 ml ampoule – Up to 10 inj available on a PSO	16.37	10	✓ Max Health

ATROPINE SULPHATE

* Inj 600 mcg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	12.07	10	✓ Martindale
--	-------	----	---------------------

DIGOXIN

* Tab 62.5 mcg – Up to 30 tab available on a PSO	7.00	240	✓ Lanoxin PG
* Tab 250 mcg – Up to 30 tab available on a PSO	15.20	240	✓ Lanoxin
* Oral liq 50 mcg per ml	16.60	60 ml	✓ Lanoxin
			✓ Lanoxin S29 <small>\$29</small>

DISOPYRAMIDE PHOSPHATE

▲ Cap 100 mg	23.87	100	✓ Rythmodan
--------------------	-------	-----	--------------------

FLECAINIDE ACETATE

▲ Tab 50 mg	19.95	60	✓ Flecainide BNM
▲ Cap long-acting 100 mg	39.51	90	✓ Flecainide Controlled Release Teva
▲ Cap long-acting 200 mg	61.06	90	✓ Flecainide Controlled Release Teva
Inj 10 mg per ml, 15 ml ampoule	100.00	5	✓ Tambacor

MEXILETINE HYDROCHLORIDE

▲ Cap 150 mg	162.00	100	✓ Mexiletine Hydrochloride USP <small>\$29</small>
▲ Cap 250 mg	202.00	100	✓ Mexiletine Hydrochloride USP <small>\$29</small>

PROPAFENONE HYDROCHLORIDE

▲ Tab 150 mg	40.90	50	✓ Rytmonorm
--------------------	-------	----	--------------------

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

Antihypotensives

MIDODRINE – Special Authority see [SA1474 below](#) – Retail pharmacy

Tab 2.5 mg	53.00	100	✓ Gutron
Tab 5 mg	79.00	100	✓ Gutron

► [SA1474](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years where patient has disabling orthostatic hypotension not due to drugs.

Note: Treatment should be started with small doses and titrated upwards as necessary. Hypertension should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Beta-Adrenoceptor Blockers

Beta Adrenoceptor Blockers

ATENOLOL

* Tab 50 mg	4.26	500	✓ Mylan Atenolol
* Tab 100 mg	7.30	500	✓ Mylan Atenolol
* Oral liq 25 mg per 5 ml	21.25	300 ml OP	✓ Atenolol AFT
			✓ Atenolol AFT
			S29 S29

Restricted to children under 12 years of age.

BISOPROLOL FUMARATE

* Tab 2.5 mg	3.53	90	✓ Bosvate
* Tab 5 mg	5.15	90	✓ Bosvate
* Tab 10 mg	9.40	90	✓ Bosvate

CARVEDILOL

* Tab 6.25 mg	2.24	60	✓ Carvedilol Sandoz
* Tab 12.5 mg	2.30	60	✓ Carvedilol Sandoz
* Tab 25 mg	2.95	60	✓ Carvedilol Sandoz

CELIPROLOL

* Tab 200 mg	21.40	180	✓ Celol
--------------------	-------	-----	----------------

LABETALOL

* Tab 100 mg	14.50	100	✓ Trandate
* Tab 200 mg	27.00	100	✓ Trandate
* Inj 5 mg per ml, 20 ml ampoule	59.06 (88.60)	5	Trandate
* inj 5 mg per ml, 20 ml vial	42.29 (48.20)	1	Alvogen S29

METOPROLOL SUCCINATE

* Tab long-acting 23.75 mg	1.03	30	✓ Betaloc CR
* Tab long-acting 47.5 mg	1.25	30	✓ Betaloc CR
* Tab long-acting 95 mg	1.99	30	✓ Betaloc CR
* Tab long-acting 190 mg	3.00	30	✓ Betaloc CR

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
METOPROLOL TARTRATE				
* Tab 50 mg	5.66	100	✓	Apo-Metoprolol
* Tab 100 mg	7.55	60	✓	Apo-Metoprolol
* Tab long-acting 200 mg.....	23.40	28	✓	Slow-Lopresor
* Inj 1 mg per ml, 5 ml vial.....	29.50	5	✓	Metoprolol IV Mylan
NADOLOL				
* Tab 40 mg	16.69	100	✓	Apo-Nadolol
* Tab 80 mg	26.43	100	✓	Apo-Nadolol
PINDOLOL				
* Tab 5 mg	13.22	100	✓	Apo-Pindolol
* Tab 10 mg	23.12	100	✓	Apo-Pindolol
* Tab 15 mg	33.31	100	✓	Apo-Pindolol
PROPRANOLOL				
* Tab 10 mg	4.64	100	✓	Apo-Propranolol
* Tab 40 mg	5.72	100	✓	Apo-Propranolol
* Cap long-acting 160 mg	18.17	100	✓	Cardinol LA
* Oral liq 4 mg per ml – Special Authority see SA1327 below – Retail pharmacy.....	CBS	500 ml	✓	Roxane <small>S29</small>

► **SA1327** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
- 2 For the treatment of a child under 12 years with cardiac arrhythmias or congenital cardiac abnormalities.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
- 2 For the treatment of a child under 12 years with cardiac arrhythmias or congenital cardiac abnormalities.

SOTALOL

* Tab 80 mg	32.58	500	✓	Mylan
* Tab 160 mg	10.98	100	✓	Mylan

TIMOLOL

* Tab 10 mg	10.55	100	✓	Apo-Timol
-------------------	-------	-----	---	------------------

Calcium Channel Blockers

Dihydropyridine Calcium Channel Blockers

AMLODIPINE

Tab 2.5 mg	1.72	100	✓	Apo-Amlodipine
Tab 5 mg	3.33	250	✓	Apo-Amlodipine
Tab 10 mg	4.40	250	✓	Apo-Amlodipine

FELODIPINE

* Tab long-acting 2.5 mg.....	1.45	30	✓	Plendil ER
* Tab long-acting 5 mg.....	3.93	90	✓	Felo 5 ER
* Tab long-acting 10 mg.....	4.32	90	✓	Felo 10 ER

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
NIFEDIPINE				
* Tab long-acting 10 mg.....	10.63	60	✓	Adalat 10
			✓	Adefin ^{\$29}
* Tab long-acting 20 mg.....	17.72	100	✓	Nyefax Retard
* Tab long-acting 30 mg.....	3.14	30	✓	Adalat Oros
* Tab long-acting 60 mg.....	5.67	30	✓	Adalat Oros
			✓	Adefin XL

Other Calcium Channel Blockers

DILTIAZEM HYDROCHLORIDE				
* Tab 30 mg	4.60	100	✓	Dilzem
* Tab 60 mg	8.50	100	✓	Dilzem
* Cap long-acting 120 mg	33.42	500	✓	Apo-Diltiazem CD
* Cap long-acting 180 mg	50.05	500	✓	Apo-Diltiazem CD
* Cap long-acting 240 mg	66.76	500	✓	Apo-Diltiazem CD
PERHEXILINE MALEATE				
* Tab 100 mg	62.90	100	✓	Pexsig
VERAPAMIL HYDROCHLORIDE				
* Tab 40 mg	7.01	100	✓	Isoptin
* Tab 80 mg	11.74	100	✓	Isoptin
* Tab long-acting 120 mg.....	36.02	100	✓	Isoptin Retard ^{\$29}
			✓	Isoptin SR
			✓	Isoptin SR
* Tab long-acting 240 mg.....	15.12	30	✓	Isoptin SR
* Inj 2.5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	25.00	5	✓	Isoptin

Centrally-Acting Agents

CLONIDINE				
* Patch 2.5 mg, 100 mcg per day – Only on a prescription.....	10.34	4	✓	Mylan
Mylan to be Sole Supply on 1 November 2020				
* Patch 5 mg, 200 mcg per day – Only on a prescription.....	13.18	4	✓	Mylan
Mylan to be Sole Supply on 1 November 2020				
* Patch 7.5 mg, 300 mcg per day – Only on a prescription.....	16.93	4	✓	Mylan
Mylan to be Sole Supply on 1 November 2020				
CLONIDINE HYDROCHLORIDE				
* Tab 25 mcg.....	8.75	112	✓	Clonidine BNM
* Tab 150 mcg.....	34.32	100	✓	Catapres
* Inj 150 mcg per ml, 1 ml ampoule	25.96	10	✓	Medsurge
METHYLDOPA				
* Tab 250 mg	15.10	100	✓	Methyldopa Mylan
	52.85	500	✓	Methyldopa Mylan
				\$29 ^{\$29}

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

Diuretics

Loop Diuretics

BUMETANIDE

* Tab 1 mg	4.91	30	✓ Burinex S29 <small>S29</small>
	16.36	100	✓ Burinex
* Inj 500 mcg per ml, 4 ml vial	7.95	5	✓ Burinex

FUROSEMIDE [FRUSEMIDE]

* Tab 40 mg – Up to 30 tab available on a PSO	7.24	1,000	✓ Apo-Furosemide
* Tab 500 mg	25.00	50	✓ Urex Forte
* Oral liq 10 mg per ml	11.20	30 ml OP	✓ Lasix
* Inj 10 mg per ml, 25 ml ampoule	60.65	6	✓ Lasix
* Inj 10 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	1.15	5	✓ Frusemide-Clarix

Potassium Sparing Diuretics

AMILORIDE HYDROCHLORIDE

Oral liq 1 mg per ml	30.00	25 ml OP	✓ Biomed
----------------------------	-------	----------	-----------------

EPLERENONE – Special Authority see SA1728 below – Retail pharmacy

Tab 50 mg	17.00	30	✓ Inspira
Tab 25 mg	11.87	30	✓ Inspira

►SA1728 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has heart failure with ejection fraction less than 40%; and
- 2 Either:
 - 2.1 Patient is intolerant to optimal dosing of spironolactone; or
 - 2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone.

METOLAZONE

Tab 5 mg	CBS	1	✓ Metolazone <small>S29</small>
		50	✓ Zaroxolyn <small>S29</small>

SPIRONOLACTONE

* Tab 25 mg	4.38	100	✓ Spiractin
* Tab 100 mg	11.80	100	✓ Spiractin
Oral liq 5 mg per ml	30.60	25 ml OP	✓ Biomed

Potassium Sparing Combination Diuretics

AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE

* Tab 5 mg with furosemide 40 mg	8.63	28	✓ Frumil
--	------	----	-----------------

AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE

* Tab 5 mg with hydrochlorothiazide 50 mg	5.00	50	✓ Moduretic
---	------	----	--------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Thiazide and Related Diuretics

BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]

* Tab 2.5 mg – Up to 150 tab available on a PSO 20.00 500 ✓ **Arrow-Bendrofluazide**

a) May be supplied on a PSO for reasons other than emergency.

b) Arrow-Bendrofluazide to be Sole Supply on 1 December 2020

* Tab 5 mg 34.55 500 ✓ **Arrow-Bendrofluazide**

Arrow-Bendrofluazide to be Sole Supply on 1 December 2020

CHLOROTHIAZIDE

Oral liq 50 mg per ml 26.00 25 ml OP ✓ **Biomed**

CHLORTALIDONE [CHLORTHALIDONE]

* Tab 25 mg 6.50 50 ✓ **Hygroton**

INDAPAMIDE

* Tab 2.5 mg 10.45 90 ✓ **Dapa-Tabs**

Dapa-Tabs to be Sole Supply on 1 November 2020

Lipid-Modifying Agents

Fibrates

BEZAFIBRATE

* Tab 200 mg 19.01 90 ✓ **Bezalip**

* Tab long-acting 400 mg 12.89 30 ✓ **Bezalip Retard**

GEMFIBROZIL – Subsidy by endorsement

Subsidy by endorsement – Subsidised for patients who were taking gemfibrozil prior to 1 August 2020 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of gemfibrozil.

* Tab 600 mg 19.56 60 ✓ **Lipazil**

(Lipazil Tab 600 mg to be delisted 1 January 2021)

Other Lipid-Modifying Agents

ACIPIMOX

* Cap 250 mg 21.56 30 ✓ **Olbetam**
✓ **Olbetam S29** S29

NICOTINIC ACID

Tab 50 mg 4.12 100 ✓ **Apo-Nicotinic Acid**

Tab 500 mg 17.89 100 ✓ **Apo-Nicotinic Acid**

Resins

COLESTIPOL HYDROCHLORIDE

Grans for oral liq 5 g 28.60 30 ✓ **Colestid**

Subsidy
(Manufacturer's Price)
\$ Per Fully
Subsidised
✓ Brand or
Generic
Manufacturer

HMG CoA Reductase Inhibitors (Statins)

ATORVASTATIN

* Tab 10 mg	6.96	500	✓ Lorstat
* Tab 20 mg	9.99	500	✓ Lorstat
* Tab 40 mg	15.93	500	✓ Lorstat
* Tab 80 mg	27.19	500	✓ Lorstat

PRAVASTATIN

* Tab 10 mg	3.55	28	✓ Pravastatin Mylan
* Tab 20 mg	4.72	100	✓ Apo-Pravastatin
* Tab 40 mg	4.65	28	✓ Pravastatin Mylan
	8.06	100	✓ Apo-Pravastatin

SIMVASTATIN

* Tab 10 mg	1.23	90	✓ Simvastatin Mylan
Simvastatin Mylan to be Sole Supply on 1 November 2020			
* Tab 20 mg	2.03	90	✓ Simvastatin Mylan
Simvastatin Mylan to be Sole Supply on 1 November 2020			
* Tab 40 mg	3.58	90	✓ Simvastatin Mylan
Simvastatin Mylan to be Sole Supply on 1 November 2020			
* Tab 80 mg	7.12	90	✓ Simvastatin Mylan
Simvastatin Mylan to be Sole Supply on 1 November 2020			

Selective Cholesterol Absorption Inhibitors

EZETIMIBE – Special Authority see [SA1045 below](#) – Retail pharmacy

* Tab 10 mg	1.95	30	✓ Ezetimibe Sandoz
Ezetimibe Sandoz to be Sole Supply on 1 October 2020			

►SA1045 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
 - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 x normal) when treated with one statin; or
 - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
 - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

EZETIMIBE WITH SIMVASTATIN – Special Authority see [SA1046 on the next page](#) – Retail pharmacy

Tab 10 mg with simvastatin 10 mg	5.15	30	✓ Zimybe
Tab 10 mg with simvastatin 20 mg	6.15	30	✓ Zimybe
Tab 10 mg with simvastatin 40 mg	7.15	30	✓ Zimybe
Tab 10 mg with simvastatin 80 mg	8.15	30	✓ Zimybe

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

►SA1046 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to less than or equal to 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Nitrates

GLYCERYL TRINITRATE

* Oral pump spray, 400 mcg per dose – Up to 250 dose available on a PSO	4.45	250 dose OP	✓ Nitrolingual Pump Spray
* Patch 25 mg, 5 mg per day	15.73	30	✓ Nitroderm TTS
* Patch 50 mg, 10 mg per day	18.62	30	✓ Nitroderm TTS

ISOSORBIDE MONONITRATE

* Tab 20 mg	19.55	100	✓ Ismo 20
Ismo 20 to be Sole Supply on 1 November 2020			
* Tab long-acting 40 mg.....	8.20	30	✓ Ismo 40 Retard
Ismo 40 Retard to be Sole Supply on 1 November 2020			
* Tab long-acting 60 mg.....	9.25	90	✓ Duride
Duride to be Sole Supply on 1 November 2020			

Sympathomimetics

ADRENALINE

Inj 1 in 1,000, 1 ml ampoule – Up to 5 inj available on a PSO	4.98	5	✓ Aspen Adrenaline
	10.76		✓ DBL Adrenaline
Inj 1 in 10,000, 10 ml ampoule – Up to 5 inj available on a PSO	27.00	5	✓ Hospira
	49.00	10	✓ Aspen Adrenaline

ISOPRENALINE [ISOPROTERENOL]

* Inj 200 mcg per ml, 1 ml ampoule	36.80	25	
	(164.20)		Isuprel

Vasodilators

HYDRALAZINE HYDROCHLORIDE

* Tab 25 mg – Special Authority see SA1321 on the next page – Retail pharmacy.....	CBS	1	✓ Hydralazine
		56	✓ Onelink ^{S29}
		84	✓ AMDIPHARM ^{S29}
		100	✓ Onelink ^{S29}
* Inj 20 mg ampoule.....	25.90	5	✓ Apresoline

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

►SA1321 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 For the treatment of refractory hypertension; or
- 2 For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.

MINOXIDIL

▲ Tab 10 mg 70.00 100 ✓ **Loniten**

NICORANDIL

▲ Tab 10 mg 25.57 60 ✓ **Ikorel**

▲ Tab 20 mg 32.28 60 ✓ **Ikorel**

PAPAVERINE HYDROCHLORIDE

* Inj 12 mg per ml, 10 ml ampoule 217.90 5 ✓ **Hospira**

PENTOXIFYLLINE [OXPENTIFYLLINE]

Tab 400 mg 42.26 50 ✓ **Trental 400**

Endothelin Receptor Antagonists

AMBRISENTAN – Special Authority see SA1702 below – Retail pharmacy

Tab 5 mg 4,585.00 30 ✓ **Volibris**

Tab 10 mg 4,585.00 30 ✓ **Volibris**

►SA1702 Special Authority for Subsidy

Special Authority approved by the Pulmonary Arterial Hypertension Panel

Notes: Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms or:

The Coordinator, PAH Panel

PHARMAC, PO Box 10-254, WELLINGTON

Tel: (04) 916 7561, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz

BOSENTAN – Special Authority see SA1908 below – Retail pharmacy

Tab 62.5 mg 141.00 60 ✓ **Bosentan Dr Reddy's**

Tab 125 mg 141.00 60 ✓ **Bosentan Dr Reddy's**

►SA1908 Special Authority for Subsidy

Initial application only from a respiratory specialist, cardiologist or medical practitioner on the recommendation of a respiratory physician or cardiologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice) clinical classifications; and
- 3 PAH is at NYHA/WHO functional class II, III, or IV; and
- 4 Any of the following:
 - 4.1 Both:
 - 4.1.1 Bosentan is to be used as PAH monotherapy; and
 - 4.1.2 Either:
 - 4.1.2.1 Patient is intolerant or contraindicated to sildenafil; or
 - 4.1.2.2 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease; or

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 4.2 Both:
 - 4.2.1 Bosentan is to be used as PAH dual therapy; and
 - 4.2.2 Either:
 - 4.2.2.1 Patient has tried a PAH monotherapy for at least three months and failed to respond; or
 - 4.2.2.2 Patient deteriorated while on a PAH monotherapy; or
- 4.3 Both:
 - 4.3.1 Bosentan is to be used as PAH triple therapy; and
 - 4.3.2 Any of the following:
 - 4.3.2.1 Patient is on the lung transplant list; or
 - 4.3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
 - 4.3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
 - 4.3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Bosentan is to be used as PAH monotherapy; and
 - 1.2 Patient is stable or has improved while on bosentan; or
- 2 Both:
 - 2.1 Bosentan is to be used as PAH dual therapy; and
 - 2.2 Patient has tried a PAH monotherapy for at least three months and either failed to respond or later deteriorated; or
- 3 Both:
 - 3.1 Bosentan is to be used as PAH triple therapy; and
 - 3.2 Any of the following:
 - 3.2.1 Patient is on the lung transplant list; or
 - 3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
 - 3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
 - 3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.

Phosphodiesterase Type 5 Inhibitors

SILDENAFIL – Special Authority see [SA1909 below](#) – Retail pharmacy

Tab 25 mg	0.64	4	✓ Vedafil
Tab 50 mg	0.64	4	✓ Vedafil
Tab 100 mg	6.60	12	✓ Vedafil

➔ **SA1909** Special Authority for Subsidy

Initial application — (**Raynaud's Phenomenon***) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has Raynaud's Phenomenon*; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs); and
- 4 Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated).

Initial application — (Pulmonary arterial hypertension*) only from a respiratory specialist, cardiologist or medical practitioner on the recommendation of a respiratory specialist or cardiologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 Any of the following:
 - 2.1 PAH is in Group 1 of the WHO (Venice) clinical classifications; or
 - 2.2 PAH is in Group 4 of the WHO (Venice) clinical classifications; or
 - 2.3 PAH is in Group 5 of the WHO (Venice) clinical classifications; and
- 3 Any of the following:
 - 3.1 PAH is in NYHA/WHO functional class II; or
 - 3.2 PAH is in NYHA/WHO functional class III; or
 - 3.3 PAH is in NYHA/WHO functional class IV; and
- 4 Either:
 - 4.1 All of the following:
 - 4.1.1 Patient has a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.2 Either:
 - 4.1.2.1 Patient has a mean pulmonary artery pressure (PAPm) > 25 mmHg; or
 - 4.1.2.2 Patient is peri Fontan repair; and
 - 4.1.3 Patient has a pulmonary vascular resistance (PVR) of at least 3 Wood Units or at least 240 International Units (dyn s cm⁻⁵); or
 - 4.2 Testing for PCWP, PAPm, or PVR cannot be performed due to the patient's young age, or health system capacity constraints.

Note: Indications marked with * are unapproved indications.

Initial application — (erectile dysfunction due to spinal cord injury) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has a documented history of traumatic or non-traumatic spinal cord injury; and
- 2 Patient has erectile dysfunction secondary to spinal cord injury requiring pharmacological treatment.

Renewal — (erectile dysfunction due to spinal cord injury) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Prostacyclin Analogues

EPOPSTENOL — Special Authority see [SA1696 below](#) – Retail pharmacy

Inj 500 mcg vial.....	36.61	1	✓ Veletri
Inj 1.5 mg vial	73.21	1	✓ Veletri

»SA1696 Special Authority for Subsidy

Special Authority approved by the Pulmonary Arterial Hypertension Panel

Notes: Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms or:

The Coordinator, PAH Panel

PHARMAC, PO Box 10-254, WELLINGTON

Tel: (04) 916 7561, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz

ILOPROST — Special Authority see [SA1705 on the next page](#) – Retail pharmacy

Nebuliser soln 10 mcg per ml, 2 ml	740.10	30	✓ Ventavis
--	--------	----	------------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

➤SA1705 Special Authority for Subsidy

Special Authority approved by the Pulmonary Arterial Hypertension Panel

Notes: Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms or:

The Coordinator, PAH Panel

PHARMAC, PO Box 10-254, WELLINGTON

Tel: (04) 916 7561, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Antiacne Preparations

For systemic antibacterials, refer to INFECTIONS, Antibacterials, [page 88](#)

ADAPALENE

- Maximum of 30 g per prescription
- Only on a prescription

Crm 0.1%.....	22.89	30 g OP	✓ Differin
Gel 0.1%.....	22.89	30 g OP	✓ Differin

ISOTRETINOIN – Special Authority see [SA1475 below](#) – Retail pharmacy

Cap 5 mg.....	8.14	60	✓ Oratane
Cap 10 mg.....	13.34	120	✓ Oratane
Cap 20 mg.....	20.49	120	✓ Oratane

►SA1475 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- Applicant has an up to date knowledge of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- Either:
 - Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
- Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

TRETINOIN

Crm 0.5 mg per g – Maximum of 50 g per prescription	13.90	50 g OP	✓ ReTrieve
---	-------	---------	------------

Antibacterials Topical

For systemic antibacterials, refer to INFECTIONS, Antibacterials, [page 88](#)

HYDROGEN PEROXIDE

* Crm 1%.....	8.56	10 g OP	✓ Crystaderm
		15 g OP	✓ Crystaderm

DERMATOLOGICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
MUPIROICIN				
Oint 2%.....	6.60 (9.26)	15 g OP		Bactroban
a) Only on a prescription				
b) Not in combination				
SODIUM FUSIDATE [FUSIDIC ACID]				
Crm 2%.....	1.59	5 g OP	✓ Foban	
a) Maximum of 5 g per prescription				
b) Only on a prescription				
c) Not in combination				
Oint 2%.....	1.59	5 g OP	✓ Foban	
a) Maximum of 5 g per prescription				
b) Only on a prescription				
c) Not in combination				
SULFADIAZINE SILVER				
Crm 1%.....	10.80	50 g OP	✓ Flamazine	
a) Up to 250 g available on a PSO				
b) Not in combination				

Antifungals Topical

For systemic antifungals, refer to INFECTIONS, Antifungals, [page 95](#)

AMOROLFINE

- a) Only on a prescription
- b) Not in combination

Nail soln 5%.....	14.93	5 ml OP	✓ MycoNail
MycoNail to be Sole Supply on 1 October 2020			

CICLOPIROX OLAMINE

- a) Only on a prescription
- b) Not in combination

Nail-soln 8%	5.72	7 ml OP	✓ Apo-Ciclopirox
--------------------	------	---------	-------------------------

CLOTRIMAZOLE

* Crm 1%.....	0.70	20 g OP	✓ Clomazol
a) Only on a prescription			
b) Not in combination			

* Soln 1%	4.36 (7.55)	20 ml OP	Canesten
a) Only on a prescription			
b) Not in combination			

ECONAZOLE NITRATE

Crm 1%.....	1.00 (7.48)	20 g OP	Pevaryl
-------------	----------------	---------	---------

- a) Only on a prescription
- b) Not in combination

Foaming soln 1%, 10 ml sachets.....	9.89 (17.23)	3	Pevaryl
-------------------------------------	-----------------	---	---------

- a) Only on a prescription
- b) Not in combination

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
MICONAZOLE NITRATE			
* Crm 2%.....	0.74	15 g OP	✓ Multichem
a) Only on a prescription			
b) Not in combination			
* Lotn 2%	4.36 (10.03)	30 ml OP	Daktarin
a) Only on a prescription			
b) Not in combination			
* Tinct 2%.....	4.36 (12.10)	30 ml OP	Daktarin
a) Only on a prescription			
b) Not in combination			

Antipruritic Preparations

CALAMINE

- a) Only on a prescription
b) Not in combination

Crm, aqueous, BP	1.26	100 g	✓ healthE Calamine Aqueous Cream BP
------------------------	------	-------	--

CROTAMITON

- a) Only on a prescription
b) Not in combination

Crm 10%.....	3.29	20 g OP	✓ Itch-Soothe
--------------	------	---------	----------------------

MENTHOL – Only in combination

- 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain
2) With or without other dermatological galenicals.

Crystals.....	6.92	25 g	✓ MidWest
	29.60	100 g	✓ MidWest

Corticosteroids Topical

For systemic corticosteroids, refer to CORTICOSTEROIDS AND RELATED AGENTS, [page 78](#)

Corticosteroids - Plain

BETAMETHASONE DIPROPIONATE

Crm 0.05%.....	2.96	15 g OP	✓ Diprosone
	36.00	50 g OP	✓ Diprosone
Oint 0.05%.....	2.96	15 g OP	✓ Diprosone
	36.00	50 g OP	✓ Diprosone
Oint 0.05% in propylene glycol base	4.33	30 g OP	✓ Diprosone OV

BETAMETHASONE VALERATE

* Crm 0.1%.....	3.45	50 g OP	✓ Beta Cream
* Oint 0.1%.....	3.45	50 g OP	✓ Beta Ointment
* Lotn 0.1%	18.00	50 ml OP	✓ Betnovate

CLOBETASOL PROPIONATE

* Crm 0.05%.....	2.18	30 g OP	✓ Dermol
* Oint 0.05%.....	2.12	30 g OP	✓ Dermol

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

DERMATOLOGICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CLOBETASONE BUTYRATE				
Crm 0.05%.....	5.38 (7.09)	30 g OP		Eumovate
DIFLUCORTOLONE VALERATE				
Crm 0.1%.....	8.97 (15.86)	50 g OP		Nerisone
Fatty oint 0.1%.....	8.97 (15.86)	50 g OP		Nerisone
<i>(Nerisone Crm 0.1% to be delisted 1 December 2020)</i> <i>(Nerisone Fatty oint 0.1% to be delisted 1 August 2021)</i>				
HYDROCORTISONE				
* Crm 1% – Only on a prescription.....	3.70	100 g OP	✓	Hydrocortisone (PSM)
	17.15	500 g	✓	Hydrocortisone (PSM)
* Powder – Only in combination.....	49.95	25 g	✓	ABM
Up to 5% in a dermatological base (not proprietary Topical Corticosteroid – Plain) with or without other dermatological galenicals				
HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN				
Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – Only on a prescription.....	10.57	250 ml	✓	DP Lotn HC
DP Lotn HC to be Sole Supply on 1 October 2020				
HYDROCORTISONE BUTYRATE				
Lipocream 0.1%.....	6.85	100 g OP	✓	Locoid Lipocream
Oint 0.1%.....	13.70	100 g OP	✓	Locoid
Milky emul 0.1%.....	13.70	100 ml OP	✓	Locoid Crelo
METHYLPREDNISOLONE ACEPONATE				
Crm 0.1%.....	4.46	15 g OP	✓	Advantan
Advantan to be Sole Supply on 1 December 2020				
Oint 0.1%.....	4.46	15 g OP	✓	Advantan
Advantan to be Sole Supply on 1 December 2020				
MOMETASONE FUROATE				
Crm 0.1%.....	1.51	15 g OP	✓	Elocon Alcohol Free
	2.50	50 g OP	✓	Elocon Alcohol Free
Oint 0.1%.....	1.51	15 g OP	✓	Elocon
	2.90	50 g OP	✓	Elocon
Lotn 0.1%.....	6.30	30 ml OP	✓	Elocon
TRIAMCINOLONE ACETONIDE				
Crm 0.02%.....	6.30	100 g OP	✓	Aristocort
Aristocort to be Sole Supply on 1 November 2020				
Oint 0.02%.....	6.35	100 g OP	✓	Aristocort
Aristocort to be Sole Supply on 1 November 2020				
Corticosteroids - Combination				
BETAMETHASONE VALERATE WITH CLIOQUINOL – Only on a prescription				
Crm 0.1% with clioquinol 3%.....	3.49 (4.90)	15 g OP		Betnovate-C

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUSIDIC ACID]				
Crm 0.1% with sodium fusidate (fusidic acid) 2%.....	3.49 (10.45)	15 g OP		Fucicort
a) Maximum of 15 g per prescription				
b) Only on a prescription				
HYDROCORTISONE WITH MICONAZOLE – Only on a prescription				
* Crm 1% with miconazole nitrate 2%.....	2.00	15 g OP	✓	<u>Micreme H</u>
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN – Only on a prescription				
Crm 1% with natamycin 1% and neomycin sulphate 0.5%	3.35	15 g OP	✓	<u>Pimafucort</u>
Oint 1% with natamycin 1% and neomycin sulphate 0.5%.....	3.35	15 g OP	✓	<u>Pimafucort</u>
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN				
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g – Only on a prescription	3.49 (9.28)	15 g OP		Viaderm KC

Disinfecting and Cleansing Agents

CHLORHEXIDINE GLUCONATE – Subsidy by endorsement

a) No more than 500 ml per month				
b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly.				
* Handrub 1% with ethanol 70%	4.29	500 ml	✓	<u>healthE</u>
* Soln 4% wash.....	3.98	500 ml	✓	<u>healthE</u>
<i>(healthE Handrub 1% with ethanol 70% to be delisted 1 November 2020)</i>				
<i>(healthE Soln 4% wash to be delisted 1 November 2020)</i>				

TRICLOSAN – Subsidy by endorsement

a) Maximum of 500 ml per prescription				
b)				
a) Only if prescribed for a patient identified with Methicillin-resistant Staphylococcus aureus (MRSA) prior to elective surgery in hospital and the prescription is endorsed accordingly; or				
b) Only if prescribed for a patient with recurrent Staphylococcus aureus infection and the prescription is endorsed accordingly				
Soln 1%	5.90	500 ml OP	✓	<u>healthE</u>
<i>(healthE Soln 1% to be delisted 1 November 2020)</i>				

Barrier Creams and Emollients

Barrier Creams

DIMETHICONE				
* Crm 5% pump bottle.....	4.48	500 ml OP	✓	<u>healthE</u> <u>Dimethicone 5%</u>
* Crm 10% pump bottle.....	4.52	500 ml OP	✓	<u>healthE</u> <u>Dimethicone 10%</u>
ZINC AND CASTOR OIL				
* Oint.....	4.25	500 g	✓	<u>Boucher</u>

Emollients

AQUEOUS CREAM				
* Crm.....	1.92	500 g	✓	<u>Boucher</u>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CETOMACROGOL				
* Crm BP.....	2.48	500 g	✓	healthE
CETOMACROGOL WITH GLYCEROL				
Crm 90% with glycerol 10%.....	2.35	500 ml OP	✓	ADE
			✓	Boucher
	3.10	1,000 ml OP	✓	Kenkay Sorbolene
			✓	ADE
			✓	Boucher
EMULSIFYING OINTMENT				
* Oint BP.....	3.59	500 g	✓	AFT
OIL IN WATER EMULSION				
* Crm.....	2.19	500 g	✓	O/W Fatty Emulsion Cream
PARAFFIN				
Oint liquid paraffin 50% with white soft paraffin 50%.....	5.35	500 ml OP	✓	healthE
UREA				
* Crm 10%.....	1.37	100 g OP	✓	healthE Urea Cream
WOOL FAT WITH MINERAL OIL – Only on a prescription				
* Lotn hydrous 3% with mineral oil.....	5.60	1,000 ml		
	(11.95)			DP Lotion
	1.40	250 ml OP		
	(4.53)			DP Lotion
	5.60	1,000 ml		
	(20.53)			Alpha-Keri Lotion
	(23.91)			BK Lotion
	1.40	250 ml OP		
	(7.73)			BK Lotion

Other Dermatological Bases

PARAFFIN				
White soft – Only in combination.....	4.99	450 g	✓	healthE
	19.99	2,500 g	✓	healthE
Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid – Plain.				

Minor Skin Infections

POVIDONE IODINE				
Oint 10%.....	7.40	65 g OP	✓	Betadine
a) Maximum of 130 g per prescription				
b) Only on a prescription				
c) Betadine to be Sole Supply on 1 October 2020				
Antiseptic Solution 10%.....	2.55	100 ml	✓	Riodine
Antiseptic soln 10%.....	3.83	15 ml	✓	Riodine
	5.40	500 ml	✓	Riodine
Skin preparation, povidone iodine 10% with 30% alcohol.....	1.63	100 ml		
	(3.48)			Betadine Skin Prep
Skin preparation, povidone iodine 10% with 70% alcohol.....	1.63	100 ml		
	(7.78)			Pfizer

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Parasiticial Preparations

DIMETHICONE

* Lotn 4%	4.98	200 ml OP	✓ healthE Dimethicone 4% Lotion
-----------------	------	-----------	--

IVERMECTIN – Special Authority see [SA1225 below](#) – Retail pharmacy

Tab 3 mg – Up to 100 tab available on a PSO	17.20	4	✓ Stromectol
---	-------	---	---------------------

- 1) PSO for institutional use only. Must be endorsed with the name of the institution for which the PSO is required and a valid Special Authority for patient of that institution.
- 2) Ivermectin available on BSO provided the BSO includes a valid Special Authority for a patient of the institution.
- 3) For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or prisons.

►SA1225 Special Authority for Subsidy

Initial application — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 The patient is in the community; and
 - 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
 - 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Initial application — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 Filaricides; or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

Renewal — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- microbiologist; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 The patient is in the community; and
 - 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
 - 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Renewal — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist.

Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 Filaricides; or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

PERMETHRIN

Crm 5%.....	5.75	30 g OP	✓ Lyderm
Lyderm to be Sole Supply on 1 November 2020			
Lotn 5%.....	3.99	30 ml OP	✓ A-Scabies
A-Scabies to be Sole Supply on 1 November 2020			

PHENOTHRIN

Shampoo 0.5%.....	11.36	200 ml OP	✓ Parasidose
-------------------	-------	-----------	--------------

Psoriasis and Eczema Preparations

ACITRETIN – Special Authority see [SA1476 below](#) – Retail pharmacy

Cap 10 mg.....	17.86	60	✓ Novatretin
Novatretin to be Sole Supply on 1 October 2020			
Cap 25 mg.....	41.36	60	✓ Novatretin
Novatretin to be Sole Supply on 1 October 2020			

►SA1476 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around acitretin and is competent to prescribe acitretin; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

3 Either:

- 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
- 3.2 Patient is male.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
- 2 Patient is male.

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Foam spray 500 mcg with calcipotriol 50 mcg per g	59.95	60 g OP	✓ Enstilar
Gel 500 mcg with calcipotriol 50 mcg per g	52.24	60 g OP	✓ Daivobet
Oint 500 mcg with calcipotriol 50 mcg per g	19.95	30 g OP	✓ Daivobet

CALCIPOTRIOL

Oint 50 mcg per g	40.00	120 g OP	✓ Daivonex
-------------------------	-------	----------	-------------------

COAL TAR

Soln BP – Only in combination	36.25	200 ml	✓ Midwest
<ol style="list-style-type: none"> 1) Up to 10% only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain 2) With or without other dermatological galenicals. 			

COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULPHUR

Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and allantoin crm 2.5%	6.59 (8.00) 3.43 (4.35)	75 g OP 30 g OP	 Egopsoryl TA Egopsoryl TA
---	----------------------------------	------------------------	--------------------------------------

COAL TAR WITH SALICYLIC ACID AND SULPHUR

Soln 12% with salicylic acid 2% and sulphur 4% oint	4.97	25 g OP	✓ Coco-Scalp
	7.95	40 g OP	✓ Coco-Scalp

PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCIN – Only on a prescription

* Soln 2.3% with trolamine laurilsulfate and fluorescein sodium	4.44	500 ml	✓ Pinetarsol
Pinetarsol to be Sole Supply on 1 November 2020			

SALICYLIC ACID

Powder – Only in combination	18.88	250 g	✓ Midwest ✓ PSM
<ol style="list-style-type: none"> 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain or collodion flexible 2) With or without other dermatological galenicals. 			

SULPHUR

Precipitated – Only in combination	6.35	100 g	✓ Midwest
<ol style="list-style-type: none"> 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain 2) With or without other dermatological galenicals. 			

Scalp Preparations

BETAMETHASONE VALERATE		
* Scalp app 0.1%	7.75	100 ml OP ✓ Beta Scalp
CLOBETASOL PROPIONATE		
* Scalp app 0.05%	5.69	30 ml OP ✓ Dermol
HYDROCORTISONE BUTYRATE		
Scalp lotn 0.1%	7.30	100 ml OP ✓ Locoid
KETOCONAZOLE		
Shampoo 2%	3.23	100 ml OP ✓ Sebizole
a) Maximum of 100 ml per prescription		
b) Only on a prescription		
c) Sebizole to be Sole Supply on 1 November 2020		

Sunscreens

SUNSCREENS, PROPRIETARY – Subsidy by endorsement

Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly.

Lotn,	5.10	200 g OP ✓ Marine Blue Lotion SPF 50+
-------------	------	--

Wart Preparations

For salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS, [page 68](#)

IMIQUIMOD		
Crm 5%, 250 mg sachet	21.72	24 ✓ Perrigo
PODOPHYLLOTOXIN		
Soln 0.5%	33.60	3.5 ml OP ✓ Condyline
a) Maximum of 3.5 ml per prescription		
b) Only on a prescription		

Other Skin Preparations

Antineoplastics

FLUOROURACIL SODIUM		
Crm 5%	7.95	20 g OP ✓ Efudix

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Contraceptives - Non-hormonal

Condoms

CONDOMS

* 49 mm – Up to 144 dev available on a PSO	11.42	144	✓ <u>Moments</u>
* 53 mm.....	0.95	10	✓ <u>Moments</u>
	11.64	144	✓ <u>Moments</u>
a) Maximum of 60 dev per prescription			
b) Up to 60 dev available on a PSO			
* 53 mm, 0.05 mm thickness.....	0.95	10	✓ <u>Moments</u>
	11.42	144	✓ <u>Moments</u>
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 53 mm, chocolate, brown	0.95	10	✓ <u>Moments</u>
	11.64	144	✓ <u>Moments</u>
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 53 mm, strawberry, red.....	0.95	10	✓ <u>Moments</u>
	11.64	144	✓ <u>Moments</u>
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 56 mm.....	0.97	10	✓ <u>Moments</u>
	11.64	144	✓ <u>Moments</u>
a) Maximum of 60 dev per prescription			
b) Up to 60 dev available on a PSO			
* 56 mm, 0.05 mm thickness.....	1.30	12	✓ <u>Gold Knight</u>
	15.57	144	✓ <u>Gold Knight</u>
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 56 mm, 0.08 mm thickness.....	0.97	10	✓ <u>Moments</u>
	11.64	144	✓ <u>Moments</u>
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 56 mm, 0.08 mm thickness, red	0.97	10	✓ <u>Moments</u>
	11.64	144	✓ <u>Moments</u>
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 56 mm, chocolate	1.30	12	✓ <u>Gold Knight</u>
	15.57	144	✓ <u>Gold Knight</u>
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 56 mm, strawberry.....	1.30	12	✓ <u>Gold Knight</u>
	15.57	144	✓ <u>Gold Knight</u>
a) Up to 60 dev available on a PSO			
b) Maximum of 60 dev per prescription			
* 60 mm – Up to 144 dev available on a PSO	14.87	144	✓ <u>Shield XL</u>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Contraceptive Devices				
INTRA-UTERINE DEVICE				
a) Up to 40 dev available on a PSO				
b) Only on a PSO				
* IUD 29.1 mm length x 23.2 mm width	18.45	1	✓	Choice TT380 Short
* IUD 33.6 mm length x 29.9 mm width	18.45	1	✓	Choice TT380 Standard
* IUD 35.5 mm length x 19.6 mm width	15.50	1	✓	Choice Load 375

Contraceptives - Hormonal

Combined Oral Contraceptives

►SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Patient is on a Social Welfare benefit; or
 - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

ETHINYLOESTRADIOL WITH DESOGESTREL

* Tab 20 mcg with desogestrel 150 mcg and 7 inert tab	6.62	84	
	(19.80)		Mercilon 28
a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500 above			
b) Up to 84 tab available on a PSO			
* Tab 30 mcg with desogestrel 150 mcg and 7 inert tab	6.62	84	
	(19.80)		Marvelon 28
a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500 above			
b) Up to 84 tab available on a PSO			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ETHINYLOESTRADIOL WITH LEVONORGESTREL				
* Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – Up to 112 tab available on a PSO	2.18 6.45	84 112	✓ ✓	Microgynon 20 ED Femme-Tab ED
* Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab – Up to 84 tab available on a PSO	9.45	84	✓	Microgynon 50 ED
* Tab 30 mcg with levonorgestrel 150 mcg	6.62 (16.50)	63		Microgynon 30
a) Higher subsidy of \$15.00 per 63 tab with Special Authority see SA0500 on the previous page				
b) Up to 63 tab available on a PSO				
* Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – Up to 112 tab available on a PSO	1.77 6.45	84 112	✓ ✓	Levlen ED Femme-Tab ED
ETHINYLOESTRADIOL WITH NORETHISTERONE				
Tab 35 mcg with norethisterone 1 mg and 7 inert tab – Up to 84 tab available on a PSO	6.95	84	✓	Brevinor 1/28
Tab 35 mcg with norethisterone 500 mcg and 7 inert tab – Up to 84 tab available on a PSO	6.62	84	✓ ✓	Necon Norimin
	8.83	112	✓	Brevinor 28

(Brevinor 28 Tab 35 mcg with norethisterone 500 mcg and 7 inert tab to be delisted 1 January 2021)

Progestogen-only Contraceptives

► **SA0500** Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:
Both:

- 1 Either:
 - 1.1 Patient is on a Social Welfare benefit; or
 - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:
Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LEVONORGESTREL				
* Tab 30 mcg – Up to 84 tab available on a PSO	16.50	84	✓	Microlut
	22.00	112	✓	Microlut
* Subdermal implant (2 × 75 mg rods) – Up to 3 pack available on a PSO	106.92	1	✓	Jadelle
Jadelle to be Sole Supply on 1 December 2020				
MEDROXYPROGESTERONE ACETATE				
Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a PSO	7.98	1	✓	Depo-Provera
NORETHISTERONE				
Tab 350 mcg – Up to 84 tab available on a PSO	6.25	84	✓	Noriday 28

Emergency Contraceptives

LEVONORGESTREL				
* Tab 1.5 mg	4.95	1	✓	Postinor-1
a) Maximum of 2 tab per prescription				
b) Up to 5 tab available on a PSO				
c) Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A.				

Antiandrogen Oral Contraceptives

Prescribers may code prescriptions “contraceptive” (code “O”) when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows:

- \$5.00 prescription charge (patient co-payment) will apply.
- prescription may be written for up to six months supply.

Prescriptions coded in any other way are subject to the non contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.

CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL

* Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs – Up to 168 tab available on a PSO	4.67	168	✓	Ginet
---	------	-----	---	--------------

Gynaecological Anti-infectives

ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC ACID

Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator	8.43 (24.00)	100 g OP		Aci-Jel
---	-----------------	----------	--	---------

CLOTRIMAZOLE

* Vaginal crm 1% with applicators	2.50	35 g OP	✓	Clomazol
* Vaginal crm 2% with applicators	3.00	20 g OP	✓	Clomazol

MICONAZOLE NITRATE

* Vaginal crm 2% with applicator	6.89	40 g OP	✓	Micreme
Micreme to be Sole Supply on 1 November 2020				

NYSTATIN

Vaginal crm 100,000 u per 5 g with applicator(s)	4.00	75 g OP	✓	Nilstat
Nilstat to be Sole Supply on 1 October 2020				

Myometrial and Vaginal Hormone Preparations

ERGOMETRINE MALEATE

Inj 500 mcg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	105.00	5	✓	DBL Ergometrine
--	--------	---	---	------------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
OESTRIOL				
* Crm 1 mg per g with applicator.....	6.62	15 g OP	✓	Ovestin
Ovestin to be Sole Supply on 1 October 2020				
* Pessaries 500 mcg.....	6.86	15	✓	Ovestin
Ovestin to be Sole Supply on 1 October 2020				
OXYTOCIN – Up to 5 inj available on a PSO				
Inj 5 iu per ml, 1 ml ampoule	3.98	5	✓	Oxytocin BNM
Inj 10 iu per ml, 1 ml ampoule	4.98	5	✓	Oxytocin BNM
OXYTOCIN WITH ERGOMETRINE MALEATE – Up to 5 inj available on a PSO				
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml.....	15.00	5	✓	Syntometrine

Pregnancy Tests - hCG Urine

PREGNANCY TESTS - HCG URINE

- a) Up to 200 test available on a PSO
- b) Only on a PSO

Cassette	12.00	40 test OP	✓	Smith BioMed Rapid Pregnancy Test
----------------	-------	------------	---	--

Urinary Agents

For urinary tract Infections refer to INFECTIONS, Antibacterials, [page 106](#)

5-Alpha Reductase Inhibitors

FINASTERIDE – Special Authority see [SA0928 below](#) – Retail pharmacy

* Tab 5 mg	4.81	100	✓	Ricit
------------------	------	-----	---	--------------

➔ [SA0928](#) **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 Either:
 - 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
 - 2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

Note: Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.

Alpha-1A Adrenoreceptor Blockers

TAMSULOSIN HYDROCHLORIDE – Special Authority see [SA1032 below](#) – Retail pharmacy

* Cap 400 mcg	17.73	100	✓	Tamsulosin-Rex
---------------------	-------	-----	---	-----------------------

➔ [SA1032](#) **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

Other Urinary Agents

OXYBUTYNIN

* Tab 5 mg	11.70	500	✓ Apo-Oxybutynin
* Oral liq 5 mg per 5 ml	60.40	473 ml	✓ Apo-Oxybutynin

POTASSIUM CITRATE

Oral liq 3 mmol per ml – Special Authority see [SA1083 below](#) –

Retail pharmacy.....	31.80	200 ml OP	✓ Biomed
----------------------	-------	-----------	----------

► [SA1083](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Both:

- 1 The patient has recurrent calcium oxalate urolithiasis; and
- 2 The patient has had more than two renal calculi in the two years prior to the application.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

SODIUM CITRO-TARTRATE

* Grans eff 4 g sachets	2.22	28	✓ Ural
Ural to be Sole Supply on 1 October 2020			

SOLIFENACIN SUCCINATE

Tab 5 mg	3.00	30	✓ Solifenacin Mylan
Tab 10 mg	5.50	30	✓ Solifenacin Mylan

Detection of Substances in Urine

ORTHO-TOLIDINE

* Compound diagnostic sticks.....	7.50 (8.25)	50 test OP	Hemastix
-----------------------------------	----------------	------------	----------

TETRABROMOPHENOL

* Blue diagnostic strips.....	7.02 (13.92)	100 test OP	Albustix
-------------------------------	-----------------	-------------	----------

Obstetric Preparations

Antiprogesterones

MIFEPRISTONE

Subsidised on a PSO only if from a Family Planning New Zealand Clinic or an abortion service provider with a DHB contract and the PSO is endorsed with the name of the institution for which the PSO is required.

Tab 200 mg	180.00	3	✓ Mifegyne
a) Up to 15 tab available on a PSO			
b) Only on a PSO			

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Calcium Homeostasis

CALCITONIN

* Inj 100 iu per ml, 1 ml ampoule 121.00 5 ✓ **Miacalcic**

CINACALCET – Special Authority see [SA1618 below](#) – Retail pharmacy

Tab 30 mg – Wastage claimable 210.30 28 ✓ **Sensipar**

►SA1618 Special Authority for Subsidy

Initial application only from a nephrologist or endocrinologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
 - 1.2 The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
 - 1.3 The patient is symptomatic; or
- 2 All of the following:
 - 2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriopathy); and
 - 2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L); and
 - 2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.

Renewal only from a nephrologist or endocrinologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient's serum calcium level has fallen to < 3mmol/L; and
- 2 The patient has experienced clinically significant symptom improvement.

Note: This does not include parathyroid adenomas unless these have become malignant.

ZOLEDRONIC ACID

Inj 4 mg per 5 ml, vial – Special Authority see [SA1687 below](#) –

Retail pharmacy 38.03 1 ✓ **Zoledronic acid**
Mylan

►SA1687 Special Authority for Subsidy

Initial application — (bone metastases) only from an oncologist, haematologist or palliative care specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Patient has hypercalcaemia of malignancy; or
- 2 Both:
 - 2.1 Patient has bone metastases or involvement; and
 - 2.2 Patient has severe bone pain resistant to standard first-line treatments; or
- 3 Both:
 - 3.1 Patient has bone metastases or involvement; and
 - 3.2 Patient is at risk of skeletal-related events pathological fracture, spinal cord compression, radiation to bone or surgery to bone.

Initial application — (early breast cancer) only from an oncologist or medical practitioner on the recommendation of a oncologist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

continued...

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1 Treatment to be used as adjuvant therapy for early breast cancer; and
- 2 Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
- 3 Treatment to be administered at a minimum interval of 6-monthly for a maximum of 2 years.

Corticosteroids and Related Agents for Systemic Use

BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE

* Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml.....	19.20	5		
	(36.96)			Celestone Chronodose

DEXAMETHASONE

* Tab 0.5 mg – Up to 60 tab available on a PSO	0.99	30	✓	<u>Dexamethosone</u>
* Tab 4 mg – Up to 30 tab available on a PSO	1.90	30	✓	<u>Dexamethosone</u>
Oral liq 1 mg per ml	45.00	25 ml OP	✓	<u>Biomed</u>

DEXAMETHASONE PHOSPHATE

Dexamethasone phosphate injection will not be funded for oral use.

* Inj 4 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	9.25	10	✓	<u>Dexamethasone Phosphate Panpharma</u>
* Inj 4 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	16.37	10	✓	<u>Dexamethasone Phosphate Panpharma</u>

FLUDROCORTISONE ACETATE

* Tab 100 mcg.....	14.32	100	✓	<u>Florinef</u>
--------------------	-------	-----	---	-----------------

HYDROCORTISONE

* Tab 5 mg	8.10	100	✓	<u>Douglas</u>
* Tab 20 mg	20.32	100	✓	<u>Douglas</u>
* Inj 100 mg vial	5.30	1	✓	<u>Solu-Cortef</u>
a) Up to 5 inj available on a PSO				
b) Only on a PSO				

METHYLPREDNISOLONE

* Tab 4 mg	112.00	100	✓	<u>Medrol</u>
* Tab 100 mg	194.00	20	✓	<u>Medrol</u>

METHYLPREDNISOLONE (AS SODIUM SUCCINATE)

Inj 40 mg vial	18.90	1	✓	<u>Solu-Medrol-Act- O-Vial</u>
Inj 125 mg vial	28.90	1	✓	<u>Solu-Medrol-Act- O-Vial</u>
Inj 500 mg vial	22.78	1	✓	<u>Solu-Medrol-Act- O-Vial</u>
Inj 1 g vial	27.83	1	✓	<u>Solu-Medrol</u>

METHYLPREDNISOLONE ACETATE

Inj 40 mg per ml, 1 ml vial.....	44.40	5	✓	<u>Depo-Medrol</u>
----------------------------------	-------	---	---	--------------------

PREDNISOLONE

* Oral liq 5 mg per ml – Up to 30 ml available on a PSO	6.00	30 ml OP	✓	<u>Redipred</u>
Restricted to children under 12 years of age.				

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PREDNISONE				
* Tab 1 mg	10.68	500	✓	Apo-Prednisone
* Tab 2.5 mg	12.09	500	✓	Apo-Prednisone
* Tab 5 mg – Up to 30 tab available on a PSO	11.09	500	✓	Apo-Prednisone
* Tab 20 mg – Up to 30 tab available on a PSO	29.03	500	✓	Apo-Prednisone
TETRACOSACTRIN				
* Inj 250 mcg per ml, 1 ml ampoule	75.00	1	✓	UK Synacthen ^{\$29}
			✓	AU Synacthen
			✓	Synacthen
* Inj 1 mg per ml, 1 ml ampoule	690.00	1	✓	Synacthen Depot
			✓	Synacthene Retard ^{\$29}
TRIAMCINOLONE ACETONIDE				
Inj 10 mg per ml, 1 ml ampoule	20.80	5	✓	Kenacort-A 10
	26.62		✓	Adcortyl ^{\$29}
Kenacort-A 10 to be Sole Supply on 1 November 2020				
Inj 40 mg per ml, 1 ml ampoule	11.30	1	✓	Triaver ^{\$29}
	51.10	5	✓	Kenacort-A 40
	70.62		✓	Kenalog ^{\$29}
Kenacort-A 40 to be Sole Supply on 1 November 2020				

Sex Hormones Non Contraceptive

Androgen Agonists and Antagonists

CYPROTERONE ACETATE				
Tab 50 mg	13.17	50	✓	Siterone
Tab 100 mg	26.75	50	✓	Siterone
TESTOSTERONE				
Patch 5 mg per day	90.00	30	✓	Androderm
TESTOSTERONE CIPIONATE				
Inj 100 mg per ml, 10 ml vial.....	76.50	1	✓	Depo-Testosterone
TESTOSTERONE ESTERS				
Inj 250 mg per ml, 1 ml.....	12.98	1	✓	Sustanon Ampoules
TESTOSTERONE UNDECANOATE				
Cap 40 mg.....	21.00	60	✓	Andriol Testocaps
Inj 250 mg per ml, 4 ml vial.....	86.00	1	✓	Reandron 1000

Hormone Replacement Therapy - Systemic

Prescribing Guideline

HRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Oestrogens				
OESTRADIOL – See prescribing guideline on the previous page				
* Tab 1 mg	4.12 (11.10)	28 OP		Estrofem
* Tab 2 mg	4.12 (11.10)	28 OP		Estrofem
* Patch 100 mcg per 24 hours	7.91	4	✓	Climara
a) No more than 1 patch per week				
b) Only on a prescription				
* Patch 50 mcg per 24 hours	7.04	4	✓	Climara
a) No more than 1 patch per week				
b) Only on a prescription				
Patch 25 mcg per day.....	6.12	8	✓	Estradot
a) No more than 2 patch per week				
b) Only on a prescription				
Patch 50 mcg per day.....	7.04	8	✓	Estradot 50 mcg
a) No more than 2 patch per week				
b) Only on a prescription				
Patch 75 mcg per day.....	7.91	8	✓	Estradot
a) No more than 2 patch per week				
b) Only on a prescription				
Patch 100 mcg per day.....	7.91	8	✓	Estradot
a) No more than 2 patch per week				
b) Only on a prescription				
OESTRADIOL VALERATE – See prescribing guideline on the previous page				
* Tab 1 mg	12.36	84	✓	Progynova
* Tab 2 mg	12.36	84	✓	Progynova
OESTROGENS – See prescribing guideline on the previous page				
* Conjugated, equine tab 300 mcg.....	3.01 (13.50)	28		Premarin
* Conjugated, equine tab 625 mcg.....	4.12 (13.50)	28		Premarin

Progestogens

MEDROXYPROGESTERONE ACETATE – See prescribing guideline on the previous page				
* Tab 2.5 mg	3.75	30	✓	Provera
* Tab 5 mg	14.00	100	✓	Provera
* Tab 10 mg	7.15	30	✓	Provera

Progestogen and Oestrogen Combined Preparations

OESTRADIOL WITH NORETHISTERONE – See prescribing guideline on the previous page				
* Tab 1 mg with 0.5 mg norethisterone acetate	5.40 (18.10)	28 OP		Kliovance
* Tab 2 mg with 1 mg norethisterone acetate	5.40 (18.10)	28 OP		Kliogest
* Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6).....	5.40 (18.10)	28 OP		Trisequens

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Other Oestrogen Preparations				
ETHINYLOESTRADIOL				
* Tab 10 mcg.....	17.60	100	✓	NZ Medical and Scientific
OESTRIOL				
* Tab 2 mg	7.00	30	✓	Ovestin
Other Progestogen Preparations				
LEVONORGESTREL				
* Intra-uterine device 52 mg.....	269.50	1	✓	Mirena
* Intra-uterine device 13.5 mg.....	215.60	1	✓	Jaydess
MEDROXYPROGESTERONE ACETATE				
Tab 100 mg	101.00	100	✓	Provera HD
NORETHISTERONE				
* Tab 5 mg – Up to 30 tab available on a PSO	18.29	100	✓	Primolut N
PROGESTERONE				
Cap 100 mg – Special Authority see SA1609 below – Retail pharmacy.....	16.50	30	✓	Utrogestan
► SA1609 Special Authority for Subsidy				
Initial application only from an obstetrician or gynaecologist. Approvals valid for 12 months for applications meeting the following criteria:				
Both:				
1 For the prevention of pre-term labour*; and				
2 Either:				
2.1 The patient has a short cervix on ultrasound (defined as < 25 mm at 16 to 28 weeks); or				
2.2 The patient has a history of pre-term birth at less than 28 weeks.				
Renewal only from an obstetrician or gynaecologist. Approvals valid for 12 months for applications meeting the following criteria:				
All of the following:				
1 For the prevention of pre-term labour*; and				
2 Treatment is required for second or subsequent pregnancy; and				
3 Either:				
3.1 The patient has a short cervix on ultrasound (defined as < 25 mm at 16 to 28 weeks); or				
3.2 The patient has a history of pre-term birth at less than 28 weeks.				
Note: Indications marked with * are unapproved indications.				
Thyroid and Antithyroid Agents				
CARBIMAZOLE				
* Tab 5 mg	10.80	100	✓	AFT Carbimazole <small>S29</small> Neo-Mercazole

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LEVOTHYROXINE				
* Tab 25 mcg.....	3.89	90	✓	Synthroid
* Tab 50 mcg.....	1.71	28	✓	Mercury Pharma
	4.05	90	✓	Synthroid
	64.28	1,000	✓	Eltroxin
* Tab 100 mcg.....	1.78	28	✓	Mercury Pharma
	4.21	90	✓	Synthroid
	66.78	1,000	✓	Eltroxin

PROPYLTHIOURACIL – Special Authority see [SA1199 below](#) – Retail pharmacy

Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.

Tab 50 mg	35.00	100	✓	PTU <small>S29</small>
-----------------	-------	-----	---	-------------------------------

➔ **SA1199** **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has hyperthyroidism; and
- 2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

Trophic Hormones

Growth Hormones

SOMATROPIN (OMNITROPE) – Special Authority see [SA1629 below](#) – Retail pharmacy

* Inj 5 mg cartridge	34.88	1	✓	Omnitrope
* Inj 10 mg cartridge.....	69.75	1	✓	Omnitrope
* Inj 15 mg cartridge.....	104.63	1	✓	Omnitrope

➔ **SA1629** **Special Authority for Subsidy**

Initial application — (**growth hormone deficiency in children**) only from a paediatric endocrinologist or endocrinologist.

Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or
- 2 All of the following:
 - 2.1 Height velocity < 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
 - 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
 - 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
 - 2.5 Appropriate imaging of the pituitary gland has been obtained.

Renewal — (**growth hormone deficiency in children**) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

All of the following:

- 1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

Renewal — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
- 3 A current bone age is 14 years or under; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and
- 3 A current bone age is < 14 years or under (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Renewal — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initial application — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:
 - 6.1 The patient has a GFR less than or equal to 30 ml/min/1.73m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l) × 40 = corrected GFR (ml/min/1.73m² in a child who may or may not be receiving dialysis; or
 - 6.2 The patient has received a renal transplant and has received < 5mg/ m²/day of prednisone or equivalent for at least 6 months..

Renewal — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initial application — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient is aged six months or older; and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 The patient is aged two years or older; and
 - 5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
 - 5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Renewal — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

Initial application — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Renewal — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has been treated with somatropin for < 12 months; and
 - 1.2 There has been an improvement in Quality of Life defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
 - 1.3 Serum IGF-I levels have been increased within ± 1 SD of the mean of the normal range for age and sex; and
 - 1.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients, or 1 mg per day for female patients; or
- 2 All of the following:
 - 2.1 The patient has been treated with somatropin for more than 12 months; and
 - 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
 - 2.3 Serum IGF-I levels have continued to be maintained within ± 1 SD of the mean of the normal range for age and sex (other than for obvious external factors); and
 - 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
GnRH Analogues				
GOSERELIN				
Implant 3.6 mg, syringe	66.48	1	✓ Zoladex	
Implant 10.8 mg, syringe	177.50	1	✓ Zoladex	
LEUPRORELIN				
Additional subsidy by endorsement where the patient is a child or adolescent and is unable to tolerate administration of goserelin and the prescription is endorsed accordingly.				
Inj 3.75 mg prefilled dual chamber syringe – Higher subsidy of \$221.60 per 1 inj with Endorsement	66.48 (221.60)	1		Lucrin Depot 1-month
Inj 11.25 mg prefilled dual chamber syringe – Higher subsidy of \$591.68 per 1 inj with Endorsement	177.50 (591.68)	1		Lucrin Depot 3-month

Vasopressin Agonists

DESMOPRESSIN ACETATE

Tab 100 mcg – Special Authority see SA1401 below – Retail pharmacy.....	25.00	30	✓ Minirin	
Tab 200 mcg – Special Authority see SA1401 below – Retail pharmacy.....	54.45	30	✓ Minirin	
▲ Nasal drops 100 mcg per ml.....	39.03	2.5 ml OP	✓ Minirin	
▲ Nasal spray 10 mcg per dose.....	27.95	6 ml OP	✓ Desmopressin-PH&T	
Desmopressin-PH&T to be Sole Supply on 1 November 2020				
Inj 4 mcg per ml, 1 ml – Special Authority see SA1401 below – Retail pharmacy.....	67.18	10	✓ Minirin	

» [SA1401](#) Special Authority for Subsidy

Initial application — (Desmopressin tablets for Nocturnal enuresis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has primary nocturnal enuresis; and
- 2 The nasal forms of desmopressin are contraindicated; and
- 3 An enuresis alarm is contraindicated.

Initial application — (Desmopressin tablets for Diabetes insipidus) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has cranial diabetes insipidus; and
- 2 The nasal forms of desmopressin are contraindicated.

Renewal — (Desmopressin tablets) from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from the treatment.

Initial application — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the patient cannot use desmopressin nasal spray or nasal drops.

Renewal — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

Other Endocrine Agents

CABERGOLINE

Tab 0.5 mg – Maximum of 2 tab per prescription; can be

waived by Special Authority see SA1370 below.....	3.75	2	✓ Dostinex
	15.20	8	✓ Dostinex

►SA1370 Special Authority for Waiver of Rule

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 pathological hyperprolactinemia; or
- 2 acromegaly*.

Renewal — (for patients who have previously been funded under Special Authority form SA1031) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has previously held a valid Special Authority which has expired and the treatment remains appropriate and the patient is benefiting from treatment.

Note: Indication marked with * is an unapproved indication.

CLOMIFENE CITRATE

Tab 50 mg	29.84	10	✓ Mylan Clomiphen ^{\$29}
-----------------	-------	----	--------------------------------------

DANAZOL

Cap 100 mg	19.13	28	✓ Mylan ^{\$29}
Cap 200 mg	97.83	100	✓ Azol

METYRAPONE

Cap 250 mg	558.00	50	✓ Metopirone
------------------	--------	----	--------------

Metopirone to be Sole Supply on 1 November 2020

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Anthelmintics

ALBENDAZOLE – Special Authority see [SA1318 below](#) – Retail pharmacy

Tab 400 mg	469.20	60	✓ Eskazole ^{§29}
------------------	--------	----	---------------------------

► [SA1318](#) Special Authority for Subsidy

Initial application only from an infectious disease specialist or clinical microbiologist. Approvals valid for 6 months where the patient has hydatids.

Renewal only from an infectious disease specialist or clinical microbiologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefitting from the treatment.

MEBENDAZOLE – Only on a prescription

Tab 100 mg	24.19	24	✓ De-Worm
Oral liq 100 mg per 5 ml	2.18	15 ml	Vermox
	(7.17)		

PRAZIQUANTEL

Tab 600 mg	68.00	8	✓ Biltricide
------------------	-------	---	--------------

Antibacterials

a) For topical antibacterials, refer to DERMATOLOGICALS, [page 61](#)

b) For anti-infective eye preparations, refer to SENSORY ORGANS, [page 241](#)

Cephalosporins and Cephamycins

CEFACTOR MONOHYDRATE

Cap 250 mg	24.70	100	✓ <u>Ranbaxy-Cefaclor</u>
Grans for oral liq 125 mg per 5 ml – Wastage claimable	3.53	100 ml	✓ <u>Ranbaxy-Cefaclor</u>
	4.33		✓ Keflor

(Keflor Grans for oral liq 125 mg per 5 ml to be delisted 1 December 2020)

CEFALEXIN

Cap 250 mg	3.33	20	✓ <u>Cephalexin ABM</u>
			✓ Ibilex ^{§29}
Cap 500 mg	3.95	20	✓ <u>Cephalexin ABM</u>
Grans for oral liq 25 mg per ml – Wastage claimable	8.75	100 ml	✓ <u>Cefalexin Sandoz</u>
Grans for oral liq 50 mg per ml – Wastage claimable	11.75	100 ml	✓ <u>Cefalexin Sandoz</u>

(Ibilex ^{§29} Cap 250 mg to be delisted 1 February 2021)

CEFAZOLIN – Subsidy by endorsement

Only if prescribed for dialysis or cellulitis in accordance with a DHB approved protocol and the prescription is endorsed accordingly.

Inj 500 mg vial	3.39	5	✓ AFT
-----------------------	------	---	-------

AFT to be Sole Supply on 1 November 2020

Inj 1 g vial	3.49	5	✓ AFT
--------------------	------	---	-------

AFT to be Sole Supply on 1 November 2020

CEFTRIAXONE – Subsidy by endorsement

a) Up to 10 inj available on a PSO

b) Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of gonorrhoea, or the treatment of pelvic inflammatory disease, or the treatment of suspected meningococcal disease, and the prescription or PSO is endorsed accordingly.

Inj 500 mg vial	0.89	1	✓ <u>Ceftriaxone-AFT</u>
Inj 1 g vial	3.99	5	✓ <u>Ceftriaxone-AFT</u>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CEFUROXIME AXETIL – Subsidy by endorsement				
Only if prescribed for prophylaxis of endocarditis and the prescription is endorsed accordingly.				
Tab 250 mg	45.93	50	✓	Zinnat

Macrolides

AZITHROMYCIN – Maximum of 5 days treatment per prescription; can be waived by Special Authority see [SA1683 below](#)
A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised on Special Authority.

Tab 250 mg	8.19	30	✓	Apo-Azithromycin
Tab 500 mg – Up to 8 tab available on a PSO	0.93	2	✓	Apo-Azithromycin
Grans for oral liq 200 mg per 5 ml (40 mg per ml) – Wastage claimable	14.38	15 ml	✓	Zithromax

► [SA1683](#) Special Authority for Waiver of Rule

Initial application — (**bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections**) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Patient has received a lung transplant, stem cell transplant, or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*; or
- 2 Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*; or
- 3 Patient has cystic fibrosis and has chronic infection with *Pseudomonas aeruginosa* or *Pseudomonas*-related gram negative organisms*; or
- 4 Patient has an atypical *Mycobacterium* infection.

Note: Indications marked with * are unapproved indications.

Initial application — (**non-cystic fibrosis bronchiectasis***) only from a respiratory specialist or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*;
- 2 Patient is aged 18 and under; and
- 3 Either:
 - 3.1 Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
 - 3.2 Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

Note: Indications marked with * are unapproved indications.

Renewal — (**non-cystic fibrosis bronchiectasis***) only from a respiratory specialist or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
- 2 Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and
- 3 The patient will not receive more than a total of 24 months' azithromycin cumulative treatment (see note).

The patient must not have had more than 1 prior approval.

Note: No further renewals will be subsidised. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised. Indications marked with * are unapproved indications

CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see [SA1857 on the next page](#)

Tab 250 mg	3.98	14	✓	Apo-Clarithromycin
Grans for oral liq 250 mg per 5 ml – Wastage claimable.....	192.00	50 ml	✓	Klacid

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓	

►SA1857 Special Authority for Waiver of Rule

Initial application — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Atypical mycobacterial infection; or
- 2 Mycobacterium tuberculosis infection where there is drug-resistance or intolerance to standard pharmaceutical agents.

Initial application — (Helicobacter pylori eradication) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 For the eradication of helicobacter pylori in a patient unable to swallow tablets; and
- 2 For use only in combination with omeprazole and amoxicillin as part of a triple therapy regimen.

Initial application — (Prophylaxis of infective endocarditis) from any relevant practitioner. Approvals valid for 3 months where prophylaxis of infective endocarditis associated with surgical or dental procedures if amoxicillin is contra-indicated.

Renewal — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

ERYTHROMYCIN (AS LACTOBIONATE)

Inj 1 g vial	10.00	1	✓ Erythrocin IV
--------------------	-------	---	------------------------

ERYTHROMYCIN ETHYL SUCCINATE

Tab 400 mg	16.95	100	✓ E-Mycin
------------------	-------	-----	------------------

a) Up to 20 tab available on a PSO

b) Up to 2 x the maximum PSO quantity for RFPP

Grans for oral liq 200 mg per 5 ml	5.00	100 ml	✓ E-Mycin
--	------	--------	------------------

a) Up to 300 ml available on a PSO

b) Up to 2 x the maximum PSO quantity for RFPP

c) Wastage claimable

Grans for oral liq 400 mg per 5 ml	6.77	100 ml	✓ E-Mycin
--	------	--------	------------------

a) Up to 200 ml available on a PSO

b) Wastage claimable

ERYTHROMYCIN STEARATE

Tab 250 mg – Up to 30 tab available on a PSO	14.95	100	
	(22.29)		ERA

Tab 500 mg	29.90	100	
	(44.58)		ERA

ROXITHROMYCIN

Tab disp 50 mg	8.29	10	✓ Rulide D
----------------------	------	----	-------------------

Restricted to children under 12 years of age.

Tab 150 mg	8.28	50	✓ Arrow-Roxithromycin
------------------	------	----	------------------------------

Tab 300 mg	16.33	50	✓ Arrow-Roxithromycin
------------------	-------	----	------------------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Penicillins				
AMOXICILLIN				
Cap 250 mg	22.50	500	✓	Alphamox
a) Up to 30 cap available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP				
Cap 500 mg	36.98	500	✓	Alphamox
a) Up to 30 cap available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP				
Grans for oral liq 125 mg per 5 ml	1.40	100 ml	✓	Alphamox 125
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
c) Alphamox 125 to be Sole Supply on 1 November 2020				
Grans for oral liq 250 mg per 5 ml	1.73	100 ml	✓	Alphamox 250
a) Up to 300 ml available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP				
c) Wastage claimable				
d) Alphamox 250 to be Sole Supply on 1 November 2020				
Inj 250 mg vial	10.67	10	✓	Ibiamox
Inj 500 mg vial	12.41	10	✓	Ibiamox
Inj 1 g vial – Up to 5 inj available on a PSO	17.29	10	✓	Ibiamox
AMOXICILLIN WITH CLAVULANIC ACID				
Tab 500 mg with clavulanic acid 125 mg – Up to 30 tab available on a PSO	1.88	20	✓	Augmentin
Grans for oral liq amoxicillin 25 mg with clavulanic acid 6.25 mg per ml	5.00	100 ml	✓	Augmentin
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Grans for oral liq amoxicillin 50 mg with clavulanic acid 12.5 mg per ml – Up to 200 ml available on a PSO	2.20	100 ml OP	✓	Curam
BENZATHINE BENZYL PENICILLIN				
Inj 900 mg (1.2 million units) in 2.3 ml syringe – Up to 5 inj available on a PSO	344.93	10	✓	Bicillin LA
BENZYL PENICILLIN SODIUM [PENICILLIN G]				
Inj 600 mg (1 million units) vial – Up to 5 inj available on a PSO	11.09	10	✓	Sandoz
25.88	25		✓	Pan-Penicillin G Sodium S29
Sandoz to be Sole Supply on 1 November 2020				
(Pan-Penicillin G Sodium S29 Inj 600 mg (1 million units) vial to be delisted 1 November 2020)				

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
FLUCLOXACILLIN				
Cap 250 mg – Up to 30 cap available on a PSO.....	16.83	250	✓	Staphlex
Cap 500 mg – Up to 30 cap available on a PSO.....	56.61	500	✓	Staphlex
Grans for oral liq 25 mg per ml.....	2.29	100 ml	✓	AFT
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Grans for oral liq 50 mg per ml.....	3.68	100 ml	✓	AFT
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Inj 250 mg vial	9.00	10	✓	Flucloxin
Inj 500 mg vial	9.40	10	✓	Flucloxin
Inj 1 g vial – Up to 5 inj available on a PSO	5.70	5	✓	Flucil
Flucil to be Sole Supply on 1 November 2020				
PHENOXYMETHYLPENICILLIN (PENICILLIN V)				
Cap 250 mg – Up to 30 cap available on a PSO.....	2.59	50	✓	Cilicaine VK
Cap 500 mg.....	4.26	50	✓	Cilicaine VK
a) Up to 20 cap available on a PSO				
b) Up to 2 x the maximum PSO quantity for RFPP				
Grans for oral liq 125 mg per 5 ml.....	2.99	100 ml	✓	AFT
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Grans for oral liq 250 mg per 5 ml.....	3.99	100 ml	✓	AFT
a) Up to 300 ml available on a PSO				
b) Up to 2 x the maximum PSO quantity for RFPP				
c) Wastage claimable				
PROCAINE PENICILLIN				
Inj 1.5 g in 3.4 ml syringe – Up to 5 inj available on a PSO.....	123.50	5	✓	Cilicaine

Tetracyclines

DOXYCYCLINE				
* Tab 100 mg – Up to 30 tab available on a PSO.....	64.43	500	✓	Doxine
MINOCYCLINE HYDROCHLORIDE				
* Tab 50 mg – Additional subsidy by Special Authority see SA1355 below – Retail pharmacy	5.79 (12.05)	60		Mino-tabs
* Cap 100 mg.....	19.32 (52.04)	100		Minomycin

►SA1355 Special Authority for Manufacturers Price

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has rosacea.

TETRACYCLINE – Special Authority see SA1332 on the next page – Retail pharmacy

Tab 250 mg	21.42	28	✓	Accord <small>§29</small>
Cap 500 mg.....	46.00	30	✓	Tetracyclin Wolff <small>§29</small>

(Tetracyclin Wolff §29 Cap 500 mg to be delisted 1 December 2020)

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA1332 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:
Both:

- 1 For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy; and
- 2 For use only in combination with bismuth as part of a quadruple therapy regimen.

Other Antibiotics

For topical antibiotics, refer to DERMATOLOGICALS, [page 61](#)

CIPROFLOXACIN

Recommended for patients with any of the following:

- i) microbiologically confirmed and clinically significant pseudomonas infection; or
- ii) prostatitis; or
- iii) pyelonephritis; or
- iv) gonorrhoea.

Tab 250 mg – Up to 5 tab available on a PSO	2.42	28	✓ Ciproflox
Ciproflox to be Sole Supply on 1 November 2020			
Tab 500 mg – Up to 5 tab available on a PSO	3.40	28	✓ Ciproflox
Ciproflox to be Sole Supply on 1 November 2020			
Tab 750 mg	5.95	28	✓ Ciproflox
Ciproflox to be Sole Supply on 1 November 2020			

CLINDAMYCIN

Cap hydrochloride 150 mg	4.61	24	✓ Dalacin C
Inj phosphate 150 mg per ml, 4 ml ampoule	39.00	10	✓ Dalacin C

COLISTIN SULPHOMETHATE – Retail pharmacy-Specialist – Subsidy by endorsement

Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.

Inj 150 mg	65.00	1	✓ Colistin-Link
------------------	-------	---	-----------------

GENTAMICIN SULPHATE

Inj 10 mg per ml, 1 ml ampoule – Subsidy by endorsement.....	25.00	5	✓ DBL Gentamicin
Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.			
Inj 10 mg per ml, 2 ml ampoule – Subsidy by endorsement.....	182.00	10	✓ Teligent S29
Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.			
Inj 40 mg per ml, 2 ml ampoule – Subsidy by endorsement.....	17.50	10	✓ Pfizer
	87.50	50	✓ Pfizer
Only if prescribed for a dialysis or cystic fibrosis patient or complicated urinary tract infection and the prescription is endorsed accordingly.			

MOXIFLOXACIN – Special Authority see SA1740 below – Retail pharmacy

No patient co-payment payable

Tab 400 mg	42.00	5	✓ Avelox
Avelox to be Sole Supply on 1 December 2020			

►SA1740 Special Authority for Subsidy

Initial application — (Tuberculosis) only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

1 Both:

1.1 Active tuberculosis*; and

1.2 Any of the following:

1.2.1 Documented resistance to one or more first-line medications; or

1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or

1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or

1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or

1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or

2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*; or

3 Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.

Note: Indications marked with * are unapproved indications.

Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Mycoplasma genitalium) only from a sexual health specialist or Practitioner on the recommendation of a sexual health specialist. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium* and is symptomatic; and

2 Either:

2.1 Has tried and failed to clear infection using azithromycin; or

2.2 Has laboratory confirmed azithromycin resistance; and

3 Treatment is only for 7 days.

Initial application — (Penetrating eye injury) only from an ophthalmologist. Approvals valid for 1 month where the patient requires prophylaxis following a penetrating eye injury and treatment is for 5 days only.

Note: Indications marked with * are unapproved indications.

PAROMOMYCIN – Special Authority see [SA1689 below](#) – Retail pharmacy

Cap 250 mg.....	126.00	16	✓ Humatin ^{\$29}
-----------------	--------	----	---------------------------

➔**SA1689** Special Authority for Subsidy

Initial application only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria:

Either:

1 Patient has confirmed cryptosporidium infection; or

2 For the eradication of Entamoeba histolytica carriage.

Renewal only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria:

Either:

1 Patient has confirmed cryptosporidium infection; or

2 For the eradication of Entamoeba histolytica carriage.

PYRIMETHAMINE – Special Authority see [SA1328 below](#) – Retail pharmacy

Tab 25 mg	48.00	30	✓ Daraprim ^{\$29}
-----------------	-------	----	----------------------------

➔**SA1328** Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

1 For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; or

2 For pregnant patients for the term of the pregnancy; or

3 For infants with congenital toxoplasmosis until 12 months of age.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SODIUM FUSIDATE [FUSIDIC ACID]				
Tab 250 mg	34.50	12	✓	Fucidin
SULFADIAZINE SODIUM – Special Authority see SA1331 below – Retail pharmacy				
Tab 500 mg	543.20	56	✓	Wockhardt S29
►SA1331 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:				
Any of the following:				
1 For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; or				
2 For pregnant patients for the term of the pregnancy; or				
3 For infants with congenital toxoplasmosis until 12 months of age.				
TOBRAMYCIN				
Inj 40 mg per ml, 2 ml vial – Subsidy by endorsement	15.00	5	✓	Tobramycin Mylan
Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				
Solution for inhalation 60 mg per ml, 5 ml – Subsidy by endorsement.....	2,200.00	56 dose	✓	TOBI
a) Wastage claimable				
b) Only if prescribed for a cystic fibrosis patient and the prescription is endorsed accordingly.				
TRIMETHOPRIM				
* Tab 300 mg – Up to 30 tab available on a PSO	16.50	50	✓	TMP
TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]				
* Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – Up to 30 tab available on a PSO.....	53.96	500	✓	Trisul
* Oral liq 8 mg sulphamethoxazole 40 mg per ml – Up to 200 ml available on a PSO	2.97	100 ml	✓	Deprim
VANCOMYCIN – Subsidy by endorsement				
Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis or for treatment of Clostridium difficile following metronidazole failure and the prescription is endorsed accordingly.				
Inj 500 mg vial	2.35	1	✓	Mylan
Mylan to be Sole Supply on 1 October 2020				

Antifungals

- a) For topical antifungals refer to DERMATOLOGICALS, [page 62](#)
b) For topical antifungals refer to GENITO URINARY, [page 74](#)

FLUCONAZOLE				
Cap 50 mg.....	2.75	28	✓	Mylan
Mylan to be Sole Supply on 1 November 2020				
Cap 150 mg.....	0.65	1	✓	Mylan
Mylan to be Sole Supply on 1 November 2020				
Cap 200 mg.....	12.89	28	✓	Mylan
Mylan to be Sole Supply on 1 November 2020				
Powder for oral suspension 10 mg per ml – Special Authority see SA1359 on the next page – Retail pharmacy	34.56	35 ml	✓	Diflucan S29 S29
	98.50		✓	Diflucan
Wastage claimable				

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA1359 Special Authority for Subsidy

Initial application — (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires prophylaxis for, or treatment of systemic candidiasis; and
- 2 Patient is unable to swallow capsules.

Initial application — (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Patient is at moderate to high risk of invasive fungal infection; and
- 3 Patient is unable to swallow capsules.

Renewal — (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires prophylaxis for, or treatment of systemic candidiasis; and
- 2 Patient is unable to swallow capsules.

Renewal — (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient remains immunocompromised; and
- 2 Patient remains at moderate to high risk of invasive fungal infection; and
- 3 Patient is unable to swallow capsules.

ITRACONAZOLE

Cap 100 mg.....	4.27	15	✓ Itirazole
Oral liq 10 mg per ml – Special Authority see SA1322 below –			
Retail pharmacy.....	141.80	150 ml OP	✓ Sporanox

►SA1322 Special Authority for Subsidy

Initial application only from an infectious disease specialist, clinical microbiologist, clinical immunologist or any relevant practitioner on the recommendation of a infectious disease physician, clinical microbiologist or clinical immunologist. Approvals valid for 6 months where the patient has a congenital immune deficiency.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefitting from the treatment.

KETOCONAZOLE

Tab 200 mg – PCT	CBS	30	✓ Link Healthcare ^{\$29}
			✓ Nizoral ^{\$29}
		100	✓ Strides Shasun ^{\$29}

NYSTATIN

Tab 500,000 u	14.16	50	
	(17.09)		Nilstat
Cap 500,000 u	12.81	50	
	(15.47)		Nilstat

POSACONAZOLE – Special Authority see SA1285 on the next page – Retail pharmacy

Tab modified-release 100 mg.....	869.86	24	✓ Noxafil
Oral liq 40 mg per ml	761.13	105 ml OP	✓ Noxafil

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

➤SA1285 Special Authority for Subsidy

Initial application only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*.

Renewal only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment.

Note: * Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids (1 mg or greater per kilogram of body weight per day for patients with acute GVHD or 0.8 mg or greater per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.

TERBINAFINE

* Tab 250 mg	1.33	14	✓ Deolate
--------------------	------	----	------------------

VORICONAZOLE – Special Authority see SA1273 below – Retail pharmacy

Tab 50 mg	91.00	56	✓ Vttack
-----------------	-------	----	-----------------

Tab 200 mg	350.00	56	✓ Vttack
------------------	--------	----	-----------------

Powder for oral suspension 40 mg per ml – Wastage

claimable	1,437.00	70 ml	✓ Vfend
-----------------	----------	-------	----------------

➤SA1273 Special Authority for Subsidy

Initial application — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient has proven or probable invasive aspergillus infection; or
 - 3.2 Patient has possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as *Fusarium* spp. and *Scedosporium* spp.

Renewal — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist.

Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient continues to require treatment for proven or probable invasive aspergillus infection; or
 - 3.2 Patient continues to require treatment for possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as *Fusarium* spp. and *Scedosporium* spp.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Antimalarials

PRIMAQUINE – Special Authority see [SA1684 below](#) – Retail pharmacy

Tab 7.5 mg	117.00	56	✓ Primacin <small>\$29</small>
------------------	--------	----	--------------------------------

► [SA1684](#) Special Authority for Subsidy

Initial application only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 The patient has vivax or ovale malaria; and
- 2 Primaquine is to be given for a maximum of 21 days.

Renewal only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 The patient has relapsed vivax or ovale malaria; and
- 2 Primaquine is to be given for a maximum of 21 days.

Antiparasitics

Antiprotozoals

QUININE SULPHATE

* Tab 300 mg	61.91	500	✓ Q 300
--------------------	-------	-----	---------

Antitrichomonal Agents

METRONIDAZOLE

Tab 200 mg – Up to 30 tab available on a PSO	33.15	250	✓ Metrogyl
--	-------	-----	------------

Metrogyl to be Sole Supply on 1 December 2020

Tab 400 mg – Up to 15 tab available on a PSO	5.23	21	✓ Metrogyl
--	------	----	------------

Metrogyl to be Sole Supply on 1 December 2020

Oral liq benzoate 200 mg per 5 ml	25.00	100 ml	✓ Flagyl-S
---	-------	--------	------------

Suppos 500 mg	24.48	10	✓ Flagyl
---------------------	-------	----	----------

ORNIDAZOLE

Tab 500 mg	32.95	10	✓ Arrow-Ornidazole
------------------	-------	----	--------------------

Antituberculotics and Antileprotics

Note: There is no co-payment charge for all pharmaceuticals listed in the Antituberculotics and Antileprotics group regardless of immigration status.

CLOFAZIMINE – Retail pharmacy-Specialist

- a) No patient co-payment payable
- b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist.

* Cap 50 mg	442.00	100	✓ Lamprene <small>\$29</small>
-------------------	--------	-----	--------------------------------

CYCLOSERINE – Retail pharmacy-Specialist

- a) No patient co-payment payable
- b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician.

Cap 250 mg	344.00	60	✓ Cyclostin <small>\$29</small>
------------------	--------	----	---------------------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DAPSONE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or dermatologist				
Tab 25 mg	268.50	100	✓	Dapsone
Tab 100 mg	329.50	100	✓	Dapsone
ETHAMBUTOL HYDROCHLORIDE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician				
Tab 100 mg	85.73	100	✓	EMB Fatol S29
Tab 400 mg	49.34	56	✓	Myambutol S29
ISONIAZID – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician				
* Tab 100 mg	22.00	100	✓	PSM
ISONIAZID WITH RIFAMPICIN – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician				
* Tab 100 mg with rifampicin 150 mg.....	85.54	100	✓	Rifinah
* Tab 150 mg with rifampicin 300 mg.....	170.60	100	✓	Rifinah
PARA-AMINO SALICYLIC ACID – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease specialist, clinical microbiologist or respiratory physician				
Grans for oral liq 4 g sachet	280.00	30	✓	Paser S29
PROTIONAMIDE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease specialist, clinical microbiologist or respiratory physician				
Tab 250 mg	305.00	100	✓	Peteha S29
PYRAZINAMIDE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, clinical microbiologist or respiratory physician				
* Tab 500 mg	59.00	100	✓	AFT-Pyrazinamide
RIFABUTIN – Retail pharmacy-Specialist				
a) No patient co-payment payable				
b) Prescriptions must be written by, or on the recommendation of, an infectious disease physician, respiratory physician or gastroenterologist				
* Cap 150 mg	299.75	30	✓	Mycobutin

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
RIFAMPICIN – Subsidy by endorsement				
a) No patient co-payment payable				
b) For confirmed recurrent <i>Staphylococcus aureus</i> infection in combination with other effective anti-staphylococcal antimicrobial based on susceptibilities and the prescription is endorsed accordingly; can be waived by endorsement - Retail pharmacy - Specialist. Specialist must be an internal medicine physician, clinical microbiologist, dermatologist, paediatrician, or public health physician.				
* Cap 150 mg.....	58.54	100	✓	Rifadin
Rifadin to be Sole Supply on 1 November 2020				
* Cap 300 mg.....	122.06	100	✓	Rifadin
Rifadin to be Sole Supply on 1 November 2020				
* Oral liq 100 mg per 5 ml.....	12.60	60 ml	✓	Rifadin
Rifadin to be Sole Supply on 1 November 2020				

Antivirals

For eye preparations refer to Eye Preparations, Anti-Infective Preparations, [page 241](#)

Hepatitis B Treatment

ADEFOVIR DIPIVOXIL – Special Authority see SA0829 below – Retail pharmacy				
Tab 10 mg	670.00	30	✓	Hepsera
<i>(Hepsera Tab 10 mg to be delisted 1 March 2021)</i>				

➔ [SA0829](#) Special Authority for Subsidy

Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine, defined as:
- 2 Patient has raised serum ALT ($> 1 \times \text{ULN}$); and
- 3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load 10 fold or higher over nadir; and
- 4 Detection of M204I or M204V mutation; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 Patient is cirrhotic; and
 - 5.1.2 adefovir dipivoxil to be used in combination with lamivudine; or
 - 5.2 Both:
 - 5.2.1 Patient is not cirrhotic; and
 - 5.2.2 adefovir dipivoxil to be used as monotherapy.

Renewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatment.

Notes: Lamivudine should be added to adefovir dipivoxil if a patient develops documented resistance to adefovir dipivoxil, defined as:

- i) raised serum ALT ($> 1 \times \text{ULN}$); and
- ii) HBV DNA greater than 100,000 copies per mL, or viral load 10 fold or higher over nadir; and
- iii) Detection of N236T or A181T/V mutation.

Adefovir dipivoxil should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg+ prior to commencing adefovir dipivoxil.

The recommended dose of adefovir dipivoxil is no more than 10mg daily.

In patients with renal insufficiency adefovir dipivoxil dose should be reduced in accordance with the datasheet guidelines.

Adefovir dipivoxil should be avoided in pregnant women and children.

ENTECAVIR				
* Tab 0.5 mg	52.00	30	✓	Entecavir Sandoz

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LAMIVUDINE – Special Authority see SA1685 below – Retail pharmacy				
Tab 100 mg	6.95	28	✓	Zetlam
Zetlam to be Sole Supply on 1 November 2020				
Oral liq 5 mg per ml	270.00	240 ml OP	✓	Zeffix
» SA1685 Special Authority for Subsidy				
Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.				
Approvals valid for 1 year where used for the treatment or prevention of hepatitis B.				
Renewal from any relevant practitioner. Approvals valid for 2 years where used for the treatment or prevention of hepatitis B.				
TENOFIVIR DISOPROXIL				
Tenofovir disoproxil prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA1651., page 104				
* Tab 245 mg (300.6 mg as a succinate)	38.10	30	✓	Tenofovir Disoproxil Teva

Herpesvirus Treatments

ACICLOVIR				
* Tab dispersible 200 mg	1.60	25	✓	Lovir
* Tab dispersible 400 mg	5.38	56	✓	Lovir
* Tab dispersible 800 mg	5.98	35	✓	Lovir
VALACICLOVIR				
Tab 500 mg	5.75	30	✓	Vaclovir
Tab 1,000 mg	11.35	30	✓	Vaclovir
VALGANCICLOVIR – Special Authority see SA1404 below – Retail pharmacy				
Tab 450 mg	225.00	60	✓	Valganciclovir Mylan

»[SA1404](#) Special Authority for Subsidy

Initial application — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Renewal — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
- 2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin.

Initial application — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist.

Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and
- 2 Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Renewal — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Initial application — (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a lung transplant; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

2 Either:

- 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
- 2.2 The recipient is cytomegalovirus positive.

Initial application — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Renewal — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions.

Hepatitis C Treatment

GLECAPREVIR WITH PIBRENTASVIR – [Xpharm]

Note the supply of treatment is via PHARMAC's approved direct distribution supply. Further details can be found on PHARMAC's website <https://www.pharmac.govt.nz/hepatitis-c-treatments>

Tab 100 mg with pibrentasvir 40 mg	24,750.00	84 OP	✓ Maviret
--	-----------	-------	-----------

LEDIPASVIR WITH SOFOSBUVIR – [Xpharm] – Special Authority see [SA1605 below](#)

No patient co-payment payable

Tab 90 mg with sofosbuvir 400 mg.....	24,363.46	28	✓ Harvoni
---------------------------------------	-----------	----	-----------

► [SA1605](#) Special Authority for Subsidy

Special Authority approved by the Hepatitis C Treatment Panel (HepCTP)

Notes: By application to the Hepatitis C Treatment Panel (HepCTP).

Applications will be considered by HepCTP and approved subject to confirmation of eligibility.

Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz/hepatitis-c-treatments> or:

The Coordinator, Hepatitis C Treatment Panel

PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 460 4990,

Email: heccpanel@pharmac.govt.nz

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

HIV Prophylaxis and Treatment

EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Subsidy by endorsement; can be waived by Special Authority see [SA1904](#) below

Endorsement for treatment of HIV: Prescription is deemed to be endorsed if emtricitabine with tenofovir disoproxil is co-prescribed with another antiretroviral subsidised under Special Authority SA1651 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Emtricitabine with tenofovir disoproxil prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals, and counts as two antiretroviral medications, for the purposes of Special Authority SA1651, [page 104](#) There is an approval process to become a named specialist to prescribe antiretroviral therapy in New Zealand. Further information is available on the PHARMAC website.

Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) 61.15 30 ✓ **Teva**

►SA1904 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:
All of the following:

- 1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or <https://ashm.org.au/HIV/PrEP/> for training materials); and
- 2 Patient has undergone testing for HIV, syphilis and Hep B if not immune in the previous two weeks; and
- 3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 3 months and is not contraindicated for treatment; and
- 4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
- 5 Patient has tested HIV negative and is not at risk of HIV seroconversion; and
- 6 Either:

6.1 All of the following:

- 6.1.1 Patient is male or transgender; and
- 6.1.2 Patient has sex with men; and
- 6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
- 6.1.4 Any of the following:
 - 6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
 - 6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
 - 6.1.4.3 Patient has used methamphetamine in the last three months; or

6.2 All of the following:

- 6.2.1 Patient has a regular partner who has HIV infection; and
- 6.2.2 Partner is either not on treatment or has a detectable viral load; and
- 6.2.3 Condoms have not been consistently used.

Renewal from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:
All of the following:

- 1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or <https://ashm.org.au/HIV/PrEP/> for training materials); and
- 2 Patient has undergone testing for HIV, syphilis and Hep B if not immune in the previous two weeks; and
- 3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 12 months and is not contraindicated for treatment; and
- 4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
- 5 Patient has tested HIV negative and is not at risk of HIV seroconversion; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

6 Either:

6.1 All of the following:

- 6.1.1 Patient is male or transgender; and
- 6.1.2 Patient has sex with men; and
- 6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
- 6.1.4 Any of the following:
 - 6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
 - 6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
 - 6.1.4.3 Patient has used methamphetamine in the last three months; or

6.2 All of the following:

- 6.2.1 Patient has a regular partner who has HIV infection; and
- 6.2.2 Partner is either not on treatment or has a detectable viral load; and
- 6.2.3 Condoms have not been consistently used.

Antiretrovirals

►SA1651 Special Authority for Subsidy

Initial application — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the patient has confirmed HIV infection.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

prophylaxis is required.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ – Special Authority see SA1651 on the previous page – Retail pharmacy		
Tab 200 mg	190.15	90 ✓ Stocrin
Tab 600 mg	63.38	30 ✓ Stocrin
ETRAVIRINE – Special Authority see SA1651 on the previous page – Retail pharmacy		
Tab 200 mg	770.00	60 ✓ Intencele
NEVIRAPINE – Special Authority see SA1651 on the previous page – Retail pharmacy		
Tab 200 mg	60.00	60 ✓ Nevirapine
		Alphapharm
Oral suspension 10 mg per ml.....	203.55	240 ml ✓ Viramune
		Suspension

Nucleosides Reverse Transcriptase Inhibitors

ABACAVIR SULPHATE – Special Authority see SA1651 on the previous page – Retail pharmacy		
Tab 300 mg	180.00	60 ✓ Ziagen
Oral liq 20 mg per ml	256.31	240 ml OP ✓ Ziagen
ABACAVIR SULPHATE WITH LAMIVUDINE – Special Authority see SA1651 on the previous page – Retail pharmacy		
Note: abacavir with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.		
Tab 600 mg with lamivudine 300 mg.....	63.00	30 ✓ Kivexa
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL – Special Authority see SA1651 on the previous page – Retail pharmacy		
Note: Efavirenz with emtricitabine and tenofovir disoproxil counts as three anti-retroviral medications for the purposes of the anti-retroviral Special Authority		
Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil		
245 mg (300 mg as a maleate).....	106.88	30 ✓ Mylan

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
EMTRICITABINE – Special Authority see SA1651 on page 104 – Retail pharmacy				
Cap 200 mg.....	307.20	30	✓	Emtriva
LAMIVUDINE – Special Authority see SA1651 on page 104 – Retail pharmacy				
Tab 150 mg.....	84.50	60	✓	Lamivudine Alphapharm
Lamivudine Alphapharm to be Sole Supply on 1 November 2020				
Oral liq 10 mg per ml.....	102.50	240 ml OP	✓	3TC
ZIDOVUDINE [AZT] – Special Authority see SA1651 on page 104 – Retail pharmacy				
Cap 100 mg.....	152.25	100	✓	Retrovir
Oral liq 10 mg per ml.....	30.45	200 ml OP	✓	Retrovir
ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority see SA1651 on page 104 – Retail pharmacy				
Note: zidovudine [AZT] with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.				
Tab 300 mg with lamivudine 150 mg.....	33.00	60	✓	Alphapharm

Protease Inhibitors

ATAZANAVIR SULPHATE – Special Authority see SA1651 on page 104 – Retail pharmacy				
Cap 150 mg.....	141.68	60	✓	Teva
Cap 200 mg.....	188.91	60	✓	Teva
DARUNAVIR – Special Authority see SA1651 on page 104 – Retail pharmacy				
Tab 400 mg.....	335.00	60	✓	Prezista
Tab 600 mg.....	476.00	60	✓	Prezista
LOPINAVIR WITH RITONAVIR – Special Authority see SA1651 on page 104 – Retail pharmacy				
Tab 100 mg with ritonavir 25 mg.....	183.75	60	✓	Kaletra
Tab 200 mg with ritonavir 50 mg.....	463.00	120	✓	Kaletra
Oral liq 80 mg with ritonavir 20 mg per ml.....	735.00	300 ml OP	✓	Kaletra
RITONAVIR – Special Authority see SA1651 on page 104 – Retail pharmacy				
Tab 100 mg.....	43.31	30	✓	Norvir

Strand Transfer Inhibitors

DOLUTEGRAVIR – Special Authority see SA1651 on page 104 – Retail pharmacy				
Tab 50 mg.....	1,090.00	30	✓	Tivicay
RALTEGRAVIR POTASSIUM – Special Authority see SA1651 on page 104 – Retail pharmacy				
Tab 400 mg.....	1,090.00	60	✓	Isentress
Tab 600 mg.....	1,090.00	60	✓	Isentress HD

Immune Modulators

Guidelines for the use of interferon in the treatment of hepatitis C:

Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects.

Patients should be otherwise fit.

Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

Criteria for Treatment

- 1) Diagnosis

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or
- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following.

Exclusion Criteria

- 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease).
- 2) Pregnancy.
- 3) Neutropenia ($< 2.0 \times 10^9$) and/or thrombocytopenia.
- 4) Continuing alcohol abuse and/or continuing intravenous drug users.

Dosage

The current recommended dosage is 3 million units of interferon alfa-2a or interferon alfa-2b administered subcutaneously 3 times a week for 52 weeks (twelve months)

Exit Criteria

The patient's response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment ALT level at this stage.

INTERFERON ALFA-2A – PCT

See prescribing guideline [on the previous page](#)

Inj 3 m iu prefilled syringe.....	38.00	1	✓ Roferon-A
-----------------------------------	-------	---	-------------

(Roferon-A Inj 3 m iu prefilled syringe to be delisted 1 December 2020)

PEGYLATED INTERFERON ALFA-2A – Special Authority see SA1936 below – Retail pharmacy

a) See prescribing guideline [on the previous page](#)

b) Note: PHARMAC will consider funding ribavirin for the small group of patients who have a clinical need for ribavirin and meet Special Authority criteria. Please contact the Hepatitis C Coordinator at PHARMAC on 0800-023-588 option 4.

Inj 180 mcg prefilled syringe.....	500.00	4	✓ Pegasys
------------------------------------	--------	---	-----------

►SA1936 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or
 - 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and
- 2 Maximum of 48 weeks therapy.

Notes:

- Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
- Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml

Renewal — (Chronic hepatitis C - genotype 1 infection) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 3.1 Patient has responder relapsed; or
- 3.2 Patient was a partial responder; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist.

Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naïve; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (Metavir Stage F2 or greater or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Initial application — (myeloproliferative disorder or cutaneous T cell lymphoma) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 Patient has a cutaneous T cell lymphoma*; or
- 2 All of the following:
 - 2.1 Patient has a myeloproliferative disorder*; and
 - 2.2 Patient is intolerant of hydroxyurea; and
 - 2.3 Treatment with anagrelide and busulfan is not clinically appropriate; or
- 3 Both:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 3.1 Patient has a myeloproliferative disorder; and
- 3.2 Patient is pregnant, planning pregnancy or lactating.

Renewal — (myeloproliferative disorder or cutaneous T cell lymphoma) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment; and
- 3 Either:
 - 3.1 Patient has a cutaneous T cell lymphoma*; or
 - 3.2 Both:
 - 3.2.1 Patient has a myeloproliferative disorder*; and
 - 3.2.2 Either:
 - 3.2.2.1 Remains intolerant of hydroxyurea and treatment with anagrelide and busulfan remains clinically inappropriate; or
 - 3.2.2.2 Patient is pregnant, planning pregnancy or lactating.

Note: Indications marked with * are unapproved indications.

Notes:

- Approved dose is 180 mcg once weekly.
- The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alfa 2a dose should be reduced to 135 mcg once weekly.
- In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
- Pegylated Interferon-alfa 2a is not approved for use in children.

Urinary Tract Infections

METHENAMINE (HEXAMINE) HIPPURATE

* Tab 1 g	40.01	100	✓ Hiprex
-----------------	-------	-----	----------

NITROFURANTOIN

* Tab 50 mg – Up to 30 tab available on a PSO	22.20	100	✓ Nifuran
* Tab 100 mg	37.50	100	✓ Nifuran

NORFLOXACIN

Tab 400 mg – Subsidy by endorsement.....	135.00	100	✓ Arrow-Norfloxacin
--	--------	-----	---------------------

Only if prescribed for a patient with an uncomplicated urinary tract infection that is unresponsive to a first line agent or with proven resistance to first line agents and the prescription is endorsed accordingly.

MUSCULOSKELETAL SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Anticholinesterases				
NEOSTIGMINE METILSULFATE				
Inj 2.5 mg per ml, 1 ml ampoule	19.60	10	✓ Juno ^{\$29}	
	98.00	50	✓ AstraZeneca	
PYRIDOSTIGMINE BROMIDE				
▲ Tab 60 mg	45.79	100	✓ Mestinon	
Non-Steroidal Anti-Inflammatory Drugs				
DICLOFENAC SODIUM				
* Tab EC 25 mg	1.23	50	✓ Diclofenac Sandoz	
* Tab 50 mg dispersible	1.50	20	✓ Voltaren D	
* Tab EC 50 mg	1.23	50	✓ Diclofenac Sandoz	
* Tab long-acting 75 mg	22.80	500	✓ Apo-Diclo SR	
* Tab long-acting 100 mg	25.15	500	✓ Apo-Diclo SR	
* Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO	13.20	5	✓ Voltaren	
* Suppos 12.5 mg	2.04	10	✓ Voltaren	
* Suppos 25 mg	2.44	10	✓ Voltaren	
* Suppos 50 mg – Up to 10 supp available on a PSO	4.22	10	✓ Voltaren	
* Suppos 100 mg	7.00	10	✓ Voltaren	
IBUPROFEN				
* Tab 200 mg	11.71	1,000	✓ Relieve	
Tab long-acting 800 mg	5.99	30	✓ Ibuprofen SR BNM	
	7.99		✓ Brufen SR	
Ibuprofen SR BNM to be Sole Supply on 1 December 2020				
* Oral liq 20 mg per ml	1.88	200 ml	✓ Ethics	
(Brufen SR Tab long-acting 800 mg to be delisted 1 December 2020)				
KETOPROFEN				
* Cap long-acting 200 mg	12.07	28	✓ Oruvail SR	
MEFENAMIC ACID				
* Cap 250 mg	1.25	50		
	(9.16)			Ponstan
	0.50	20		
	(5.60)			Ponstan
NAPROXEN				
* Tab 250 mg	32.69	500	✓ Noflam 250	
* Tab 500 mg	22.19	250	✓ Noflam 500	
* Tab long-acting 750 mg	6.16	28	✓ Naprosyn SR 750	
* Tab long-acting 1 g	8.21	28	✓ Naprosyn SR 1000	
SULINDAC				
* Tab 100 mg	9.57	56	✓ Mylan ^{\$29}	
* Tab 200 mg	15.10	50	✓ Acilin	
	16.91	56	✓ Sulindac Mylan ^{\$29}	
TENOXICAM				
* Tab 20 mg	9.15	100	✓ Tilcotil	
* Inj 20 mg vial	9.95	1	✓ AFT	

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

NSAIDs Other

CELECOXIB

Cap 100 mg	3.63	60	✓ Celecoxib Pfizer
Cap 200 mg	2.30	30	✓ Celebrex
			✓ Celecoxib Pfizer

Topical Products for Joint and Muscular Pain

CAPSAICIN

Crn 0.025% – Special Authority see SA1289 below – Retail			
pharmacy	6.95	25 g OP	✓ Zostrix
	9.95	45 g OP	✓ Zostrix
	13.27	60 g OP	✓ Rugby Capsaicin Topical Cream <small>\$29</small>

►SA1289 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

Antirheumatoid Agents

HYDROXYCHLOROQUINE – Subsidy by endorsement

Subsidised only if prescribed for rheumatoid arthritis, systemic or discoid lupus erythematosus, malaria treatment or suppression, relevant dermatological conditions (cutaneous forms of lupus and lichen planus, cutaneous vasculitides and mucosal ulceration)*, sarcoidosis (pulmonary and non-pulmonary)*, and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of hydroxychloroquine. Note: Indication marked with a * is an unapproved indication.

* Tab 200 mg	7.98	100	✓ <u>Plaquenil</u>
LEFLUNOMIDE			
Tab 10 mg	2.90	30	✓ Apo-Leflunomide
	6.00		✓ Arava
Arava to be Sole Supply on 1 December 2020			
Tab 20 mg	2.90	30	✓ Apo-Leflunomide
	6.00		✓ Arava
Arava to be Sole Supply on 1 December 2020			
<i>(Apo-Leflunomide Tab 10 mg to be delisted 1 December 2020)</i>			
<i>(Apo-Leflunomide Tab 20 mg to be delisted 1 December 2020)</i>			
PENICILLAMINE			
Tab 125 mg	67.23	100	✓ D-Penamine
Tab 250 mg	110.12	100	✓ D-Penamine

Drugs Affecting Bone Metabolism

Alendronate for Osteoporosis

ALENDRONATE SODIUM

* Tab 70 mg	2.44	4	✓ <u>Fosamax</u>
-------------------	------	---	------------------

ALENDRONATE SODIUM WITH COLECALCIFEROL

* Tab 70 mg with colecalciferol 5,600 iu	1.51	4	✓ <u>Fosamax Plus</u>
--	------	---	-----------------------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Other Treatments

DENOSUMAB – Special Authority see [SA1777 below](#) – Retail pharmacy

Inj 60 mg prefilled syringe.....	326.00	1	✓ Prolia
----------------------------------	--------	---	----------

►SA1777 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 Either:
 - 2.1 The patient is female and postmenopausal; or
 - 2.2 The patient is male or non-binary; and
- 3 Any of the following:
 - 3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or
 - 3.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 3.4 Documented T-Score less than or equal to -3.0 (see Note); or
 - 3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 3.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 4 Zoledronic acid is contraindicated because the patient's creatinine clearance is less than 35 mL/min; and
- 5 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes); and
- 6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body
- e) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PAMIDRONATE DISODIUM				
Inj 3 mg per ml, 10 ml vial.....	5.98	1	✓	Pamisol
Inj 6 mg per ml, 10 ml vial.....	15.02	1	✓	Pamisol
Inj 9 mg per ml, 10 ml vial.....	17.05	1	✓	Pamisol

RALOXIFENE HYDROCHLORIDE – Special Authority see [SA1779 below](#) – Retail pharmacy

* Tab 60 mg	53.76	28	✓	Evista
-------------------	-------	----	---	---------------

► **SA1779** **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score less than or equal to -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause – Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

RISEDRONATE SODIUM

Tab 35 mg	3.10	4	✓	Risedronate Sandoz
-----------------	------	---	---	---------------------------

TERIPARATIDE – Special Authority see [SA1139 below](#) – Retail pharmacy

Inj 250 mcg per ml, 2.4 ml	490.00	1	✓	Forteo
----------------------------------	--------	---	---	---------------

► **SA1139** **Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

funded antiresorptive agent at adequate doses (see Notes).

Notes:

- The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- A maximum of 18 months of treatment (18 cartridges) will be subsidised.

ZOLEDRONIC ACID

Inj 0.05 mg per ml, 100 ml, vial – Special Authority see

SA1780 below – Retail pharmacy 60.00 100 ml OP ✓ **Aclasta**

► **SA1780** Special Authority for Subsidy

Initial application — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- Paget's disease; and
- Any of the following:
 - Bone or articular pain; or
 - Bone deformity; or
 - Bone, articular or neurological complications; or
 - Asymptomatic disease, but risk of complications; or
 - Preparation for orthopaedic surgery; and
- The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- Any of the following:
 - History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - History of two significant osteoporotic fractures demonstrated radiologically; or
 - Documented T-Score less than or equal to -3.0 (see Note); or
 - A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

year for applications meeting the following criteria:

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Renewal — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
 - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
 - 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is continuing systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score less than or equal to -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 The patient has had a Special Authority approval for alendronate (Underlying was glucocorticosteroid therapy but patient now meets the 'Underlying cause - Osteoporosis' criteria) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Notes:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

continued...

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Hyperuricaemia and Antigout

ALLOPURINOL

* Tab 100 mg	11.47	500	✓ DP-Allopurinol
DP-Allopurinol to be Sole Supply on 1 November 2020			
* Tab 300 mg	28.57	500	✓ DP-Allopurinol
DP-Allopurinol to be Sole Supply on 1 November 2020			

BENZBROMARONE – Special Authority see SA1537 below – Retail pharmacy

Tab 50 mg	22.50	100	✓ Nardcarcin mite ^{S29}
Tab 100 mg	13.50	30	✓ Desuric ^{S29}
			✓ Urinorm ^{S29}
	45.00	100	✓ Benzbromaron AL
			100 ^{S29}

►SA1537 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- Patient has been diagnosed with gout; and
- Any of the following:
 - The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - Both:
 - The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Notes); and
 - The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
 - All of the following:
 - The patient is taking azathioprine and requires urate-lowering therapy; and
 - Allopurinol is contraindicated; and
 - Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and
- The patient is receiving monthly liver function tests.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefitting from the treatment; and
- 2 There is no evidence of liver toxicity and patient is continuing to receive regular (at least every three months) liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity.

In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at www.rheumatology.org.nz/home/resources-2/

COLCHICINE

* Tab 500 mg 9.58 100 ✓ **Colgout**

FEBUXOSTAT – Special Authority see SA1931 below – Retail pharmacy

Tab 80 mg 39.50 28 ✓ **Adenuric**

Tab 120 mg 39.50 28 ✓ **Adenuric**

►SA1931 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); or
 - 2.4 The patient has previously had an initial Special Authority approval for benzbromarone for treatment of gout.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from treatment.

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

PROBENECID

* Tab 500 mg 55.00 100 ✓ **Probenecid-AFT**

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Muscle Relaxants				
BACLOFEN				
* Tab 10 mg	4.20	100	✓	Pacifen
Inj 0.05 mg per ml, 1 ml ampoule – Subsidy by endorsement.....	11.55	1	✓	Lioresal Intrathecal
Subsidised only for use in a programmable pump in patients where oral antispastic agents have been ineffective or have caused intolerable side effects and the prescription is endorsed accordingly.				
Inj 2 mg per ml, 5 ml ampoule – Subsidy by endorsement.....	372.98	5	✓	Medsurge
Subsidised only for use in a programmable pump in patients where oral antispastic agents have been ineffective or have caused intolerable side effects and the prescription is endorsed accordingly.				
DANTROLENE				
Cap 25 mg	97.50	100	✓	Dantrium
			✓	Dantrium S29 <small>S29</small>
Cap 50 mg	77.00	100	✓	Dantrium
ORPHENADRINE CITRATE				
Tab 100 mg	18.54	100	✓	Norflex

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Agents for Parkinsonism and Related Disorders

Dopamine Agonists and Related Agents

AMANTADINE HYDROCHLORIDE

▲ Cap 100 mg 38.24 60 ✓ Symmetrel

APOMORPHINE HYDROCHLORIDE

▲ Inj 10 mg per ml, 2 ml ampoule 59.50 5 ✓ Movapo

▲ Inj 10 mg per ml, 5 ml ampoule 121.84 5 ✓ Movapo

BROMOCRIPTINE MESYLATE

* Tab 2.5 mg 32.08 100 ✓ Apo-Bromocriptine

ENTACAPONE

▲ Tab 200 mg 22.00 100 ✓ Entapone

LEVODOPA WITH BENSERAZIDE

* Tab dispersible 50 mg with benserazide 12.5 mg 13.25 100 ✓ Madopar Rapid

* Cap 50 mg with benserazide 12.5 mg 13.75 100 ✓ Madopar 62.5

* Cap 100 mg with benserazide 25 mg 15.80 100 ✓ Madopar 125

* Cap long-acting 100 mg with benserazide 25 mg 22.85 100 ✓ Madopar HBS

* Cap 200 mg with benserazide 50 mg 26.25 100 ✓ Madopar 250

LEVODOPA WITH CARBIDOPA

* Tab 100 mg with carbidopa 25 mg 17.97 100 ✓ Kinson

21.11 ✓ Sinemet

Sinemet to be Sole Supply on 1 December 2020

* Tab long-acting 100 mg with carbidopa 25 mg 23.84 100 ✓ Mylan ^{\$29}

* Tab long-acting 200 mg with carbidopa 50 mg 37.15 100 ✓ Sinemet CR

46.73 ✓ Mylan ^{\$29}

* Tab 250 mg with carbidopa 25 mg 38.39 100 ✓ Sinemet

Sinemet to be Sole Supply on 1 December 2020

(Kinson Tab 100 mg with carbidopa 25 mg to be delisted 1 December 2020)

(Mylan ^{\$29} Tab long-acting 100 mg with carbidopa 25 mg to be delisted 1 December 2020)

PRAMIPEXOLE HYDROCHLORIDE

▲ Tab 0.25 mg 6.12 100 ✓ Ramipex

▲ Tab 1 mg 20.73 100 ✓ Ramipex

ROPINIROLE HYDROCHLORIDE

▲ Tab 0.25 mg 2.85 84 ✓ Ropin

3.39 100 ✓ Mylan ^{\$29}

▲ Tab 1 mg 3.95 84 ✓ Ropin

4.70 100 ✓ Mylan ^{\$29}

▲ Tab 2 mg 5.48 84 ✓ Ropin

▲ Tab 5 mg 12.50 84 ✓ Ropin

SELEGILINE HYDROCHLORIDE

* Tab 5 mg 22.00 100 ✓ Apo-Selegiline
^{\$29}

TOLCAPONE

▲ Tab 100 mg 152.38 100 ✓ Tasmar

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Anticholinergics				
BENZATROPINE MESYLATE				
Tab 2 mg	7.99	60	✓	Benztrop
Inj 1 mg per ml, 2 ml	95.00	5	✓	Cogentin
			✓	Phebra
	190.00	10	✓	Omega
a) Up to 10 inj available on a PSO				
b) Only on a PSO				
c) Phebra to be Sole Supply on 1 December 2020				
<i>(Cogentin Inj 1 mg per ml, 2 ml to be delisted 1 December 2020)</i>				
<i>(Omega Inj 1 mg per ml, 2 ml to be delisted 1 December 2020)</i>				
PROCYCLIDINE HYDROCHLORIDE				
Tab 5 mg	7.40	100	✓	Kemadrin

Agents for Essential Tremor, Chorea and Related Disorders

RILUZOLE – Special Authority see [SA1403 below](#) – Retail pharmacy

Wastage claimable

Tab 50 mg	130.00	56	✓	Rilutek
-----------------	--------	----	---	----------------

►SA1403 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
- 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
- 3 The patient has not undergone a tracheostomy; and
- 4 The patient has not experienced respiratory failure; and
- 5 Any of the following:
 - 5.1 The patient is ambulatory; or
 - 5.2 The patient is able to use upper limbs; or
 - 5.3 The patient is able to swallow.

Renewal from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 The patient has not undergone a tracheostomy; and
- 2 The patient has not experienced respiratory failure; and
- 3 Any of the following:
 - 3.1 The patient is ambulatory; or
 - 3.2 The patient is able to use upper limbs; or
 - 3.3 The patient is able to swallow.

TETRABENAZINE

Tab 25 mg	91.10	112	✓	Motetis
-----------------	-------	-----	---	----------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Anaesthetics

Local

LIDOCAINE [LIGNOCAINE]

Gel 2%, tube – Subsidy by endorsement	14.50	30 ml	✓ Xylocaine 2% Jelly
a) Up to 150 ml available on a PSO			
b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly.			
Gel 2%, 11 ml urethral syringe – Subsidy by endorsement.....	42.00	10	✓ Instillagel Lido
a) Up to 5 each available on a PSO			
b) Subsidised only if prescribed for urethral, cervical or rectal administration and the prescription is endorsed accordingly.			

LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE

Oral (gel) soln 2%	38.00	200 ml	✓ Mucosooth
Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO	8.75	25	✓ Lidocaine-Clarix
.....	17.50	50	
.....	(35.00)		Xylocaine
Inj 2%, 5 ml ampoule – Up to 5 inj available on a PSO	8.25	25	✓ Lidocaine-Clarix
Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO	12.00	5	
.....	(20.00)		Xylocaine
Inj 1%, 20 ml vial – Up to 5 inj available on a PSO	6.20	5	✓ Lidocaine-Clarix
Inj 2%, 20 ml vial – Up to 5 inj available on a PSO	6.45	5	✓ Lidocaine-Clarix

LIDOCAINE [LIGNOCAINE] WITH CHLORHEXIDINE

Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes –			
Subsidy by endorsement	81.50	10	✓ Pfizer
a) Up to 5 each available on a PSO			
b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly.			

Topical Local Anaesthetics

►SA0906 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years where the patient is a child with a chronic medical condition requiring frequent injections or venepuncture.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

LIDOCAINE [LIGNOCAINE] – Special Authority see [SA0906 above](#) – Retail pharmacy

Crm 4%	5.40	5 g OP	✓ LMX4
.....	27.00	30 g OP	✓ LMX4

LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE – Special Authority see [SA0906 above](#) – Retail pharmacy

Crm 2.5% with prilocaïne 2.5%	45.00	30 g OP	✓ EMLA
Crm 2.5% with prilocaïne 2.5% (5 g tubes)	45.00	5	✓ EMLA

Analgesics

For Anti-inflammatory NSAIDs refer to MUSCULOSKELETAL, [page 110](#)

Non-opioid Analgesics

For aspirin & chloroform application refer Standard Formulae, [page 248](#)

ASPIRIN

* Tab dispersible 300 mg – Up to 30 tab available on a PSO	4.50	100	✓ Ethics Aspirin
--	------	-----	-------------------------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CAPSAICIN – Subsidy by endorsement				
Subsidised only if prescribed for post-herpetic neuralgia or diabetic peripheral neuropathy and the prescription is endorsed accordingly.				
Crm 0.075%.....	12.50	45 g OP	✓	Zostrix HP
	15.83	57 g OP	✓	Rugby Capsaicin Topical Cream <small>\$29</small>
NEFOPAM HYDROCHLORIDE				
Tab 30 mg	23.40	90	✓	Acupan
PARACETAMOL				
Tab 500 mg - blister pack	0.50	20	✓	Medco
			✓	Paracare
			✓	Pharmacy Health
	1.12		✓	Ethics Paracetamol Classic
	2.48	100	✓	Paracare
			✓	Pharmacy Health
	11.75	96	✓	Panadol Mini Caps
	24.82	1,000	✓	Paracetamol Pharmicare
			✓	Pharmicare
a) Maximum of 300 tab per prescription; can be waived by endorsement				
b) Up to 30 tab available on a PSO				
c)				
1) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater, and the prescription is annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition.				
2) Maximum of 100 tab per dispensing for non-endorsed patients. If quantities prescribed for more than 100 tabs (for non-endorsed patients), then dispense in repeat dispensings not exceeding 100 tab per dispensing.				
Tab 500 mg - bottle pack – Maximum of 300 tab per prescription; can be waived by endorsement	24.82	1,000	✓	Pharmicare
1) Subsidy by endorsement for higher quantities is available for patients with long term conditions who require regular daily dosing for one month or greater, and the prescription is annotated accordingly. Pharmacists may annotate the prescription as endorsed where dispensing history supports a long-term condition.				
2) Maximum of 100 tab per dispensing for non-endorsed patients. If quantities prescribed for more than 100 tabs (for non-endorsed patients), then dispense in repeat dispensings not exceeding 100 tab per dispensing.				
* Oral liq 120 mg per 5 ml	5.45	1,000 ml	✓	Paracare
a) Up to 200 ml available on a PSO				
b) Not in combination				
c) Paracare to be Sole Supply on 1 November 2020				
* Oral liq 250 mg per 5 ml	6.25	1,000 ml	✓	Paracare Double Strength
a) Up to 100 ml available on a PSO				
b) Not in combination				
c) Paracare Double Strength to be Sole Supply on 1 November 2020				
* Suppos 125 mg	3.29	10	✓	Gacet
* Suppos 250 mg	3.79	10	✓	Gacet
* Suppos 500 mg	12.40	50	✓	Gacet

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Opioid Analgesics				
CODEINE PHOSPHATE – Safety medicine; prescriber may determine dispensing frequency				
Tab 15 mg	6.25	100	✓ PSM	
PSM to be Sole Supply on 1 November 2020				
Tab 30 mg	7.45	100	✓ PSM	
PSM to be Sole Supply on 1 November 2020				
Tab 60 mg	14.25	100	✓ PSM	
PSM to be Sole Supply on 1 November 2020				
DIHYDROCODEINE TARTRATE				
Tab long-acting 60 mg	8.60	60	✓ <u>DHC Continus</u>	
FENTANYL				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Inj 50 mcg per ml, 2 ml ampoule	1.78	5	✓ Fentanyl GH	
	3.56	10	✓ Boucher and Muir	
Inj 50 mcg per ml, 10 ml ampoule	9.41	10	✓ Boucher and Muir	
Patch 12.5 mcg per hour	2.95	5	✓ Fentanyl Sandoz	
Patch 25 mcg per hour	3.66	5	✓ Fentanyl Sandoz	
Patch 50 mcg per hour	6.65	5	✓ Fentanyl Sandoz	
Patch 75 mcg per hour	9.25	5	✓ Fentanyl Sandoz	
Patch 100 mcg per hour	11.40	5	✓ Fentanyl Sandoz	
(Fentanyl GH Inj 50 mcg per ml, 2 ml ampoule to be delisted 1 January 2021)				
METHADONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
d) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets).				
e) For methadone hydrochloride oral liquid refer Standard Formulae, page 248				
Tab 5 mg	1.40	10	✓ Methatabs	
Oral liq 2 mg per ml	5.79	200 ml	✓ Biodone	
Oral liq 5 mg per ml	5.79	200 ml	✓ Biodone Forte	
Oral liq 10 mg per ml	6.79	200 ml	✓ Biodone Extra Forte	
Inj 10 mg per ml, 1 ml	61.00	10	✓ AFT	
MORPHINE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Oral liq 1 mg per ml	9.28	200 ml	✓ RA-Morph	
Oral liq 2 mg per ml	16.24	200 ml	✓ RA-Morph	
Oral liq 5 mg per ml	19.44	200 ml	✓ Ordine ^{S29}	
			✓ RA-Morph	
Oral liq 10 mg per ml	27.74	200 ml	✓ Ordine ^{S29}	
			✓ RA-Morph	

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
MORPHINE SULPHATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Tab immediate-release 10 mg.....	2.80	10	✓	Sevredol
Sevredol to be Sole Supply on 1 November 2020				
Tab long-acting 10 mg.....	1.93	10	✓	Arrow-Morphine LA
Tab immediate-release 20 mg.....	5.52	10	✓	Sevredol
Sevredol to be Sole Supply on 1 November 2020				
Tab long-acting 30 mg.....	2.85	10	✓	Arrow-Morphine LA
Tab long-acting 60 mg.....	5.60	10	✓	Arrow-Morphine LA
Cap long-acting 10 mg	2.05	10	✓	m-Eslon
Cap long-acting 30 mg	3.00	10	✓	m-Eslon
Cap long-acting 60 mg	6.12	10	✓	m-Eslon
Cap long-acting 100 mg	7.13	10	✓	m-Eslon
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	6.27	5	✓	DBL Morphine Sulphate
Inj 10 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	4.47	5	✓	DBL Morphine Sulphate
Inj 15 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	4.76	5	✓	DBL Morphine Sulphate
Inj 30 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	6.19	5	✓	DBL Morphine Sulphate
<i>(Arrow-Morphine LA Tab long-acting 10 mg to be delisted 1 October 2020)</i>				
OXYCODONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Tab controlled-release 5 mg.....	2.15	20	✓	Oxycodone Sandoz
Tab controlled-release 10 mg.....	2.15	20	✓	Oxycodone Sandoz
Tab controlled-release 20 mg.....	2.15	20	✓	Oxycodone Sandoz
Tab controlled-release 40 mg.....	3.20	20	✓	Oxycodone Sandoz
Tab controlled-release 80 mg.....	10.98	20	✓	Oxycodone Sandoz
Cap immediate-release 5 mg	1.88	20	✓	OxyNorm
Cap immediate-release 10 mg	3.32	20	✓	OxyNorm
Cap immediate-release 20 mg	5.81	20	✓	OxyNorm
Oral liq 5 mg per 5 ml	11.20	250 ml	✓	OxyNorm
Inj 10 mg per ml, 1 ml ampoule	7.28	5	✓	OxyNorm
Inj 10 mg per ml, 2 ml ampoule	14.36	5	✓	OxyNorm
Inj 50 mg per ml, 1 ml ampoule	30.60	5	✓	OxyNorm
PARACETAMOL WITH CODEINE – Safety medicine; prescriber may determine dispensing frequency				
* Tab paracetamol 500 mg with codeine phosphate 8 mg.....	18.21	1,000	✓	Paracetamol + Codeine (Relieve)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PETHIDINE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequency				
Tab 50 mg	4.46	10	✓ PSM	
Inj 50 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	4.98	5	✓ DBL Pethidine Hydrochloride	
Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	5.12	5	✓ DBL Pethidine Hydrochloride	
TRAMADOL HYDROCHLORIDE				
Tab sustained-release 100 mg	1.52	20	✓ Tramal SR 100	
Tramal SR 100 to be Sole Supply on 1 November 2020				
Tab sustained-release 150 mg	2.10	20	✓ Tramal SR 150	
Tramal SR 150 to be Sole Supply on 1 November 2020				
Tab sustained-release 200 mg	2.75	20	✓ Tramal SR 200	
Tramal SR 200 to be Sole Supply on 1 November 2020				
Cap 50 mg	2.80	100	✓ Arrow-Tramadol	
Arrow-Tramadol to be Sole Supply on 1 December 2020				

Antidepressants

Cyclic and Related Agents

AMITRIPTYLINE – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg	2.49	100	✓ Arrow-Amitriptyline	
Arrow-Amitriptyline to be Sole Supply on 1 December 2020				
Tab 25 mg	1.51	100	✓ Arrow-Amitriptyline	
Arrow-Amitriptyline to be Sole Supply on 1 December 2020				
Tab 50 mg	2.51	100	✓ Arrow-Amitriptyline	
Arrow-Amitriptyline to be Sole Supply on 1 December 2020				
CLOMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg	13.99	100	✓ Anafranil ^{S29}	
			✓ Apo-Clomipramine	
Tab 25 mg	4.73	50	✓ Apo-Clomipramine	
	9.46	100	✓ Apo-Clomipramine	
DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – Subsidy by endorsement				
a) Safety medicine; prescriber may determine dispensing frequency				
b) Subsidy by endorsement – Subsidised for patients who were taking dosulepin [dothiepin] hydrochloride prior to 1 June 2019 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of dosulepin [dothiepin] hydrochloride.				
Tab 75 mg	4.93	30	✓ Dosulepin Mylan	
Cap 25 mg	7.83	50	✓ Dosulepin Mylan ^{S29}	
IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg	5.48	50	✓ Tofranil	
	10.96	100	✓ Tofranil	
Tab 25 mg	8.80	50	✓ Tofranil	

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

MAPROTIline HYDROCHLORIDE – Subsidy by endorsement

- Safety medicine; prescriber may determine dispensing frequency
- Subsidy by endorsement – Subsidised for patients who were taking maprotiline hydrochloride prior to 1 September 2020 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of maprotiline hydrochloride.

Tab 25 mg	7.52	30	✓	Ludiomil
	12.53	50	✓	Ludiomil
	25.06	100	✓	Ludiomil
Tab 75 mg	14.01	20	✓	Ludiomil
	21.01	30	✓	Ludiomil

(Ludiomil Tab 25 mg to be delisted 1 February 2021)

(Ludiomil Tab 25 mg to be delisted 1 February 2021)

(Ludiomil Tab 25 mg to be delisted 1 February 2021)

(Ludiomil Tab 75 mg to be delisted 1 August 2021)

(Ludiomil Tab 75 mg to be delisted 1 August 2021)

NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg	2.44	100	✓	Norpress
Tab 25 mg	5.98	180	✓	Norpress

Monoamine-Oxidase Inhibitors (MAOIs) - Non Selective

PHENELZINE SULPHATE – Subsidy by endorsement

Subsidy by endorsement – Subsidised for patients who were taking phenelzine sulphate prior to 1 April 2020 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of phenelzine sulphate.

* Tab 15 mg	70.80	60	✓	Lupin ^{S29}
			✓	Nardil ^{S29} ^{S29}
	118.00	100	✓	Nardil

(Lupin ^{S29} Tab 15 mg to be delisted 1 October 2020)

(Nardil ^{S29} ^{S29} Tab 15 mg to be delisted 1 October 2020)

(Nardil Tab 15 mg to be delisted 1 October 2020)

TRANLYCYPROMINE SULPHATE

Tab 10 mg	12.85	28	✓	Parnate ^{S29} ^{S29}
	22.94	50	✓	Parnate
	96.00	100	✓	Parnate ^{S29} ^{S29}

Monoamine-Oxidase Type A Inhibitors

MOCLOBEMIDE

* Tab 150 mg	6.40	60	✓	Aurorix
* Tab 300 mg	9.80	60	✓	Aurorix

Selective Serotonin Reuptake Inhibitors

CITALOPRAM HYDROBROMIDE

* Tab 20 mg	1.52	84	✓	PSM Citalopram
-------------------	------	----	---	----------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ESCITALOPRAM				
* Tab 10 mg	1.11	28	✓	Escitalopram- Apotex
* Tab 20 mg	1.90	28	✓	Escitalopram- Apotex
FLUOXETINE HYDROCHLORIDE				
* Tab dispersible 20 mg, scored – Subsidy by endorsement.....	1.98	30	✓	Fluox
	9.93		✓	Arrow-Fluoxetine
Subsidised by endorsement				
1) When prescribed for a patient who cannot swallow whole tablets or capsules and the prescription is endorsed accordingly; or				
2) When prescribed in a daily dose that is not a multiple of 20 mg in which case the prescription is deemed to be endorsed. Note: Tablets should be combined with capsules to facilitate incremental 10 mg doses.				
Cap 20 mg	2.91	84	✓	Fluox
	7.49	90	✓	Arrow-Fluoxetine
PAROXETINE				
* Tab 20 mg	3.61	90	✓	Loxamine
SERTRALINE				
Tab 50 mg	0.92	30	✓	Setrona
* Tab 100 mg	1.61	30	✓	Setrona

Other Antidepressants

MIRTAZAPINE				
Tab 30 mg	2.63	30	✓	Apo-Mirtazapine
Tab 45 mg	3.48	30	✓	Apo-Mirtazapine
VENLAFAXINE				
* Cap 37.5 mg	6.38	84	✓	Enlafax XR
* Cap 75 mg	8.11	84	✓	Enlafax XR
* Cap 150 mg	11.16	84	✓	Enlafax XR

Antiepilepsy Drugs

Agents for Control of Status Epilepticus

CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency				
Inj 1 mg per ml, 1 ml	21.00	5	✓	Rivotril
DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency				
Inj 5 mg per ml, 2 ml ampoule – Subsidy by endorsement.....	23.66	5	✓	Hospira
a) Up to 5 inj available on a PSO				
b) Only on a PSO				
c) PSO must be endorsed "not for anaesthetic procedures".				
Rectal tubes 5 mg – Up to 5 tube available on a PSO	43.50	5	✓	Stesolid
Rectal tubes 10 mg – Up to 5 tube available on a PSO	40.87	5	✓	Stesolid
<i>(Stesolid Rectal tubes 10 mg to be delisted 1 December 2020)</i>				
PARALDEHYDE				
* Inj 5 ml	1,500.00	5	✓	AFT <small>S29</small>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PHENYTOIN SODIUM				
* Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	88.63	5	✓	Hospira
* Inj 50 mg per ml, 5 ml ampoule – Up to 5 inj available on a PSO	133.92	5	✓	Hospira

Control of Epilepsy

CARBAMAZEPINE				
* Tab 200 mg	14.53	100	✓	Tegretol
* Tab long-acting 200 mg	16.98	100	✓	Tegretol CR
* Tab 400 mg	34.58	100	✓	Tegretol
* Tab long-acting 400 mg	39.17	100	✓	Tegretol CR
* Oral liq 20 mg per ml	26.37	250 ml	✓	Tegretol
CLOBAZAM – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg	9.12	50	✓	Frisium
CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency				
Oral drops 2.5 mg per ml	7.38	10 ml OP	✓	Rivotril
ETHOSUXIMIDE				
Cap 250 mg	140.88	100	✓	Zarontin
Oral liq 250 mg per 5 ml	56.35	200 ml	✓	Zarontin
GABAPENTIN				
Note: Not subsidised in combination with subsidised pregabalin				
* Cap 100 mg	2.65	100	✓	<u>Apo-Gabapentin</u>
* Cap 300 mg	4.07	100	✓	<u>Apo-Gabapentin</u>
* Cap 400 mg	5.64	100	✓	<u>Apo-Gabapentin</u>
LACOSAMIDE – Special Authority see SA1125 below – Retail pharmacy				
▲ Tab 50 mg	25.04	14	✓	Vimpat
▲ Tab 100 mg	50.06	14	✓	Vimpat
	200.24	56	✓	Vimpat
▲ Tab 150 mg	75.10	14	✓	Vimpat
	300.40	56	✓	Vimpat
▲ Tab 200 mg	400.55	56	✓	Vimpat

►SA1125 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:
Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LAMOTRIGINE				
▲ Tab dispersible 2 mg	55.00	30	✓	Lamictal
▲ Tab dispersible 5 mg	15.00	56	✓	Arrow-Lamotrigine
	50.00	30	✓	Lamictal
* Tab dispersible 25 mg	2.76	56	✓	Logem
* Tab dispersible 50 mg	3.31	56	✓	Logem
* Tab dispersible 100 mg	4.40	56	✓	Logem
<i>(Arrow-Lamotrigine Tab dispersible 5 mg to be delisted 1 October 2020)</i>				
LEVETIRACETAM				
Tab 250 mg	4.99	60	✓	Everet
Tab 500 mg	8.79	60	✓	Everet
Tab 750 mg	14.39	60	✓	Everet
Tab 1,000 mg	18.59	60	✓	Everet
Oral liq 100 mg per ml	44.78	300 ml OP	✓	Levetiracetam-AFT
PHENOBARBITONE				
For phenobarbitone oral liquid refer Standard Formulae, page 248				
* Tab 15 mg	40.00	500	✓	PSM
* Tab 30 mg	40.00	500	✓	PSM
PHENYTOIN SODIUM				
* Tab 50 mg	75.00	200	✓	Dilantin Infatab
Cap 30 mg	74.00	200	✓	Dilantin
Cap 100 mg	37.00	200	✓	Dilantin
* Oral liq 30 mg per 5 ml	22.03	500 ml	✓	Dilantin
PREGABALIN				
Note: Not subsidised in combination with subsidised gabapentin				
* Cap 25 mg	2.25	56	✓	Pregabalin Pfizer
* Cap 75 mg	2.65	56	✓	Pregabalin Pfizer
* Cap 150 mg	4.01	56	✓	Pregabalin Pfizer
* Cap 300 mg	7.38	56	✓	Pregabalin Pfizer
PRIMIDONE				
* Tab 250 mg	17.25	100	✓	Apo-Primidone
	62.00	200	✓	Mysoline S29 ^{S29}
SODIUM VALPROATE				
Tab 100 mg	13.65	100	✓	Epilim Crushable
Tab 200 mg EC	27.44	100	✓	Epilim
Tab 500 mg EC	52.24	100	✓	Epilim
* Oral liq 200 mg per 5 ml	20.48	300 ml	✓	Epilim S/F Liquid
			✓	Epilim Syrup
			✓	Epilim IV
* Inj 100 mg per ml, 4 ml	41.50	1		
STIRIPENTOL – Special Authority see SA1330 below – Retail pharmacy				
Cap 250 mg	509.29	60	✓	Diacomit ^{S29}
Powder for oral liq 250 mg sachet	509.29	60	✓	Diacomit ^{S29}

► **SA1330** Special Authority for Subsidy

Initial application only from a paediatric neurologist or Practitioner on the recommendation of a paediatric neurologist.

Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has confirmed diagnosis of Dravet syndrome; and

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

TOPIRAMATE

▲ Tab 25 mg	11.07	60	✓ Arrow-Topiramate
	26.04		✓ Topiramate Actavis
▲ Tab 50 mg	18.81	60	✓ Topamax
	44.26		✓ Arrow-Topiramate
▲ Tab 100 mg	31.99	60	✓ Topiramate Actavis
	75.25		✓ Topamax
▲ Tab 200 mg	55.19	60	✓ Arrow-Topiramate
	129.85		✓ Topiramate Actavis
▲ Sprinkle cap 15 mg	20.84	60	✓ Topamax
▲ Sprinkle cap 25 mg	26.04	60	✓ Topamax

VIGABATRIN – Special Authority see [SA1907 below](#) – Retail pharmacy

▲ Tab 500 mg	119.30	100	✓ Sabril
--------------------	--------	-----	----------

➔SA1907 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Both:

1 Either:

1.1 Patient has infantile spasms; or

1.2 Both:

1.2.1 Patient has epilepsy; and

1.2.2 Either:

1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or

1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2 Either:

2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or

2.2 It is impractical or impossible (due to comorbid conditions, or health system capacity constraints) to monitor the patient's visual fields..

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and

2 Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

- 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
- 2.2 It is impractical or impossible (due to comorbid conditions, or health system capacity constraints) to monitor the patient's visual fields..

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, [page 110](#)

Acute Migraine Treatment

RIZATRIPTAN

Tab orodispersible 10 mg.....	3.65	30	✓ Rizamelt
Rizamelt to be Sole Supply on 1 October 2020			

SUMATRIPTAN

Tab 50 mg	24.44	100	✓ Apo-Sumatriptan
Tab 100 mg	46.23	100	✓ Apo-Sumatriptan
Inj 12 mg per ml, 0.5 ml prefilled pen	34.00	2 OP	✓ Imigran
a) Brand switch fee payable (Pharmacode 2597330) - see page 246 for details			
b) Maximum of 10 inj per prescription			

Prophylaxis of Migraine

For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYSTEM, [page 50](#)

PIZOTIFEN

* Tab 500 mcg.....	23.21	100	✓ Sandomigran
--------------------	-------	-----	---------------

Antinausea and Vertigo Agents

For Antispasmodics refer to ALIMENTARY TRACT, [page 8](#)

APREPITANT – Special Authority see [SA0987 below](#) – Retail pharmacy

Cap 2 x 80 mg and 1 x 125 mg	84.00	3 OP	✓ Emend Tri-Pack
------------------------------------	-------	------	------------------

►SA0987 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

BETAHISTINE DIHYDROCHLORIDE

* Tab 16 mg	3.88	84	✓ Vergo 16
Vergo 16 to be Sole Supply on 1 November 2020			

CYCLIZINE HYDROCHLORIDE

Tab 50 mg	0.55	10	✓ Nausicalm
-----------------	------	----	-------------

CYCLIZINE LACTATE

Inj 50 mg per ml, 1 ml	14.95	5	✓ Nausicalm
------------------------------	-------	---	-------------

DOMPERIDONE

* Tab 10 mg	2.25	100	✓ Pharmacy Health
-------------------	------	-----	-------------------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
HYOSCINE HYDROBROMIDE				
* Inj 400 mcg per ml, 1 ml ampoule	93.00	10	✓	Martindale <small>S29</small>
Patch 1.5 mg – Special Authority see SA1927 below – Retail pharmacy.....	14.11	2	✓	Scopoderm TTS
►SA1927 Special Authority for Subsidy				
Initial application — (control of intractable nausea, vomiting or inability to swallow saliva or clozapine induced hypersalivation) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:				
Either:				
1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or				
2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective.				
Initial application — (pandemic circumstances- symptomatic relief of respiratory secretions in palliative care) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:				
All of the following:				
1 Requires palliative care in the community setting; and				
2 Requires symptomatic relief of respiratory secretions that is not possible with 'as required subcutaneous hyoscine injections' due to COVID-19 constraints on the health sector; and				
3 Access to a syringe driver for administration of injectable hyoscine is not possible due to COVID-19 constraints on the health sector.				
Renewal — (control of intractable nausea, vomiting or inability to swallow saliva or clozapine induced hypersalivation) from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.				
METOCLOPRAMIDE HYDROCHLORIDE				
* Tab 10 mg – Up to 30 tab available on a PSO	1.30	100	✓	Metoclopramide Actavis 10
Metoclopramide Actavis 10 to be Sole Supply on 1 October 2020				
* Inj 5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	9.50	10	✓	Pfizer
ONDANSETRON				
* Tab 4 mg	2.68	50	✓	Onrex
* Tab disp 4 mg – Up to 10 tab available on a PSO	0.76	10	✓	Ondansetron ODT-DRLA
Ondansetron ODT-DRLA to be Sole Supply on 1 October 2020				
* Tab 8 mg	4.57	50	✓	Onrex
* Tab disp 8 mg – Up to 10 tab available on a PSO	1.13	10	✓	Ondansetron ODT-DRLA
Ondansetron ODT-DRLA to be Sole Supply on 1 October 2020				
PROCHLORPERAZINE				
* Tab 3 mg buccal.....	5.97 (30.00)	50		Buccastem
* Tab 5 mg – Up to 30 tab available on a PSO	8.00	250	✓	Nausafix
Nausafix to be Sole Supply on 1 December 2020				
* Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO	25.81	10	✓	Stemetil

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
Antipsychotics			
General			
AMISULPRIDE – Safety medicine; prescriber may determine dispensing frequency			
Tab 100 mg	5.15	30	✓ <u>Sulprix</u>
	17.16	100	✓ <u>Amisulpride</u> Mylan ^{\$29}
Tab 200 mg	14.96	60	✓ <u>Sulprix</u>
Tab 400 mg	29.78	60	✓ <u>Sulprix</u>
ARIPRAZOLE – Safety medicine; prescriber may determine dispensing frequency			
Tab 5 mg	17.50	30	✓ <u>Aripiprazole Sandoz</u>
	28.58	49	✓ <u>Aripiprazole 1A</u> Pharma ^{\$29}
Tab 10 mg	17.50	30	✓ <u>Aripiprazole Sandoz</u>
Tab 15 mg	17.50	30	✓ <u>Aripiprazole Sandoz</u>
Tab 20 mg	17.50	30	✓ <u>Aripiprazole Sandoz</u>
Tab 30 mg	17.50	30	✓ <u>Aripiprazole Sandoz</u>
CHLORPROMAZINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency			
Tab 10 mg – Up to 30 tab available on a PSO	14.83	100	✓ <u>Largactil</u>
Tab 25 mg – Up to 30 tab available on a PSO	15.62	100	✓ <u>Largactil</u>
Tab 100 mg – Up to 30 tab available on a PSO	36.73	100	✓ <u>Largactil</u>
Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO	30.79	10	✓ <u>Largactil</u>
CLOZAPINE – Hospital pharmacy [HP4]			
Safety medicine; prescriber may determine dispensing frequency			
Tab 25 mg	5.69	50	✓ <u>Clozaril</u>
	6.69		✓ <u>Clopine</u>
	11.36	100	✓ <u>Clozaril</u>
	13.37		✓ <u>Clopine</u>
Tab 50 mg	8.67	50	✓ <u>Clopine</u>
	17.33	100	✓ <u>Clopine</u>
Tab 100 mg	14.73	50	✓ <u>Clozaril</u>
	17.33		✓ <u>Clopine</u>
	29.45	100	✓ <u>Clozaril</u>
	34.65		✓ <u>Clopine</u>
Tab 200 mg	34.65	50	✓ <u>Clopine</u>
	69.30	100	✓ <u>Clopine</u>
Suspension 50 mg per ml	17.33	100 ml	✓ <u>Clopine</u>
HALOPERIDOL – Safety medicine; prescriber may determine dispensing frequency			
Tab 500 mcg – Up to 30 tab available on a PSO	6.23	100	✓ <u>Serenace</u>
Tab 1.5 mg – Up to 30 tab available on a PSO	9.43	100	✓ <u>Serenace</u>
Tab 5 mg – Up to 30 tab available on a PSO	29.72	100	✓ <u>Serenace</u>
Oral liq 2 mg per ml – Up to 200 ml available on a PSO	23.84	100 ml	✓ <u>Serenace</u>
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	21.55	10	✓ <u>Serenace</u>
LEVOMEPROMAZINE – Safety medicine; prescriber may determine dispensing frequency			
Tab 25 mg (33.8 mg as a maleate)	16.10	100	✓ <u>Nozinan (Swiss)</u>
Tab 25 mg as a maleate	16.10	100	✓ <u>Nozinan</u>
Tab 100 mg (135 mg as a maleate)	41.75	100	✓ <u>Nozinan (Swiss)</u>
Tab 100 mg as a maleate	41.75	100	✓ <u>Nozinan</u>

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LEVOMEPROMAZINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency				
Inj 25 mg per ml, 1 ml ampoule	33.50	10	✓	Nozinan
LITHIUM CARBONATE – Safety medicine; prescriber may determine dispensing frequency				
Tab 250 mg – Subsidy by endorsement.....	34.30	500	✓	Lithicarb FC
Subsidised for patients who were taking lithium carbonate tab 250 mg prior to 1 January 2020 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of lithium carbonate.				
Tab long-acting 400 mg.....	72.00	100	✓	Priadel
Cap 250 mg.....	9.42	100	✓	Douglas
<i>(Lithicarb FC Tab 250 mg to be delisted 1 November 2020)</i>				
OLANZAPINE – Safety medicine; prescriber may determine dispensing frequency				
Tab 2.5 mg	1.35	28	✓	Zypine
Zypine to be Sole Supply on 1 November 2020				
Tab 5 mg	1.58	28	✓	Zypine
Zypine to be Sole Supply on 1 November 2020				
Tab orodispersible 5 mg.....	1.81	28	✓	Zypine ODT
Zypine ODT to be Sole Supply on 1 November 2020				
Tab 10 mg	2.01	28	✓	Zypine
Zypine to be Sole Supply on 1 November 2020				
Tab orodispersible 10 mg.....	2.38	28	✓	Zypine ODT
Zypine ODT to be Sole Supply on 1 November 2020				
PERICYAZINE – Safety medicine; prescriber may determine dispensing frequency				
Tab 2.5 mg	10.49	84	✓	Neulactil
	12.49	100	✓	Neulactil
Tab 10 mg	37.34	84	✓	Neulactil
	44.45	100	✓	Neulactil
QUETIAPINE – Safety medicine; prescriber may determine dispensing frequency				
Tab 25 mg	2.15	90	✓	Quetapel
Quetapel to be Sole Supply on 1 November 2020				
Tab 100 mg	5.06	90	✓	Quetapel
Quetapel to be Sole Supply on 1 November 2020				
Tab 200 mg	8.90	90	✓	Quetapel
Quetapel to be Sole Supply on 1 November 2020				
Tab 300 mg	12.86	90	✓	Quetapel
Quetapel to be Sole Supply on 1 November 2020				
RISPERIDONE – Safety medicine; prescriber may determine dispensing frequency				
Tab 0.5 mg	1.86	60	✓	Risperidone (Teva)
Risperidone (Teva) to be Sole Supply on 1 December 2020				
Tab 1 mg	2.06	60	✓	Risperidone (Teva)
Risperidone (Teva) to be Sole Supply on 1 December 2020				
Tab 2 mg	2.29	60	✓	Risperidone (Teva)
Risperidone (Teva) to be Sole Supply on 1 December 2020				
Tab 3 mg	2.50	60	✓	Risperidone (Teva)
Risperidone (Teva) to be Sole Supply on 1 December 2020				
Tab 4 mg	3.42	60	✓	Risperidone (Teva)
Risperidone (Teva) to be Sole Supply on 1 December 2020				
Oral liq 1 mg per ml	8.90	30 ml	✓	Risperon
Risperon to be Sole Supply on 1 November 2020				

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ZIPRASIDONE – Safety medicine; prescriber may determine dispensing frequency				
Cap 20 mg.....	14.50	60	✓	Zusdone
Cap 40 mg.....	24.70	60	✓	Zusdone
Cap 60 mg.....	33.80	60	✓	Zusdone
Cap 80 mg.....	39.70	60	✓	Zusdone
ZUCLOPENTHIXOL HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg.....	31.45	100	✓	Clopirox

Depot Injections

FLUPENTHIXOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency				
Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO.....	13.14	5	✓	Fluanxol
Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO.....	20.90	5	✓	Fluanxol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO.....	40.87	5	✓	Fluanxol
HALOPERIDOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency				
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO.....	28.39	5	✓	Haldol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO.....	55.90	5	✓	Haldol Concentrate
			✓	Haldol
				Decanoas S29

OLANZAPINE – Special Authority see [SA1428 below](#) – Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 210 mg vial.....	252.00	1	✓	Zyprexa Relprevv
Inj 300 mg vial.....	414.00	1	✓	Zyprexa Relprevv
Inj 405 mg vial.....	504.00	1	✓	Zyprexa Relprevv

➡SA1428 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: The patient should be monitored for post-injection syndrome for at least two hours after each injection.

PALIPERIDONE – Special Authority see [SA1429 below](#) – Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 25 mg syringe.....	194.25	1	✓	Invega Sustenna
Inj 50 mg syringe.....	271.95	1	✓	Invega Sustenna
Inj 75 mg syringe.....	357.42	1	✓	Invega Sustenna
Inj 100 mg syringe.....	435.12	1	✓	Invega Sustenna
Inj 150 mg syringe.....	435.12	1	✓	Invega Sustenna

➡SA1429 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:
Either:

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Paliperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialling paliperidone depot injection.

RISPERIDONE – Special Authority see [SA1427 below](#) – Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 25 mg vial	135.98	1	✓ Risperdal Consta
Inj 37.5 mg vial	178.71	1	✓ Risperdal Consta
Inj 50 mg vial	217.56	1	✓ Risperdal Consta

► [SA1427](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Risperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialling risperidone depot injection.

ZUCLOPENTHIXOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency

Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO	19.80	5	✓ Clopixol
--	-------	---	-------------------

Anxiolytics

BUSPIRONE HYDROCHLORIDE

* Tab 5 mg	20.23	100	✓ Orion
* Tab 10 mg	13.16	100	✓ Orion

CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency

Tab 500 mcg	5.64	100	✓ Paxam
Tab 2 mg	10.78	100	✓ Paxam

DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency

Tab 2 mg	61.07	500	✓ Arrow-Diazepam
Arrow-Diazepam to be Sole Supply on 1 December 2020			
Tab 5 mg	73.60	500	✓ Arrow-Diazepam
Arrow-Diazepam to be Sole Supply on 1 December 2020			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency				
Tab 1 mg	9.72	250	✓	Ativan
Tab 2.5 mg	12.50	100	✓	Ativan
OXAZEPAM – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg	6.17	100	✓	Ox-Pam
Tab 15 mg	8.53	100	✓	Ox-Pam

Multiple Sclerosis Treatments

DIMETHYL FUMARATE – Special Authority see SA1559 below – Retail pharmacy

Wastage claimable

Cap 120 mg	520.00	14	✓	Tecfidera
Cap 240 mg	2,000.00	56	✓	Tecfidera

►SA1559 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz
Wellington	

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Entry Criteria

- Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- patients must have:
 - EDSS score 0 - 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - a gadolinium enhancing lesion; or
 - a Diffusion Weighted Imaging positive lesion; or
 - a T2 lesion with associated local swelling; or
 - a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - new T2 lesions compared with a previous MR scan; and
- A significant relapse must:
 - be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - last at least one week;
 - start at least one month after the onset of a previous relapse;

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
- f) be distinguishable from the effects of general fatigue; and
- g) not be associated with a fever ($T > 37.5^{\circ}\text{C}$); and
- e) applications must be made by the patient's neurologist or general physician; and
- f) patients must have no previous history of lack of response to dimethyl fumarate; and
- g) patients must have not previously had intolerance to dimethyl fumarate; and
- h) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- 1) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDDSS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- 2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) intolerance to dimethyl fumarate; or
- 4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab, fingolimod, dimethyl fumarate, teriflunomide and ocrelizumab is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

FINGOLIMOD – Special Authority see [SA1562 below](#) – Retail pharmacy

Wastage claimable

Cap 0.5 mg.....	2,200.00	28	✓ Gilenya
-----------------	----------	----	-----------

►SA1562 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz
Wellington	

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Entry Criteria

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- 2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- 3) patients must have:
 - a) EDSS score 0 - 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- 4) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever ($T > 37.5^{\circ}\text{C}$); and
- 5) applications must be made by the patient's neurologist or general physician; and
- 6) patients must have no previous history of lack of response to fingolimod; and
- 7) patients must have not previously had intolerance to fingolimod; and
- 8) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- 1) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDDS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- 2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) intolerance to fingolimod; or
- 4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab, fingolimod, dimethyl fumarate, teriflunomide and ocrelizumab is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

NATALIZUMAB – Special Authority see [SA1563 below](#) – Retail pharmacy

Inj 20 mg per ml, 15 ml vial.....	1,750.00	1	✓ Tysabri
-----------------------------------	----------	---	-----------

►SA1563 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz
Wellington	

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Entry Criteria

- 1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- 2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- 3) patients must have:
 - a) EDSS score 0 - 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- 4) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T> 37.5°C); and
- 5) applications must be made by the patient's neurologist or general physician; and
- 6) treatment must be initiated and supervised by a neurologist who is registered in the Tysabri Australasian Prescribing Programme operated by the supplier; and
- 7) patients must have no previous history of lack of response to natalizumab; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 8) patients must have not previously had intolerance to natalizumab; and
- 9)
 - a) Patient is JC virus negative, or
 - b) Patient is JC virus positive and has given written informed consent acknowledging an understanding of the risk of progressive multifocal leucoencephalopathy (PML) associated with natalizumab
- 10) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- 1) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDDS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- 2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) intolerance to natalizumab; or
- 4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier.

Switching between natalizumab, fingolimod, dimethyl fumarate, teriflunomide and ocrelizumab is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

OCRELIZUMAB – Special Authority see [SA1867 below](#) – Retail pharmacy

Inj 30 mg per ml, 10 ml vial.....	9,346.00	1	✓ Ocrevus
-----------------------------------	----------	---	-----------

►SA1867 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz
Wellington	

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Entry Criteria

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

continued...

- c) patients must have:
 - a) EDSS score 0 - 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
 - d) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever ($T > 37.5^{\circ}\text{C}$); and
 - e) applications must be made by the patient's neurologist or general physician; and
 - f) patients must have no previous history of lack of response to ocrelizumab; and
 - g) patients must have not previously had intolerance to ocrelizumab; and
 - h) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- 1) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDDSS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- 2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) intolerance to ocrelizumab; or
- 4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab, fingolimod, dimethyl fumarate, teriflunomide and ocrelizumab is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

TERIFLUNOMIDE – Special Authority see [SA1560 on the next page](#) – Retail pharmacy

Wastage claimable

Tab 14 mg	1,582.62	28	✓ Aubagio
-----------------	----------	----	-----------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA1560 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz
Wellington	

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Entry Criteria

- 1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- 2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- 3) patients must have:
 - a) EDSS score 0 - 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- 4) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever ($T > 37.5^{\circ}\text{C}$); and
- 5) applications must be made by the patient's neurologist or general physician; and
- 6) patients must have no previous history of lack of response to teriflunomide; and
- 7) patients must have not previously had intolerance to teriflunomide; and
- 8) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- 1) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDDSS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- b) 1.0 to 3.0; or
- c) 1.5 to 3.5; or
- d) 2.0 to 4.0; or
- e) 2.5 to 4.5; or
- f) 3.0 to 4.5; or
- g) 3.5 to 4.5; or
- h) 4.0 to 4.5.

- 2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) intolerance to teriflunomide; or
- 4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab, fingolimod, dimethyl fumarate, teriflunomide and ocrelizumab is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

Other Multiple Sclerosis Treatments

GLATIRAMER ACETATE – Special Authority see [SA1808 below](#) – Retail pharmacy

Inj 40 mg prefilled syringe.....	2,275.00	12	✓ Copaxone
----------------------------------	----------	----	------------

►SA1808 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccordinator@pharmac.govt.nz
Wellington	

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, 40 mg glatiramer acetate 3 times weekly will be subsidised.

Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. As a new Special Authority approval number is required the MSTAC coordinator should be notified of the change and a new prescription provided.

Entry Criteria

- 1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- 2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- 3) patients must have:
 - a) EDSS score 0 - 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- i) a gadolinium enhancing lesion; or
- ii) a Diffusion Weighted Imaging positive lesion; or
- iii) a T2 lesion with associated local swelling; or
- iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
- v) new T2 lesions compared with a previous MR scan; and

4) A significant relapse must:

- a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
- b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
- c) last at least one week;
- d) start at least one month after the onset of a previous relapse;
- e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
- f) be distinguishable from the effects of general fatigue; and
- g) not be associated with a fever ($T > 37.5^{\circ}\text{C}$); and

5) applications must be made by the patient's neurologist; and

6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate; and

7) patients must have either:

- a) intolerance to both natalizumab and fingolimod; or
- b) treatment with both natalizumab and fingolimod is considered clinically inappropriate; and

8) patient will not be co-prescribed natalizumab or fingolimod.

Stopping Criteria

Any of the following:

1) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment.

Progression of disability is defined as progress by any of the following EDSS Points:

- a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
- b) 1.0 to 3.0; or
- c) 1.5 to 3.5; or
- d) 2.0 to 4.0; or
- e) 2.5 to 4.5; or
- f) 3.0 to 4.5; or
- g) 3.5 to 4.5; or
- h) 4.0 to 4.5.

2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or

3) intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or

4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Treatment with interferon beta -1-beta, interferon beta-1-alpha and glatiramer acetate, is permitted only if treatment with both natalizumab and fingolimod is not tolerated or treatment with both would be clinically inappropriate. Beta-interferon or glatiramer acetate will not be funded as second line treatments if EDSS progression has occurred on treatment with natalizumab or fingolimod. Patients who have an increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet the EDSS Stopping Criteria at annual review may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa. Patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa for increased relapses only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to increasing relapse rate over 12 months of treatment). If a relapse has resulted in an

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur. In this setting anti-JCV antibody positive status may be accepted as a clinically inappropriate reason for treatment with natalizumab.

INTERFERON BETA-1-ALPHA – Special Authority see [SA1809 below](#) – Retail pharmacy

Inj 6 million iu prefilled syringe.....	1,170.00	4	✓ Avonex
Injection 6 million iu per 0.5 ml pen injector.....	1,170.00	4	✓ Avonex Pen

►SA1809 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccordinator@pharmac.govt.nz
Wellington	

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, 40 mg glatiramer acetate 3 times weekly will be subsidised.

Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. As a new Special Authority approval number is required the MSTAC coordinator should be notified of the change and a new prescription provided.

Entry Criteria

- 1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- 2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- 3) patients must have:
 - a) EDSS score 0 - 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- 4) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

continued...

- f) be distinguishable from the effects of general fatigue; and
- g) not be associated with a fever (T> 37.5°C); and
- 5) applications must be made by the patient's neurologist; and
- 6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate; and
- 7) patients must have either:
 - a) intolerance to both natalizumab and fingolimod; or
 - b) treatment with both natalizumab and fingolimod is considered clinically inappropriate; and
- 8) patient will not be co-prescribed natalizumab or fingolimod.

Stopping Criteria

Any of the following:

- 1) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment.
Progression of disability is defined as progress by any of the following EDDS Points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- 2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- 4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Treatment with interferon beta -1-beta, interferon beta-1-alpha and glatiramer acetate, is permitted only if treatment with both natalizumab and fingolimod is not tolerated or treatment with both would be clinically inappropriate. Beta-interferon or glatiramer acetate will not be funded as second line treatments if EDSS progression has occurred on treatment with natalizumab or fingolimod. Patients who have an increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet the EDSS Stopping Criteria at annual review may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa. Patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa for increased relapses only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to increasing relapse rate over 12 months of treatment). If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur. In this setting anti-JCV antibody positive status may be accepted as a clinically inappropriate reason for treatment with natalizumab.

INTERFERON BETA-1-BETA – Special Authority see SA1810 below – Retail pharmacy

Inj 8 million iu per 1 ml..... 1,322.89 15 ✓ Betaferon

➡SA1810 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms or:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

The coordinator

Phone: 04 460 4990

Multiple Sclerosis Treatment Assessment Committee

Facsimile: 04 916 7571

PHARMAC PO Box 10 254

Email: mstacordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, 40 mg glatiramer acetate 3 times weekly will be subsidised.

Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. As a new Special Authority approval number is required the MSTAC coordinator should be notified of the change and a new prescription provided.

Entry Criteria

- 1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- 2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- 3) patients must have:
 - a) EDSS score 0 - 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- 4) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever ($T > 37.5^{\circ}\text{C}$); and
- 5) applications must be made by the patient's neurologist; and
- 6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate; and
- 7) patients must have either:
 - a) intolerance to both natalizumab and fingolimod; or
 - b) treatment with both natalizumab and fingolimod is considered clinically inappropriate; and
- 8) patient will not be co-prescribed natalizumab or fingolimod.

Stopping Criteria

Any of the following:

- 1) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability is defined as progress by any of the following EDDSS Points:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - 1.0 to 3.0; or
 - 1.5 to 3.5; or
 - 2.0 to 4.0; or
 - 2.5 to 4.5; or
 - 3.0 to 4.5; or
 - 3.5 to 4.5; or
 - 4.0 to 4.5.
- increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
 - intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
 - non-compliance with treatment, including refusal to undergo annual assessment.

Note: Treatment with interferon beta -1-beta, interferon beta-1-alpha and glatiramer acetate, is permitted only if treatment with both natalizumab and fingolimod is not tolerated or treatment with both would be clinically inappropriate. Beta-interferon or glatiramer acetate will not be funded as second line treatments if EDSS progression has occurred on treatment with natalizumab or fingolimod. Patients who have an increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet the EDSS Stopping Criteria at annual review may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa. Patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa for increased relapses only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to increasing relapse rate over 12 months of treatment). If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur. In this setting anti-JCV antibody positive status may be accepted as a clinically inappropriate reason for treatment with natalizumab.

Sedatives and Hypnotics

MELATONIN – Special Authority see [SA1666 below](#) – Retail pharmacy

Tab modified-release 2 mg – No more than 5 tab per day.....	28.22	30	✓ Circadin
---	-------	----	------------

➔SA1666 Special Authority for Subsidy

Initial application only from a psychiatrist, paediatrician, neurologist, respiratory specialist or medical practitioner on the recommendation of a psychiatrist, paediatrician, neurologist or respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder)*; and
- Behavioural and environmental approaches have been tried and were unsuccessful, or are inappropriate; and
- Funded modified-release melatonin is to be given at doses no greater than 10 mg per day; and
- Patient is aged 18 years or under*.

Renewal only from a psychiatrist, paediatrician, neurologist, respiratory specialist or medical practitioner on the recommendation of a psychiatrist, paediatrician, neurologist or respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- Patient is aged 18 years or under*; and
- Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined); and
- Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and distressing insomnia; and
- Funded modified-release melatonin is to be given at doses no greater than 10 mg per day.

Note: Indications marked with * are unapproved indications.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
MIDAZOLAM – Safety medicine; prescriber may determine dispensing frequency				
Inj 1 mg per ml, 5 ml ampoule	4.30	10	✓	Midazolam-Claris
Inj 1 mg per ml, 5 ml plastic ampoule – Up to 10 inj available on a PSO	14.90	10	✓	Pfizer
On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only.				
Inj 5 mg per ml, 3 ml ampoule	2.50	5	✓	Midazolam-Claris
Inj 5 mg per ml, 3 ml plastic ampoule – Up to 5 inj available on a PSO	11.90	5	✓	Pfizer
On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only.				
NITRAZEPAM – Subsidy by endorsement				
a) Safety medicine; prescriber may determine dispensing frequency				
b) Subsidy by endorsement – subsidised for patients who were taking nitrazepam prior to 1 August 2019 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of nitrazepam in the preceding 12 months.				
Tab 5 mg	5.22	100	✓	Nitrados
<i>(Nitrados Tab 5 mg to be delisted 1 January 2021)</i>				
PHENOBARBITONE SODIUM – Special Authority see SA1386 below – Retail pharmacy				
Inj 200 mg per ml, 1 ml ampoule	68.00	10	✓	Max Health <small>S29</small>
►SA1386 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:				
Both:				
1 For the treatment of terminal agitation that is unresponsive to other agents; and				
2 The applicant is part of a multidisciplinary team working in palliative care.				
TEMAZEPAM – Safety medicine; prescriber may determine dispensing frequency				
Tab 10 mg	1.33	25	✓	Normison
Normison to be Sole Supply on 1 November 2020				
TRIAZOLAM – Safety medicine; prescriber may determine dispensing frequency				
Tab 125 mcg.....	5.10 (9.85)	100		Hypam
Tab 250 mcg.....	4.10 (11.20)	100		Hypam
ZOPICLONE – Safety medicine; prescriber may determine dispensing frequency				
Tab 7.5 mg	9.56	500	✓	Zopiclone Actavis

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Stimulants/ADHD Treatments				
ATOMOXETINE				
Cap 10 mg.....	18.41 (107.03)	28	✓	Generic Partners Strattera
Generic Partners to be Sole Supply on 1 December 2020				
Cap 18 mg.....	27.06 (107.03)	28	✓	Generic Partners Strattera
Generic Partners to be Sole Supply on 1 December 2020				
Cap 25 mg.....	29.22 (107.03)	28	✓	Generic Partners Strattera
Generic Partners to be Sole Supply on 1 December 2020				
Cap 40 mg.....	29.22 (107.03)	28	✓	Generic Partners Strattera
Generic Partners to be Sole Supply on 1 December 2020				
Cap 60 mg.....	46.51 (107.03)	28	✓	Generic Partners Strattera
Generic Partners to be Sole Supply on 1 December 2020				
Cap 80 mg.....	56.45 (139.11)	28	✓	Generic Partners Strattera
Generic Partners to be Sole Supply on 1 December 2020				
Cap 100 mg.....	58.48 (139.11)	28	✓	Generic Partners Strattera
Generic Partners to be Sole Supply on 1 December 2020				
<i>(Strattera Cap 10 mg to be delisted 1 December 2020)</i>				
<i>(Strattera Cap 18 mg to be delisted 1 December 2020)</i>				
<i>(Strattera Cap 25 mg to be delisted 1 December 2020)</i>				
<i>(Strattera Cap 40 mg to be delisted 1 December 2020)</i>				
<i>(Strattera Cap 60 mg to be delisted 1 December 2020)</i>				
<i>(Strattera Cap 80 mg to be delisted 1 December 2020)</i>				
<i>(Strattera Cap 100 mg to be delisted 1 December 2020)</i>				
DEXAMFETAMINE SULFATE – Special Authority see SA1149 below – Retail pharmacy				
a) Only on a controlled drug form				
b) Safety medicine; prescriber may determine dispensing frequency				
Tab 5 mg.....	20.00	100	✓	PSM

► **SA1149** Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:

- 3.1 Applicant is a paediatrician or psychiatrist; or
- 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE – Special Authority see [SA1150 below](#) – Retail pharmacy

a) Only on a controlled drug form			
b) Safety medicine; prescriber may determine dispensing frequency			
Tab immediate-release 5 mg.....	3.20	30	✓ Rubifen
Tab immediate-release 10 mg.....	3.00	30	✓ Ritalin
			✓ Rubifen
Tab immediate-release 20 mg.....	7.85	30	✓ Rubifen
Tab sustained-release 20 mg.....	10.95	30	✓ Rubifen SR
	50.00	100	✓ Ritalin SR

(Ritalin SR Tab sustained-release 20 mg to be delisted 1 June 2021)

► [SA1150](#) Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE – Special Authority see [SA1151 below](#) – Retail pharmacy

a) Only on a controlled drug form			
b) Safety medicine; prescriber may determine dispensing frequency			
Tab extended-release 18 mg.....	18.20	30	✓ Methylphenidate ER - Teva
	58.96		✓ Concerta
Tab extended-release 27 mg.....	22.00	30	✓ Methylphenidate ER - Teva
	65.44		✓ Concerta
Tab extended-release 36 mg.....	22.40	30	✓ Methylphenidate ER - Teva
	71.93		✓ Concerta
Tab extended-release 54 mg.....	26.40	30	✓ Methylphenidate ER - Teva
	86.24		✓ Concerta
Cap modified-release 10 mg	15.60	30	✓ Ritalin LA
Cap modified-release 20 mg	20.40	30	✓ Ritalin LA
Cap modified-release 30 mg	25.52	30	✓ Ritalin LA
Cap modified-release 40 mg	30.60	30	✓ Ritalin LA

►►**SA1151** **Special Authority for Subsidy**

Initial application only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing; and
- 4 Either:
 - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
 - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

Both:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

MODAFINIL – Special Authority see [SA1932 below](#) – Retail pharmacy

Tab 100 mg	32.00	30	✓	Modavigil
	64.00	60	✓	Modavigil

►SA1932 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 2 Any of the following:
 - 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
 - 2.2 A multiple sleep latency test is not possible due to COVID-19 constraints on the health sectors; or
 - 2.3 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
- 3 Either:
 - 3.1 An effective dose of a subsidised formulation of methylphenidate or dexamfetamine has been trialled and discontinued because of intolerable side effects; or
 - 3.2 Methylphenidate and dexamfetamine are contraindicated.

Renewal only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

* Tab 5 mg	4.34	90	✓	Donepezil-Rex
Donepezil-Rex to be Sole Supply on 1 December 2020				
* Tab 10 mg	6.64	90	✓	Donepezil-Rex
Donepezil-Rex to be Sole Supply on 1 December 2020				

RIVASTIGMINE – Special Authority see [SA1488 below](#) – Retail pharmacy

Patch 4.6 mg per 24 hour	48.75	30	✓	Generic Partners
Patch 9.5 mg per 24 hour	48.75	30	✓	Generic Partners

►SA1488 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The patient has been diagnosed with dementia; and
- 2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Treatments for Substance Dependence

BUPRENORPHINE WITH NALOXONE – Special Authority see [SA1203 below](#) – Retail pharmacy

a) No patient co-payment payable

b) Safety medicine; prescriber may determine dispensing frequency

Tab sublingual 2 mg with naloxone 0.5 mg	18.37	28	✓ <u>Buprenorphine</u> <u>Naloxone BNM</u>
Tab sublingual 8 mg with naloxone 2 mg	53.12	28	✓ <u>Buprenorphine</u> <u>Naloxone BNM</u>

►SA1203 Special Authority for Subsidy

Initial application — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health..

Initial application — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and
- 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and
- 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and
- 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient.

Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxification) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient received but failed detoxification with buprenorphine with naloxone; and
- 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and
- 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

BUPROPION HYDROCHLORIDE

Tab modified-release 150 mg	11.00	30	✓ Zyban
-----------------------------------	-------	----	----------------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
DISULFIRAM				
Tab 200 mg	153.00	100	✓	Antabuse
NALTREXONE HYDROCHLORIDE – Special Authority see SA1408 below – Retail pharmacy				
Tab 50 mg	112.55	30	✓	Naltracord

► [SA1408](#) Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

NICOTINE

a) Nicotine will not be funded in amounts less than 4 weeks of treatment.

b) Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A.

Patch 7 mg – Up to 28 patch available on a PSO	18.14	28	✓	Habitrol
Patch 7 mg for direct distribution only – [Xpharm]	3.94	7	✓	Habitrol
Patch 14 mg – Up to 28 patch available on a PSO	19.95	28	✓	Habitrol
Patch 14 mg for direct distribution only – [Xpharm]	4.52	7	✓	Habitrol
Patch 21 mg – Up to 28 patch available on a PSO	22.86	28	✓	Habitrol
Patch 21 mg for direct distribution only – [Xpharm]	5.18	7	✓	Habitrol
Lozenge 1 mg – Up to 216 loz available on a PSO	19.18	216	✓	Habitrol
Lozenge 1 mg for direct distribution only – [Xpharm]	3.20	36	✓	Habitrol
Lozenge 2 mg – Up to 216 loz available on a PSO	21.02	216	✓	Habitrol
Lozenge 2 mg for direct distribution only – [Xpharm]	3.24	36	✓	Habitrol
Gum 2 mg (Fruit) – Up to 384 piece available on a PSO	38.21	384	✓	Habitrol
Gum 2 mg (Fruit) for direct distribution only – [Xpharm]	8.64	96	✓	Habitrol
Gum 2 mg (Mint) – Up to 384 piece available on a PSO	38.21	384	✓	Habitrol
Gum 2 mg (Mint) for direct distribution only – [Xpharm]	8.64	96	✓	Habitrol
Gum 4 mg (Fruit) – Up to 384 piece available on a PSO	44.17	384	✓	Habitrol
Gum 4 mg (Fruit) for direct distribution only – [Xpharm]	10.01	96	✓	Habitrol
Gum 4 mg (Mint) – Up to 384 piece available on a PSO	44.17	384	✓	Habitrol
Gum 4 mg (Mint) for direct distribution only – [Xpharm]	10.01	96	✓	Habitrol

VARENICLINE TARTRATE – Special Authority see [SA1845 on the next page](#) – Retail pharmacy

- A maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval, including the starter pack
- Varenicline will not be funded in amounts less than 4 weeks of treatment.
- The 6-month time period in which a patient can receive a funded 12-week course of varenicline tartrate starts from the date the Special Authority is approved.

Tab 0.5 mg x 11 and 1 mg x 42	25.64	53 OP	✓	Varenicline Pfizer
Tab 1 mg	27.10	56	✓	Varenicline Pfizer

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA1845 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not had a Special Authority for varenicline approved in the last 6 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 12 weeks' funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 It has been 6 months since the patient's previous Special Authority was approved; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 5 The patient is not pregnant; and
- 6 The patient will not be prescribed more than 12 weeks' funded varenicline (see note).

The patient must not have had an approval in the past 6 months.

Notes: a maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval.

This includes the 4-week 'starter' pack.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

Chemotherapeutic Agents

Alkylating Agents

BENDAMUSTINE HYDROCHLORIDE – PCT only – Specialist – Special Authority see [SA1667](#) below

Inj 25 mg vial	271.35	1	✓ Ribomustin
Inj 100 mg vial	1,085.38	1	✓ Ribomustin
Inj 1 mg for ECP	11.40	1 mg	✓ Baxter

►SA1667 Special Authority for Subsidy

Initial application — (treatment naive CLL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has Binet stage B or C, or progressive stage A chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is chemotherapy treatment naive; and
- 3 The patient is unable to tolerate toxicity of full-dose FCR; and
- 4 Patient has ECOG performance status 0-2; and
- 5 Patient has a Cumulative Illness Rating Scale (CIRS) score of < 6; and
- 6 Bendamustine is to be administered at a maximum dose of 100 mg/m² on days 1 and 2 every 4 weeks for a maximum of 6 cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL). Chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has indolent low grade NHL requiring treatment; and
- 2 Patient has a WHO performance status of 0-2; and
- 3 Either:
 - 3.1 Both:
 - 3.1.1 Patient is treatment naive; and
 - 3.1.2 Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+); or
 - 3.2 All of the following:
 - 3.2.1 Patient has relapsed refractory disease following prior chemotherapy; and
 - 3.2.2 The patient has not received prior bendamustine therapy; and
 - 3.2.3 Either:
 - 3.2.3.1 Both:
 - 3.2.3.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
 - 3.2.3.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or
 - 3.2.3.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

Both:

- 1 Patients have not received a bendamustine regimen within the last 12 months; and
- 2 Either:
 - 2.1 Both:

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
continued...			
2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and			
2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or			
2.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.			
Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenstrom's macroglobulinaemia.			
BUSULFAN – PCT – Retail pharmacy-Specialist			
Tab 2 mg	89.25	100	✓ Myleran
CARBOPLATIN – PCT only – Specialist			
Inj 10 mg per ml, 45 ml vial.....	32.59	1	✓ DBL Carboplatin
	45.20		✓ Carboplatin Ebewe
	48.50		✓ Carbaccord
Inj 1 mg for ECP	0.10	1 mg	✓ Baxter
CARMUSTINE – PCT only – Specialist			
Inj 100 mg vial	1,387.00	1	✓ BICNU
			✓ Bicnu Heritage S29
Inj 100 mg for ECP	1,387.00	100 mg OP	✓ Baxter
CHLORAMBUCIL – PCT – Retail pharmacy-Specialist			
Tab 2 mg	29.06	25	✓ Leukeran FC
CISPLATIN – PCT only – Specialist			
Inj 1 mg per ml, 50 ml vial.....	12.29	1	✓ DBL Cisplatin
	15.00		✓ Cisplatin Ebewe
Inj 1 mg per ml, 100 ml vial.....	19.70	1	✓ DBL Cisplatin
	21.00		✓ Cisplatin Ebewe
Inj 1 mg for ECP	0.25	1 mg	✓ Baxter
CYCLOPHOSPHAMIDE			
Tab 50 mg – PCT – Retail pharmacy-Specialist.....	79.00	50	✓ Endoxan S29
	158.00	100	✓ Procytox S29
Wastage claimable			
Inj 1 g vial – PCT – Retail pharmacy-Specialist.....	35.65	1	✓ Endoxan
	127.80	6	✓ Cytoxan
Inj 2 g vial – PCT only – Specialist	71.25	1	✓ Endoxan
Inj 1 mg for ECP – PCT only – Specialist.....	0.04	1 mg	✓ Baxter
IFOSFAMIDE – PCT only – Specialist			
Inj 1 g.....	96.00	1	✓ Holoxan
Inj 2 g.....	180.00	1	✓ Holoxan
Inj 1 mg for ECP	0.10	1 mg	✓ Baxter
LOMUSTINE – PCT – Retail pharmacy-Specialist			
Cap 10 mg.....	132.59	20	✓ CeeNU
Cap 40 mg.....	399.15	20	✓ CeeNU
MELPHALAN			
Tab 2 mg – PCT – Retail pharmacy-Specialist.....	40.70	25	✓ Alkeran
Inj 50 mg – PCT only – Specialist.....	67.80	1	✓ Alkeran
	213.00		✓ Alkeran s29 S29
	420.00		✓ Tillomed S29

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
OXALIPLATIN – PCT only – Specialist				
Inj 100 mg vial	25.01	1	✓	Oxaliplatin Actavis 100
	110.00		✓	Oxaliplatin Ebewe
Inj 5 mg per ml, 20 ml vial.....	46.32	1	✓	Oxaliplatin Accord
Inj 1 mg for ECP	0.48	1 mg	✓	Baxter
THIOTEPA – PCT only – Specialist				
Inj 15 mg vial	CBS	1	✓	Bedford ^{S29}
			✓	THIO-TEPA ^{S29}
			✓	Tepadina ^{S29}
Inj 100 mg vial	CBS	1	✓	Tepadina ^{S29}

Antimetabolites

AZACITIDINE – PCT only – Specialist – Special Authority see SA1467 below

Inj 100 mg vial	139.00	1	✓	Azacitidine Dr Reddy's
	605.00		✓	Vidaza
Inj 1 mg for ECP	1.53	1 mg	✓	Baxter

►SA1467 Special Authority for Subsidy

Initial application only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
 - 1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
 - 1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and
- 2 The patient has performance status (WHO/ECOG) grade 0-2; and
- 3 The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and
- 4 The patient has an estimated life expectancy of at least 3 months.

Renewal only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
CALCIUM FOLINATE				
Tab 15 mg – PCT – Retail pharmacy-Specialist.....	114.69	10	✓	DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist.....	17.10	5	✓	Hospira
Inj 10 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist.....	7.28	1	✓	Calcium Folate Sandoz
Inj 10 mg per ml, 10 ml vial – PCT only – Specialist	9.49	1	✓	Calcium Folate Sandoz
Inj 100 mg – PCT only – Specialist.....	7.33	1	✓	Calcium Folate Ebewe
Inj 300 mg – PCT only – Specialist.....	22.51	1	✓	Calcium Folate Ebewe
Inj 10 mg per ml, 35 ml vial – PCT only – Specialist	25.14	1	✓	Calcium Folate Sandoz
Inj 1 g – PCT only – Specialist.....	67.51	1	✓	Calcium Folate Ebewe
Inj 10 mg per ml, 100 ml vial – PCT only – Specialist	72.00	1	✓	Calcium Folate Sandoz
Inj 1 mg for ECP – PCT only – Specialist.....	0.06	1 mg	✓	Baxter
CAPECITABINE – Retail pharmacy-Specialist				
Tab 150 mg	10.00	60	✓	Capercit
Tab 500 mg	49.00	120	✓	Capercit
CLADRIBINE – PCT only – Specialist				
Inj 1 mg per ml, 10 ml.....	749.96	1	✓	Leustatin
Inj 10 mg for ECP	749.96	10 mg OP	✓	Baxter
CYTARABINE				
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist.....	400.00	5	✓	Pfizer
Inj 100 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist	41.36	1	✓	Pfizer
Inj 1 mg for ECP – PCT only – Specialist.....	0.25	10 mg	✓	Baxter
Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist.....	80.00	100 mg OP	✓	Baxter
FLUDARABINE PHOSPHATE				
Tab 10 mg – PCT – Retail pharmacy-Specialist.....	412.00	20	✓	Fludara Oral
Inj 50 mg vial – PCT only – Specialist.....	576.45	5	✓	Fludarabine Ebewe
Inj 50 mg for ECP – PCT only – Specialist.....	115.29	50 mg OP	✓	Baxter
FLUOROURACIL				
Inj 50 mg per ml, 20 ml vial – PCT only – Specialist	12.00	1	✓	Fluorouracil Ebewe
Inj 50 mg per ml, 100 ml vial – PCT only – Specialist	30.00	1	✓	Fluorouracil Ebewe
Inj 1 mg for ECP – PCT only – Specialist.....	0.66	100 mg	✓	Baxter
GEMCITABINE HYDROCHLORIDE – PCT only – Specialist				
Inj 1 g, 26.3 ml vial.....	62.50	1	✓	DBL Gemcitabine
Inj 1 g.....	15.89	1	✓	Gemcitabine Ebewe
Inj 1 mg for ECP	0.02	1 mg	✓	Baxter
IRINOTECAN HYDROCHLORIDE – PCT only – Specialist				
Inj 20 mg per ml, 5 ml vial.....	71.44	1	✓	Irinotecan Accord S29
			✓	Irinotecan Actavis 100
	100.00		✓	Irinotecan-Rex
Inj 1 mg for ECP	0.75	1 mg	✓	Baxter

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
MERCAPTOPURINE				
Tab 50 mg – PCT – Retail pharmacy-Specialist.....	37.00	25	✓	Puri-nethol
Oral suspension 20 mg per ml – Retail pharmacy-Specialist – Special Authority see SA1725 below	428.00	100 ml OP	✓	Allmercap
►SA1725 Special Authority for Subsidy				
Initial application only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where the patient requires a total dose of less than one full 50 mg tablet per day.				
Renewal only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where patient still requires a total dose of less than one full 50 mg tablet per day.				
METHOTREXATE				
* Tab 2.5 mg – PCT – Retail pharmacy-Specialist.....	8.05	90	✓	Trexate
* Tab 10 mg – PCT – Retail pharmacy-Specialist.....	31.75	90	✓	Trexate
* Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	47.50	5	✓	Hospira
* Inj 7.5 mg prefilled syringe.....	14.61	1	✓	Methotrexate Sandoz
* Inj 10 mg prefilled syringe.....	14.66	1	✓	Methotrexate Sandoz
* Inj 15 mg prefilled syringe.....	14.77	1	✓	Methotrexate Sandoz
* Inj 20 mg prefilled syringe.....	14.88	1	✓	Methotrexate Sandoz
* Inj 25 mg prefilled syringe.....	14.99	1	✓	Methotrexate Sandoz
* Inj 30 mg prefilled syringe.....	15.09	1	✓	Methotrexate Sandoz
* Inj 25 mg per ml, 2 ml vial – PCT – Retail pharmacy-Specialist.....	30.00	5	✓	DBL Methotrexate Onco-Vial
* Inj 25 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist.....	45.00	1	✓	DBL Methotrexate Onco-Vial
* Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist	25.00	1	✓	Methotrexate Ebewe
* Inj 100 mg per ml, 50 ml vial – PCT – Retail pharmacy-Specialist	79.99	1	✓	Methotrexate Ebewe
Methotrexate Ebewe to be Sole Supply on 1 October 2020				
* Inj 1 mg for ECP – PCT only – Specialist.....	0.06	1 mg	✓	Baxter
* Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist.....	4.73	5 mg OP	✓	Baxter
PEMETREXED – PCT only – Specialist – Special Authority see SA1679 below				
Inj 100 mg vial	60.89	1	✓	Juno Pemetrexed
Inj 500 mg vial	217.77	1	✓	Juno Pemetrexed
Inj 1 mg for ECP	0.55	1 mg	✓	Baxter

►SA1679 Special Authority for Subsidy

Initial application — (mesothelioma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

Both:

- 1 Patient has been diagnosed with mesothelioma; and
- 2 Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.

Renewal — (mesothelioma) only from a relevant specialist or medical practitioner on the recommendation of a relevant

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

specialist. Approvals valid for 8 months for applications meeting the following criteria:

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment; and
- 3 Pemetrexed to be administered at a dose of 500mg/m² every 21 days for a maximum of 6 cycles.

Initial application — (non-small cell lung carcinoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

Both:

- 1 Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient has chemotherapy-naïve disease; and
 - 2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles; or
 - 2.2 All of the following:
 - 2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and
 - 2.2.2 Patient has not received prior funded treatment with pemetrexed; and
 - 2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

Renewal — (non-small cell lung carcinoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment; and
- 3 Pemetrexed is to be administered at a dose of 500mg/m² every 21 days.

THIOGUANINE – PCT – Retail pharmacy-Specialist

Tab 40 mg	126.31	25	✓ Lanvis
-----------------	--------	----	----------

Other Cytotoxic Agents

AMSACRINE – PCT only – Specialist

Inj 50 mg per ml, 1.5 ml ampoule	1,500.00	6	✓ Amsidine ^{S29}
	4,736.00		✓ Amsidine ^{S29}
Inj 75 mg.....	1,250.00	5	✓ AmsaLyo ^{S29}

ANAGRELIDE HYDROCHLORIDE – PCT – Retail pharmacy-Specialist

Cap 0.5 mg	CBS	100	✓ Agrylin ^{S29} ^{S29}
	1,175.87		✓ Teva ^{S29}
			✓ Agrylin

ARSENIC TRIOXIDE – PCT only – Specialist

Inj 1 mg per ml, 10 ml vial.....	4,817.00	10	✓ Phenasen
Inj 10 mg for ECP	481.70	10 mg OP	✓ Baxter

BLEOMYCIN SULPHATE – PCT only – Specialist

Inj 15,000 iu, vial.....	161.01	1	✓ DBL Bleomycin Sulfate
Inj 1,000 iu for ECP	12.45	1,000 iu	✓ Baxter

BORTEZOMIB – PCT only – Specialist – Special Authority see [SA1889 on the next page](#)

Inj 3.5 mg vial	105.00	1	✓ Bortezomib Dr-Reddy's
Inj 1 mg for ECP	31.20	1 mg	✓ Baxter

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
►SA1889 Special Authority for Subsidy				
Initial application — (multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:				
Either:				
1 The patient has symptomatic multiple myeloma; or				
2 The patient has symptomatic systemic AL amyloidosis *.				
Note: Indications marked with * are unapproved indications.				
COLASPASE [L-ASPARAGINASE] – PCT only – Specialist				
Inj 10,000 iu.....	102.32	1	✓	Leunase
Inj 10,000 iu for ECP	102.32	10,000 iu OP	✓	Baxter
<i>(Leunase Inj 10,000 iu to be delisted 1 December 2020)</i>				
<i>(Baxter Inj 10,000 iu for ECP to be delisted 1 December 2020)</i>				
DACARBAZINE – PCT only – Specialist				
Inj 200 mg vial	62.70	1	✓	DBL Dacarbazine
	580.60	10	✓	Dacarbazine APP S29
Inj 200 mg for ECP	62.70	200 mg OP	✓	Baxter
DACTINOMYCIN [ACTINOMYCIN D] – PCT only – Specialist				
Inj 0.5 mg vial	255.00	1	✓	Cosmegen
Inj 0.5 mg for ECP	255.00	0.5 mg OP	✓	Baxter
DAUNORUBICIN – PCT only – Specialist				
Inj 2 mg per ml, 10 ml	149.50	1	✓	Pfizer
Inj 20 mg for ECP	149.50	20 mg OP	✓	Baxter
DOCETAXEL – PCT only – Specialist				
Inj 10 mg per ml, 2 ml vial.....	12.40	1	✓	DBL Docetaxel
Inj 20 mg.....	48.75	1	✓	Docetaxel Sandoz
Inj 10 mg per ml, 8 ml vial.....	26.95	1	✓	DBL Docetaxel
Inj 20 mg per ml, 4 ml vial.....	26.95	1	✓	Docetaxel Accord S29
Inj 80 mg.....	195.00	1	✓	Docetaxel Sandoz
Inj 1 mg for ECP.....	0.55	1 mg	✓	Baxter
DOXORUBICIN HYDROCHLORIDE – PCT only – Specialist				
Inj 2 mg per ml, 5 ml vial.....	10.00	1	✓	Doxorubicin Ebewe
Inj 2 mg per ml, 25 ml vial.....	11.50	1	✓	Doxorubicin Ebewe
	17.00		✓	Arrow-Doxorubicin
Inj 2 mg per ml, 50 ml vial.....	23.00	1	✓	Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial	56.15	1	✓	Doxorubicin Ebewe
	65.00		✓	Arrow-Doxorubicin
Inj 1 mg for ECP.....	0.29	1 mg	✓	Baxter
EPIRUBICIN HYDROCHLORIDE – PCT only – Specialist				
Inj 2 mg per ml, 5 ml vial.....	25.00	1	✓	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial.....	30.00	1	✓	Epirubicin Ebewe
Inj 2 mg per ml, 100 ml vial.....	85.00	1	✓	Epirubicin Ebewe
Inj 1 mg for ECP	0.43	1 mg	✓	Baxter
ETOPOSIDE				
Cap 50 mg – PCT – Retail pharmacy-Specialist	340.73	20	✓	Vepesid
Cap 100 mg – PCT – Retail pharmacy-Specialist	340.73	10	✓	Vepesid
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist.....	7.90	1	✓	Rex Medical
Inj 1 mg for ECP – PCT only – Specialist.....	0.09	1 mg	✓	Baxter

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ETOPOSIDE PHOSPHATE – PCT only – Specialist				
Inj 100 mg (of etoposide base).....	40.00	1	✓	Etopophos
Inj 1 mg (of etoposide base) for ECP	0.47	1 mg	✓	Baxter
HYDROXYUREA [HYDROXYCARBAMIDE] – PCT – Retail pharmacy-Specialist				
Cap 500 mg	23.82	100	✓	Devatis
	31.76		✓	Hydrea
<i>(Hydrea Cap 500 mg to be delisted 1 February 2021)</i>				
IDARUBICIN HYDROCHLORIDE				
Inj 5 mg vial – PCT only – Specialist	93.00	1	✓	Zavedos
Inj 10 mg vial – PCT only – Specialist	198.00	1	✓	Zavedos
Inj 1 mg for ECP – PCT only – Specialist	21.84	1 mg	✓	Baxter
LENALIDOMIDE – Retail pharmacy-Specialist – Special Authority see SA1897 below				
Wastage claimable				
Cap 5 mg	5,122.76	28	✓	Revlimid
Cap 10 mg	4,655.25	21	✓	Revlimid
	6,207.00	28	✓	Revlimid
Cap 15 mg	5,429.39	21	✓	Revlimid
	7,239.18	28	✓	Revlimid
Cap 25 mg	7,627.00	21	✓	Revlimid

►SA1897 Special Authority for Subsidy

Initial application — (Relapsed/refractory disease) only from a haematologist or any relevant practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has relapsed or refractory multiple myeloma with progressive disease; and
- 2 Patient has not previously been treated with lenalidomide; and
- 3 Either:
 - 3.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or
 - 3.2 Both:
 - 3.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
 - 3.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and
- 4 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Initial application — (Maintenance following first-line autologous stem cell transplant (SCT)) only from a haematologist or any relevant practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has newly diagnosed symptomatic multiple myeloma and has undergone first-line treatment that included an autologous stem cell transplantation; and
- 2 Patient has at least a stable disease response in the first 100 days after transplantation; and
- 3 Lenalidomide maintenance is to be commenced within 6 months of transplantation; and
- 4 The patient has ECOG performance score of 0-1; and
- 5 Lenalidomide to be administered at a maximum dose of 15 mg/day.

Renewal — (Relapsed/refractory disease) only from a haematologist or any relevant practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Renewal — (Maintenance following first line autologous SCT) only from a haematologist or any relevant practitioner on the

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

MESNA

Tab 400 mg – PCT – Retail pharmacy-Specialist.....	314.00	50	✓	Uromitexan
Tab 600 mg – PCT – Retail pharmacy-Specialist.....	448.50	50	✓	Uromitexan
Inj 100 mg per ml, 4 ml ampoule – PCT only – Specialist.....	177.45	15	✓	Uromitexan
Inj 100 mg per ml, 10 ml ampoule – PCT only – Specialist.....	407.40	15	✓	Uromitexan
Inj 1 mg for ECP – PCT only – Specialist.....	2.96	100 mg	✓	Baxter

MITOMYCIN C – PCT only – Specialist

Inj 5 mg vial	851.37	1	✓	Teva
Inj 20 mg vial	816.32	1	✓	Omegapharm ^{\$29}
Inj 1 mg for ECP	175.38	1 mg	✓	Baxter

(Omegapharm ^{\$29} Inj 20 mg vial to be delisted 1 November 2020)

MITOZANTRONE – PCT only – Specialist

Inj 2 mg per ml, 10 ml vial.....	97.50	1	✓	Mitozantrone Ebewe
Inj 1 mg for ECP	5.51	1 mg	✓	Baxter

OLAPARIB – Retail pharmacy-Specialist – Special Authority see SA1883 below

Tab 100 mg	3,701.00	56	✓	Lynparza
Tab 150 mg	3,701.00	56	✓	Lynparza
Cap 50 mg – Wastage claimable.....	7,402.00	448	✓	Lynparza

►SA1883 Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
- 2 There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation; and
- 3 Patient has received at least two lines of previous treatment with platinum-based chemotherapy; and
- 4 Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line of platinum-based chemotherapy; and
- 5 Patient's disease must have achieved partial or complete response to treatment with the immediately preceding platinum-based regimen; and
- 6 Patient's disease has not progressed following prior treatment with olaparib; and
- 7 Treatment will be commenced within 8 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and
- 8 Treatment to be administered as maintenance treatment; and
- 9 Treatment not to be administered in combination with other chemotherapy.

Renewal only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from treatment; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
2 No evidence of progressive disease; and				
3 Treatment to be administered as maintenance treatment; and				
4 Treatment not to be administered in combination with other chemotherapy.				
Note: "Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.				
PACLITAXEL – PCT only – Specialist				
Inj 30 mg.....	47.30	5	✓	Paclitaxel Ebewe
Inj 100 mg.....	24.00	1	✓	Paclitaxel Ebewe
	91.67		✓	Paclitaxel Actavis
Inj 150 mg.....	26.69	1	✓	Paclitaxel Ebewe
	137.50		✓	Anzatax
			✓	Paclitaxel Actavis
Inj 300 mg.....	44.00	1	✓	Paclitaxel Ebewe
	275.00		✓	Anzatax
			✓	Paclitaxel Actavis
Inj 1 mg for ECP	0.20	1 mg	✓	Baxter
PEGASPARGASE – PCT only – Special Authority see SA1325 below				
Inj 750 iu per ml, 5 ml vial.....	3,455.00	1	✓	Oncaspar LYO S29
▶SA1325 Special Authority for Subsidy				
Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.				
Approvals valid for 12 months for applications meeting the following criteria:				
All of the following:				
1 The patient has newly diagnosed acute lymphoblastic leukaemia; and				
2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and				
3 Treatment is with curative intent.				
Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:				
All of the following:				
1 The patient has relapsed acute lymphoblastic leukaemia; and				
2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and				
3 Treatment is with curative intent.				
PENTOSTATIN [DEOXYCOFORMYCIN] – PCT only – Specialist				
Inj 10 mg.....	CBS	1	✓	Nipent S29
PROCARBAZINE HYDROCHLORIDE – PCT – Retail pharmacy-Specialist				
Cap 50 mg.....	980.00	50	✓	Natulan S29
TEMOZOLOMIDE – Special Authority see SA1741 on the next page – Retail pharmacy				
Cap 5 mg.....	9.13	5	✓	Temaccord
Cap 20 mg.....	16.38	5	✓	Temaccord
	18.30		✓	Apo-Temozolomide
	136.00	14	✓	Accord S29
Cap 100 mg.....	35.98	5	✓	Temaccord
	40.20		✓	Apo-Temozolomide
	532.00	14	✓	Accord S29
Cap 140 mg.....	50.12	5	✓	Temaccord
	400.00		✓	Amneal S29
Cap 180 mg.....	620.00	14	✓	Accord S29
Cap 250 mg.....	86.34	5	✓	Temaccord
	688.00		✓	Amneal S29

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA1741 Special Authority for Subsidy

Initial application — (high grade gliomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
 - 1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of 5 days treatment per cycle, at a maximum dose of 200 mg/m² per day.

Initial application — (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
- 2 Temozolomide is to be given in combination with capecitabine; and
- 3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
- 4 Temozolomide to be discontinued at disease progression.

Initial application — (ewing's sarcoma) only from a relevant specialist. Approvals valid for 9 months where the patient has relapsed/refractory Ewing's sarcoma.

Renewal — (high grade gliomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has glioblastoma multiforme; and
 - 1.2 The treatment remains appropriate and the patient is benefitting from treatment; or
- 2 All of the following:
 - 2.1 Patient has anaplastic astrocytoma*; and
 - 2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
 - 2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

Renewal — (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Renewal — (ewing's sarcoma) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a * is an unapproved indication. Temozolomide is not subsidised for the treatment of relapsed high grade glioma.

THALIDOMIDE – Retail pharmacy-Specialist – Special Authority see [SA1124 on the next page](#)

Cap 50 mg	378.00	28	✓ Thalomid
Cap 100 mg	756.00	28	✓ Thalomid

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA1124 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis*.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with * is an unapproved indication.

TRETINOIN

Cap 10 mg – PCT – Retail pharmacy-Specialist	479.50	100	✓ Vesanoid
--	--------	-----	------------

VENETOCLAX – Retail pharmacy-Specialist – Special Authority see SA1868 below

Tab 14 x 10 mg, 7 x 50 mg, 21 x 100 mg	1,771.86	42 OP	✓ Venclexta
Tab 10 mg	95.78	14 OP	✓ Venclexta
Tab 50 mg	239.44	7 OP	✓ Venclexta
Tab 100 mg – Wastage claimable	8,209.41	120	✓ Venclexta

►SA1868 Special Authority for Subsidy

Initial application — (relapsed/refractory chronic lymphocytic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 7 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic lymphocytic leukaemia requiring treatment; and
- 2 Patient has received at least one prior therapy for chronic lymphocytic leukaemia; and
- 3 Patient has not previously received funded venetoclax; and
- 4 The patient's disease has relapsed within 36 months of previous treatment; and
- 5 Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax; and
- 6 Patient has an ECOG performance status of 0-2.

Renewal — (relapsed/refractory chronic lymphocytic leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment; and
- 2 Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is required due to disease progression or unacceptable toxicity.

Initial application — (previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has previously untreated chronic lymphocytic leukaemia; and
- 2 There is documentation confirming that patient has 17p deletion by FISH testing or TP53 mutation by sequencing; and
- 3 Patient has an ECOG performance status of 0-2.

Renewal — (previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where the treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL)* and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are Unapproved indications.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
VINBLASTINE SULPHATE				
Inj 1 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialist.....	270.37	5	✓	DBL Vinblastine <small>S29</small>
Inj 1 mg for ECP – PCT only – Specialist.....	6.00	1 mg	✓	Hospira Baxter
VINCRIStINE SULPHATE				
Inj 1 mg per ml, 1 ml vial – PCT – Retail pharmacy-Specialist.....	74.52	5	✓	DBL Vincristine Sulfate
Inj 1 mg per ml, 2 ml vial – PCT – Retail pharmacy-Specialist.....	102.73	5	✓	DBL Vincristine Sulfate
Inj 1 mg for ECP – PCT only – Specialist.....	12.60	1 mg	✓	Baxter
VINOReLBINE – PCT only – Specialist				
Inj 10 mg per ml, 1 ml vial.....	12.00	1	✓	Navelbine
	42.00		✓	Vinorelbine Ebewe
Inj 10 mg per ml, 5 ml vial.....	56.00	1	✓	Navelbine
	210.00		✓	Vinorelbine Ebewe
Inj 1 mg for ECP.....	1.25	1 mg	✓	Baxter

Protein-tyrosine Kinase Inhibitors

ALECTINIB – Retail pharmacy-Specialist – Special Authority see [SA1870 below](#)

Wastage claimable

Cap 150 mg..... 7,935.00 224 ✓ **Alecensa**

► **SA1870** Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-small cell lung cancer; and
- 2 There is documentation confirming that the patient has an ALK tyrosine kinase gene rearrangement using an appropriate ALK test; and
- 3 Patient has an ECOG performance score of 0-2.

Renewal only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of progressive disease according to RECIST criteria; and
- 2 The patient is benefitting from and tolerating treatment.

DASATINIB – Special Authority see [SA1805 below](#) – Retail pharmacy

Wastage claimable

Tab 20 mg 3,774.06 60 ✓ **Sprycel**
 Tab 50 mg 6,214.20 60 ✓ **Sprycel**
 Tab 70 mg 7,692.58 60 ✓ **Sprycel**

► **SA1805** Special Authority for Subsidy

Initial application only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

1 Both:

- 1.1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.2 Maximum dose of 140 mg/day; or
- 2 Both:
 - 2.1 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); and
 - 2.2 Maximum dose of 140 mg/day; or
- 3 All of the following:
 - 3.1 The patient has a diagnosis of CML in chronic phase; and
 - 3.2 Maximum dose of 100 mg/day; and
 - 3.3 Any of the following:
 - 3.3.1 Patient has documented treatment failure* with imatinib; or
 - 3.3.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or
 - 3.3.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system; or
 - 3.3.4 Patients is enrolled in the KISS study** and requires dasatinib treatment according to the study protocol.

Renewal only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Lack of treatment failure while on dasatinib*; and
- 2 Dasatinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML.

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines. **Kinase-Inhibition Study with Sprycel Start-up
<https://www.cancertrialsnz.ac.nz/kiss/>

ERLOTINIB – Retail pharmacy-Specialist – Special Authority see [SA1915 below](#)

Tab 100 mg	764.00	30	✓ Tarceva
Tab 150 mg	1,146.00	30	✓ Tarceva

►SA1915 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
- 3 Either:
 - 3.1 Patient is treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient has discontinued gefitinib due to intolerance; and
 - 3.2.2 The cancer did not progress while on gefitinib; and
- 4 Erlotinib is to be given for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Renewal — (pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Erlotinib to be discontinued at progression; and
- 3 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

GEFITINIB – Retail pharmacy-Specialist – Special Authority see [SA1916 on the next page](#)

Tab 250 mg	1,700.00	30	✓ Iressa
------------------	----------	----	----------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA1916 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 Either:
 - 2.1 Patient is treatment naive; or
 - 2.2 Both:
 - 2.2.1 The patient has discontinued erlotinib due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on erlotinib; and
- 3 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
- 4 Gefitinib is to be given for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Renewal — (pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Gefitinib to be discontinued at progression; and
- 3 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

IMATINIB MESILATE

Note: Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

Tab 100 mg – [Xpharm] – Special Authority see [SA1460](#)

below	2,400.00	60	✓ Glivec
* Cap 100 mg	98.00	60	✓ Imatinib-AFT
* Cap 400 mg	197.50	30	✓ Imatinib-AFT

►SA1460 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms, and prescriptions should be sent to:

The CML/GIST Co-ordinator Phone: (04) 460 4990
 PHARMAC Facsimile: (04) 916 7571
 PO Box 10 254 Email: cmlgistcoordinator@pharmac.govt.nz
 Wellington

Special Authority criteria for GIST – access by application

Funded for patients:

- a) With a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST).
- b) Maximum dose of 400 mg/day.
- c) Applications to be made and subsequent prescriptions can be written by an oncologist.
- d) Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).

LAPATINIB DITOSYLATE – Special Authority see [SA1191 on the next page](#) – Retail pharmacy

Tab 250 mg	1,899.00	70	✓ Tykerb
------------------	----------	----	----------

(Tykerb Tab 250 mg to be delisted 1 June 2021)

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA1191 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Lapatinib not to be given in combination with trastuzumab; and
 - 1.4 Lapatinib to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on trastuzumab; and
 - 2.4 Lapatinib not to be given in combination with trastuzumab; and
 - 2.5 Lapatinib to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
- 3 Lapatinib not to be given in combination with trastuzumab; and
- 4 Lapatinib to be discontinued at disease progression.

NILOTINIB – Special Authority see [SA1489 below](#) – Retail pharmacy

Wastage claimable

Cap 150 mg	4,680.00	120	✓ Tasigna
Cap 200 mg	6,532.00	120	✓ Tasigna

►SA1489 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
- 2 Either:
 - 2.1 Patient has documented CML treatment failure* with imatinib; or
 - 2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

Renewal only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
- 2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PALBOCICLIB – Retail pharmacy-Specialist – Special Authority see SA1894 below				
Wastage claimable				
Cap 75 mg	4,000.00	21	✓	Ibrance
Cap 100 mg	4,000.00	21	✓	Ibrance
Cap 125 mg	4,000.00	21	✓	Ibrance

➔ [SA1894](#) Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a Medical oncologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has unresectable locally advanced or metastatic breast cancer; and
- 2 There is documentation confirming disease is hormone-receptor positive and HER2-negative; and
- 3 Patient has an ECOG performance score of 0-2; and
- 4 Either:
 - second or subsequent line setting
 - 4.1 Disease has relapsed or progressed during prior endocrine therapy; or
 - 4.2 Both:
 - first line setting
 - 4.2.1 Patient is amenorrhoeic, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
 - 4.2.2 Either:
 - 4.2.2.1 Patient has not received prior systemic treatment for metastatic disease; or
 - 4.2.2.2 All of the following:
 - 4.2.2.2.1 Patient commenced treatment with palbociclib in combination with an endocrine agent prior to 1 April 2020; and
 - 4.2.2.2.2 Patient has not received prior systemic endocrine treatment for metastatic disease; and
 - 4.2.2.2.3 There is no evidence of progressive disease; and
- 5 Treatment must be used in combination with an endocrine partner.

Renewal only from a medical oncologist or medical practitioner on the recommendation of a Medical oncologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment must be used in combination with an endocrine partner; and
- 2 No evidence of progressive disease; and
- 3 The treatment remains appropriate and the patient is benefitting from treatment.

PAZOPANIB – Special Authority see [SA1190 below](#) – Retail pharmacy

Tab 200 mg	1,334.70	30	✓	Votrient
Tab 400 mg	2,669.40	30	✓	Votrient

➔ [SA1190](#) Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on sunitinib; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of less than or equal to 70; or
 - 5.6 2 or more sites of organ metastasis; and
- 6 Pazopanib to be used for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

RUXOLITINIB – Special Authority see [SA1890 below](#) – Retail pharmacy

Wastage claimable

Tab 5 mg	2,500.00	56	✓ Jakavi
Tab 15 mg	5,000.00	56	✓ Jakavi
Tab 20 mg	5,000.00	56	✓ Jakavi

►SA1890 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
- 2 Either:
 - 2.1 A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; or
 - 2.2 Both:
 - 2.2.1 A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
 - 2.2.2 Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy; and
- 3 A maximum dose of 20 mg twice daily is to be given.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 A maximum dose of 20 mg twice daily is to be given.

SUNITINIB – Special Authority see [SA1917 on the next page](#) – Retail pharmacy

Cap 12.5 mg	2,315.38	28	✓ Sutent
Cap 25 mg	4,630.77	28	✓ Sutent
Cap 50 mg	9,261.54	28	✓ Sutent

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA1917 Special Authority for Subsidy

Initial application — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of less than or equal to 70; or
 - 5.6 2 or more sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Initial application — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or
 - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Renewal — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6

Renewal — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non measurable disease); or
- 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Renewal — (GIST pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal (GIST); and
- 2 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 3 Sunitinib is to be discontinued at progression; and
- 4 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

Endocrine Therapy

For GnRH ANALOGUES – refer to HORMONE PREPARATIONS, Tropic Hormones, [page 82](#)

ABIRATERONE ACETATE – Retail pharmacy-Specialist – Special Authority see [SA1914 below](#)

Wastage claimable

Tab 250 mg 4,276.19 120 ✓ Zytiga

➡SA1914 Special Authority for Subsidy

Initial application only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has prostate cancer; and
- 2 Patient has metastases; and
- 3 Patient's disease is castration resistant; and
- 4 Either:
 - 4.1 All of the following:
 - 4.1.1 Patient is symptomatic; and
 - 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
 - 4.1.3 Patient has ECOG performance score of 0-1; and
 - 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
 - 4.2 All of the following:
 - 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
 - 4.2.2 Patient has ECOG performance score of 0-2; and
 - 4.2.3 Patient has not had prior treatment with abiraterone.

Renewal — (abiraterone acetate) only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 No evidence of clinical disease progression; and
- 2 No initiation of taxane chemotherapy with abiraterone; and
- 3 The treatment remains appropriate and the patient is benefiting from treatment.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
BICALUTAMIDE				
Tab 50 mg	3.80	28	✓	Binarex
FLUTAMIDE				
Tab 250 mg	119.50	100	✓	Flutamin
FULVESTRANT – Retail pharmacy-Specialist – Special Authority see SA1895 below				
Inj 50 mg per ml, 5 ml prefilled syringe	1,068.00	2	✓	Faslodex
►SA1895 Special Authority for Subsidy				
Initial application only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist.				
Approvals valid for 6 months for applications meeting the following criteria:				
All of the following:				
1 Patient has oestrogen-receptor positive locally advanced or metastatic breast cancer; and				
2 Patient has disease progression following prior treatment with an aromatase inhibitor or tamoxifen for their locally advanced or metastatic disease; and				
3 Treatment to be given at a dose of 500 mg monthly following loading doses; and				
4 Treatment to be discontinued at disease progression.				
Renewal only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 6 months for applications meeting the following criteria:				
All of the following:				
1 Treatment remains appropriate and patient is benefitting from treatment; and				
2 Treatment to be given at a dose of 500 mg monthly; and				
3 There is no evidence of disease progression.				
MEGESTROL ACETATE				
Tab 160 mg	63.53	30	✓	Apo-Megestrol
OCTREOTIDE				
Inj 100 mcg per ml, 1 ml ampoule	18.69	5	✓	Octreotide GH ^{S29}
Inj 50 mcg per ml, 1 ml vial	30.64	5	✓	DBL Octreotide
			✓	Octreotide
				MaxRx ^{S29}
Inj 100 mcg per ml, 1 ml vial	18.69	5	✓	DBL Octreotide
Inj 500 mcg per ml, 1 ml ampoule	72.50	5	✓	Octreotide GH ^{S29}
Inj 500 mcg per ml, 1 ml vial	72.50	5	✓	DBL Octreotide
	222.00		✓	Octreotide
				(Sun) ^{S29}
Inj 50 mcg per ml, 1 ml ampoule	30.64	5	✓	Octreotide GH ^{S29}
OCTREOTIDE LAR (SOMATOSTATIN ANALOGUE) – Special Authority see SA1918 below – Retail pharmacy				
Inj LAR 10 mg prefilled syringe	1,772.50	1	✓	Sandostatin LAR
Inj LAR 20 mg prefilled syringe	2,358.75	1	✓	Sandostatin LAR
Inj LAR 30 mg prefilled syringe	2,951.25	1	✓	Sandostatin LAR

►SA1918 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Note: Indications marked with * are unapproved indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

Initial application — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:
 - 2.2.1 Patient has failed surgery; or
 - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 3 Both:
 - 3.1 Insulinomas; and
 - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
 - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
 - 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

Renewal — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Acromegaly - pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has acromegaly; and
- 2 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

3 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

TAMOXIFEN CITRATE

* Tab 10 mg	15.00	60	✓	Tamoxifen Sandoz
Tamoxifen Sandoz to be Sole Supply on 1 November 2020				
* Tab 20 mg	6.65	60	✓	Tamoxifen Sandoz
Tamoxifen Sandoz to be Sole Supply on 1 November 2020				

Aromatase Inhibitors

ANASTROZOLE

* Tab 1 mg	5.04	30	✓	Rolin
------------------	------	----	---	-------

EXEMESTANE

* Tab 25 mg	14.50	30	✓	Pfizer Exemestane
-------------------	-------	----	---	-------------------

LETROZOLE

* Tab 2.5 mg	4.68	30	✓	Letrole
--------------------	------	----	---	---------

Immunosuppressants

Cytotoxic Immunosuppressants

AZATHIOPRINE

* Tab 25 mg	7.35	60	✓	Azamun
* Tab 50 mg	7.60	100	✓	Azamun
* Inj 50 mg vial	199.00	1	✓	Imuran

MYCOPHENOLATE MOFETIL

Tab 500 mg	35.90	50	✓	Cellcept
Cap 250 mg	35.90	100	✓	Cellcept
Powder for oral liq 1 g per 5 ml – Subsidy by endorsement	187.25	165 ml OP	✓	Cellcept

Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.

Fusion Proteins

ETANERCEPT – Special Authority see [SA1949 below](#) – Retail pharmacy

Inj 25 mg	690.00	4	✓	Enbrel
Inj 50 mg autoinjector	1,050.00	4	✓	Enbrel
Inj 50 mg prefilled syringe	1,050.00	4	✓	Enbrel

►SA1949 Special Authority for Subsidy

Initial application — (adult-onset Still's disease) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 Either:

1.1.1 The patient has had an initial Special Authority approval for adalimumab for adult-onset Still's disease (AOSD); or

1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

2 All of the following:

- 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
- 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
- 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 The patient has a sustained improvement in inflammatory markers and functional status.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

1.1 Applicant is a rheumatologist; or

1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

2 Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and

3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab; or

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or

2 All of the following:

2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and

2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.5 Both:

2.5.1 Either:

2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or

2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician's global assessment indicating severe disease.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

1.1 Applicant is a named specialist or rheumatologist; or

1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporine, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.

Note: Indications marked with * are unapproved indications.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist.

Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 2.3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

All of the following:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Either:
 - 2.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 2.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Initial application — (undifferentiated spondyloarthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day (or maximum tolerated dose); and
- 4 Patient has tried and not responded to at least three months of leflunomide at a dose of up to 20 mg daily (or maximum tolerated dose); and
- 5 Any of the following:
 - 5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with * are unapproved indications.

Renewal — (undifferentiated spondyloarthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

continued...

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg dose every 7 days.

Immune Modulators

ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist

Inj 50 mg per ml, 5 ml	2,351.25	5	✓ ATGAM
------------------------------	----------	---	---------

BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Specialist

Subsidised only for bladder cancer.

Inj 2-8 x 100 million CFU	149.37	1	✓ OncoTICE
---------------------------------	--------	---	------------

Inj 40 mg per ml, vial	176.90	3	✓ SII-Onco-BCG <small>\$29</small>
------------------------------	--------	---	------------------------------------

(SII-Onco-BCG \$29 Inj 40 mg per ml, vial to be delisted 1 April 2021)

Monoclonal Antibodies

ADALIMUMAB – Special Authority see [SA1950 below](#) – Retail pharmacy

Inj 20 mg per 0.4 ml prefilled syringe.....	1,599.96	2	✓ Humira
Inj 40 mg per 0.8 ml prefilled pen	1,599.96	2	✓ HumiraPen
Inj 40 mg per 0.8 ml prefilled syringe.....	1,599.96	2	✓ Humira

➔**SA1950** Special Authority for Subsidy

Initial application — (adult-onset Still's disease) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Both:

1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

2 The patient has a sustained improvement in inflammatory markers and functional status.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and

1.2 Either:

- 1.2.1 The patient has experienced intolerable side effects from etanercept; or
- 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or

2 All of the following:

- 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
- 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
- 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
- 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and

2.5 Either:

- 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
- 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and

2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2 Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from infliximab; or
 - 1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for chronic ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
 - 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Renewal — (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

Initial application — (Crohn's disease - adults) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Renewal — (Crohn's disease - adults) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Either:
 - 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 2.1.2 CDAI score is 150 or less; or
 - 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Crohn's disease - children) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Renewal — (Crohn's disease - children) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Either:
 - 2.1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
 - 2.1.2 PCDAI score is 15 or less; or
 - 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that PCDAI score cannot be assessed; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (fistulising Crohn's disease) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application; and
- 4 The patient will be assessed for response to treatment after 4 months' adalimumab treatment (see Note).

Note: A maximum of 4 months' adalimumab will be subsidised on an initial Special Authority approval for fistulising Crohn's disease.

Renewal — (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
 - 2.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initial application — (hidradenitis suppurativa) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
- 2 Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or patient has demonstrated intolerance to or has contraindications for systemic antibiotics; and
- 3 The patient has 3 or more active lesions (e.g. inflammatory nodules, abscesses, draining fistulae); and
- 4 The patient has a Dermatology Quality of Life Index of 10 or more and the assessment is no more than 1 month old at time of application; and
- 5 Following the initial loading doses, adalimumab is to be administered at doses no greater than 40mg every 7 days.

Renewal — (hidradenitis suppurativa) only from a dermatologist or Practitioner on the recommendation of a dermatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and
- 3 Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for juvenile idiopathic arthritis; or

2 All of the following:

2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.2 Patient diagnosed with JIA; and

2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.5 Both:

2.5.1 Either:

2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or

2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician's global assessment indicating severe disease.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

1.1 Applicant is a named specialist or rheumatologist; or

1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

3 Either:

3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept; or

1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or

2 All of the following:

2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and

2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and

2.4 Either:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
- 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.

Note: Note: Indications marked with * are unapproved indications.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist.

Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Initial application — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has severe Behcet's disease that is significantly impacting the patient's quality of life (see Notes); and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

2 Either:

- 2.1 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has not responded adequately to treatment with infliximab (see Notes); or
- 2.2 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has experienced intolerable side effects from treatment with infliximab; and

3 The patient is experiencing significant loss of quality of life; and

4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: Behcet's disease diagnosed according to the International Study Group for Behcet's disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al, J Rheumatol. 2004;31:931-7.

Renewal — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept; or

1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or

2 All of the following:

2.1 Either:

2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or

2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

2.3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

2.4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1.1 Applicant is a dermatologist; or
- 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

2 Either:

2.1 Both:

- 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
- 2.1.2 Either:
 - 2.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 2.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or

2.2 Both:

- 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
- 2.2.2 Either:
 - 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment

Initial application — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from infliximab; or
 - 1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for severe ocular inflammation; or

2 Both:

- 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
- 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Renewal — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1 Any of the following:

- 1.1 The patient has had a good clinical response following 3 initial doses; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

AFLIBERCEPT – Special Authority see [SA1772 below](#) – Retail pharmacy

Inj 40 mg per ml, 0.1 ml vial..... 1,250.00 1 ✓ Eylea

➔SA1772 Special Authority for Subsidy

Initial application — (wet age related macular degeneration) only from an ophthalmologist. Approvals valid for 3 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Wet age-related macular degeneration (wet AMD); or
 - 1.1.2 Polypoidal choroidal vasculopathy; or
 - 1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
 - 1.2 Either:
 - 1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
 - 1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
 - 1.3 There is no structural damage to the central fovea of the treated eye; and
 - 1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or
- 2 Either:
 - 2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or
 - 2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Initial application — (diabetic macular oedema) only from an ophthalmologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has centre involving diabetic macular oedema (DMO); and
- 2 Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
- 3 Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision; and
- 4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
- 5 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Renewal — (wet age related macular degeneration) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 3 There is no structural damage to the central fovea of the treated eye.

Renewal — (diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

the following criteria:

All of the following:

- 1 There is stability or two lines of Snellen visual acuity gain; and
- 2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
- 3 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 4 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
- 5 After each consecutive 12 months treatment with (2nd line anti-VEGF agent), patient has retrialled with at least one injection of bevacizumab and had no response.

CETUXIMAB – PCT only – Specialist – Special Authority see [SA1697 below](#)

Inj 5 mg per ml, 20 ml vial.....	364.00	1	✓	Erbitux
Inj 5 mg per ml, 100 ml vial.....	1,820.00	1	✓	Erbitux
Inj 1 mg for ECP.....	3.82	1 mg	✓	Baxter

➔SA1697 Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck; and
- 2 Patient is contraindicated to, or is intolerant of, cisplatin; and
- 3 Patient has good performance status; and
- 4 To be administered in combination with radiation therapy.

INFLIXIMAB – PCT only – Special Authority see [SA1951 below](#)

Inj 100 mg.....	806.00	1	✓	Remicade
Inj 1 mg for ECP.....	8.29	1 mg	✓	Baxter

➔SA1951 Special Authority for Subsidy

Initial application — (Graft vs host disease) from any medical practitioner. Approvals valid without further renewal unless notified where patient has steroid-refractory acute graft vs. host disease of the gut.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
- 3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

Renewal — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

significant response to treatment in the opinion of the physician; and

- 3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Renewal — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

Renewal — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initial application — (severe ocular inflammation) from any medical practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
 - 2.2 Any of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
- 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
- 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Renewal — (severe ocular inflammation) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initial application — (chronic ocular inflammation) from any medical practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
 - 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Renewal — (chronic ocular inflammation) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (Pulmonary sarcoidosis) from any medical practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
- 2 Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

Initial application — (Crohn's disease (adults)) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Renewal — (Crohn's disease (adults)) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
 - 1.2 CDAI score is 150 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initial application — (Crohn's disease (children)) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Renewal — (Crohn's disease (children)) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
 - 1.2 PCDAI score is 15 or less; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initial application — (fistulising Crohn's disease) only from a gastroenterologist. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e).

Renewal — (fistulising Crohn's disease) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
 - 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initial application — (acute severe fulminant ulcerative colitis) only from a gastroenterologist. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient has acute, severe fulminant ulcerative colitis; and
- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful.

Renewal — (severe fulminant ulcerative colitis) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initial application — (severe ulcerative colitis) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has histologically confirmed ulcerative colitis; and
- 2 Either:
 - 2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is greater than or equal to 4; or
 - 2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is greater than or equal to 65; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Renewal — (severe ulcerative colitis) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
- 2 Either:
 - 2.1 Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
 - 2.2 Patient is under 18 years and the PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab; and
- 3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initial application — (plaque psoriasis) only from a dermatologist. Approvals valid for 3 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Renewal — (plaque psoriasis) only from a dermatologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or
- 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initial application — (neurosarcoidosis) only from a neurologist. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Biopsy consistent with diagnosis of neurosarcoidosis; and
- 2 Patient has CNS involvement; and
- 3 Patient has steroid-refractory disease; and
- 4 Either:
 - 4.1 IV cyclophosphamide has been tried; or
 - 4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

Renewal — (neurosarcoidosis) only from a neurologist. Approvals valid for 18 months for applications meeting the following criteria:

Either:

- 1 A withdrawal period has been tried and the patient has relapsed; or
- 2 All of the following:
 - 2.1 A withdrawal period has been considered but would not be clinically appropriate; and
 - 2.2 There has been a marked reduction in prednisone dose; and
 - 2.3 Either:
 - 2.3.1 There has been an improvement in MRI appearances; or
 - 2.3.2 Marked improvement in other symptomology.

Initial application — (severe Behcet's disease) from any medical practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The patient has severe Behcet's disease which is significantly impacting the patient's quality of life (see Notes); and
- 2 Either:
 - 2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes); or
 - 2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and
- 3 The patient is experiencing significant loss of quality of life.

Notes:

- a) Behcet's disease diagnosed according to the International Study Group for Behcet's Disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al J Rheumatol. 2004;31:931-7.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- b) Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

Renewal — (severe Behcet's disease) from any medical practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*;
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.

Note: Indications marked with * are unapproved indications.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

MEPOLIZUMAB – Special Authority see [SA1896 below](#) – Retail pharmacy

Inj 100 mg vial	1,638.00	1	✓ Nucala
-----------------------	----------	---	----------

➔ **SA1896 Special Authority for Subsidy**

Initial application — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and
- 4 Patient has a blood eosinophil count of greater than 0.5×10^9 cells/L in the last 12 months; and
- 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long acting beta-2 agonist, or budesonide/formoterol as part of the single maintenance and reliever therapy regimen, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
 - 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and
- 7 Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

the first dose to assess response to treatment.

Renewal — (Severe eosinophilic asthma) only from a respiratory physician or clinical immunologist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 Either:
 - 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with mepolizumab; or
 - 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

OBINUTUZUMAB – PCT only – Specialist – Special Authority see [SA1627 below](#)

Inj 25 mg per ml, 40 ml vial.....	5,910.00	1	✓ Gazyva
Inj 1 mg for ECP	6.21	1 mg	✓ Baxter

►SA1627 Special Authority for Subsidy

Initial application — (chronic lymphocytic leukaemia) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is obinutuzumab treatment naive; and
- 3 The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
- 4 Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and
- 5 Patient has good performance status; and
- 6 Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* Neutrophil greater than or equal to $1.5 \times 10^9/L$ and platelets greater than or equal to $75 \times 10^9/L$.

OMALIZUMAB – Special Authority see [SA1744 below](#) – Retail pharmacy

Inj 150 mg prefilled syringe.....	450.00	1	✓ Xolair
Inj 150 mg vial	450.00	1	✓ Xolair

►SA1744 Special Authority for Subsidy

Initial application — (severe asthma) only from a respiratory specialist or clinical immunologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 6 years or older; and
- 2 Patient has a diagnosis of severe asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/mL at baseline; and
- 5 Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or formoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Either:

- 6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 12 months, unless contraindicated or not tolerated; or
- 6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
- 7 Patient has an Asthma Control Test (ACT) score of 10 or less; and
- 8 Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

Initial application — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
 - 2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; or
 - 2.2 Patient has a Urticaria Control Test (UCT) of 8 or less; and
- 3 Any of the following:
 - 3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
 - 3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
 - 3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and
- 4 Either:
 - 4.1 Treatment to be stopped if inadequate response* following 4 doses; or
 - 4.2 Complete response* to 6 doses of omalizumab.

Renewal — (severe asthma) only from a clinical immunologist or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

Renewal — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Patient has previously adequately responded* to 6 doses of omalizumab; or
- 2 Both:
 - 2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
 - 2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

PERTUZUMAB – PCT only – Specialist – Special Authority see [SA1606 on the next page](#)

Inj 30 mg per ml, 14 ml vial.....	3,927.00	1	✓ Perjeta
Inj 420 mg for ECP	3,927.00	420 mg OP	✓ Baxter

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓	

►SA1606 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 Patient is chemotherapy treatment naïve; or
 - 2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
- 3 The patient has good performance status (ECOG grade 0-1); and
- 4 Pertuzumab to be administered in combination with trastuzumab; and
- 5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
- 6 Pertuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

RITUXIMAB (MABTHERA) – PCT only – Specialist – Special Authority see SA1901 below

Inj 100 mg per 10 ml vial	1,075.50	2	✓ Mabthera
Inj 500 mg per 50 ml vial	2,688.30	1	✓ Mabthera
Inj 1 mg for ECP	5.64	1 mg	✓ Baxter (Mabthera)

►SA1901 Special Authority for Subsidy

Renewal — (ANCA associated vasculitis) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; or
 - 1.2 All of the following:
 - 1.2.1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
 - 1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
 - 1.2.3 The patient does not have chromosome 17p deletion CLL; and
 - 1.2.4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Renewal — (Neuromyelitis Optica Spectrum Disorder) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
- The patient has responded to the most recent course of rituximab; and
- The patient has not received rituximab in the previous 6 months.

Renewal — (Post-transplant) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- The patient has had a rituximab treatment-free interval of 12 months or more; and
- The patient has B-cell post-transplant lymphoproliferative disorder*; and
- To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.

Renewal — (Severe Refractory Myasthenia Gravis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- An initial response lasting at least 12 months was demonstrated; and
- Either:
 - The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
 - Both:
 - The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
 - Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Renewal — (Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- Patient who was previously treated with rituximab for nephrotic syndrome*; and
- Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Steroid resistant nephrotic syndrome (SRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- Patient who was previously treated with rituximab for nephrotic syndrome*; and
- Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months,

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (aggressive CD20 positive NHL) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Renewal — (haemophilia with inhibitors) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Renewal — (immune thrombocytopenic purpura (ITP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Renewal — (indolent, low-grade lymphomas or hairy cell leukaemia*) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Renewal — (pure red cell aplasia (PRCA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 weeks where patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

Initial application — (rheumatoid arthritis - TNF inhibitors contraindicated) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
 - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 6 Either:
 - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 7 Either:
 - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
- 8 Either:
 - 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initial application — (rheumatoid arthritis - prior TNF inhibitor use) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Both:
 - 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Renewal — (rheumatoid arthritis - re-treatment in 'partial responders' to rituximab) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
 - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Renewal — (rheumatoid arthritis - re-treatment in 'responders' to rituximab) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
 - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Renewal — (severe cold haemagglutinin disease (CHAD)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Renewal — (thrombotic thrombocytopenic purpura (TTP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (treatment refractory systemic lupus erythematosus (SLE)) only from a rheumatologist, nephrologist or Practitioner on the recommendation of a rheumatologist or nephrologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Renewal — (warm autoimmune haemolytic anaemia (warm AIHA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

RITUXIMAB (RIXIMYO) – PCT only – Specialist – Special Authority see [SA1937 below](#)

Inj 100 mg per 10 ml vial	275.33	2	✓ Riximyo
Inj 500 mg per 50 ml vial	688.20	1	✓ Riximyo
Inj 1 mg for ECP	1.38	1 mg	✓ Baxter (Riximyo)

►SA1937 Special Authority for Subsidy

Initial application — (ABO-incompatible organ transplant) from any relevant practitioner. Approvals valid without further renewal unless notified where patient is to undergo an ABO-incompatible solid organ transplant*.

Note: Indications marked with * are unapproved indications.

Initial application — (ANCA associated vasculitis) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and
- 3 Any of the following:
 - 3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
 - 3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
 - 3.3 Cyclophosphamide and methotrexate are contraindicated; or
 - 3.4 Patient is a female of child-bearing potential; or
 - 3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are unapproved indications.

Renewal — (ANCA associated vasculitis) from any relevant practitioner. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (Antibody-mediated organ transplant rejection) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has been diagnosed with antibody-mediated organ transplant rejection*.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Note: Indications marked with * are unapproved indications.

Initial application — (Chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 Any of the following:
 - 2.1 The patient is rituximab treatment naive; or
 - 2.2 Either:
 - 2.2.1 The patient is chemotherapy treatment naive; or
 - 2.2.2 Both:
 - 2.2.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
 - 2.2.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; or
 - 2.3 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; and
- 3 The patient has good performance status; and
- 4 Either:
 - 4.1 The patient does not have chromosome 17p deletion CLL; or
 - 4.2 Rituximab treatment is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia; and
- 5 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles; and
- 6 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

Renewal — (Chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; or
 - 1.2 All of the following:
 - 1.2.1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
 - 1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
 - 1.2.3 The patient does not have chromosome 17p deletion CLL; and
 - 1.2.4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and
- 2 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Initial application — (Neuromyelitis Optica Spectrum Disorder(NMOSD)) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
- 2 Either:
 - 2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
 - 2.2 All of the following:
 - 2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
 - 2.2.2 The patient is receiving treatment with mycophenolate; and
 - 2.2.3 The patients is receiving treatment with corticosteroids.

Renewal — (Neuromyelitis Optica Spectrum Disorder) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
- 2 The patients has responded to the most recent course of rituximab; and
- 3 The patient has not received rituximab in the previous 6 months.

Initial application — (Post-transplant) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are unapproved indications.

Renewal — (Post-transplant) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.

Initial application — (Severe Refractory Myasthenia Gravis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 Either:
 - 2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or
 - 2.2 Both:
 - 2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and
 - 2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Renewal — (Severe Refractory Myasthenia Gravis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 2 years for applications meeting the following criteria:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

All of the following:

- 1 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Either:
 - 3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
 - 3.2 Both:
 - 3.2.1 The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
 - 3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Initial application — (Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS))

only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient is a child with SDNS* or FRNS*; and
- 2 Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
- 3 Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
- 4 Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
- 5 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (Steroid resistant nephrotic syndrome (SRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
- 2 Treatment with tacrolimus for at least 3 months has been ineffective; and
- 3 Genetic causes of nephrotic syndrome have been excluded; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Steroid resistant nephrotic syndrome (SRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (aggressive CD20 positive NHL) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Renewal — (aggressive CD20 positive NHL) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Initial application — (haemophilia with inhibitors) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 Patient has mild congenital haemophilia complicated by inhibitors; or
- 2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
- 3 Patient has acquired haemophilia.

Renewal — (haemophilia with inhibitors) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Initial application — (immune thrombocytopenic purpura (ITP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
 - 1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
- 2 Any of the following:
 - 2.1 Treatment with steroids and splenectomy have been ineffective; or

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
- 2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy); and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (immune thrombocytopenic purpura (ITP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (indolent, low-grade lymphomas or hairy cell leukaemia*) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Renewal — (indolent, low-grade lymphomas or hairy cell leukaemia*) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Initial application — (pure red cell aplasia (PRCA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 weeks where patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are unapproved indications.

Renewal — (pure red cell aplasia (PRCA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 weeks where patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

Initial application — (severe cold haemagglutinin disease (CHAD)) only from a haematologist or Practitioner on the

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has cold haemagglutinin disease*; and
- 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (severe cold haemagglutinin disease (CHAD)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (thrombotic thrombocytopenic purpura (TTP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Both:

- 1 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks; and
- 2 Either:
 - 2.1 Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
 - 2.2 Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are unapproved indications.

Renewal — (thrombotic thrombocytopenic purpura (TTP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (treatment refractory systemic lupus erythematosus (SLE)) only from a rheumatologist, nephrologist or Practitioner on the recommendation of a rheumatologist or nephrologist. Approvals valid for 7 months for applications meeting the following criteria:

All of the following:

- 1 The patient has severe, immediately life- or organ-threatening SLE*; and
- 2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
- 3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
- 4 Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

Renewal — (treatment refractory systemic lupus erythematosus (SLE)) only from a rheumatologist, nephrologist or Practitioner on the recommendation of a rheumatologist or nephrologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Initial application — (warm autoimmune haemolytic anaemia (warm AIHA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has warm autoimmune haemolytic anaemia*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (warm autoimmune haemolytic anaemia (warm AIHA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (severe antisynthetase syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed antisynthetase syndrome; and
- 2 Patient has severe, immediately life or organ threatening disease, including interstitial lung disease; and
- 3 Either:
 - 3.1 Treatment with at least 3 immunosuppressants (oral steroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has not be effective at controlling active disease; or
 - 3.2 Rapid treatment is required due to life threatening complications; and
- 4 Maximum of four 1,000mg infusions of rituximab.

Renewal — (severe antisynthetase syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in inflammatory markers, muscle strength and pulmonary function; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 Maximum of two cycles of 2 x 1,000mg infusions of rituximab given two weeks apart.

Initial application — (graft versus host disease) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

All of the following:

- 1 Patient has refractory graft versus host disease following transplant; and
- 2 Treatment with at least 3 immunosuppressants (oral steroids, ciclosporin, tacrolimus, mycophenolate, sirolimus) has not been effective at controlling active disease; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Initial application — (severe chronic inflammatory demyelinating polyneuropathy) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe chronic inflammatory demyelinating polyneuropathy (CIPD); and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
 - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
 - 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Renewal — (severe chronic inflammatory demyelinating polyneuropathy) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function compared to baseline; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initial application — (anti-NMDA receptor autoimmune encephalitis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe anti-NMDA receptor autoimmune encephalitis; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
 - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
 - 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Renewal — (anti-NMDA receptor autoimmune encephalitis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 The patient has experienced a relapse and now requires further treatment; and

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓	

continued...

- One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initial application — (CD20+ low grade or follicular B-cell NHL) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- Both:
 - The patient has CD20+ low grade or follicular B-cell NHL with relapsed disease following prior chemotherapy; and
 - To be used for a maximum of 6 treatment cycles; or
- Both:
 - The patient has CD20+ low grade or follicular B-cell NHL requiring first-line systemic chemotherapy; and
 - To be used for a maximum of 6 treatment cycles.

Renewal — (CD20+ low grade or follicular B-cell NHL) from any relevant practitioner. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- Rituximab is to be used for maintenance in CD20+ low grade or follicular B-cell NHL following induction with first-line systemic chemotherapy; and
- Patient is intended to receive rituximab maintenance therapy for 2 years at a dose of 375 mg/m² every 8 weeks (maximum of 12 cycles).

SECUKINUMAB – Special Authority see [SA1754 below](#) – Retail pharmacy

Inj 150 mg per ml, 1 ml prefilled syringe..... 1,599.00 2 ✓ Cosentyx

➔ **SA1754** Special Authority for Subsidy

Initial application — (severe chronic plaque psoriasis – second-line biologic) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule, for severe chronic plaque psoriasis; and
- Either:
 - The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
 - The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and
- A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- The most recent PASI or DLQI assessment is no more than 1 month old at the time of application.

Initial application — (severe chronic plaque psoriasis – first-line biologic) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- Either:
 - Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

prior treatment course; and

- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Renewal — (severe chronic plaque psoriasis – first and second-line biologic) only from a dermatologist or medical practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
 - 1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
- 2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

SILTUXIMAB – Special Authority see [SA1596 below](#) – Retail pharmacy

Note: Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Inj 100 mg vial	770.57	1	✓ Sylvant
Inj 400 mg vial	3,082.33	1	✓ Sylvant

► **SA1596** Special Authority for Subsidy

Initial application only from a haematologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Renewal only from a haematologist or rheumatologist. Approvals valid for 12 months where the treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

TOCILIZUMAB – PCT only – Special Authority see [SA1858 below](#)

Inj 20 mg per ml, 4 ml vial.....	220.00	1	✓ Actemra
Inj 20 mg per ml, 10 ml vial.....	550.00	1	✓ Actemra
Inj 20 mg per ml, 20 ml vial.....	1,100.00	1	✓ Actemra
Inj 1 mg for ECP	2.85	1 mg	✓ Baxter

► **SA1858** Special Authority for Subsidy

Initial application — (cytokine release syndrome) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient is enrolled in the Children's Oncology Group AALL1731 trial; and
 - 1.2 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
 - 1.3 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg, maximum of 12 mg/kg); or

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

2 All of the following:

- 2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial; and
- 2.2 The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
- 2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

Initial application — (previous use) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient was being treated with tocilizumab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 rheumatoid arthritis; or
 - 2.2 systemic juvenile idiopathic arthritis; or
 - 2.3 adult-onset Still's disease; or
 - 2.4 polyarticular juvenile idiopathic arthritis; or
 - 2.5 idiopathic multicentric Castleman's disease.

Initial application — (Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Either:
 - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
 - 3.2 Both:
 - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and
 - 3.2.2 Either:
 - 3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
 - 3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Initial application — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 2 Tocilizumab is to be used as monotherapy; and
- 3 Either:
 - 3.1 Treatment with methotrexate is contraindicated; or
 - 3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
- 4 Either:
 - 4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
- 5 Either:
 - 5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
 - 5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 6 Either:
 - 6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (systemic juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
- 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Initial application — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initial application — (polyarticular juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for juvenile idiopathic arthritis (JIA); and
 - 1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or
- 2 All of the following:
 - 2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
 - 2.2 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
- 2.4 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Initial application — (idiopathic multicentric Castleman's disease) only from a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

Renewal — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Renewal — (systemic juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months where the patient has a sustained improvement in inflammatory markers and functional status.

Renewal — (polyarticular juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (idiopathic multicentric Castleman's disease) only from a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist. Approvals valid for 12 months where the treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
TRASTUZUMAB – PCT only – Specialist – Special Authority see SA1632 below				
Inj 150 mg vial	1,350.00	1	✓	Herceptin
Inj 440 mg vial	3,875.00	1	✓	Herceptin
Inj 1 mg for ECP	9.36	1 mg	✓	Baxter

► **SA1632 Special Authority for Subsidy**

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 2.2 Both:
 - 2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on lapatinib; and
- 3 Either:
 - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 3.2 All of the following:
 - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 4 Trastuzumab not to be given in combination with lapatinib; and
- 5 Trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

Initial application — (early breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria:

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
 - 3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Renewal — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
- 3 Any of the following:
 - 3.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 3.2 Both:
 - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 3.2.2 The cancer did not progress whilst on lapatinib; or
 - 3.3 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 4 Either:
 - 4.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 4.2 All of the following:
 - 4.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 4.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 4.2.3 The patient has good performance status (ECOG grade 0-1); and
- 5 Trastuzumab not to be given in combination with lapatinib; and
- 6 Trastuzumab to be discontinued at disease progression.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

TRASTUZUMAB EMTANSINE – PCT only – Specialist – Special Authority see [SA1871](#) below

Inj 100 mg vial	2,320.00	1	✓ Kadcyła
Inj 160 mg vial	3,712.00	1	✓ Kadcyła
Inj 1 mg for ECP	23.20	1 mg	✓ Baxter

►SA1871 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and
- 3 Either:
 - 3.1 The patient has received prior therapy for metastatic disease*; or
 - 3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy*; and
- 4 Patient has a good performance status (ECOG 0-1); and
- 5 Either:
 - 5.1 Patient does not have symptomatic brain metastases; or
 - 5.2 Patient has brain metastases and has received prior local CNS therapy; and
- 6 Treatment to be discontinued at disease progression.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab emtansine; and
- 2 Treatment to be discontinued at disease progression.

Note: *Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Programmed Cell Death-1 (PD-1) Inhibitors

NIVOLUMAB – PCT only – Specialist – Special Authority see [SA1911](#) below

Inj 10 mg per ml, 4 ml vial.....	1,051.98	1	✓ Opdivo
Inj 10 mg per ml, 10 ml vial.....	2,629.96	1	✓ Opdivo
Inj 1 mg for ECP	27.62	1 mg	✓ Baxter

►SA1911 Special Authority for Subsidy

Initial application only from a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Patient has measurable disease as defined by RECIST version 1.1; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 Patient has not received funded pembrolizumab; or
 - 4.2 Both:
 - 4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
 - 4.2.2 The cancer did not progress while the patient was on pembrolizumab; and
- 5 Baseline measurement of overall tumour burden is documented (see Note); and
- 6 Documentation confirming that the patient has been informed and acknowledges that funded treatment with nivolumab will not be continued if their disease progresses.

Renewal only from a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
 - 1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
 - 1.1.3 Patient has stable disease according to RECIST criteria (see Note); and
 - 1.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and
 - 1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
 - 1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with nivolumab.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

PEMBROLIZUMAB – PCT only – Specialist – Special Authority see [SA1910 below](#)

Inj 25 mg per ml, 4 ml vial.....	4,680.00	1	✓ Keytruda
Inj 1 mg for ECP	49.14	1 mg	✓ Baxter

►SA1910 Special Authority for Subsidy

Initial application — (unresectable or metastatic melanoma) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
- 2 Patient has measurable disease as defined by RECIST version 1.1; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 Patient has not received funded nivolumab; or
 - 4.2 Both:
 - 4.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance; and
 - 4.2.2 The cancer did not progress while the patient was on nivolumab; and
- 5 Baseline measurement of overall tumour burden is documented (see Note); and
- 6 Documentation confirming that the patient has been informed and acknowledges that funded treatment with pembrolizumab will not be continued if their disease progresses.

Renewal — (unresectable or metastatic melanoma) only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
 - 1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
 - 1.1.3 Patient has stable disease according to RECIST criteria (see Note); and
 - 1.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and
 - 1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
 - 1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with pembrolizumab.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks.

Response definitions as follows:

- **Complete Response:** Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- **Partial Response:** At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- **Progressive Disease:** At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- **Stable Disease:** Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

Other Immunosuppressants

CICLOSPORIN

Cap 25 mg	44.63	50	✓ Neoral
Cap 50 mg	88.91	50	✓ Neoral
Cap 100 mg	177.81	50	✓ Neoral
Oral liq 100 mg per ml	198.13	50 ml OP	✓ Neoral

EVEROLIMUS – Special Authority see [SA1913](#) below – Retail pharmacy

Wastage claimable

Tab 10 mg	6,512.29	30	✓ Afinitor
Tab 5 mg	4,555.76	30	✓ Afinitor

➔SA1913 Special Authority for Subsidy

Initial application only from a neurologist or oncologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has tuberous sclerosis; and
- 2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.

Renewal only from a neurologist or oncologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Everolimus to be discontinued at progression of SEGAs.

Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.

Renewal — (pandemic circumstances) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Everolimus to be discontinued at progression of SEGAs; and
- 3 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector.

Note: : MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SIROLIMUS – Special Authority see SA0866 below – Retail pharmacy				
Tab 1 mg	749.99	100	✓	Rapamune
Tab 2 mg	1,499.99	100	✓	Rapamune
Oral liq 1 mg per ml	449.99	60 ml OP	✓	Rapamune

►SA0866 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR < 30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease

TACROLIMUS – Special Authority see [SA1745 below](#) – Retail pharmacy

Cap 0.5 mg	49.60	100	✓	Tacrolimus Sandoz
Cap 0.75 mg	99.30	100	✓	Tacrolimus Sandoz
Cap 1 mg	84.30	100	✓	Tacrolimus Sandoz
Cap 5 mg	248.20	50	✓	Tacrolimus Sandoz

►SA1745 Special Authority for Subsidy

Initial application — (organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

Note: Subsidy applies for either primary or rescue therapy.

Initial application — (non-transplant indications*) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient requires long-term systemic immunosuppression; and
- 2 Ciclosporin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response.

Note: Indications marked with * are unapproved indications

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Antiallergy Preparations

Allergic Emergencies

ICATIBANT – Special Authority see [SA1558 below](#) – Retail pharmacy

Inj 10 mg per ml, 3 ml prefilled syringe.....	2,668.00	1	✓ Firazyr
---	----------	---	-----------

► **SA1558** Special Authority for Subsidy

Initial application only from a clinical immunologist or relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and
- 2 The patient has undergone product training and has agreed upon an action plan for self-administration.

Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Allergy Desensitisation

► **SA1367** Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

BEE VENOM ALLERGY TREATMENT – Special Authority see [SA1367 above](#) – Retail pharmacy

Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent	285.00	1 OP	✓ Venomil ^{\$29}
Treatment kit - 1 vial 550 mcg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml	305.00	1 OP	✓ Albey
Treatment kit - 1 vial 550 mcg freeze dried venom, with diluent	305.00	1 OP	✓ Hymenoptera ^{\$29}

WASP VENOM ALLERGY TREATMENT – Special Authority see [SA1367 above](#) – Retail pharmacy

Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml	305.00	1 OP	✓ Albey
Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze dried venom, with diluent	305.00	1 OP	✓ Hymenoptera ^{\$29}
Treatment kit (Paper wasp venom) - 6 vials 120 mcg freeze dried venom, with diluent	305.00	1 OP	✓ Venomil ^{\$29}
Treatment kit (Yellow Jacket venom) - 1 vial 550 mcg freeze dried venom, with diluent	305.00	1 OP	✓ Hymenoptera ^{\$29}
Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freeze dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml	305.00	1 OP	✓ Albey
Treatment kit (Yellow jacket venom) - 6 vials 120 mcg freeze dried venom, with diluent	305.00	1 OP	✓ Venomil ^{\$29}

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Antihistamines				
CETIRIZINE HYDROCHLORIDE				
* Tab 10 mg	1.12	100	✓ <u>Zista</u>	
* Oral liq 1 mg per ml	2.99	200 ml	✓ <u>Histaclear</u>	
CHLORPHENIRAMINE MALEATE				
* Oral liq 2 mg per 5 ml	9.37	500 ml	✓ <u>Histafen</u>	
DEXTROCHLORPHENIRAMINE MALEATE				
* Tab 2 mg	2.02	40		
	(8.40)			Polaramine
	1.01	20		
	(5.99)			Polaramine
* Oral liq 2 mg per 5 ml	1.77	100 ml		
	(10.29)			Polaramine
FEXOFENADINE HYDROCHLORIDE				
* Tab 60 mg	4.34	20		
	(8.23)			Telfast
* Tab 120 mg	4.74	10		
	(8.23)			Telfast
	14.22	30		
	(26.44)			Telfast
LORATADINE				
* Tab 10 mg	1.69	100	✓ <u>Lorafix</u>	
* Oral liq 1 mg per ml	2.15	120 ml	✓ <u>Lorfast</u>	
PROMETHAZINE HYDROCHLORIDE				
* Tab 10 mg	1.68	50	✓ <u>Allersoothe</u>	
* Tab 25 mg	1.89	50	✓ <u>Allersoothe</u>	
* Oral liq 1 mg per 1 ml	2.69	100 ml	✓ <u>Allersoothe</u>	
* Inj 25 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	17.87	5	✓ <u>Hospira</u>	

Inhaled Corticosteroids

BECLOMETHASONE DIPROPIONATE				
Aerosol inhaler, 50 mcg per dose	9.30	200 dose OP	✓ <u>Qvar</u>	
Aerosol inhaler, 50 mcg per dose CFC-free	8.54	200 dose OP	✓ <u>Beclazone 50</u>	
Aerosol inhaler, 100 mcg per dose	15.50	200 dose OP	✓ <u>Qvar</u>	
Aerosol inhaler, 100 mcg per dose CFC-free	12.50	200 dose OP	✓ <u>Beclazone 100</u>	
Aerosol inhaler, 250 mcg per dose CFC-free	22.67	200 dose OP	✓ <u>Beclazone 250</u>	
BUDESONIDE				
Powder for inhalation, 100 mcg per dose	17.00	200 dose OP	✓ <u>Pulmicort Turbuhaler</u>	
Powder for inhalation, 200 mcg per dose	19.00	200 dose OP	✓ <u>Pulmicort Turbuhaler</u>	
Powder for inhalation, 400 mcg per dose	32.00	200 dose OP	✓ <u>Pulmicort Turbuhaler</u>	

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
FLUTICASONE				
Aerosol inhaler, 50 mcg per dose.....	7.19	120 dose OP	✓	Flixotide
Powder for inhalation, 50 mcg per dose.....	7.50	60 dose OP	✓	Flixotide Accuhaler
Powder for inhalation, 100 mcg per dose.....	7.50	60 dose OP	✓	Flixotide Accuhaler
Aerosol inhaler, 125 mcg per dose.....	13.60	120 dose OP	✓	Flixotide
Aerosol inhaler, 250 mcg per dose.....	24.62	120 dose OP	✓	Flixotide
Powder for inhalation, 250 mcg per dose.....	13.60	60 dose OP	✓	Flixotide Accuhaler

Inhaled Long-acting Beta-adrenoceptor Agonists

EFORMOTEROL FUMARATE

Powder for inhalation, 12 mcg per dose, and monodose device.....	20.64 (35.80)	60 dose		Foradil
--	------------------	---------	--	---------

EFORMOTEROL FUMARATE DIHYDRATE

Powder for inhalation 4.5 mcg per dose, breath activated (equivalent to eformoterol fumarate 6 mcg metered dose).....	10.32 (16.90)	60 dose OP		Oxis Turbuhaler
--	------------------	------------	--	-----------------

INDACATEROL

Powder for inhalation 150 mcg.....	61.00	30 dose OP	✓	Onbrez Breezhaler
Powder for inhalation 300 mcg.....	61.00	30 dose OP	✓	Onbrez Breezhaler

SALMETEROL

Aerosol inhaler CFC-free, 25 mcg per dose.....	25.00	120 dose OP	✓	Serevent
Aerosol inhaler 25 mcg per dose.....	9.90	120 dose OP	✓	Meterol
Powder for inhalation, 50 mcg per dose, breath activated	25.00	60 dose OP	✓	Serevent Accuhaler

(Meterol Aerosol inhaler 25 mcg per dose to be delisted 1 January 2021)

Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

BUDESONIDE WITH EFORMOTEROL

Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg	18.23	120 dose OP	✓	Vannair
Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg	33.74	120 dose OP	✓	Symbicort Turbuhaler 100/6
Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg	21.40	120 dose OP	✓	Vannair
Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg	44.08	120 dose OP	✓	Symbicort Turbuhaler 200/6
Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg – No more than 2 dose per day	44.08	60 dose OP	✓	Symbicort Turbuhaler 400/12

FLUTICASONE FUROATE WITH VILANTEROL

Powder for inhalation 100 mcg with vilanterol 25 mcg	44.08	30 dose OP	✓	Breo Ellipta
--	-------	------------	---	---------------------

FLUTICASONE WITH SALMETEROL

Aerosol inhaler 50 mcg with salmeterol 25 mcg	25.79	120 dose OP	✓	Seretide
Aerosol inhaler 125 mcg with salmeterol 25 mcg	32.60	120 dose OP	✓	Seretide
Powder for inhalation 100 mcg with salmeterol 50 mcg – No more than 2 dose per day.....	33.74	60 dose OP	✓	Seretide Accuhaler
Powder for inhalation 250 mcg with salmeterol 50 mcg – No more than 2 dose per day.....	44.08	60 dose OP	✓	Seretide Accuhaler

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Beta-Adrenoceptor Agonists

SALBUTAMOL

Oral liq 400 mcg per ml	20.00	150 ml	✓	<u>Ventolin</u>
Infusion 1 mg per ml, 5 ml	118.38	10	✓	<u>Ventolin</u>
Inj 500 mcg per ml, 1 ml – Up to 5 inj available on a PSO	53.00	5	✓	<u>Ventolin</u>

Inhaled Beta-Adrenoceptor Agonists

SALBUTAMOL

Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000 dose available on a PSO	3.80	200 dose OP	✓	<u>Respigen</u> ✓ <u>SalAir</u> Ventolin
(6.00)				
Nebuliser soln, 1 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO	3.93	20	✓	<u>Asthalin</u>
Nebuliser soln, 2 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO	4.03	20	✓	<u>Asthalin</u>

TERBUTALINE SULPHATE

Powder for inhalation, 200 mcg per dose (equivalent to 250 mcg metered dose), breath activated	22.20	120 dose OP	✓	<u>Bricanyl Turbuhaler</u>
Powder for inhalation, 250 mcg per dose, breath activated	27.30	200 dose OP	✓	<u>Bricanyl Turbuhaler</u>

(Bricanyl Turbuhaler Powder for inhalation, 250 mcg per dose, breath activated to be delisted 1 October 2020)

Anticholinergic Agents

IPRATROPIUM BROMIDE

Aerosol inhaler, 20 mcg per dose CFC-free – Up to 400 dose available on a PSO	16.20	200 dose OP	✓	<u>Atrovent</u>
Nebuliser soln, 250 mcg per ml, 1 ml ampoule – Up to 40 neb available on a PSO	3.35	20	✓	<u>Univent</u>
Nebuliser soln, 250 mcg per ml, 2 ml ampoule – Up to 40 neb available on a PSO	11.73	20	✓	<u>Univent</u>

(Univent Nebuliser soln, 250 mcg per ml, 1 ml ampoule to be delisted 1 January 2021)

Inhaled Beta-Adrenoceptor Agonists with Anticholinergic Agents

SALBUTAMOL WITH IPRATROPIUM BROMIDE

Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg per dose CFC-free	12.19	200 dose OP	✓	<u>Duolin HFA</u>
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule – Up to 20 neb available on a PSO	5.20	20	✓	<u>Duolin</u>

Long-Acting Muscarinic Antagonists

GLYCOPYRRONIUM – Subsidy by endorsement

- Inhaled glycopyrronium treatment will not be subsidised if patient is also receiving treatment with subsidised tiotropium or umeclidinium.
- Glycopyrronium powder for inhalation 50 mcg per dose is subsidised only for patients who have been diagnosed as having COPD, and the prescription is endorsed accordingly.

Powder for inhalation 50 mcg per dose	61.00	30 dose OP	✓	<u>Seebri Breezhaler</u>
---	-------	------------	---	--------------------------

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

TIOTROPIUM BROMIDE – Subsidy by endorsement

- Tiotropium treatment will not be subsidised if patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.
- Tiotropium bromide is subsidised only for patients who have been diagnosed as having COPD, and the prescription is endorsed accordingly. Patients who had tiotropium dispensed before 1 October 2018 with a valid Special Authority are deemed endorsed.

Powder for inhalation, 18 mcg per dose	50.37	30 dose	✓ Spiriva
Soln for inhalation 2.5 mcg per dose	50.37	60 dose OP	✓ Spiriva Respimat

UMECLIDINIUM – Subsidy by endorsement

- Umeclidinium will not be subsidised if patient is also receiving treatment with subsidised inhaled glycopyrronium or tiotropium bromide.
- Umeclidinium powder for inhalation 62.5 mcg per dose is subsidised only for patients who have been diagnosed as having COPD, and the prescription is endorsed accordingly.

Powder for inhalation 62.5 mcg per dose	61.50	30 dose OP	✓ Incruse Ellipta
---	-------	------------	--------------------------

Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

Combination long acting muscarinic antagonist and long acting beta-2 agonist will not be subsidised if patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

►SA1584 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Patient has been stabilised on a long acting muscarinic antagonist; and
- 2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined).

GLYCOPYRRONIUM WITH INDACATEROL – Special Authority see [SA1584 above](#) – Retail pharmacy

Powder for Inhalation 50 mcg with indacaterol 110 mcg	81.00	30 dose OP	✓ Ultibro Breezhaler
---	-------	------------	-----------------------------

TIOTROPIUM BROMIDE WITH OLODATEROL – Special Authority see [SA1584 above](#) – Retail pharmacy

Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg	81.00	60 dose OP	✓ Spiolto Respimat
---	-------	------------	---------------------------

UMECLIDINIUM WITH VILANTEROL – Special Authority see [SA1584 above](#) – Retail pharmacy

Powder for inhalation 62.5 mcg with vilanterol 25 mcg	77.00	30 dose OP	✓ Anoro Ellipta
---	-------	------------	------------------------

Antifibrotics

NINTEDANIB – Special Authority see [SA1928 below](#) – Retail pharmacy

Note: Nintedanib not subsidised in combination with subsidised pirfenidone.

Cap 100 mg	2,554.00	60 OP	✓ Ofev
Cap 150 mg	3,870.00	60 OP	✓ Ofev

►SA1928 Special Authority for Subsidy

Initial application — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Nintedanib is to be discontinued at disease progression (See Note); and
- 4 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with pirfenidone; or
 - 5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

Renewal — (idiopathic pulmonary fibrosis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 3 Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

PIRFENIDONE – Retail pharmacy-Specialist – Special Authority see [SA1929 below](#)

Note: Pirfenidone is not subsidised in combination with subsidised nintedanib.

Tab 801 mg	3,645.00	90	✓ Esbriet
Cap 267 mg – Wastage claimable.....	3,645.00	270	✓ Esbriet

►SA1929 Special Authority for Subsidy

Initial application — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note); and
- 4 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with nintedanib; or
 - 5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

Renewal — (idiopathic pulmonary fibrosis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

Leukotriene Receptor Antagonists

MONTELUKAST

* Tab 4 mg	4.25	28	✓ Montelukast Mylan
* Tab 5 mg	4.25	28	✓ Montelukast Mylan
* Tab 10 mg	3.95	28	✓ Montelukast Mylan
			✓ Montelukast Mylan

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Mast Cell Stabilisers

NEDOCROMIL – Subsidy by endorsement

Subsidy by endorsement – Subsidised for patients who were taking nedocromil prior to 1 July 2020 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of nedocromil.

Aerosol inhaler, 2 mg per dose CFC-free.....28.07 112 dose OP ✓ **Tilade**

(Tilade Aerosol inhaler, 2 mg per dose CFC-free to be delisted 1 February 2021)

SODIUM CROMOGLICATE – Subsidy by endorsement

Subsidy by endorsement – Subsidised for patients who were taking sodium cromoglicate prior to 1 July 2020 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of sodium cromoglicate.

Aerosol inhaler, 5 mg per dose CFC-free.....28.07 112 dose OP ✓ **Intal Forte CFC Free**

(Intal Forte CFC Free Aerosol inhaler, 5 mg per dose CFC-free to be delisted 1 May 2021)

Methylxanthines

AMINOPHYLLINE

* Inj 25 mg per ml, 10 ml ampoule – Up to 5 inj available on a

PSO.....124.37 5 ✓ **DBL Aminophylline**

THEOPHYLLINE

* Tab long-acting 250 mg.....23.02 100 ✓ **Nuelin-SR**

* Oral liq 80 mg per 15 ml.....16.60 500 ml ✓ **Nuelin**

Mucolytics

DORNASE ALFA – Special Authority see [SA0611 below](#) – Retail pharmacy

Nebuliser soln, 2.5 mg per 2.5 ml ampoule.....250.00 6 ✓ **Pulmozyme**

► [SA0611](#) Special Authority for Subsidy

Special Authority approved by the Cystic Fibrosis Advisory Panel

Notes: Application details may be obtained from PHARMAC's website www.pharmac.govt.nz/SAForms or:

The Co-ordinator, Cystic Fibrosis Advisory Panel Phone: (04) 460 4990

PHARMAC, PO Box 10 254

Facsimile: (04) 916 7571

Wellington

Email: CFPanel@pharmac.govt.nz

Prescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.

SODIUM CHLORIDE

Not funded for use as a nasal drop.

Soln 7%.....24.50 90 ml OP ✓ **Biomed**

Nasal Preparations

Allergy Prophylactics

BUDESONIDE

Metered aqueous nasal spray, 50 mcg per dose.....2.54 200 dose OP ✓ **SteroClear**

SteroClear to be Sole Supply on 1 October 2020

Metered aqueous nasal spray, 100 mcg per dose.....2.84 200 dose OP ✓ **SteroClear**

SteroClear to be Sole Supply on 1 October 2020

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

RESPIRATORY SYSTEM AND ALLERGIES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
FLUTICASONE PROPIONATE				
Metered aqueous nasal spray, 50 mcg per dose	1.98	120 dose OP	✓	Flixonase Hayfever & Allergy
IPRATROPIUM BROMIDE				
Aqueous nasal spray, 0.03%	4.61	15 ml OP	✓	Univent

Respiratory Devices

MASK FOR SPACER DEVICE

a) Up to 50 dev available on a PSO				
b) Only on a PSO				
c) Only for children aged six years and under				
Small	2.20	1	✓	e-chamber Mask

PEAK FLOW METER

a) Up to 25 dev available on a PSO				
b) Only on a PSO				
Low range	9.54	1	✓	Mini-Wright AFS Low Range
Normal range	9.54	1	✓	Mini-Wright Standard

SPACER DEVICE

a) Up to 50 dev available on a PSO				
b) Only on a PSO				
220 ml (single patient)	2.95	1	✓	e-chamber Turbo
510 ml (single patient)	5.12	1	✓	e-chamber La Grande
800 ml	6.50	1	✓	Volumatic

Respiratory Stimulants

CAFFEINE CITRATE

Oral liq 20 mg per ml (10 mg base per ml)	15.10	25 ml OP	✓	Biomed
---	-------	----------	---	---------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Ear Preparations

ACETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BENZETHONIUM

For Vosol ear drops with hydrocortisone powder refer Standard Formulae, [page 248](#)

Ear drops 2% with 1, 2-Propanediol diacetate 3% and

benzethonium chloride 0.02%	6.97	35 ml OP	✓ Vosol
-----------------------------------	------	----------	---------

FLUMETASONE PIVALATE

Ear drops 0.02% with clioquinol 1%	4.46	7.5 ml OP	✓ Lococorten-Viaform ED's ✓ Locorten-Vioform
--	------	-----------	--

TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN

Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate

2.5 mg and gramicidin 250 mcg per g	5.16	7.5 ml OP	✓ Kenacomb
---	------	-----------	------------

Ear/Eye Preparations

DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN

Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and

gramicidin 50 mcg per ml	4.50 (9.27)	8 ml OP	Sofradex
--------------------------------	----------------	---------	----------

FRAMYCETIN SULPHATE

Ear/Eye drops 0.5%.....	4.13 (8.65)	8 ml OP	Soframycin
-------------------------	----------------	---------	------------

Eye Preparations

Eye preparations are only funded for use in the eye, unless explicitly stated otherwise.

Anti-Infective Preparations

ACICLOVIR

* Eye oint 3%	14.92	4.5 g OP	✓ ViruPOS
---------------------	-------	----------	-----------

CHLORAMPHENICOL

Eye oint 1%	1.55	5 g OP	✓ Devatis
Eye drops 0.5%	1.54	10 ml OP	✓ Chlorafast

Funded for use in the ear*. Indications marked with * are unapproved indications.

CIPROFLOXACIN

Eye drops 0.3% – Subsidy by endorsement.....	9.99	5 ml OP	✓ Ciprofloxacin Teva
--	------	---------	----------------------

When prescribed for the treatment of bacterial keratitis or severe bacterial conjunctivitis resistant to chloramphenicol; or for the second line treatment of chronic suppurative otitis media (CSOM)*; and the prescription is endorsed accordingly.
Note: Indication marked with a * is an unapproved indication.

GENTAMICIN SULPHATE

Eye drops 0.3%	11.40	5 ml OP	✓ Genoptic
----------------------	-------	---------	------------

PROPAMIDINE ISETHIONATE

* Eye drops 0.1%	2.97 (14.55)	10 ml OP	Brolene
------------------------	-----------------	----------	---------

SODIUM FUSIDATE [FUSIDIC ACID]

Eye drops 1%	5.29	5 g OP	✓ Fucithalmic
--------------------	------	--------	---------------

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
TOBRAMYCIN				
Eye oint 0.3%	10.45	3.5 g OP	✓	Tobrex
Eye drops 0.3%	11.48	5 ml OP	✓	Tobrex

Corticosteroids and Other Anti-Inflammatory Preparations

DEXAMETHASONE				
* Eye oint 0.1%	5.86	3.5 g OP	✓	Maxidex
* Eye drops 0.1%	4.50	5 ml OP	✓	Maxidex
Ocular implant 700 mcg – Special Authority see SA1680 below				
– Retail pharmacy.....	1,444.50	1	✓	Ozurdex

►SA1680 Special Authority for Subsidy

Initial application — (Diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has diabetic macular oedema with pseudophakic lens; and
- 2 Patient has reduced visual acuity of between 6/9 - 6/48 with functional awareness of reduction in vision; and
- 3 Either:
 - 3.1 Patient's disease has progressed despite 3 injections with bevacizumab; or
 - 3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and
- 4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Renewal — (Diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Initial application — (Women of child bearing age with diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has diabetic macular oedema; and
- 2 Patient has reduced visual acuity of between 6/9 - 6/48 with functional awareness of reduction in vision; and
- 3 Patient is of child bearing potential and has not yet completed a family; and
- 4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Renewal — (Women of child bearing age with diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Patient is of child bearing potential and has not yet completed a family; and
- 3 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE

* Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g.....	5.39	3.5 g OP	✓	Maxitrol
* Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml.....	4.50	5 ml OP	✓	Maxitrol

DICLOFENAC SODIUM				
Eye drops 0.1%	13.80	5 ml OP	✓	Voltaren Ophtha

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
FLUOROMETHOLONE				
* Eye drops 0.1%	3.09	5 ml OP	✓ FML	
	5.20		✓ Flucon	
LEVOCABASTINE				
Eye drops 0.5 mg per ml	8.71	4 ml OP		Livostin
	(10.34)			
LODOXAMIDE				
Eye drops 0.1%	8.71	10 ml OP	✓ Lomide	
PREDNISOLONE ACETATE				
Eye drops 1%	5.93	10 ml OP	✓ Prednisolone-AFT	
	7.00	5 ml OP	✓ Pred Forte	
PREDNISOLONE SODIUM PHOSPHATE – Special Authority see SA1715 below – Retail pharmacy				
Eye drops 0.5%, single dose (preservative free)	38.50	20 dose	✓ Minims	
			Prednisolone	

► **SA1715** Special Authority for Subsidy

Initial application only from an ophthalmologist or optometrist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has severe inflammation; and
- 2 Patient has a confirmed allergic reaction to preservative in eye drops.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

SODIUM CROMOGLICATE

Eye drops 2%	1.79	5 ml OP	✓ Rexacrom
--------------------	------	---------	-------------------

Glaucoma Preparations - Beta Blockers

BETAXOLOL

* Eye drops 0.25%	11.80	5 ml OP	✓ Betoptic S
* Eye drops 0.5%	7.50	5 ml OP	✓ Betoptic

TIMOLOL

* Eye drops 0.25%	1.81	5 ml OP	✓ Arrow-Timolol
Arrow-Timolol to be Sole Supply on 1 December 2020			
* Eye drops 0.5%	2.04	5 ml OP	✓ Arrow-Timolol
Arrow-Timolol to be Sole Supply on 1 December 2020			
* Eye drops 0.5%, gel forming	3.78	2.5 ml OP	✓ Timoptol XE

Glaucoma Preparations - Carbonic Anhydrase Inhibitors

ACETAZOLAMIDE

* Tab 250 mg	17.03	100	✓ Diamox
--------------------	-------	-----	-----------------

BRINZOLAMIDE

* Eye drops 1%	9.77	5 ml OP	✓ Azopt
----------------------	------	---------	----------------

DORZOLAMIDE HYDROCHLORIDE

* Eye drops 2%	9.77	5 ml OP	
	(17.44)		Trusopt

DORZOLAMIDE WITH TIMOLOL

* Eye drops 2% with timolol 0.5%	2.87	5 ml OP	✓ Dortimopt
--	------	---------	--------------------

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
Glaucoma Preparations - Prostaglandin Analogues			
BIMATOPROST			
* Eye drops 0.03%	3.30	3 ml OP	✓ Bimatoprost Multichem
LATANOPROST			
* Eye drops 0.005%	1.57	2.5 ml OP	✓ Teva
TRAVOPROST			
* Eye drops 0.004%	7.30	5 ml OP	✓ Travopt
	19.50	2.5 ml OP	✓ Travatan
Glaucoma Preparations - Other			
BRIMONIDINE TARTRATE			
* Eye drops 0.2%	4.29	5 ml OP	✓ Arrow-Brimonidine
BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE			
* Eye drops 0.2% with timolol maleate 0.5%	18.50	5 ml OP	✓ Combigan
PILOCARPINE HYDROCHLORIDE			
* Eye drops 1%	4.26	15 ml OP	✓ Isopto Carpine
* Eye drops 2%	5.35	15 ml OP	✓ Isopto Carpine
* Eye drops 4%	7.99	15 ml OP	✓ Isopto Carpine
Subsidised for oral use pursuant to the Standard Formulae.			
* Eye drops 2% single dose – Special Authority see SA0895 below – Retail pharmacy	31.95	20 dose	✓ Minims Pilocarpine
➔ SA0895 Special Authority for Subsidy			
Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:			
Either:			
1 Patient has to use an unpreserved solution due to an allergy to the preservative; or			
2 Patient wears soft contact lenses.			
Note: Minims for a general practice are considered to be “tools of trade” and are not approved as special authority items.			
Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.			
Mydriatics and Cycloplegics			
ATROPINE SULPHATE			
* Eye drops 1%	17.36	15 ml OP	✓ Atropt
Atropt to be Sole Supply on 1 October 2020			
CYCLOPENTOLATE HYDROCHLORIDE			
* Eye drops 1%	8.76	15 ml OP	✓ Cyclogyl
TROPICAMIDE			
* Eye drops 0.5%	7.15	15 ml OP	✓ Mydriacyl
* Eye drops 1%	8.66	15 ml OP	✓ Mydriacyl
Preparations for Tear Deficiency			
For acetylcysteine eye drops refer Standard Formulae, page 248			
HYPROMELLOSE			
* Eye drops 0.5%	2.00 (3.92)	15 ml OP	Methopt

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
HYPROMELLOSE WITH DEXTRAN				
* Eye drops 0.3% with dextran 0.1%.....	2.30	15 ml OP	✓	Poly-Tears

Preservative Free Ocular Lubricants

►SA1388 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Confirmed diagnosis by slit lamp of severe secretory dry eye; and
- 2 Either:
 - 2.1 Patient is using eye drops more than four times daily on a regular basis; or
 - 2.2 Patient has had a confirmed allergic reaction to preservative in eye drop.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient continues to require lubricating eye drops and has benefited from treatment.

CARBOMER – Special Authority see [SA1388 above](#) – Retail pharmacy

Ophthalmic gel 0.3%, 0.5 g8.25 30 ✓ **Poly-Gel**

MACROGOL 400 AND PROPYLENE GLYCOL – Special Authority see [SA1388 above](#) – Retail pharmacy

Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml4.30 24 ✓ **Systane Unit Dose**

SODIUM HYALURONATE [HYALURONIC ACID] – Special Authority see [SA1388 above](#) – Retail pharmacy

Eye drops 1 mg per ml22.00 10 ml OP ✓ **Hylo-Fresh**

Hylo-Fresh has a 6 month expiry after opening. The Pharmacy Procedures Manual restriction allowing one bottle per month is not relevant and therefore only the prescribed dosage to the nearest OP may be claimed.

Other Eye Preparations

NAPHAZOLINE HYDROCHLORIDE

* Eye drops 0.1%4.15 15 ml OP ✓ **Naphcon Forte**

OLOPATADINE

Eye drops 0.1%2.20 5 ml OP ✓ **Olopatadine Teva**
10.00 ✓ **Patanol**

Olopatadine Teva to be Sole Supply on 1 October 2020

(Patanol Eye drops 0.1% to be delisted 1 October 2020)

PARAFFIN LIQUID WITH WOOL FAT

* Eye oint 3% with wool fat 3%3.63 3.5 g OP ✓ **Poly-Visc**

RETINOL PALMITATE

Eye oint 138 mcg per g3.80 5 g OP ✓ **VitA-POS**

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
- 2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

DEFERIPRONE – Special Authority see [SA1480 below](#) – Retail pharmacy

Tab 500 mg	533.17	100	✓ Ferriprox
Oral liq 100 mg per 1 ml	266.59	250 ml OP	✓ Ferriprox

➤ **SA1480** **Special Authority for Subsidy**

Initial application only from a haematologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; or
- 2 The patient has been diagnosed with chronic iron overload due to acquired red cell aplasia.

DEFERRIOXAMINE MESILATE

* Inj 500 mg vial	84.53	10	✓ DBL Desferrioxamine Mesylate for Inj BP
-------------------------	-------	----	--

SODIUM CALCIUM EDETATE

* Inj 200 mg per ml, 5 ml	53.31 (156.71)	6	Calcium Disodium Versenate
---------------------------------	-------------------	---	-------------------------------

Standard Formulae

ACETYLCYSTEINE EYE DROPS

Acetylcysteine inj 200 mg per ml, 10 ml	qs
Suitable eye drop base	qs

PHENOBARBITONE ORAL LIQUID

Phenobarbitone Sodium	1 g
Glycerol BP	70 ml
Water	to 100 ml

ASPIRIN AND CHLOROFORM APPLICATION

Aspirin Soluble tabs 300 mg	12 tabs
Chloroform	to 100 ml

PHENOBARBITONE SODIUM PAEDIATRIC ORAL LIQUID (10 mg per ml)

Phenobarbitone Sodium	400 mg
Glycerol BP	4 ml
Water	to 40 ml

CODEINE LINCTUS (3 mg per 5 ml)

Codeine phosphate	60 mg
Glycerol	40 ml
Preservative	qs
Water	to 100 ml

PILOCARPINE ORAL LIQUID

Pilocarpine 4% eye drops	qs
Preservative	qs
Water	to 500 ml

CODEINE LINCTUS (15 mg per 5 ml)

Codeine phosphate	300 mg
Glycerol	40 ml
Preservative	qs
Water	to 100 ml

(Preservative should be used if quantity supplied is for more than 5 days.)

SALIVA SUBSTITUTE FORMULA

Methylcellulose	5 g
Preservative	qs
Water	to 500 ml

FOLINIC MOUTHWASH

Calcium folinate 15 mg tab	1 tab
Preservative	qs
Water	to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.)

(Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.)

SODIUM CHLORIDE ORAL LIQUID

Sodium chloride inj 23.4%, 20 ml	qs
Water	qs

(Only funded if prescribed for treatment of hyponatraemia)

MAGNESIUM HYDROXIDE 8% MIXTURE

Magnesium hydroxide paste 29%	275 g
Methyl hydroxybenzoate	1.5 g
Water	to 1,000 ml

VANCOMYCIN ORAL SOLUTION (50 mg per ml)

Vancomycin 500 mg injection	10 vials
Glycerol BP	40 ml
Water	to 100 ml

METHADONE MIXTURE

Methadone powder	qs
Glycerol	qs
Water	to 100 ml

(Only funded if prescribed for treatment of Clostridium difficile following metronidazole failure)

METHYL HYDROXYBENZOATE 10% SOLUTION

Methyl hydroxybenzoate	10 g
Propylene glycol	to 100 ml

(Use 1 ml of the 10% solution per 100 ml of oral liquid mixture)

VOSOL EAR DROPS

WITH HYDROCORTISONE POWDER 1%

Hydrocortisone powder	1%
Vosol Ear Drops	to 35 ml

OMEPRAZOLE SUSPENSION

Omeprazole capules or powder	qs
Sodium bicarbonate powder BP	8.4 g
Water	to 100 ml

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Extemporaneously Compounded Preparations and Galenicals

CHLOROFORM

- a) Only in combination
- b) Maximum of 100 ml per prescription
- c) Only in aspirin and chloroform application.
- d) Note: This product is no longer being manufactured by the supplier and will be delisted from the Schedule at a date to be determined.

Chloroform BP25.50 500 ml ✓ **PSM**

(PSM Chloroform BP to be delisted 1 November 2020)

CODEINE PHOSPHATE – Safety medicine; prescriber may determine dispensing frequency

Powder – Only in combination63.09 25 g
(90.09) Douglas

Only in extemporaneously compounded codeine linctus.

COLLODION FLEXIBLE

Note: This product is no longer being manufactured by the supplier and will be delisted from the Schedule at a date to be determined.

Collodion flexible19.30 100 ml ✓ **PSM**

COMPOUND HYDROXYBENZOATE – Only in combination

Only in extemporaneously compounded oral mixtures.

Soln30.00 100 ml ✓ Midwest

GLYCERIN WITH SODIUM SACCHARIN – Only in combination

Only in combination with Ora-Plus.

Suspension30.95 473 ml ✓ Ora-Sweet SF

GLYCERIN WITH SUCROSE – Only in combination

Only in combination with Ora-Plus.

Suspension30.95 473 ml ✓ Ora-Sweet

GLYCEROL

- * Liquid – Only in combination3.23 500 ml ✓ **healthE Glycerol BP**
 - a) Only in extemporaneously compounded oral liquid preparations.
 - b) healthE Glycerol BP to be Sole Supply on 1 October 2020

MAGNESIUM HYDROXIDE

Paste 29%22.61 500 g ✓ **PSM**

(PSM Paste 29% to be delisted 1 January 2021)

METHADONE HYDROCHLORIDE

- a) Only on a controlled drug form
- b) No patient co-payment payable
- c) Safety medicine; prescriber may determine dispensing frequency
- d) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets).

Powder7.84 1 g ✓ **AFT**

METHYL HYDROXYBENZOATE

Powder8.98 25 g ✓ Midwest

METHYLCELLULOSE

Powder36.95 100 g ✓ MidWest

Suspension – Only in combination30.95 473 ml ✓ Ora-Plus

METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN – Only in combination

Suspension30.95 473 ml ✓ Ora-Blend SF

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

* Three months or six months, as applicable, dispensed all-at-once

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE – Only in combination				
Suspension.....	30.95	473 ml	✓	<u>Ora-Blend</u>
PHENOBARBITONE SODIUM				
Powder – Only in combination.....	52.50	10 g	✓	<u>MidWest</u>
	325.00	100 g	✓	<u>MidWest</u>
Only in children up to 12 years				
PROPYLENE GLYCOL				
Only in extemporaneously compounded methyl hydroxybenzoate 10% solution.				
Liq.....	11.25	500 ml	✓	<u>Midwest</u>
SODIUM BICARBONATE				
Powder BP – Only in combination.....	10.05	500 g	✓	<u>Midwest</u>
Only in extemporaneously compounded omeprazole and lansoprazole suspension.				
SYRUP (PHARMACEUTICAL GRADE) – Only in combination				
Only in extemporaneously compounded oral liquid preparations.				
Liq.....	14.95	500 ml	✓	<u>Midwest</u>
WATER				
Tap – Only in combination.....	0.00	1 ml	✓	<u>Tap water</u>

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per ✓	

Nutrient Modules

Carbohydrate

►SA1930 Special Authority for Subsidy

Initial application — (Cystic fibrosis or kidney disease) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- Either:
- 1 cystic fibrosis; or
 - 2 chronic kidney disease.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Any of the following:
- 1 cancer in children; or
 - 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
 - 3 faltering growth in an infant/child; or
 - 4 bronchopulmonary dysplasia; or
 - 5 premature and post premature infant; or
 - 6 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified where the patient has inborn errors of metabolism.

Renewal — (Cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE SUPPLEMENT – Special Authority see SA1930 above – Hospital pharmacy [HP3]
Powder5.29 400 g OP ✓ Polycal

Carbohydrate And Fat

►SA1376 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1 Infant or child aged four years or under; and
- 2 cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 infant or child aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children; or
 - 2.2 faltering growth; or
 - 2.3 bronchopulmonary dysplasia; or
 - 2.4 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE AND FAT SUPPLEMENT – Special Authority see [SA1376 on the previous page](#) – Hospital pharmacy [HP3]

Powder (neutral)	60.31	400 g OP	✓ Duocal Super Soluble Powder
------------------------	-------	----------	----------------------------------

Fat

»SA1523 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 faltering growth in an infant/child; or
- 2 bronchopulmonary dysplasia; or
- 3 fat malabsorption; or
- 4 lymphangiectasia; or
- 5 short bowel syndrome; or
- 6 infants with necrotising enterocolitis; or
- 7 biliary atresia; or
- 8 for use in a ketogenic diet; or
- 9 chyle leak; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

10 ascites; or

11 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Renewal — (Inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner.

Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT SUPPLEMENT – Special Authority see [SA1523 on the previous page](#) – Hospital pharmacy [HP3]

Emulsion (neutral)	12.30	200 ml OP	✓ Calogen
	30.75	500 ml OP	✓ Calogen
Emulsion (strawberry).....	12.30	200 ml OP	✓ Calogen
Oil	30.00	500 ml OP	✓ MCT oil (Nutricia)
Oil, 250 ml	114.92	4 OP	✓ Liquigen

Protein

► [SA1524](#) Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 protein losing enteropathy; or
- 2 high protein needs; or
- 3 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEMENT – Special Authority see [SA1524 above](#) – Hospital pharmacy [HP3]

Powder	7.90	225 g OP	✓ Protifar
	8.95	227 g OP	✓ Resource Beneprotein

Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed)

Respiratory Products

►SA1094 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has CORD and hypercapnia, defined as a CO₂ value exceeding 55 mmHg.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CORD ORAL FEED 1.5KCAL/ML – Special Authority see [SA1094 above](#) – Hospital pharmacy [HP3]

Liquid.....	1.66	237 ml OP	✓ Pulmocare
-------------	------	-----------	-------------

(Pulmocare Liquid to be delisted 1 October 2020)

Diabetic Products

►SA1095 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see [SA1095 above](#) – Hospital pharmacy [HP3]

Liquid.....	7.50	1,000 ml OP	✓ Diason RTH
			✓ Glucerna Select RTH

DIABETIC ORAL FEED 1KCAL/ML – Special Authority see [SA1095 above](#) – Hospital pharmacy [HP3]

Liquid (strawberry).....	1.50	200 ml OP	✓ Diasip
Liquid (vanilla)	1.50	200 ml OP	✓ Diasip
	1.88	250 ml OP	✓ Glucerna Select
	1.78	237 ml OP	
	(2.10)		Resource Diabetic
	(2.10)		Sustagen Diabetic

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Fat Modified Products

►SA1525 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:
Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or
- 3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED – Special Authority see SA1525 above – Hospital pharmacy [HP3]
Powder60.48 400 g OP ✓ Monogen

Paediatric Products For Children Awaiting Liver Transplant

►SA1098 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who requires a liver transplant.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA1098 above – Hospital pharmacy [HP3]
Powder (unflavoured)78.97 400 g OP ✓ Heparon Junior

Paediatric Products For Children With Chronic Renal Failure

►SA1099 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- Both:
- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA1099 on the previous page – Hospital pharmacy [HP3]				
Liquid.....	54.00	400 g OP	✓	Kindergen

Paediatric Products

► **SA1379** Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
 - 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 any condition causing malabsorption; or
 - 2.3 faltering growth in an infant/child; or
 - 2.4 increased nutritional requirements; or
 - 2.5 the child is being transitioned from TPN or tube feeding to oral feeding.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]				
Liquid.....	6.00	500 ml OP	✓	Nutrini Energy RTH
PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]				
Liquid.....	2.68	500 ml OP	✓	Nutrini RTH
			✓	Pediasure RTH
PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]				
Liquid.....	6.00	500 ml OP	✓	Nutrini Energy Multi Fibre
PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]				
Liquid (strawberry).....	1.60	200 ml OP	✓	Fortini
Liquid (vanilla).....	1.60	200 ml OP	✓	Fortini
PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]				
Liquid (chocolate).....	1.07	200 ml OP	✓	Pediasure
Liquid (strawberry).....	1.07	200 ml OP	✓	Pediasure
Liquid (vanilla).....	1.07	200 ml OP	✓	Pediasure
	1.34	250 ml OP	✓	Pediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1379 above – Hospital pharmacy [HP3]				
Liquid (unflavoured).....	1.60	200 ml OP	✓	Fortini Multi Fibre
Liquid (chocolate).....	1.60	200 ml OP	✓	Fortini Multi Fibre
Liquid (strawberry).....	1.60	200 ml OP	✓	Fortini Multi Fibre
Liquid (vanilla).....	1.60	200 ml OP	✓	Fortini Multi Fibre
PEPTIDE-BASED ORAL FEED – Special Authority see SA1379 above – Hospital pharmacy [HP3]				
Powder.....	43.60	400 g OP	✓	Peptamen Junior

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Renal Products

►SA1101 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

RENAL ENTERAL FEED 1.8 KCAL/ML – Special Authority see [SA1101 above](#) – Hospital pharmacy [HP3]

Liquid	6.08	500 ml OP	✓ Nepro HP RTH
--------------	------	-----------	----------------

RENAL ORAL FEED 1.8 KCAL/ML – Special Authority see [SA1101 above](#) – Hospital pharmacy [HP3]

Liquid	2.67	220 ml OP	✓ Nepro HP (strawberry) ✓ Nepro HP (vanilla)
--------------	------	-----------	--

RENAL ORAL FEED 2 KCAL/ML – Special Authority see [SA1101 above](#) – Hospital pharmacy [HP3]

Liquid	2.88 (3.31)	237 ml OP	NovaSource Renal
Liquid (apricot) 125 ml	11.52	4 OP	✓ Renilon 7.5
Liquid (caramel) 125 ml	11.52	4 OP	✓ Renilon 7.5

Specialised And Elemental Products

►SA1377 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 malabsorption; or
- 2 short bowel syndrome; or
- 3 enterocutaneous fistulas; or
- 4 eosinophilic oesophagitis; or
- 5 inflammatory bowel disease; or
- 6 patients with multiple food allergies requiring enteral feeding.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL SEMI-ELEMENTAL FEED 1.5KCAL/ML – Special Authority see [SA1377 above](#) – Hospital pharmacy [HP3]

Liquid	18.06	1,000 ml OP	✓ Vital
--------------	-------	-------------	---------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see SA1377 on the previous page – Hospital pharmacy [HP3]				
Liquid (grapefruit), 250 ml carton.....	171.00	18 OP	✓	Elemental 028 Extra
Liquid (pineapple & orange), 250 ml carton.....	171.00	18 OP	✓	Elemental 028 Extra
Liquid (summer fruits), 250 ml carton.....	171.00	18 OP	✓	Elemental 028 Extra
ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA1377 on the previous page – Hospital pharmacy [HP3]				
Powder (unflavoured)	4.50	80 g OP	✓	Vivonex TEN
SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Authority see SA1377 on the previous page – Hospital pharmacy [HP3]				
Liquid.....	12.04	1,000 ml OP	✓	Peptisorb

Paediatric Products For Children With Low Energy Requirements

»SA1196 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child aged one to eight years; and
- 2 The child has a low energy requirement but normal protein and micronutrient requirements.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 KCAL/ML – Special Authority see [SA1196 above](#) – Hospital pharmacy [HP3]

Liquid.....	4.00	500 ml OP	✓	Nutrini Low Energy Multi Fibre
-------------	------	-----------	---	---

Standard Supplements

»SA1859 Special Authority for Subsidy

Initial application — (Children - indications other than exclusive enteral nutrition for Crohn's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
 - 2.1 The patient has a condition causing malabsorption; or
 - 2.2 The patient has failure to thrive; or
 - 2.3 The patient has increased nutritional requirements; and
- 3 Nutrition goal has been set (eg reach a specific weight or BMI).

Renewal — (Children - indications other than exclusive enteral nutrition for Crohn's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

continued...

- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

Initial application — (Children - exclusive enteral nutrition for Crohn's disease) only from a gastroenterologist or dietitian on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 Dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

Renewal — (Children - exclusive enteral nutrition for Crohn's disease) from any relevant practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 General Practitioners and dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

Initial application — (Adults) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - Patient is Malnourished
 - 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m²; or
 - 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 1.3 Patient has a BMI of less than 20 kg/m² and unintentional weight loss greater than 5% within the last 3-6 months; and
- 2 Any of the following:
 - Patient has not responded to first-line dietary measures over a 4 week period by:
 - 2.1 Increasing their food intake frequency (eg snacks between meals); or
 - 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
 - 2.3 Using over the counter supplements (e.g. Complan); and
- 3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

Renewal — (Adults) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 2 Any of the following:
 - Patient is Malnourished
 - 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m²; or
 - 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 2.3 Patient has a BMI of less than 20 kg/m² and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Short-term medical condition) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Is undergoing a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:
 - 5.1 Pregnant; and

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

5.2 Any of the following:

- 5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or
- 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
- 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Renewal — (Short-term medical condition) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Has undergone a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:

5.1 Pregnant; and

5.2 Any of the following:

- 5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or
- 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
- 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Initial application — (Long-term medical condition) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions; or
- 10 Epidermolysis bullosa; or
- 11 AIDS (CD4 count < 200 cells/mm³); or
- 12 Chronic pancreatitis.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
continued...			
1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube - refer to specific medical condition criteria); or			
2 Cystic Fibrosis; or			
3 Liver disease; or			
4 Chronic Renal failure; or			
5 Inflammatory bowel disease; or			
6 Chronic obstructive pulmonary disease with hypercapnia; or			
7 Short bowel syndrome; or			
8 Bowel fistula; or			
9 Severe chronic neurological conditions.			
ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1859 on page 258 – Hospital pharmacy [HP3]			
Liquid.....	7.00	1,000 ml OP	✓ Nutrison Energy
ENTERAL FEED 1KCAL/ML – Special Authority see SA1859 on page 258 – Hospital pharmacy [HP3]			
Liquid.....	1.24	250 ml OP	✓ Isosource Standard
	5.29	1,000 ml OP	✓ Nutrison Standard RTH
			✓ Osmolite RTH
ENTERAL FEED WITH FIBRE 0.83 KCAL/ML – Special Authority see SA1859 on page 258 – Hospital pharmacy [HP3]			
Liquid.....	5.29	1,000 ml OP	✓ Nutrison 800 Complete Multi Fibre
ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA1859 on page 258 – Hospital pharmacy [HP3]			
Liquid.....	5.29	1,000 ml OP	✓ Jevity RTH
			✓ Nutrison Multi Fibre
ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1859 on page 258 – Hospital pharmacy [HP3]			
Liquid.....	1.75	250 ml OP	✓ Ensure Plus HN
	7.00	1,000 ml OP	✓ Ensure Plus RTH
			✓ Jevity HiCal RTH
			✓ Nutrison Energy Multi Fibre
ORAL FEED (POWDER) – Special Authority see SA1859 on page 258 – Hospital pharmacy [HP3]			
Note: Higher subsidy for Sustagen Hospital Formula will only be reimbursed for patients with both a valid Special Authority number and an appropriately endorsed prescription.			
Powder (chocolate) – Higher subsidy of up to \$26.00 per 850 g			
with Endorsement.....	26.00	850 g OP	✓ Ensure
	9.54	840 g OP	
	(26.00)		Sustagen Hospital Formula Active
Additional subsidy by endorsement is available for patients with fat malabsorption, fat intolerance or chyle leak. The prescription must be endorsed accordingly.			
Powder (vanilla) – Higher subsidy of up to \$26.00 per 850 g			
with Endorsement.....	8.54	857 g OP	✓ Fortisip
	26.00	850 g OP	✓ Ensure
	9.54	840 g OP	
	(26.00)		Sustagen Hospital Formula Active
Additional subsidy by endorsement is available for patients with fat malabsorption, fat intolerance or chyle leak. The prescription must be endorsed accordingly.			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ORAL FEED 1.5KCAL/ML – Special Authority see SA1859 on page 258 – Hospital pharmacy [HP3]				
Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, who have severe epidermolysis bullosa, or as exclusive enteral nutrition in children under the age of 18 years for the treatment of Crohn's disease, or for patients with COPD and hypercapnia, defined as CO2 value exceeding 55mmHg. The prescription must be endorsed accordingly.				
Liquid (banana) – Higher subsidy of \$1.26 per 200 ml with				
Endorsement	0.72 (1.26) (1.26)	200 ml OP		Ensure Plus Fortisip
Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with				
Endorsement	0.72 (1.26) (1.26)	200 ml OP		Ensure Plus Fortisip
Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml with				
Endorsement	0.72 (1.26)	200 ml OP		Ensure Plus
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with				
Endorsement	0.72 (1.26)	200 ml OP		Fortisip
Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml with				
Endorsement	0.85 (1.33) 0.72 (1.26) (1.26)	237 ml OP 200 ml OP		Ensure Plus Ensure Plus Fortisip
ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA1859 on page 258 – Hospital pharmacy [HP3]				
Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly.				
Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with				
Endorsement	0.72 (1.26)	200 ml OP		Fortisip Multi Fibre
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with				
Endorsement	0.72 (1.26)	200 ml OP		Fortisip Multi Fibre
Liquid (vanilla) – Higher subsidy of \$1.26 per 200 ml with				
Endorsement	0.72 (1.26)	200 ml OP		Fortisip Multi Fibre

High Calorie Products

► [SA1195](#) Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner.
Approvals valid for 3 years for applications meeting the following criteria:
All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 faltering growth in an infant/child; or
 - 1.3 increased nutritional requirements; or
 - 1.4 fluid restricted; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements or is fluid restricted.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL FEED 2 KCAL/ML – Special Authority see [SA1195 on the previous page](#) – Hospital pharmacy [HP3]

Liquid.....	5.50	500 ml OP	✓ Nutrison Concentrated
	11.00	1,000 ml OP	✓ Two Cal HN RTH

ORAL FEED 2 KCAL/ML – Special Authority see [SA1195 on the previous page](#) – Hospital pharmacy [HP3]

Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidermolysis bullosa. The prescription must be endorsed accordingly.

Liquid (vanilla) – Higher subsidy of \$1.90 per 200 ml with

Endorsement.....	0.96 (1.90)	200 ml OP	Two Cal HN
------------------	----------------	-----------	------------

Food Thickeners

► [SA1106](#) Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has motor neurone disease with swallowing disorder.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
FOOD THICKENER – Special Authority see SA1106 on the previous page – Hospital pharmacy [HP3]			
Powder	6.53	300 g OP	✓ Nutilis
	7.25	380 g OP	✓ Feed Thickener Karicare Aptamil

Gluten Free Foods

The funding of gluten free foods is no longer being actively managed by PHARMAC from 1 April 2011. This means that we are no longer considering the listing of new products, or making subsidy, or other changes to the existing listings. As a result we anticipate that the range of funded items will reduce over time. Management of Coeliac disease with a gluten free diet is necessary for good outcomes. A range of gluten free options are available through retail outlets.

»SA1729 Special Authority for Subsidy

Initial application — (all patients) only from a dietitian, relevant specialist or vocationally registered general practitioner.

Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Gluten enteropathy has been diagnosed by biopsy; or
- 2 Patient suffers from dermatitis herpetiformis.

Initial application — (paediatric patients diagnosed by ESPGHAN criteria) only from a paediatric gastroenterologist.

Approvals valid without further renewal unless notified where the paediatric patient fulfils ESPGHAN criteria for biopsy free diagnosis of coeliac disease.

GLUTEN FREE BAKING MIX – Special Authority see [SA1729 above](#) – Hospital pharmacy [HP3]

Powder	2.81	1,000 g OP	
	(5.15)		Healtheries Simple Baking Mix

GLUTEN FREE BREAD MIX – Special Authority see [SA1729 above](#) – Hospital pharmacy [HP3]

Powder	3.93	1,000 g OP	
	(7.32)		NZB Low Gluten Bread Mix
	3.51		
	(10.87)		Horleys Bread Mix

GLUTEN FREE FLOUR – Special Authority see [SA1729 above](#) – Hospital pharmacy [HP3]

Powder	5.62	2,000 g OP	
	(18.10)		Horleys Flour

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
GLUTEN FREE PASTA – Special Authority see SA1729 on the previous page – Hospital pharmacy [HP3]			
Buckwheat Spirals.....	2.00 (3.11)	250 g OP	Orgran
Corn and Vegetable Shells.....	2.00 (2.92)	250 g OP	Orgran
Corn and Vegetable Spirals.....	2.00 (2.92)	250 g OP	Orgran
Rice and Corn Lasagne Sheets.....	1.60 (3.82)	200 g OP	Orgran
Rice and Corn Macaroni.....	2.00 (2.92)	250 g OP	Orgran
Rice and Corn Penne	2.00 (2.92)	250 g OP	Orgran
Rice and Maize Pasta Spirals.....	2.00 (2.92)	250 g OP	Orgran
Rice and Millet Spirals.....	2.00 (3.11)	250 g OP	Orgran
Rice and corn spaghetti noodles	2.00 (2.92)	375 g OP	Orgran
Vegetable and Rice Spirals	2.00 (2.92)	250 g OP	Orgran
Italian long style spaghetti	2.00 (3.11)	220 g OP	Orgran

Foods And Supplements For Inborn Errors Of Metabolism

►SA1108 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Dietary management of homocystinuria; or
- 2 Dietary management of maple syrup urine disease; or
- 3 Dietary management of phenylketonuria (PKU); or
- 4 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE – Special Authority see [SA1108 above](#) – Hospital pharmacy [HP3]

Powder461.94 500 g OP ✓ **XMET Maxamum**

Supplements For MSUD

AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE – Special Authority see [SA1108 above](#) – Hospital pharmacy [HP3]

Powder437.22 500 g OP ✓ **MSUD Maxamum**

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

Supplements For PKU

AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see [SA1108 on the previous page](#) – Hospital pharmacy [HP3]

Tabs.....	99.00	75 OP	✓ Phlexy 10
Powder (chocolate) 36 g sachet.....	393.00	30	✓ PKU Anamix Junior Chocolate
Powder (unflavoured) 27.8 g sachets.....	936.00	30	✓ PKU Lophlex Powder
Powder (unflavoured) 28 g sachets.....	936.00	30	✓ PKU Lophlex Powder
Powder (unflavoured) 36 g sachets.....	393.00	30	✓ PKU Anamix Junior
Powder (vanilla) 36 g sachet.....	393.00	30	✓ PKU Anamix Junior Vanilla
Infant formula.....	174.72	400 g OP	✓ PKU Anamix Infant
Powder (orange).....	320.00	500 g OP	✓ XP Maxamum
Powder (unflavoured).....	320.00	500 g OP	✓ XP Maxamum
Liquid (berry).....	13.10	125 ml OP	✓ PKU Anamix Junior LQ
Liquid (orange).....	13.10	125 ml OP	✓ PKU Anamix Junior LQ
Liquid (unflavoured).....	13.10	125 ml OP	✓ PKU Anamix Junior LQ
Liquid (forest berries), 250 ml carton.....	540.00	18 OP	✓ Easiphen Liquid
Liquid (juicy tropical) 125 ml.....	936.00	30 OP	✓ PKU Lophlex LQ 20
Oral semi-solid (berries) 109 g.....	1,123.20	36 OP	✓ PKU Lophlex Sensation 20
Liquid (juicy berries) 62.5 ml.....	939.00	60 OP	✓ PKU Lophlex LQ 10
Liquid (juicy citrus) 62.5 ml.....	939.00	60 OP	✓ PKU Lophlex LQ 10
Liquid (juicy orange) 62.5 ml.....	939.00	60 OP	✓ PKU Lophlex LQ 10
Liquid (juicy berries) 125 ml.....	936.00	30 OP	✓ PKU Lophlex LQ 20
Liquid (juicy orange) 125 ml.....	936.00	30 OP	✓ PKU Lophlex LQ 20

(PKU Lophlex Powder Powder (unflavoured) 27.8 g sachets to be delisted 1 March 2021)

Foods

LOW PROTEIN BAKING MIX – Special Authority see [SA1108 on the previous page](#) – Hospital pharmacy [HP3]

Powder.....	8.22	500 g OP	✓ Loprofin Mix
-------------	------	----------	----------------

LOW PROTEIN PASTA – Special Authority see [SA1108 on the previous page](#) – Hospital pharmacy [HP3]

Animal shapes.....	11.91	500 g OP	✓ Loprofin
Lasagne.....	5.95	250 g OP	✓ Loprofin
Low protein rice pasta.....	11.91	500 g OP	✓ Loprofin
Macaroni.....	5.95	250 g OP	✓ Loprofin
Penne.....	11.91	500 g OP	✓ Loprofin
Spaghetti.....	11.91	500 g OP	✓ Loprofin
Spirals.....	11.91	500 g OP	✓ Loprofin

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

Infant Formulae

For Williams Syndrome

►SA1110 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

LOW CALCIUM INFANT FORMULA – Special Authority see SA1110 above – Hospital pharmacy [HP3]

Powder	44.40	400 g OP	✓ Locasol
--------------	-------	----------	-----------

Gastrointestinal and Other Malabsorptive Problems

AMINO ACID FORMULA – Special Authority see SA1940 below – Hospital pharmacy [HP3]

Powder	43.60	400 g OP	✓ Alfamino Junior
Powder (unflavoured)	53.00	400 g OP	✓ Elecare
			✓ Elecare LCP
			✓ Neocate Gold
			✓ Neocate Junior
			Unflavoured
			✓ Neocate SYNEO
Powder (vanilla).....	53.00	400 g OP	✓ Elecare
			✓ Neocate Junior
			Vanilla

►SA1940 Special Authority for Subsidy

Initial application — (Infants under 12 months of age) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 History of anaphylaxis to cow's milk protein formula or dairy products; or
- 2 Eosinophilic oesophagitis; or
- 3 Ultra-short gut; or
- 4 Severe Immune deficiency; or
- 5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or
- 6 Both:
 - 6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and
 - 6.2 Either:
 - 6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval number; or
 - 6.2.2 Patient has IgE mediated allergy.

Initial application — (Children 12 months of age and over) only from a paediatrician, paediatric gastroenterologist, paediatric immunologist or dietitian on the recommendation of a paediatrician, paediatric gastroenterologist or paediatric immunologist.

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Applicant is a paediatrician, paediatric gastroenterologist or paediatric immunologist; or
 - 1.2 Applicant is a dietitian and confirms that a paediatrician, paediatric gastroenterologist or paediatric immunologist has been consulted within the last 12 months and has recommended treatment for the patient; and
- 2 Any of the following:
 - 2.1 History of anaphylaxis to cow's milk protein formula or dairy products; or
 - 2.2 Eosinophilic oesophagitis; or
 - 2.3 Ultra-short gut; or
 - 2.4 Severe Immune deficiency; or
 - 2.5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or
 - 2.6 Both:
 - 2.6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and
 - 2.6.2 Either:
 - 2.6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval number; or
 - 2.6.2.2 Patient has IgE mediated allergy.

Renewal — (Infants up to 12 months of age) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 Patient has IgE mediated allergy; and
 - 1.2 All of the following:
 - 1.2.1 Patient remains allergic to cow's milk; and
 - 1.2.2 An assessment as to whether the infant can be transitioned to a cow's milk protein, soy or extensively hydrolysed infant formula has been undertaken; and
 - 1.2.3 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
 - 1.2.4 Amino acid formula is required for a nutritional deficit; and
 - 1.2.5 It has been more than three months from the previous approval; or
- 2 Both:
 - 2.1 Patient has non IgE mediated severe gastrointestinal intolerance (including eosinophilic oesophagitis, ultra-short gut and severe immune deficiency); and
 - 2.2 All of the following:
 - 2.2.1 An assessment as to whether the infant can be transitioned to a cow's milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
 - 2.2.2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
 - 2.2.3 Amino acid formula is required for a nutritional deficit; and
 - 2.2.4 It has been more than three months from the previous approval.

Renewal — (Children 12 months of age and over) only from a paediatrician, paediatric gastroenterologist, paediatric immunologist or dietitian on the recommendation of a paediatrician, paediatric gastroenterologist or paediatric immunologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Applicant is a paediatrician, paediatric gastroenterologist or paediatric immunologist; or

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

1.2 Applicant is a dietitian and confirms that a paediatrician, paediatric gastroenterologist or paediatric immunologist has been consulted within the last 12 months and has recommended treatment for the patient; and

2 Any of the following:

2.1 History of anaphylaxis to cow's milk protein formula or dairy products; or

2.2 Eosinophilic oesophagitis; or

2.3 Ultra-short gut; or

2.4 Severe Immune deficiency; or

2.5 Extensively hydrolysed formula has been trialled in an inpatient setting and is clinically inappropriate; or

2.6 Both:

2.6.1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; and

2.6.2 Either:

2.6.2.1 The patient has a valid Special Authority approval for extensively hydrolysed formula: approval number; or

2.6.2.2 Patient has IgE mediated allergy.

ENTERAL LIQUID PEPTIDE FORMULA – Special Authority see [SA1953 below](#) – Hospital pharmacy [HP3]

Liquid 1 kcal/ml.....	10.45	500 ml OP	✓ Nutrini Peptisorb
-----------------------	-------	-----------	----------------------------

Liquid 1.5 kcal/ml.....	15.68	500 ml OP	✓ Nutrini Peptisorb Energy
-------------------------	-------	-----------	-----------------------------------

►SA1953 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable; and

2 Any of the following:

2.1 Severe malabsorption; or

2.2 Short bowel syndrome; or

2.3 Intractable diarrhoea; or

2.4 Biliary atresia; or

2.5 Cholestatic liver diseases causing malabsorption; or

2.6 Cystic fibrosis; or

2.7 Proven fat malabsorption; or

2.8 Severe intestinal motility disorders causing significant malabsorption; or

2.9 Intestinal failure; or

2.10 Both:

2.10.1 The patient is currently receiving funded amino acid formula; and

2.10.2 The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula; and

3 Either:

3.1 A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable; or

3.2 For step down from intravenous nutrition.

Note: A reasonable trial is defined as a 2-4 week trial.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1 An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken; and
- 2 The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula; and
- 3 General practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

EXTENSIVELY HYDROLYSED FORMULA – Special Authority see [SA1557 below](#) – Hospital pharmacy [HP3]

Powder	15.21	450 g OP	✓	Aptamil Gold+ Pepti Junior
	30.42	900 g OP	✓	Allerpro 1
			✓	Allerpro 2

►SA1557 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure; or
- 11 All of the following:
 - 11.1 For step down from Amino Acid Formula; and
 - 11.2 The infant is currently receiving funded amino acid formula; and
 - 11.3 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
 - 11.4 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Fluid Restricted

PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML – Special Authority see [SA1698 on the next page](#) – Hospital pharmacy [HP3]

Liquid	2.35	125 ml OP	✓	Infatrin1
--------------	------	-----------	---	------------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
---	------------------------------	-------------------------------------

►SA1698 Special Authority for Subsidy

Initial application only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is fluid restricted or volume intolerant and has been diagnosed with faltering growth; and
- 2 Patient is under the care of a paediatrician or dietitian who has recommended treatment with a high energy infant formula; and
- 3 Patient is under 18 months of age or weighs less than 8 kg.

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Renewal only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian.

Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient continues to be fluid restricted or volume intolerant and has faltering growth; and
- 2 Patient is under the care of a hospital paediatrician or dietitian who has recommended treatment with a high energy infant formula; and
- 3 Patient is under 18 months of age or weighs less than 8 kg.

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Ketogenic Diet

►SA1197 Special Authority for Subsidy

Initial application only from a metabolic physician or paediatric neurologist. Approvals valid for 3 months where the patient has intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

Renewal only from a metabolic physician or paediatric neurologist. Approvals valid for 2 years where the patient is on a ketogenic diet and the patient is benefiting from the diet.

HIGH FAT LOW CARBOHYDRATE FORMULA – Special Authority see [SA1197 above](#) – Retail pharmacy

Powder (unflavoured)	35.50	300 g OP	✓ KetoCal 4:1
			✓ Ketocal 3:1
Powder (vanilla).....	35.50	300 g OP	✓ KetoCal 4:1

SECTION I: NATIONAL IMMUNISATION SCHEDULE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Vaccinations				
ADULT DIPHTHERIA AND TETANUS VACCINE – [Xpharm]				
Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml.....	0.00	5	✓	ADT Booster
Any of the following:				
1) For vaccination of patients aged 45 and 65 years old; or				
2) For vaccination of previously unimmunised or partially immunised patients; or				
3) For revaccination following immunosuppression; or				
4) For boosting of patients with tetanus-prone wounds; or				
5) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.				
Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.				
<i>(ADT Booster Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml to be delisted 1 October 2020)</i>				
BACILLUS CALMETTE-GUERIN VACCINE – [Xpharm]				
For infants at increased risk of tuberculosis. Increased risk is defined as:				
1) living in a house or family with a person with current or past history of TB; or				
2) having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; or				
3) during their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000				
Note a list of countries with high rates of TB are available at www.health.govt.nz/tuberculosis (search for downloads) or www.bcgatlas.org/index.php .				
Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial with diluent.....	0.00	10	✓	BCG Vaccine
BCG Vaccine to be Sole Supply on 1 October 2020				
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – [Xpharm]				
Funded for any of the following criteria:				
1) A single dose for pregnant women in the second or third trimester of each pregnancy; or				
2) A single dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days, who had not been exposed to maternal vaccination at least 14 days prior to birth; or				
3) A course of up to four doses is funded for children from age 7 up to the age of 18 years inclusive to complete full primary immunisation; or				
4) An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or				
5) A single dose for vaccination of patients aged 65 years old; or				
6) A single dose for vaccination of patients aged 45 years old who have not had 4 previous tetanus doses; or				
7) For vaccination of previously unimmunised or partially immunised patients; or				
8) For revaccination following immunosuppression; or				
9) For boosting of patients with tetanus-prone wounds.				
Notes: Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.				
Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe	0.00	10	✓	Boostrix
		1	✓	Boostrix
Boostrix to be Sole Supply on 1 October 2020				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – [Xpharm]

Funded for any of the following:

- 1) A single dose for children up to the age of 7 who have completed primary immunisation; or
- 2) A course of four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
- 3) An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 4) Five doses will be funded for children requiring solid organ transplantation.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5ml syringe	0.00	10	✓ Infanrix IPV
Infanrix IPV to be Sole Supply on 1 October 2020			

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE – [Xpharm]

Funded for patients meeting any of the following criteria:

- 1) Up to four doses for children up to and under the age of 10 for primary immunisation; or
- 2) An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 3) Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Inj 30IU diphtheriattoxoid with 40IU tetanustoxoid, 25mcg pertussistoxoid, 25mcg pertussisfilamentoushaemagglutinin, 8 mcgpertactin, 80 D-AgUpoliiovirus, 10mcghepatitisBsurfaceantigen in 0.5ml syringe	0.00	10	✓ Infanrix-hexa
Infanrix-hexa to be Sole Supply on 1 October 2020			

HAEMOPHILUS INFLUENZAE TYPE B VACCINE – [Xpharm]

One dose for patients meeting any of the following:

- 1) For primary vaccination in children; or
- 2) An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or
- 3) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml.....	0.00	1	✓ Hiberix
--	------	---	------------------

NATIONAL IMMUNISATION SCHEDULE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
HEPATITIS A VACCINE – [Xpharm]				
Funded for patients meeting any of the following criteria:				
1) Two vaccinations for use in transplant patients; or				
2) Two vaccinations for use in children with chronic liver disease; or				
3) One dose of vaccine for close contacts of known hepatitis A cases.				
Inj 1440 ELISA units in 1 ml syringe.....	0.00	1	✓	Havrix
Havrix to be Sole Supply on 1 October 2020				
Inj 720 ELISA units in 0.5 ml syringe.....	0.00	1	✓	Havrix Junior
Havrix Junior to be Sole Supply on 1 October 2020				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
HEPATITIS B RECOMBINANT VACCINE – [Xpharm]			
Inj 5 mcg per 0.5 ml vial.....	0.00	1	✓ HBvaxPRO
Funded for patients meeting any of the following criteria:			
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or			
2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or			
3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or			
4) for HIV positive patients; or			
5) for hepatitis C positive patients; or			
6) for patients following non-consensual sexual intercourse; or			
7) for patients following immunosuppression; or			
8) for solid organ transplant patients; or			
9) for post-haematopoietic stem cell transplant (HSCT) patients; or			
10) following needle stick injury.			
Inj 10 mcg per 1 ml vial.....	0.00	1	✓ HBvaxPRO
Funded for patients meeting any of the following criteria:			
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or			
2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or			
3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or			
4) for HIV positive patients; or			
5) for hepatitis C positive patients; or			
6) for patients following non-consensual sexual intercourse; or			
7) for patients following immunosuppression; or			
8) for solid organ transplant patients; or			
9) for post-haematopoietic stem cell transplant (HSCT) patients; or			
10) following needle stick injury.			
Inj 20 mcg per 1 ml prefilled syringe.....	0.00	1	✓ Engerix-B
a) Funded for patients meeting any of the following criteria:			
1) for household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or			
2) for children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or			
3) for children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or			
4) for HIV positive patients; or			
5) for hepatitis C positive patients; or			
6) for patients following non-consensual sexual intercourse; or			
7) for patients following immunosuppression; or			
8) for solid organ transplant patients; or			
9) for post-haematopoietic stem cell transplant (HSCT) patients; or			
10) following needle stick injury; or			
11) for dialysis patients; or			
12) for liver or kidney transplant patients.			
b) Engerix-B to be Sole Supply on 1 October 2020			
Inj 40 mcg per 1 ml vial.....	0.00	1	✓ HBvaxPRO

NATIONAL IMMUNISATION SCHEDULE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
Funded for any of the following criteria:				
1) for dialysis patients; or				
2) for liver or kidney transplant patient.				
<i>(HBvaxPRO Inj 5 mcg per 0.5 ml vial to be delisted 1 October 2020)</i>				
<i>(HBvaxPRO Inj 10 mcg per 1 ml vial to be delisted 1 October 2020)</i>				
<i>(HBvaxPRO Inj 40 mcg per 1 ml vial to be delisted 1 October 2020)</i>				
HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV] – [Xpharm]				
Any of the following:				
1) Maximum of two doses for children aged 14 years and under; or				
2) Maximum of three doses for patients meeting any of the following criteria:				
1) People aged 15 to 26 years inclusive; or				
2) Either:				
People aged 9 to 26 years inclusive				
1) Confirmed HIV infection; or				
2) Transplant (including stem cell) patients: or				
3) Maximum of four doses for people aged 9 to 26 years inclusive post chemotherapy				
Inj 270 mcg in 0.5 ml syringe.....	0.00	10	✓	Gardasil 9
Gardasil 9 to be Sole Supply on 1 October 2020				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

INFLUENZA VACCINE

Inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine)			
– [Xpharm].....	9.00	1	✓ Afluria Quad Junior (2020 Formulation)

A) INFLUENZA VACCINE – child aged 6 months to 35 months

is available each year for patients aged 6 months to 35 months who meet the following criteria, as set by PHARMAC:

- i) have any of the following cardiovascular diseases
 - a) ischaemic heart disease, or
 - b) congestive heart failure, or
 - c) rheumatic heart disease, or
 - d) congenital heart disease, or
 - e) cerebro-vascular disease; or
- ii) have either of the following chronic respiratory diseases:
 - a) asthma, if on a regular preventative therapy, or
 - b) other chronic respiratory disease with impaired lung function; or
- iii) have diabetes; or
- iv) have chronic renal disease; or
- v) have any cancer, excluding basal and squamous skin cancers if not invasive; or
- vi) have any of the following other conditions:
 - a) autoimmune disease, or
 - b) immune suppression or immune deficiency, or
 - c) HIV, or
 - d) transplant recipients, or
 - e) neuromuscular and CNS diseases/disorders, or
 - f) haemoglobinopathies, or
 - g) on long term aspirin, or
 - h) have a cochlear implant, or
 - i) errors of metabolism at risk of major metabolic decompensation, or
 - j) pre and post splenectomy, or
 - k) down syndrome, or
- vii) have been hospitalised for respiratory illness or have a history of significant respiratory illness;

Unless meeting the criteria set out above, the following conditions are excluded from funding:

- a) asthma not requiring regular preventative therapy,
- b) hypertension and/or dyslipidaemia without evidence of end-organ disease.

- B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine).....	9.00	1	✓ Influvac Tetra (2020 formulation)
	90.00	10	✓ Afluria Quad (2020 Formulation)

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
a) Only on a prescription			
b) No patient co-payment payable			
c)			
A) INFLUENZA VACCINE – people 3 years and over			
is available each year for patients aged 3 years and over who meet the following criteria, as set by PHARMAC:			
a) all people 65 years of age and over; or			
b) people under 65 years of age who:			
i) have any of the following cardiovascular diseases:			
a) ischaemic heart disease, or			
b) congestive heart failure, or			
c) rheumatic heart disease, or			
d) congenital heart disease, or			
e) cerebo-vascular disease; or			
ii) have either of the following chronic respiratory diseases:			
a) asthma, if on a regular preventative therapy, or			
b) other chronic respiratory disease with impaired lung function; or			
iii) have diabetes; or			
iv) have chronic renal disease; or			
v) have any cancer, excluding basal and squamous skin cancers if not invasive; or			
vi) have any of the following other conditions:			
a) autoimmune disease, or			
b) immune suppression or immune deficiency, or			
c) HIV, or			
d) transplant recipients, or			
e) neuromuscular and CNS diseases/disorders, or			
f) haemoglobinopathies, or			
g) are children on long term aspirin, or			
h) have a cochlear implant, or			
i) errors of metabolism at risk of major metabolic decompensation, or			
j) pre and post splenectomy, or			
k) down syndrome, or			
vii) are pregnant; or			
c) children aged four years or less (but over three years) who have been hospitalised for respiratory illness or have a history of significant respiratory illness;			
Unless meeting the criteria set out above, the following conditions are excluded from funding:			
a) asthma not requiring regular preventative therapy,			
b) hypertension and/or dyslipidaemia without evidence of end-organ disease.			
B) Contractors will be entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with their DHB for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.			
C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.			

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

MEASLES, MUMPS AND RUBELLA VACCINE

- a) Only on a prescription
- b) No patient co-payment payable
- c)

A) Measles, mumps and rubella vaccine

A maximum of two doses for any patient meeting the following criteria:

- 1) For primary vaccination in children; or
- 2) For revaccination following immunosuppression; or
- 3) For any individual susceptible to measles, mumps or rubella; or
- 4) A maximum of three doses for children who have had their first dose prior to 12 months.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes. Although a price is listed for the vaccine, doctors can still order measles mumps and rubella vaccine free of charge, as with other Schedule vaccines.

B) Contractors will be entitled to claim payment from the Funder for the supply of measles, mumps and rubella vaccine to patients eligible under the above criteria pursuant to their contract with their DHB for subsidised immunisation, and they may only do so in respect of the measles, mumps and rubella vaccine listed in the Pharmaceutical Schedule.

C) Contractors can only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Inj, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent 0.5 ml	112.50	5	✓ MMR II
	250.00	10	✓ Priorix

Priorix to be Sole Supply on 1 October 2020

MENINGOCOCCAL (GROUPS A, C, Y AND W-135) CONJUGATE VACCINE – [Xpharm]

Either:

A) Any of the following:

- 1) Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
- 2) One dose for close contacts of meningococcal cases; or
- 3) A maximum of two doses for bone marrow transplant patients; or
- 4) A maximum of two doses for patients following immunosuppression*;

B) Both:

- 1) Person is aged between 13 and 25 years, inclusive; and
- 2) Either:

- i) One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons; or
- ii) One dose for individuals who are currently living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons, from 1 December 2019 to 30 November 2020.

Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial	0.00	1	✓ Menactra
---	------	---	------------

Menactra to be Sole Supply on 1 October 2020

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

NATIONAL IMMUNISATION SCHEDULE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

MENINGOCOCCAL C CONJUGATE VACCINE – [Xpharm]

Both:

- 1) The child is under 9 months of age; and
- 2) Any of the following:
 - 1) Up to three doses for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
 - 2) Two doses for close contacts of meningococcal cases; or
 - 3) A maximum of two doses for bone marrow transplant patients; or
 - 4) A maximum of two doses for patients pre- and post-immunosuppression*.

Note: children under nine months of age require two doses 8 weeks apart. Refer to the Immunisation Handbook for booster schedules with meningococcal ACWY vaccine.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Inj 10 mcg in 0.5 ml syringe0.00 1 ✓ **Neisvac-C**

PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE – [Xpharm]

- 1) A primary course of three doses for previously unvaccinated individuals up to the age of 59 months inclusive

Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

Inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5, 6B,

7F, 9V, 14 and 23F; 3 mcg of pneumococcal
polysaccharide serotypes 4, 18C and 19F in 0.5 ml

prefilled syringe0.00 10 ✓ **Synflorix**

Synflorix to be Sole Supply on 1 October 2020

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – [Xpharm]

Any of the following:

- 1) Two doses are funded for high risk children (over the age of 12 months and under 18 years) who have previously received two doses of the primary course of PCV10; or
- 2) Up to an additional four doses (as appropriate) are funded for high risk children aged under 5 years for (re-)immunisation of patients with any of the following:
 - a) on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
 - b) with primary immune deficiencies; or
 - c) with HIV infection; or
 - d) with renal failure, or nephrotic syndrome; or
 - e) who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
 - f) with cochlear implants or intracranial shunts; or
 - g) with cerebrospinal fluid leaks; or
 - h) receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
 - i) with chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
 - j) pre term infants, born before 28 weeks gestation; or
 - k) with cardiac disease, with cyanosis or failure; or
 - l) with diabetes; or
 - m) with Down syndrome; or
 - n) who are pre-or post-splenectomy, or with functional asplenia; or
- 3) Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients 5 years and over with HIV, for patients pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency; or
- 4) For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4,

5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5ml

syringe.....	0.00	10	✓ Prevenar 13
		1	✓ Prevenar 13

NATIONAL IMMUNISATION SCHEDULE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – [Xpharm]				
Either:				
1) Up to three doses (as appropriate) for patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency; or				
2) All of the following:				
a) Patient is a child under 18 years for (re-)immunisation; and				
b) Treatment is for a maximum of two doses; and				
c) Any of the following:				
i) on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or				
ii) with primary immune deficiencies; or				
iii) with HIV infection; or				
iv) with renal failure, or nephrotic syndrome; or				
v) who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or				
vi) with cochlear implants or intracranial shunts; or				
vii) with cerebrospinal fluid leaks; or				
viii) receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or				
ix) with chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or				
x) pre term infants, born before 28 weeks gestation; or				
xi) with cardiac disease, with cyanosis or failure; or				
xii) with diabetes; or				
xiii) with Down syndrome; or				
xiv) who are pre-or post-splenectomy, or with functional asplenia.				
Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype)	0.00	1	✓	Pneumovax 23
Pneumovax 23 to be Sole Supply on 1 October 2020				
POLIOMYELITIS VACCINE – [Xpharm]				
Up to three doses for patients meeting either of the following:				
1) For partially vaccinated or previously unvaccinated individuals; or				
2) For revaccination following immunosuppression.				
Note: Please refer to the Immunisation Handbook for appropriate schedule for catch-up programmes.				
Inj 80D antigen units in 0.5 ml syringe.....	0.00	1	✓	IPOL
IPOL to be Sole Supply on 1 October 2020				
ROTAVIRUS ORAL VACCINE – [Xpharm]				
Maximum of two doses for patients meeting the following:				
1) first dose to be administered in infants aged under 14 weeks of age; and				
2) no vaccination being administered to children aged 24 weeks or over.				
Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator.....	0.00	10	✓	Rotarix
Rotarix to be Sole Supply on 1 October 2020				

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
--	---	------------------------------	-------------------------------------

VARICELLA VACCINE [CHICKENPOX VACCINE] – [Xpharm]

Either:

- 1) Maximum of one dose for primary vaccination for either:
 - a) Any infant born on or after 1 April 2016; or
 - b) For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox), or
- 2) Maximum of two doses for any of the following:
 - a) Any of the following for non-immune patients:
 - i) with chronic liver disease who may in future be candidates for transplantation; or
 - ii) with deteriorating renal function before transplantation; or
 - iii) prior to solid organ transplant; or
 - iv) prior to any elective immunosuppression*, or
 - v) for post exposure prophylaxis who are immune competent inpatients.; or
 - b) For patients at least 2 years after bone marrow transplantation, on advice of their specialist, or
 - c) For patients at least 6 months after completion of chemotherapy, on advice of their specialist, or
 - d) For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist, or
 - e) For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella, or
 - f) For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella, or
 - g) For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

Inj 1350 PFU prefilled syringe	0.00	1	✓ Varivax
		10	✓ Varivax
Varivax to be Sole Supply on 1 October 2020			
Inj 2000 PFU prefilled syringe plus vial	0.00	1	✓ Varilrix
		10	✓ Varilrix

(Varilrix Inj 2000 PFU prefilled syringe plus vial to be delisted 1 October 2020)

(Varilrix Inj 2000 PFU prefilled syringe plus vial to be delisted 1 October 2020)

VARICELLA ZOSTER VIRUS (OKA STRAIN) LIVE ATTENUATED VACCINE [SHINGLES VACCINE] – [Xpharm]

Funded for patients meeting either of the following criteria:

- 1) One dose for all people aged 65 years; or
- 2) One dose for all people aged between 66 and 80 years inclusive from 1 April 2018 and 31 December 2020.

Inj 19,400 PFU prefilled syringe plus vial	0.00	1	✓ Zostavax
		10	✓ Zostavax

Diagnostic Agents

TUBERCULIN PPD [MANTOUX] TEST – [Xpharm]

Inj 5 TU per 0.1 ml, 1 ml vial.....	0.00	1	✓ Tubersol
Tubersol to be Sole Supply on 1 October 2020			

- Symbols -		
UK Synacthen.....	79	
3TC.....	106	
- A -		
A-Scabies.....	68	
Abacavir sulphate.....	105	
Abacavir sulphate with lamivudine.....	105	
Abiraterone acetate.....	177	
Acarbose.....	11	
Accarb.....	11	
Accuretic.....	48	
Accuretic 10.....	48	
Accuretic 20.....	48	
Acetazolamide.....	243	
Acetec.....	47	
Acetic acid with 1, 2- propanediol diacetate and benzethonium.....	241	
Acetic acid with hydroxyquinoline and ricinoleic acid.....	74	
Acetylcysteine.....	246	
Aci-Jel.....	74	
Aciclovir Infection.....	101	
Sensory.....	241	
Acidex.....	6	
Acipimox.....	54	
Acitretin.....	68	
Aclasta.....	114	
Aclin.....	110	
Actemra.....	223	
Actinomycin D.....	164	
Actrapid.....	10	
Actrapid Penfill.....	10	
Acupan.....	122	
Adalat 10.....	52	
Adalat Oros.....	52	
Adalimumab.....	187	
Adapalene.....	61	
Adcortyl.....	79	
Adefin.....	52	
Adefin XL.....	52	
Adefovir dipivoxil.....	100	
Adenuric.....	117	
ADR Cartridge 1.8.....	25	
Adrenaline.....	56	
ADT Booster.....	272	
Adult diphtheria and tetanus vaccine.....	272	
Advantan.....	64	
Advate.....	40	
Adynovate.....	40	
Afinitor.....	231	
Aflibercept.....	197	
Afluria Quad (2020 Formulation).....	277	
Afluria Quad Junior (2020 Formulation).....	277	
AFT Carbimazole.....	81	
AFT-Pyrazinamide.....	99	
Agents Affecting the Renin-Angiotensin System.....	47	
Agents for Parkinsonism and Related Disorders.....	119	
Agents Used in the Treatment of Poisonings.....	246	
Agrylin.....	163	
Agrylin S29.....	163	
Albendazole.....	88	
Albey.....	233	
Albustix.....	76	
Aldurazyme.....	30	
Alecensa.....	170	
Alectinib.....	170	
Alendronate sodium.....	111	
Alendronate sodium with colecalciferol.....	111	
Alfacalcidol.....	34	
Alfamino Junior.....	267	
Alginic acid.....	6	
Alglucosidase alfa.....	28	
Alkeran.....	159	
Alkeran s29.....	159	
Allerpro 1.....	270	
Allerpro 2.....	270	
Allersoothe.....	234	
Allmercap.....	162	
Allopurinol.....	116	
Alpha-Adrenoceptor Blockers.....	47	
Alpha-Keri Lotion.....	66	
Alphamox.....	91	
Alphamox 125.....	91	
Alphamox 250.....	91	
Alprolix.....	38	
Alu-Tab.....	6	
Aluminium hydroxide.....	6	
Alvogen.....	50	
Amantadine hydrochloride.....	119	
Ambrisentan.....	57	
Amiloride hydrochloride.....	53	
Amiloride hydrochloride with furosemide.....	53	
Amiloride hydrochloride with hydrochlorothiazide.....	53	
Aminophylline.....	239	
Amiodarone hydrochloride.....	49	
Amisulpride.....	133	
Amisulpride Mylan.....	133	
Amitriptyline.....	125	
Amlodipine.....	51	
Amneal.....	167	
Amorolfine.....	62	
Amoxicillin.....	91	
Amoxicillin with clavulanic acid.....	91	
Amphotericin B.....	33	
Amsacrine.....	163	
AmsaLyo.....	163	
Amsidine.....	163	
Amzoate.....	31	
Anaesthetics.....	121	
Anafranil.....	125	
Anagrelide hydrochloride.....	163	
Analgesics.....	121	
Anastrozole.....	180	
Andriol Testocaps.....	79	
Androderm.....	79	
Anoro Elipta.....	237	
Antabuse.....	156	
Antacids and Antiflatulents.....	6	
Anthelmintics.....	88	
Antiacne Preparations.....	61	
Antiallergy Preparations.....	233	
Antianaemics.....	37	
Antandrogen Oral Contraceptives.....	74	
Antiarrhythmics.....	49	
Antibacterials.....	88	
Antibacterials Topical.....	61	
Anticholinergic Agents.....	236	
Anticholinesterases.....	110	
Antidepressants.....	125	
Antidiarrhoeals.....	6	
Antiepilepsy Drugs.....	127	
Antifibrinolytics, Haemostatics and Local Sclerosants.....	38	
Antifibrotics.....	237	
Antifungals.....	95	
Antifungals Topical.....	62	
Antihistamines.....	234	
Antihypotensives.....	50	
Antimalarials.....	98	
Antimigraine Preparations.....	131	
Antinausea and Vertigo Agents.....	131	
Antiparasitics.....	98	
Antipruritic Preparations.....	63	
Antipsychotics.....	133	
Antiretrovirals.....	104	
Antirheumatoid Agents.....	111	
Antispasmodics and Other Agents Altering Gut Motility.....	8	
Antithrombotic Agents.....	41	

Antithymocyte globulin (equine)	187	Aripiprazole Sandoz	133	Azathioprine	180
Antitrichomonal Agents	98	Aristocort	64	Azithromycin	89
Antituberculotics and Antileprotics	98	Arrow-Amitriptyline	125	Azol	87
Antulcerants	8	Arrow-Bendrofluazide	54	Azopt	243
Antivirals	100	Arrow-Brimonidine	244	AZT	106
Anxiolytics	136	Arrow-Calcium	35	- B -	
Anzatax	167	Arrow-Diazepam	136	B-D Micro-Fine	14
Apidra	11	Arrow-Doxorubicin	164	B-D Ultra Fine	14
Apidra SoloStar	11	Arrow-Fluoxetine	127	B-D Ultra Fine II	14
Apo-Amlodipine	51	Arrow-Lamotrigine	129	Bacillus Calmette-Guerin (BCG) vaccine	187
Apo-Azithromycin	89	Arrow-Losartan & Hydrochlorothiazide	48	Bacillus Calmette-Guerin vaccine	272
Apo-Bromocriptine	119	Arrow-Morphine LA	124	Baclofen	118
Apo-Ciclopirox	62	Arrow-Norfloracin	109	Bactroban	62
Apo-Cilazapril/ Hydrochlorothiazide	48	Arrow-Ornidazole	98	Barrier Creams and Emollients	65
Apo-Clarithromycin Alimentary	9	Arrow-Quinapril 10	47	BCG Vaccine	272
Infection	89	Arrow-Quinapril 20	47	Beclazone 100	234
Apo-Clomipramine	125	Arrow-Quinapril 5	47	Beclazone 250	234
Apo-Diclo SR	110	Arrow-Roxithromycin	90	Beclazone 50	234
Apo-Diltiazem CD	52	Arrow-Timolol	243	Beclomethasone dipropionate	234
Apo-Doxazosin	47	Arrow-Topiramate	130	Bee venom allergy treatment	233
Apo-Folic Acid	38	Arrow-Tramadol	125	Bendamustine hydrochloride	158
Apo-Furosemide	53	Arsenic trioxide	163	Bendrofluazide	54
Apo-Gabapentin	128	Asacol	7	Bendroflumethiazide [Bendrofluazide]	54
Apo-Leflunomide	111	Asamax	7	Benzathine benzylpenicillin	91
Apo-Megestrol	178	Ascorbic acid	34	Benzatropine mesylate	120
Apo-Metoprolol	51	Aspen Adrenaline	56	Benzbromaron AL 100	116
Apo-Mirtazapine	127	Aspirin		Benzbromarone	116
Apo-Nadolol	51	Blood	41	Benztrop	120
Apo-Nicotinic Acid	54	Nervous	121	Benzydamine hydrochloride	32
Apo-Oxybutynin	76	Asthalin	236	Benzylicillin sodium [Penicillin G]	91
Apo-Perindopril	47	Atazanavir sulphate	106	Beta Cream	63
Apo-Pindolol	51	Atenolol	50	Beta Ointment	63
Apo-Pravastatin	55	Atenolol AFT	50	Beta Scalp	70
Apo-Prazosin	47	ATGAM	187	Beta-Adrenoceptor Agonists	236
Apo-Prednisone	79	Ativan	137	Beta-Adrenoceptor Blockers	50
Apo-Primidone	129	Atomoxetine	151	Betadine	66
Apo-Propranolol	51	Atorvastatin	55	Betadine Skin Prep	66
Apo-Pyridoxine	33	Atropine sulphate Cardiovascular	49	Betaferon	147
Apo-Selegiline S29	119	Sensory	244	Betahistine dihydrochloride	131
Apo-Sumatriptan	131	Atropt	244	Betaine	29
Apo-Temozolomide	167	Atrovent	236	Betaloc CR	50
Apo-Terazosin	47	AU Synacthen	79	Betamethasone dipropionate	63
Apo-Timol	51	Aubagio	142	Betamethasone dipropionate with calcipotriol	69
Apomorphine hydrochloride	119	Augmentin	91	Betamethasone sodium phosphate with betamethasone acetate	78
Aprepitant	131	Aurorix	126	Betamethasone valerate	63, 70
Apresoline	56	AutoSoft 30	23	Betamethasone valerate with clioquinol	64
Aptamil Gold+ Pepti Junior	270	AutoSoft 90	24	Betamethasone valerate with sodium fusidate [fusidic acid]	65
Aqueous cream	65	Avexol	93	Betaxolol	243
Aratac	49	Avonex	146		
Arava	111	Avonex Pen	146		
Aripiprazole	133	Azacididine	160		
Aripiprazole 1A Pharma	133	Azacididine Dr Reddy's	160		
		Azamun	180		

Betnovate	63	Budesonide	63	CareSens PRO	13
Betnovate-C	64	Alimentary	6	Carmellose sodium with gelatin and pectin	33
Betoptic	243	Respiratory	234, 239	Carmustine	159
Betoptic S	243	Budesonide with eformoterol	235	Carvedilol	50
Bezafibrate	54	Bumetanide	53	Carvedilol Sandoz	50
Bezalip	54	Buprenorphine Naloxone BNM	155	Catapres	52
Bezalip Retard	54	Buprenorphine with naloxone	155	CeeNU	159
Bicalutamide	178	Bupropion hydrochloride	155	Cefaclor monohydrate	88
Bicillin LA	91	Burinex	53	Cefalexin	88
BiCNU	159	Burinex S29	53	Cefalexin Sandoz	88
Bicnu Heritage	159	Buscopan	8	Cefazolin	88
Bile and Liver Therapy	10	Buspirone hydrochloride	136	Ceftriaxone	88
Biltricide	88	Busulfan	159	Ceftriaxone-AFT	88
Bimatoprost	244	- C -			
Bimatoprost Multichem	244	Cabergoline	87	Cefuroxime axetil	89
Binarex	178	Caffeine citrate	240	Celebrex	111
Binocrit	38	Calamine	63	Celecoxib	111
Biodone	123	Calcipotriol	69	Celecoxib Pfizer	111
Biodone Extra Forte	123	Calcitonin	77	Celestone Chronodose	78
Biodone Forte	123	Calcitriol	34	Celiprolol	50
Bisacodyl	28	Calcitriol-AFT	34	Cellcept	180
Bisoprolol fumarate	50	Calcium carbonate	6, 35	Celol	50
BK Lotion	66	Calcium Channel Blockers	51	Centrally-Acting Agents	52
Bleomycin sulphate	163	Calcium Disodium Versenate	247	Cephalexin ABM	88
Blood Colony-stimulating Factors	44	Calcium folinate	161	Cetirizine hydrochloride	234
Blood glucose diagnostic test meter	13	Calcium Folate Ebewe	161	Cetomacrogol	66
Blood glucose diagnostic test strip	13	Calcium Folate Sandoz	161	Cetomacrogol with glycerol	66
Blood glucose test strips (visually impaired)	13	Calcium gluconate	35	Cetuximab	198
Blood Ketone Diagnostic Test Strip	12	Calcium Homeostasis	77	Charcoal	246
Bonjela	33	Calcium polystyrene sulphonate	45	Chemotherapeutic Agents	158
Boostrix	272	Calcium Resonium	45	Chickenpox vaccine	283
Bortezomib	163	Calcium Sandoz	35	Chlorafast	241
Bortezomib Dr-Reddy's	163	Calogen	253	Chlorambucil	159
Bosentan	57	Candesartan cilexetil	48	Chloramphenicol	241
Bosentan Dr Reddy's	57	Candestar	48	Chlorhexidine gluconate	
Bosvate	50	Canesten	62	Alimentary	33
Bplex	33	Capecitabine	161	Dermatological	65
Breo Ellipta	235	Capercit	161	Chloroform	249
Brevinor 1/28	73	Capoten	47	Chlorothiazide	54
Brevinor 28	73	Capsaicin		Chlorpheniramine maleate	234
Bricanyl Turbuhaler	236	Musculoskeletal	111	Chlorpromazine hydrochloride	133
Brilinta	41	Nervous	122	Chlortalidone [Chlorthalidone]	54
Brimonidine tartrate	244	Captopril	47	Chlorthalidone	54
Brimonidine tartrate with timolol maleate	244	Carafate	10	Chlorvescent	46
Brinzolamide	243	Carbaccord	159	Choice Load 375	72
Brolene	241	Carbamazepine	128	Choice TT380 Short	72
Bromocriptine mesylate	119	Carbimazole	81	Choice TT380 Standard	72
Brufen SR	110	Carbomer	245	Choline salicylate with cetakonium chloride	33
BSF Imigran	246	Carboplatin	159	Ciclopirox olamine	62
Buccastem	132	Carboplatin Ebewe	159	Ciclosporin	231
		Cardinol X	246	Cilazapril	47
		Cardinol LA	51	Cilazapril with hydrochlorothiazide	48
		CareSens Dual	12	Cilicaine	92
		CareSens N	13	Cilicaine VK	92
		CareSens N POP	13		
		CareSens N Premier	13		

287

Dexamethasone Phosphate Panpharma.....	78	Disulfiram.....	156	Egopsoryl TA.....	69
Dexamethasone with framycetin and gramicidin.....	241	Diuretics.....	53	Elaprase.....	29
Dexamethasone with neomycin sulphate and polymyxin B sulphate.....	242	Docetaxel.....	164	Elecare.....	267
Dexamfetamine sulfate.....	151	Docetaxel Accord.....	164	Elecare LCP.....	267
Dexmethsone.....	78	Docetaxel Sandoz.....	164	Electral.....	45
Dextrochlorpheniramine maleate.....	234	Docusate sodium.....	27	Elelyso.....	31
Dextrose.....	44-45	Docusate sodium with sennosides.....	27	Elemental 028 Extra.....	258
DHC Continus.....	123	Dolutedegravir.....	106	Elocon.....	64
Diabetes.....	10	Domperidone.....	131	Elocon Alcohol Free.....	64
Diabetes Management.....	12	Donepezil hydrochloride.....	154	Eltrombopag.....	38
Diacomit.....	129	Donepezil-Rex.....	154	Eltroxin.....	82
Diagnostic Agents.....	283	Dornase alfa.....	239	EMB Fatol.....	99
Diamide Relief.....	6	Dortimopt.....	243	Emend Tri-Pack.....	131
Diamox.....	243	Dorzolamide hydrochloride.....	243	EMLA.....	121
Diasip.....	254	Dorzolamide with timolol.....	243	Emtricitabine.....	106
Diason RTH.....	254	Dostinex.....	87	Emtricitabine with tenofovir disoproxil.....	103
Diazepam.....	127, 136	Dosulepin [Dothiepin] hydrochloride.....	125	Emtriva.....	106
Diazoxide.....	10	Dosulepin Mylan.....	125	Emulsifying ointment.....	66
Dibenzyline.....	47	Dothiepin.....	125	Enalapril maleate.....	47
Diclofenac Sandoz.....	110	Doxazosin.....	47	Enbrel.....	180
Diclofenac sodium Musculoskeletal.....	110	Doxine.....	92	Endocrine Therapy.....	177
Sensory.....	242	Doxorubicin Ebewe.....	164	Endoxan.....	159
Differin.....	61	Doxorubicin hydrochloride.....	164	Engerix-B.....	275
Diffiam.....	32	Doxycycline.....	92	Enlax XR.....	127
Diflucan.....	95	DP Lotion.....	66	Enoxaparin sodium.....	42
Diflucan S29.....	95	DP Lotn HC.....	64	Enstilar.....	69
Diflucortolone valerate.....	64	DP-Allopurinol.....	116	Ensure.....	261
Digestives Including Enzymes.....	25	Dr Reddy's Omeprazole.....	9	Ensure Plus.....	262
Digoxin.....	49	Drugs Affecting Bone Metabolism.....	111	Ensure Plus HN.....	261
Dihydrocodeine tartrate.....	123	Dual blood glucose and blood ketone diagnostic test meter.....	12	Ensure Plus RTH.....	261
Dilantin.....	129	Duocal Super Soluble Powder.....	252	Entacapone.....	119
Dilantin Infatab.....	129	Duolin.....	236	Entapone.....	119
Diltiazem hydrochloride.....	52	Duolin HFA.....	236	Entecavir.....	100
Dilzem.....	52	Duride.....	56	Entecavir Sandoz.....	100
Dimethicone.....	65, 67	- E -		Entocort CIR.....	6
Dimethyl fumarate.....	137	e-chamber La Grande.....	240	Entresto 24/26.....	48
Dipentum.....	7	e-chamber Mask.....	240	Entresto 49/51.....	48
Diphtheria, tetanus and pertussis vaccine.....	272	e-chamber Turbo.....	240	Entresto 97/103.....	48
Diphtheria, tetanus, pertussis and polio vaccine.....	273	E-Mycin.....	90	Epilim.....	129
Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine.....	273	Ear Preparations.....	241	Epilim Crushable.....	129
Diprosone.....	63	Ear/Eye Preparations.....	241	Epilim IV.....	129
Diprosone OV.....	63	Easiphen Liquid.....	266	Epilim S/F Liquid.....	129
Dipyridamole.....	41	Econazole nitrate.....	62	Epilim Syrup.....	129
Disinfecting and Cleansing Agents.....	65	Efavirenz.....	105	Epirubicin Ebewe.....	164
Disopyramide phosphate.....	49	Efavirenz with emtricitabine and tenofovir disoproxil.....	105	Epirubicin hydrochloride.....	164
		Effient.....	41	Eplerenone.....	53
		Eformoterol fumarate.....	235	Epoetin alfa.....	38
		Eformoterol fumarate dihydrate.....	235	Epoprostenol.....	59
		Eftrenonacog alfa [Recombinant factor IX].....	38	Eptacog alfa [Recombinant factor Vlla].....	39
		Efudix.....	70	ERA.....	90
				Erbitux.....	198
				Ergometrine maleate.....	74
				Erlotinib.....	171
				Erythrocine IV.....	90

276
10

Ginet.....	74	Heparon Junior.....	255	Hyoscine hydrobromide.....	132
Glafiramer acetate.....	144	Hepatitis A vaccine.....	274	Hypam.....	150
Glecaprevir with pibrentasvir.....	102	Hepatitis B recombinant vaccine.....	275	Hyperuricaemia and Antigout.....	116
Glibenclamide.....	11	Hepsera.....	100	Hypromellose.....	244
Gliclazide.....	12	Herceptin.....	227	Hypromellose with dextran.....	245
Glipizide.....	12	Hiberix.....	273	- I -	
Glivec.....	172	Hiprex.....	109	Ibiamox.....	91
Glizide.....	12	Histaclear.....	234	Ibilex.....	88
Glucagen Hypokit.....	10	Histafen.....	234	Ibrance.....	174
Glucagon hydrochloride.....	10	Holoxan.....	159	Ibuprofen.....	110
Glucerna Select.....	254	Horleys Bread Mix.....	264	Ibuprofen SR BNM.....	110
Glucerna Select RTH.....	254	Horleys Flour.....	264	Icatibant.....	233
Glucobay.....	11	Hormone Replacement Therapy - Systemic.....	79	Idarubicin hydrochloride.....	165
Glucose [Dextrose].....	44	HPV.....	276	Idursulfase.....	29
Gluten Free Foods.....	264	Humalog.....	11	Ifosfamide.....	159
Glycerin with sodium saccharin.....	249	Humalog Mix 25.....	11	Ikorel.....	57
Glycerin with sucrose.....	249	Humalog Mix 50.....	11	Iloprost.....	59
Glycerol.....		Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV].....	276	Imatinib.....	172
Alimentary.....	27	Humatin.....	94	Imatinib mesilate.....	172
Extemporaneous.....	249	Humira.....	187	Imatinib-AFT.....	172
Glyceryl trinitrate.....		HumiraPen.....	187	Imigran.....	131
Alimentary.....	8	Humulin 30/70.....	11	Imipramine hydrochloride.....	125
Cardiovascular.....	56	Humulin NPH.....	11	Imiquimod.....	70
Glycopyrronium.....	236	Humulin R.....	10	Immune Modulators.....	106
Glycopyrronium bromide.....	8	Hyaluronic acid.....	245	Immunosuppressants.....	180
Glycopyrronium with indacaterol.....	237	Hydralazine.....	56	Imuran.....	180
Gold Knight.....	71	Hydralazine hydrochloride.....	56	Incruse Ellipta.....	237
Goserelin.....	86	Hydrea.....	165	Indacaterol.....	235
Gutron.....	50	Hydrocortisone.....		Indapamide.....	54
Gynaecological Anti-infectives.....	74	Dermatological.....	64	Infanrix IPV.....	273
- H -		Hormone.....	78	Infanrix-hexa.....	273
Habitrol.....	156	Hydrocortisone (PSM).....	64	Infant Formulae.....	267
Haemophilus influenzae type B vaccine.....	273	Hydrocortisone acetate.....	7	Infatrin.....	270
Haldol.....	135	Hydrocortisone acetate with pramoxine hydrochloride.....	7	Infliximab.....	198
Haldol Concentrate.....	135	Hydrocortisone and paraffin liquid and lanolin.....	64	Influenza vaccine.....	277
Haldol Decanoas.....	135	Hydrocortisone butyrate.....	64, 70	Influvac Tetra (2020 formulation).....	277
Haloperidol.....	133	Hydrocortisone with cinchocaine.....	8	Inhaled Corticosteroids.....	234
Haloperidol decanoate.....	135	Hydrocortisone with miconazole.....	65	Inhaled Long-acting Beta-adrenoceptor Agonists.....	235
Harvoni.....	102	Hydrocortisone with natamycin and neomycin.....	65	Inspra.....	53
Havrix.....	274	Hydrogen peroxide.....	61	Instillagel Lido.....	121
Havrix Junior.....	274	Hydroxocobalamin.....	33	Insulin aspart.....	11
HBvaxPRO.....	275	hydroxycarbamide.....	165	Insulin aspart with insulin aspart protamine.....	10
healthE Calamine Aqueous Cream BP.....	63	Hydroxychloroquine.....	111	Insulin glargine.....	11
healthE Dimethicone 10%.....	65	Hydroxyurea.....		Insulin glulisine.....	11
healthE Dimethicone 4% Lotion.....	67	[hydroxycarbamide].....	165	Insulin isophane.....	11
healthE Dimethicone 5%.....	65	Hygroton.....	54	Insulin isophane with insulin neutral.....	11
healthE Glycerol BP.....	249	Hypo-Fresh.....	245	Insulin lispro.....	11
healthE Urea Cream.....	66	Hymenoptera.....	233	Insulin lispro with insulin lispro protamine.....	11
Healtheries Simple Baking Mix.....	264	Hyoscine butylbromide.....	8	Insulin neutral.....	10
Hemastix.....	76			Insulin pen needles.....	14
Heparin Ratiopharm.....	43			Insulin pump.....	14
Heparin sodium.....	43			Insulin pump cartridge.....	19
Heparinised saline.....	43				

Insulin pump infusion set (steel cannula).....	20	Jadelle	74	Largactil	133
Insulin pump infusion set (steel cannula, straight insertion)	21	Jakavi	175	Laronidase	30
Insulin pump infusion set (teflon cannula).....	22	Jaydess	81	Lasix	53
Insulin pump infusion set (teflon cannula, angle insertion with insertion device)	23	Jevity HiCal RTH	261	Latanoprost.....	244
Insulin pump infusion set (teflon cannula, angle insertion)	23	Jevity RTH.....	261	Lax-Suppositories.....	28
Insulin pump infusion set (teflon cannula, straight insertion with insertion device)	24	Juno.....	110	Lax-Tab	28
Insulin pump infusion set (teflon cannula, straight insertion)	25	Juno Pemetrexed	162	Laxatives	27
Insulin pump reservoir.....	25	- K -		Laxsol	27
Insulin syringes, disposable with attached needle	14	Kadcyla.....	228	Ledipasvir with sofosbuvir	102
Intal Forte CFC Free.....	239	Kaletra	106	Leflunomide	111
Intelence	105	Keflor	88	Lenalidomide	165
Interferon alfa-2a.....	107	Kemadrin	120	Letrole	180
Interferon beta-1-alpha.....	146	Kenacomb	241	Letrozole.....	180
Interferon beta-1-beta.....	147	Kenacort-A 10.....	79	Leukeran FC.....	159
Intra-uterine device.....	72	Kenacort-A 40.....	79	Leukotriene Receptor Antagonists.....	238
Invega Sustenna.....	135	Kenalog	79	Leunase	164
IPOLE	282	Kenalog in Orabase	33	Leuporelin.....	86
Ipratropium bromide	236, 240	Kenkay Sorbolene	66	Leustatin	161
Iressa.....	171	Ketocal 3:1	271	Levetiracetam	129
Irinotecan Accord.....	161	KetoCal 4:1	271	Levetiracetam-AFT	129
Irinotecan Actavis 100	161	Ketoconazole		Levlen ED	73
Irinotecan hydrochloride	161	Dermatological	70	Levocabastine	243
Irinotecan-Rex	161	Infection	96	Levodopa with benserazide.....	119
Iron polymaltose	36	Ketogenic Diet	271	Levodopa with carbidopa.....	119
Isentress	106	Ketoprofen	110	Levomepromazine	133
Isentress HD	106	KetoSens	12	Levomepromazine hydrochloride	134
Ismo 20	56	Keytruda	230	Levonorgestrel	
Ismo 40 Retard	56	Kindergen	256	Genito-Urinary.....	74
Isoniazid	99	Kivexa.....	105	Hormone	81
Isoniazid with rifampicin.....	99	Klacid.....	89	Levothyroxine	82
Isoprenaline [Isoproterenol]	56	Kliogest	80	Lidocaine [Lignocaine].....	121
Isoproterenol.....	56	Kliovance	80	Lidocaine [Lignocaine] hydrochloride	121
Isoptin	52	Kogenate FS.....	40	Lidocaine [Lignocaine] with chlorhexidine	121
Isoptin Retard	52	Konakion MM.....	41	Lidocaine [Lignocaine] with prilocaine	121
Isoptin SR	52	Konsyl-D.....	27	Lidocaine-Clarix.....	121
Isopto Carpine	244	Kuvan	30	Lignocaine	121
Isosorbide mononitrate.....	56	- L -		Lioresal Intrathecal	118
Isosource Standard	261	L-asparaginase	164	Lipazil	54
Isotretinoin	61	Labetalol	50	Lipid-Modifying Agents	54
Ispaghula (psyllium) husk	27	Lacosamide	128	Liquigen	253
Isuprel	56	Lactulose	27	Lisinopril	47
Itch-Soothe	63	Laevolac	27	Lithicarb FC	134
Itraconazole	96	Lamictal	129	Lithium carbonate.....	134
Itrazole.....	96	Lamivudine	101, 106	Livostin	243
Ivermectin	67	Lamivudine Alphapharm	106	LMX4	121
- J -		Lamotrigine	129	Locacorten-Viaform ED's.....	241
		Lamprene	98	Local preparations for Anal and Rectal Disorders.....	8
		Lanoxin	49	Locasol	267
		Lanoxin PG.....	49	Locoid	64, 70
		Lanoxin S29.....	49	Locoid Crelo	64
		Lansoprazole	9		
		Lantus	11		
		Lantus SoloStar	11		
		Lanvis	163		
		Lanzol Relief.....	9		
		Lapatinib ditosylate.....	172		

Locoid Lipocream	64	MCT oil (Nutricia).....	253	Methylprednisolone aceponate.....	64
Locorten-Vioform	241	Measles, mumps and rubella vaccine	279	Methylprednisolone acetate.....	78
Lodoxamide.....	243	Mebendazole.....	88	Methylxanthines.....	239
Logem.....	129	Mebeverine hydrochloride	8	Metoclopramide Actavis 10	132
Lomide.....	243	Medco.....	122	Metoclopramide hydrochloride	132
Lomustine.....	159	Medrol.....	78	Metolazone	53
Loniten.....	57	Medroxyprogesterone acetate Genito-Urinary.....	74	Metopirone	87
Loperamide hydrochloride	6	Hormone	80-81	Metoprolol succinate.....	50
Lopinavir with ritonavir.....	106	Mefenamic acid	110	Metoprolol tartrate	51
Loprofin.....	266	Megestrol acetate	178	Metrogyl.....	98
Loprofin Mix.....	266	Melatonin.....	149	Metronidazole.....	98
Lorafix.....	234	Melphalan.....	159	Metoprolol IV Mylan.....	51
Loratadine.....	234	Menactra.....	279	Metyrapone	87
Lorazepam.....	137	Meningococcal (groups A, C, Y and W-135) conjugate vaccine	279	Mexiletine hydrochloride.....	49
Lorfast.....	234	Meningococcal C conjugate vaccine	280	Mexiletine Hydrochloride USP	49
Lorstat.....	55	Menthol.....	63	Miacalcic.....	77
Losartan Actavis.....	48	Mepolizumab.....	205	Micolette.....	28
Losartan potassium.....	48	Mercaptopurine.....	162	Miconazole	33
Losartan potassium with hydrochlorothiazide	48	Mercilon 28.....	72	Miconazole nitrate Dermatological	63
Lovir.....	101	Mesalazine	7	Genito-Urinary.....	74
Loxamine.....	127	Mesna.....	166	Micreme	74
Lucrin Depot 1-month	86	Mestinon.....	110	Micreme H	65
Lucrin Depot 3-month	86	Metabolic Disorder Agents	28	Microgynon 20 ED.....	73
Ludiomil.....	126	Meterol.....	235	Microgynon 30.....	73
Lupin.....	126	Metformin hydrochloride	12	Microgynon 50 ED.....	73
Lyderm.....	68	Methadone hydrochloride Extemporaneous.....	249	Microlut.....	74
Lynparza.....	166	Nervous.....	123	Midazolam	150
- M -		Methatabs.....	123	Midazolam-Claris.....	150
m-Eslon.....	124	Methenamine (hexamine) hippurate.....	109	Midodrine.....	50
Mabthera.....	208	Methopt.....	244	Mifegyne.....	76
Macrogl 3350 with potassium chloride, sodium bicarbonate and sodium chloride	27	Methotrexate.....	162	Mifepistone	76
Macrogl 400 and propylene glycol	245	Methotrexate Ebewe.....	162	Minerals	35
Madopar 125	119	Methotrexate Sandoz	162	Mini-Wright AFS Low Range.....	240
Madopar 250	119	Methyl hydroxybenzoate.....	249	Mini-Wright Standard.....	240
Madopar 62.5	119	Methylcellulose	249	Minidiab	12
Madopar HBS.....	119	Methylcellulose with glycerin and sodium saccharin	249	MiniMed 640G	14
Madopar Rapid.....	119	Methylcellulose with glycerin and sucrose	250	MiniMed Mio MMT-921A	22
Magnesium hydroxide Alimentary.....	36	Methyldopa	52	MiniMed Mio MMT-923A	22
Extemporaneous.....	249	Methyldopa Mylan	52	MiniMed Mio MMT-925A	22
Magnesium sulphate	36	Methyldopa Mylan S29.....	52	MiniMed Mio MMT-941A	22
Mantoux.....	283	Methylnaltrexone bromide	27	MiniMed Mio MMT-943A	22
Maprotiline hydrochloride	126	Methylphenidate ER - Teva.....	153	MiniMed Mio MMT-945A	22
Marevan.....	44	Methylphenidate hydrochloride	152	MiniMed Mio MMT-965A	22
Marine Blue Lotion SPF 50+	70	Methylphenidate hydrochloride extended-release	153	MiniMed Mio MMT-975A	22
Martindale Pharma	246	Methylprednisolone	78	MiniMed Quick-Set MMT-386A	22
Marvelon 28.....	72	Methylprednisolone (as sodium succinate).....	78	MiniMed Quick-Set MMT-387A	22
Mask for spacer device.....	240			MiniMed Quick-Set MMT-396A	22
Mast Cell Stabilisers.....	239			MiniMed Quick-Set MMT-397A	22
Maviret.....	102			MiniMed Quick-Set MMT-398A	22
Maxidex.....	242			MiniMed Quick-Set MMT-399A	22
Maxitrol.....	242			MiniMed Silhouette MMT-368A	22
				MiniMed Silhouette MMT-377A	22
				MiniMed Silhouette MMT-378A	22
				MiniMed Silhouette MMT-381A	22
				MiniMed Silhouette MMT-382A	22

MiniMed Silhouette MMT-383A	22	Mycophenolate mofetil.....	180	Nilotinib.....	173
MiniMed Silhouette MMT-384A	22	Mydriacyl	244	Nilstat	
MiniMed Sure-T MMT-864A	20	Mylan Atenolol.....	50	Alimentary.....	33
MiniMed Sure-T MMT-866A	20	Mylan Clomiphen.....	87	Genito-Urinary.....	74
MiniMed Sure-T MMT-874A	20	Myleran.....	159	Infection	96
MiniMed Sure-T MMT-876A	20	Myometrial and Vaginal Hormone		Nintedanib	237
MiniMed Sure-T MMT-884A	20	Preparations	74	Nipent	167
MiniMed Sure-T MMT-886A	20	Myozyme	28	Nitrados	150
Minims Pilocarpine	244	Mysoline S29	129	Nitrates	56
Minims Prednisolone	243	- N -		Nitrazepam	150
Minirin	86	Nadolol	51	Nitroderm TTS	56
Mino-tabs.....	92	Naglazyme.....	29	Nitrofurantoin.....	109
Minocycline hydrochloride	92	Nalcrom	8	Nitrolingual Pump Spray.....	56
Minomycin	92	Naloxone hydrochloride.....	246	Nivestim	44
Minor Skin Infections	66	Naltraccord	156	Nivolumab.....	229
Minoxidil.....	57	Naltrexone hydrochloride.....	156	Nizoral	96
Mirena.....	81	Naphazoline hydrochloride	245	Nodia	6
Mirtazapine	127	Naphcon Forte.....	245	Noflam 250	110
Misoprostol	8	Naprosyn SR 1000.....	110	Noflam 500	110
Mitomycin C.....	166	Naprosyn SR 750	110	Non-Steroidal Anti-Inflammatory	
Mitozantrone.....	166	Naproxen.....	110	Drugs.....	110
Mitozantrone Ebewe.....	166	Narcarcin mite.....	116	Nonacog gamma, [Recombinant	
Mixtard 30.....	11	Nardil	126	Factor IX].....	40
MMR II	279	Nardil S29.....	126	Norethisterone	
Moclobemide	126	Nasal Preparations.....	239	Genito-Urinary.....	74
Modafinil	154	Natalizumab.....	140	Hormone	81
Modavigil	154	Natulan	167	Norflex	118
Moduretic.....	53	Nausafix.....	132	Norfloracin.....	109
Molaxole	27	Nausicalm.....	131	Noriday 28	74
Moments.....	71	Navelbine.....	170	Norimin	73
Mometasone furoate.....	64	Necon	73	Normacol Plus	27
Monogen.....	255	Necodromil	239	Normison	150
Montelukast	238	Nefopam hydrochloride	122	Norpress	126
Montelukast Mylan.....	238	Neisvac-C.....	280	Nortriptyline hydrochloride.....	126
Moroctocog alfa [Recombinant factor		Neo-B12	33	Norvir	106
VIII]	40	Neo-Mercazole	81	NovaSource Renal	257
Morphine hydrochloride	123	Neocate Gold.....	267	Novatretin	68
Morphine sulphate	124	Neocate Junior Unflavoured	267	NovoMix 30 FlexPen	10
Motetis	120	Neocate Junior Vanilla.....	267	NovoRapid.....	11
Mouth and Throat.....	32	Neocate SYNEO.....	267	NovoRapid FlexPen.....	11
Movapo.....	119	Neoral	231	NovoRapid Penfill.....	11
Moxifloxacin.....	93	Neostigmine metilsulfate	110	NovoSeven RT	39
MSUD Maxamum	265	Nepro HP (strawberry).....	257	Noxafil.....	96
Mucilaginous laxatives with		Nepro HP (vanilla)	257	Nozinan	133-134
stimulants	27	Nepro HP RTH	257	Nozinan (Swiss).....	133
Mucolytics	239	Neerisone	64	Nucala	205
Mucosoothe.....	121	Neulactil.....	134	Nuelin	239
Multiple Sclerosis Treatments	137	Neulastim.....	44	Nuelin-SR	239
Multivitamin renal.....	34	NeuroTabs.....	35	Nutilis.....	264
Multivitamins.....	34	Nevirapine	105	Nutrient Modules	251
Mupirocin.....	62	Nevirapine Alphapharm.....	105	Nutrini Energy Multi Fibre	256
Muscle Relaxants	118	Nicorandil.....	57	Nutrini Energy RTH	256
Mvite.....	34	Nicotine	156	Nutrini Low Energy Multi Fibre	258
Myambutol	99	Nicotinic acid	54	Nutrini Peptisorb	269
Mycobutin.....	99	Nifedipine.....	52	Nutrini Peptisorb Energy.....	269
MycosNail.....	62	Nifuran	109	Nutrini RTH.....	256

Nutrison 800 Complete Multi Fibre	261	Ondansetron ODT-DRLA	132	Pan-Penicillin G Sodium	91
Nutrison Concentrated	263	One-Alpha	34	Panadol Mini Caps	122
Nutrison Energy	261	Onrex	132	Pancreatic enzyme	25
Nutrison Energy Multi Fibre	261	Opdivo	229	Pantoprazole	9
Nutrison Multi Fibre	261	Ora-Blend	250	Panzop Relief	9
Nutrison Standard RTH	261	Ora-Blend SF	249	Panzytrat	25
Nyefax Retard	52	Ora-Plus	249	Papaverine hydrochloride	57
Nystatin		Ora-Sweet	249	Para-amino salicylic acid	99
Alimentary	33	Ora-Sweet SF	249	Paracare	122
Genito-Urinary	74	Orabase	33	Paracare Double Strength	122
Infection	96	Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed)	254	Paracetamol	122
NZB Low Gluten Bread Mix	264	Oratane	61	Paracetamol + Codeine (Relieve)	124
- O -					
O/W Fatty Emulsion Cream	66	Ordine	123	Paracetamol Pharmacare	122
Obinutuzumab	206	Orgran	265	Paracetamol with codeine	124
Obstetric Preparations	76	Ornidazole	98	Paradigm 1.8 Reservoir	25
Ocicure	9	Orphenadrine citrate	118	Paradigm 3.0 Reservoir	25
Ocrelizumab	141	Ortho-tolidine	76	Paradigm Mio MMT-921	24
Ocrevus	141	Oruvail SR	110	Paradigm Mio MMT-923	24
Octocog alfa [Recombinant factor VIII] (Advate)	40	Osmolite RTH	261	Paradigm Mio MMT-925	24
Octocog alfa [Recombinant factor VIII] (Kogenate FS)	40	Other Endocrine Agents	87	Paradigm Mio MMT-941	24
Octreotide	178	Other Oestrogen Preparations	81	Paradigm Mio MMT-943	24
Octreotide (Sun)	178	Other Progestogen Preparations	81	Paradigm Mio MMT-945	24
Octreotide GH	178	Other Skin Preparations	70	Paradigm Mio MMT-965	24
Octreotide LAR (somatostatin analogue)	178	Ovestin		Paradigm Mio MMT-975	24
Octreotide MaxRx	178	Genito-Urinary	75	Paradigm Quick-Set MMT-386	25
Oestradiol	80	Hormone	81	Paradigm Quick-Set MMT-387	25
Oestradiol valerate	80	Ox-Pam	137	Paradigm Quick-Set MMT-387	25
Oestradiol with norethisterone	80	Oxaliplatin	160	Paradigm Quick-Set MMT-396	25
Oestriol		Oxaliplatin Accord	160	Paradigm Quick-Set MMT-399	25
Genito-Urinary	75	Oxaliplatin Actavis 100	160	Paradigm Silhouette MMT-368	23
Hormone	81	Oxaliplatin Ebewe	160	Paradigm Silhouette MMT-377	23
Oestrogens	80	Oxazepam	137	Paradigm Silhouette MMT-378	23
Ofev	237	Oxis Turbuhaler	235	Paradigm Silhouette MMT-381	23
Oil in water emulsion	66	Oxpentifylline	57	Paradigm Silhouette MMT-382	23
Olanzapine	134-135	Oxybutynin	76	Paradigm Silhouette MMT-383	23
Olaparib	166	Oxycodone hydrochloride	124	Paradigm Silhouette MMT-384	23
Olbetam	54	Oxycodone Sandoz	124	Paradigm Sure-T MMT-864	20
Olbetam S29	54	OxyNorm	124	Paradigm Sure-T MMT-866	20
Olopatadine	245	Oxytocin	75	Paradigm Sure-T MMT-874	20
Olopatadine Teva	245	Oxytocin BNM	75	Paradigm Sure-T MMT-876	20
Olisalazine	7	Oxytocin with ergometrine maleate	75	Paradigm Sure-T MMT-884	20
Omalizumab	206	Ozurdex	242	Paradigm Sure-T MMT-886	20
Omeprazole	9	- P -			
Omeprazole actavis 10	9	Pacifen	118	Paraffin	66
Omeprazole actavis 20	9	Paclitaxel	167	Paraffin liquid with wool fat	245
Omeprazole actavis 40	9	Paclitaxel Actavis	167	Paraldehyde	127
Omnitrope	82	Paclitaxel Ebewe	167	Parasidose	68
Onbrez Breezhaler	235	Paediatric Seravit	34	Parasiticial Preparations	67
Oncaspar LYO	167	Palbociclib	174	Parnate	126
OncoTICE	187	Paliperidone	135	Parnate S29	126
Ondansetron	132	Pamidronate disodium	113	Paromomycin	94
		Pamisol	113	Paroxetine	127
				Paser	99
				Patanol	245
				Paxam	136

Pazopanib.....	174	and fluorescein.....	69	Premarin.....	80
Peak flow meter.....	240	Pinetarsol.....	69	Prevenar 13.....	281
Pedialyte - Bubblegum.....	45	Pioglitazone.....	12	Prezista.....	106
Pediasure.....	256	Pirfenidone.....	238	Priadel.....	134
Pediasure RTH.....	256	Pizotifen.....	131	Primacin.....	98
Pegaspargase.....	167	PKU Anamix Infant.....	266	Primaquine.....	98
Pegasys.....	107	PKU Anamix Junior.....	266	Primidone.....	129
Pegfilgrastim.....	44	PKU Anamix Junior Chocolate.....	266	Primolut N.....	81
Pegylated interferon alfa-2a.....	107	PKU Anamix Junior LQ.....	266	Priorix.....	279
Pembrolizumab.....	230	PKU Anamix Junior Vanilla.....	266	Probenecid.....	117
Pemetrexed.....	162	PKU Lophlex LQ 10.....	266	Probenecid-AFT.....	117
Penicillamine.....	111	PKU Lophlex LQ 20.....	266	Procaine penicillin.....	92
Penicillin G.....	91	PKU Lophlex Powder.....	266	Procabazine hydrochloride.....	167
PenMix 30.....	11	PKU Lophlex Sensation 20.....	266	Prochlorperazine.....	132
PenMix 40.....	11	Plaquenil.....	111	Proctofoam.....	7
PenMix 50.....	11	Plendil ER.....	51	Proctosedyl.....	8
Pentasa.....	7	Pneumococcal (PCV10) conjugate vaccine.....	280	Procyclidine hydrochloride.....	120
Pentostatin [Deoxycoformycin].....	167	Pneumococcal (PCV13) conjugate vaccine.....	281	Procytox.....	159
Pentoxifylline [Oxpentifylline].....	57	Pneumococcal (PPV23) polysaccharide vaccine.....	282	Progesterone.....	81
Peptamen Junior.....	256	Pneumovax 23.....	282	Proglucem.....	10
Peptisooth.....	9	Podophyllotoxin.....	70	Proglycem.....	10
Peptisorb.....	258	Polaramine.....	234	Progynova.....	80
Perhexiline maleate.....	52	Poliomyelitis vaccine.....	282	Prolia.....	112
Pericyazine.....	134	Poloxamer.....	27	Promethazine hydrochloride.....	234
Perindopril.....	47	Poly-Gel.....	245	Propafenone hydrochloride.....	49
Perjeta.....	207	Poly-Tears.....	245	Propamidine isethionate.....	241
Permethrin.....	68	Poly-Visc.....	245	Propranolol.....	51
Perrigo.....	70	Polycal.....	251	Propylene glycol.....	250
Pertuzumab.....	207	Polystan.....	110	Propylthiouracil.....	82
Peteha.....	99	Posaconazole.....	96	Protaphane.....	11
Pethidine hydrochloride.....	125	Postinor-1.....	74	Protaphane Penfill.....	11
Pevaryl.....	62	Potassium chloride.....	45-46	Protifar.....	253
Pexsig.....	52	Potassium Chloride Aguetant.....	45	Protionamide.....	99
Pfizer Exemestane.....	180	Potassium citrate.....	76	Provera.....	80
Pharmacy Services.....	246	Potassium iodate.....	35	Provera HD.....	81
Pheburane.....	31	Povidone iodine.....	66	PSM Citalopram.....	126
Phenase.....	163	Pradaxa.....	43	Psoriasis and Eczema Preparations.....	68
Phenelzine sulphate.....	126	Pramipexole hydrochloride.....	119	PTU.....	82
Phenobarbitone.....	129	Prasugrel.....	41	Pulmicort Turbuhaler.....	234
Phenobarbitone sodium		Pravastatin.....	55	Pulmocare.....	254
Extemporaneous.....	250	Pravastatin Mylan.....	55	Pulmozyme.....	239
Nervous.....	150	Praziquantel.....	88	Puri-nethol.....	162
Phenothrin.....	68	Prazosin.....	47	Puria.....	34
Phenoxybenzamine hydrochloride.....	47	Pred Forte.....	243	Pyrazinamide.....	99
Phenoxymethylpenicillin (Penicillin V).....	92	Prednisolone.....	78	Pyridostigmine bromide.....	110
Phenytoin sodium.....	128-129	Prednisolone acetate.....	243	Pyridoxine hydrochloride.....	33
Phlexy 10.....	266	Prednisolone sodium phosphate.....	243	Pyrimethamine.....	94
Phosphate Phebra.....	45	Prednisolone-AFT.....	243	Pytazen SR.....	41
Phosphorus.....	45	Prednisone.....	79		
Phytomenadione.....	41	Pregabalin.....	129	- Q -	
Pilocarpine hydrochloride.....	244	Pregabalin Pfizer.....	129	Q 300.....	98
Pimafucort.....	65	Pregnancy Tests - hCG Urine.....	75	Quetapel.....	134
Pindolol.....	51			Quetiapine.....	134
Pine tar with trolamine laurilsulfate				Quick-Set MMT-392.....	25
				Quick-Set MMT-393.....	25
				Quinapril.....	47

Quinapril with hydrochlorothiazide	48	Rituximab (Riximyo)	213	Seretide	235
Quinine sulphate.....	98	Rivaroxaban	44	Seretide Accuhaler	235
Qvar.....	234	Rivastigmine.....	154	Serevent	235
- R -					
RA-Morph	123	Rivotril.....	127-128	Serevent Accuhaler	235
Raloxifene hydrochloride	113	Riximyo.....	213	Sertraline	127
Raltegravir potassium.....	106	RIXUBIS	40	Setrona	127
Ramipex	119	Rizamelt.....	131	Sevredol	124
Ranbaxy-Cefaclor.....	88	Rizatriptan	131	Sex Hormones Non Contraceptive	79
Ranitidine.....	9	Robinul	8	Shield XL	71
Ranitidine Relief	9	Roferon-A	107	shingles vaccine	283
Rapamune	232	Rolin	180	SII-Onco-BCG	187
Reandron 1000	79	Ropin	119	Sildenafil	58
Recombinant factor IX	38, 40	Ropinrole hydrochloride	119	Silhouette MMT-373	23
Recombinant factor VIIa	39	Rotarix	282	Siltuximab	223
Recombinant factor VIII	40	Rotavirus oral vaccine	282	Simvastatin	55
Rectogesic	8	Roxane		Simvastatin Mylan	55
Redipred	78	Alimentary.....	6	Sinemet	119
Relieve.....	110	Cardiovascular	51	Sinemet CR	119
Relistor	27	Roxithromycin	90	Sirolimus	232
Remicade	198	Rubifen	152	Siterone	79
Renilon 7.5	257	Rubifen SR	152	Slow-Lopresor	51
Resonium-A.....	46	Rugby Capsaicin Topical Cream Musculoskeletal	111	Smith BioMed Rapid Pregnancy Test.....	75
Resource Beneprotein.....	253	Nervous.....	122	Sodibic.....	46
Resource Diabetic	254	Rulide D	90	Sodium acid phosphate	28
Respigen	236	Ruriotocog alfa pegol [Recombinant factor VIII].....	40	Sodium alginate	6
Respiratory Devices	240	Ruxolitinib	175	Sodium benzoate.....	31
Respiratory Stimulants	240	Rythmodan	49	Sodium bicarbonate Blood.....	45-46
Retinol palmitate.....	245	Rytmonorm.....	49	Extemporaneous.....	250
ReTrieve	61	- S -			
Retrovir	106	Sabril	130	Sodium calcium edetate	247
Revimid.....	165	Sacubitril with valsartan.....	48	Sodium chloride Blood	45
Revolade	38	SalAir	236	Respiratory.....	239
Rexacrom	243	Salazopyrin	8	Sodium citrate with sodium lauryl sulphacetate	28
Ribomustin.....	158	Salazopyrin EN.....	8	Sodium citro-tartrate	76
Ricit.....	75	Salbutamol	236	Sodium cromoglicate Alimentary	8
Rifabutin	99	Salbutamol with ipratropium bromide.....	236	Respiratory.....	239
Rifadin	100	Salicylic acid	69	Sensory	243
Rifampicin.....	100	Salmeterol	235	Sodium fluoride.....	35
Rifaximin	10	Sandomigran	131	Sodium Fusidate [fusidic acid] Dermatological	62
Rifinah	99	Sandostatin LAR.....	178	Infection	95
Rilutek	120	Sapropterin dihydrochloride.....	30	Sensory	241
Riluzole.....	120	Scalp Preparations	70	Sodium hyaluronate [Hyaluronic acid].....	245
Riodine	66	Scopoderm TTS	132	Sodium phenylbutyrate	31
Risedronate Sandoz	113	Sebizole.....	70	Sodium polystyrene sulphonate	46
Risedronate sodium.....	113	Secukinumab	222	Sodium tetradecyl sulphate	40
Risperdal Consta	136	Sedatives and Hypnotics	149	Sodium valproate	129
Risperidone	134, 136	Seebri Breezhaler.....	236	Sofradex	241
Risperidone (Teva)	134	Selegiline hydrochloride	119	Soframycin	241
Risperon	134	Senna	28	Solifenacin Mylan	76
Ritalin	152	Senokot	28		
Ritalin LA	153	Sensipar	77		
Ritalin SR.....	152	SensoCard.....	13		
Ritonavir	106	Serenace	133		
Rituximab (Mabthera)	208				

Solifenacin succinate.....	76	Syntometrine.....	75	Tilcotil.....	110
Solu-Cortef.....	78	Syrup (pharmaceutical grade).....	250	Tillomed.....	159
Solu-Medrol.....	78	Systane Unit Dose.....	245	Timolol	
Solu-Medrol-Act-O-Vial.....	78	- T -		Cardiovascular.....	51
Somatropin (Omnitrope).....	82	Tacrolimus.....	232	Sensory.....	243
Sotalol.....	51	Tacrolimus Sandoz.....	232	Timoptol XE.....	243
Spacer device.....	240	Taliglucerase alfa.....	31	Tiotropium bromide.....	237
Span-K.....	46	Tambacor.....	49	Tiotropium bromide with	
Spiolto Respimat.....	237	Tamoxifen citrate.....	180	olodaterol.....	237
Spiractin.....	53	Tamoxifen Sandoz.....	180	Tivicay.....	106
Spiriva.....	237	Tamsulosin hydrochloride.....	75	TMP.....	95
Spiriva Respimat.....	237	Tamsulosin-Rex.....	75	TOBI.....	95
Spirolactone.....	53	Tandem Basal IQ.....	14	Tobramycin	
Sporanox.....	96	Tandem Cartridge.....	19	Infection.....	95
Sprycel.....	170	Tandem t:slim X2.....	14	Sensory.....	242
Staphlex.....	92	Tap water.....	250	Tobramycin Mylan.....	95
Stemetil.....	132	Tarceva.....	171	Tobrex.....	242
SteroClear.....	239	Tasigna.....	173	Tocilizumab.....	223
Stesolid.....	127	Tasmar.....	119	Tofranil.....	125
Stimulants/ADHD Treatments.....	151	Tecfidera.....	137	Tolcapone.....	119
Stripentol.....	129	Tegretol.....	128	Topamax.....	130
Stocrin.....	105	Tegretol CR.....	128	Topical Products for Joint and	
Stomahesive.....	33	Telfast.....	234	Muscular Pain.....	111
Strattera.....	151	Teligent.....	93	Topiramate.....	130
Strides Shasun.....	96	Temaccord.....	167	Topiramate Actavis.....	130
Stromectol.....	67	Temazepam.....	150	Total parenteral nutrition (TPN).....	45
Sucralfate.....	10	Temozolomide.....	167	TPN.....	45
Sulfadiazine Silver.....	62	Tenofovir disoproxil.....	101	Tramadol hydrochloride.....	125
Sulfadiazine sodium.....	95	Tenofovir Disoproxil Teva.....	101	Tramal SR 100.....	125
Sulfasalazine.....	8	Tenoxicam.....	110	Tramal SR 150.....	125
Sulindac.....	110	Tepadina.....	160	Tramal SR 200.....	125
Sulindac Mylan.....	110	Terazosin.....	47	Trandate.....	50
Sulphur.....	69	Terbinafine.....	97	Tranexamic acid.....	40
Sulprix.....	133	Terbutaline sulphate.....	236	Tranylcypromine sulphate.....	126
Sumatriptan.....	131	Teriflunomide.....	142	Trastuzumab.....	227
Sunitinib.....	175	Teriparatide.....	113	Trastuzumab emtansine.....	228
Sunscreens.....	70	Testosterone.....	79	Travatan.....	244
Sunscreens, proprietary.....	70	Testosterone cypionate.....	79	Travoprost.....	244
Sure-T MMT-863.....	20	Testosterone esters.....	79	Travopt.....	244
Sure-T MMT-873.....	20	Testosterone undecanoate.....	79	Treatments for Dementia.....	154
Sustagen Diabetic.....	254	Tetrabenazine.....	120	Treatments for Substance	
Sustagen Hospital Formula		Tetrabromophenol.....	76	Dependence.....	155
Active.....	261	Tetracosactrin.....	79	Trental 400.....	57
Sustanon Ampoules.....	79	Tetracyclin Wolff.....	92	Tretinoin	
Sutent.....	175	Tetracycline.....	92	Dermatological.....	61
Sylvant.....	223	Thalidomide.....	168	Oncology.....	169
Symbicort Turbuhaler 100/6.....	235	Thalomid.....	168	Trexate.....	162
Symbicort Turbuhaler 200/6.....	235	Theophylline.....	239	Triamcinolone acetoneide	
Symbicort Turbuhaler 400/12.....	235	Thiamine hydrochloride.....	33	Alimentary.....	33
Symmetrel.....	119	THIO-TEPA.....	160	Dermatological.....	64
Sympathomimetics.....	56	Thioguanine.....	163	Hormone.....	79
Synacthen.....	79	Thiotepa.....	160	Triamcinolone acetoneide with	
Synacthen Depot.....	79	Thymol glycerin.....	33	gramicidin, neomycin and nystatin	
Synacthene Retard.....	79	Thyroid and Antithyroid Agents.....	81	Dermatological.....	65
Synflorix.....	280	Ticagrelor.....	41	Sensory.....	241
Synthroid.....	82	Tilade.....	239	Triaver.....	79

Triazolam.....	150	Venclexta.....	169	XP Maxamum.....	266
Triclosan.....	65	Venetoclax.....	169	Xylocaine.....	121
Trimethoprim.....	95	Venlafaxine.....	127	Xylocaine 2% Jelly.....	121
Trimethoprim with sulphamethoxazole [Co-trimoxazole].....	95	Venomil.....	233	Xyntha.....	40
Trisequens.....	80	Ventavis.....	59	- Z -	
Trisul.....	95	Ventolin.....	236	Zantac.....	9
Trophic Hormones.....	82	Vepesid.....	164	Zapril.....	47
Tropicamide.....	244	Verapamil hydrochloride.....	52	Zarontin.....	128
Trusopt.....	243	Vergo 16.....	131	Zaroxolyn.....	53
TruSteel.....	21	Vermox.....	88	Zavedos.....	165
Tuberculin PPD [Mantoux] test.....	283	Vesanoid.....	169	Zeffix.....	101
Tubersol.....	283	Vexazone.....	12	Zetlam.....	101
Two Cal HN.....	263	Vfend.....	97	Ziagen.....	105
Two Cal HN RTH.....	263	Viaderm KC.....	65	Zidovudine [AZT].....	106
Tykerb.....	172	Vidaza.....	160	Zidovudine [AZT] with lamivudine.....	106
Tysabri.....	140	Vigabatrin.....	130	Zimbye.....	55
- U -		Vildagliptin with metformin hydrochloride.....	12	Zinc and castor oil.....	65
Ultibro Breezhaler.....	237	Vimpat.....	128	Zinc sulphate.....	36
Ultraproct.....	8	Vinblastine sulphate.....	170	Zincaps.....	36
Umeclidinium.....	237	Vincristine sulphate.....	170	Zinnat.....	89
Umeclidinium with vilanterol.....	237	Vinorelbine.....	170	Ziprasidone.....	135
Univent.....	236, 240	Vinorelbine Ebewe.....	170	Zista.....	234
Ural.....	76	Viramune Suspension.....	105	Zithromax.....	89
Urea.....	66	Virupos.....	241	Zoladex.....	86
Urex Forte.....	53	Vit.D3.....	34	Zoledronic acid	
Urinary Agents.....	75	VitA-POS.....	245	Hormone.....	77
Urinary Tract Infections.....	109	Vitabdeck.....	34	Musculoskeletal.....	114
Urinorm.....	116	Vital.....	257	Zoledronic acid Mylan.....	77
Uromitexan.....	166	Vitamin B complex.....	33	Zopiclone.....	150
Ursodeoxycholic acid.....	26	Vitamin B6 25.....	33	Zopiclone Actavis.....	150
Ursosan.....	26	Vitamins.....	33-34	Zostavax.....	283
Utrogestan.....	81	Vivonex TEN.....	258	Zostrix.....	111
- V -		Volibris.....	57	Zostrix HP.....	122
Vaccinations.....	272	Voltaren.....	110	Zuclopenthixol decanoate.....	136
Vaclovir.....	101	Voltaren D.....	110	Zuclopenthixol hydrochloride.....	135
Valaciclovir.....	101	Voltaren Ophtha.....	242	Zusdone.....	135
Valganciclovir.....	101	Volumatic.....	240	Zyban.....	155
Valganciclovir Mylan.....	101	Voriconazole.....	97	Zypine.....	134
Vancomycin.....	95	Vosol.....	241	Zypine ODT.....	134
Vannair.....	235	Votrient.....	174	Zyprexa Relprevv.....	135
Varenicline Pfizer.....	156	Vttack.....	97	Zytiga.....	177
Varenicline tartrate.....	156	- W -			
Varicella vaccine [Chickenpox vaccine].....	283	Warfarin sodium.....	44		
Varicella zoster virus (Oka strain) live attenuated vaccine [shingles vaccine].....	283	Wart Preparations.....	70		
Varilrix.....	283	Wasp venom allergy treatment.....	233		
Various.....	246	Water			
Varivax.....	283	Blood.....	45		
Vasodilators.....	56	Extemporaneous.....	250		
Vasopressin Agonists.....	86	Wool fat with mineral oil.....	66		
Vedafil.....	58	- X -			
Veletri.....	59	Xarelto.....	44		
		Xifaxan.....	10		
		XMET Maxamum.....	265		
		Xolair.....	206		









